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General Introduction
Bones play an important part in the overall function of the human body. Besides being a 
highly specialized supporting framework of the body, bones protect vital organs, provide 
an environment for marrow (both blood forming and fat storage), act as a mineral reservoir 
for calcium homeostasis and as storehouse for growth factors and cytokines (1). One of the 
most important properties of bone is its ability to regenerate and repair; bones constantly 
undergo reshaping (modeling) during life to help them adapt to changing biomechanical 
forces; they also undergo remodeling to remove old, microdamaged bone and replace 
it with new, mechanically stronger tissue in order to help preserve bone strength  (2). In 
fact, this process is so dynamic that it is estimated that the entire adult human skeleton is 
replaced every ten years (3).
During childhood and adolescence, longitudinal growth of the skeleton takes place. 
The maximum amount of bone accrued at the end of the growth period is known as peak 
bone mass (PBM). PBM occurs by the end of the second or early in the third decade of life(4), 
yet more than 90% of PBM is already accrued by the age of 18 years (5). Longitudinal growth 
occurs at the growth plates, where cartilage proliferates in the epiphyseal and metaphyseal 
areas of long bones, before subsequently undergoing mineralization to form primary new 
bone. This first type of bone, also known as woven bone is later replaced by secondary or 
lamellar bone (mature). Secondary bone is further classified as two types: cortical bone and 
trabecular bone (Figure 1). The cortical bone is dense, solid, and surrounds the marrow 
space while the trabecular bone that is made of a honeycomb-like network of trabecular 
plates and rods is interspersed in the bone marrow compartment. The mature skeleton is 
composed of 80% cortical bone and 20% trabecular bone overall, where different bones 
and skeletal sites within bones have different ratios of cortical to trabecular bone  (2). For 
example, the vertebra is composed of cortical to trabecular bone in a ratio of 25:75, while 
the ratio is 50:50 in the femoral head and 95:5 in the radial diaphysis (2).
Figure 1. Mature bone composition in the hip. Cortical bone is compact having higher density while trabecu-
lar bone is spongy and has a greater surface area.
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Bone ForMAtion AnD DeveloPMent
Skeletal formation occurs through two major mechanisms: intramembranous and endo-
chondral ossification(6). Osteochondral progenitors differentiate directly into osteoblasts 
to form membranous bone(6). In contrast, during endochondral ossification, endochondral 
progenitors differentiate into chondrocytes to form a cartilage template of the future bone (6).
During pregnancy, the mother has to provide sufficient calcium, and optimal levels of 
vitamin D for the embryo to ensure its normal skeletal development (7). Throughout skeletal 
growth, from fetal life until the PBM occurs, bone modeling is the process that shapes 
skeletal elements for appropriate bone morphology and mass in response to physiologic 
influences or mechanical forces (3). Bones may widen or change axis by removal or addition 
of bone to the appropriate surfaces by independent action of osteoblasts and osteoclasts in 
response to biomechanical forces (2). The process of bone maturation is of particular inter-
est, as this thesis is dedicated to bone accrual in children of school age. After achievement 
of PBM, the main process in bone metabolism consists of bone remodeling. Normally, 
there is coupling between bone formation and bone resorption carried out by a tightly 
interconnected group of osteoclasts and osteoblasts, which sequentially replace old bone 
with new bone  (8). However, as age advances, there is a so-called “uncoupling” of these 
metabolic processes and less new bone is formed than resorbed in each site remodeled, 
resulting in bone loss and structural damage(9). Interestingly, significant sexual dimorphism 
has been described in both bone accrual and loss, as shown in Figure 2.
Osteoporosis is a disease characterized by reduced bone mass and disruption of bone 
(micro)architecture with an ultimate clinical consequence of increased fracture suscep-
tibility(10). The increased risk of bone fractures has devastating outcomes for individuals 
and society in terms of decreased mobility, increased health care costs and ultimately, in-
creased mortality(11). The prevalence of osteoporosis in the European Union was estimated 
at 27.6 million subjects in 2010, with its greatest burden arising from osteoporotic fractures 
comprising the vertebrae, forearm, hip, and proximal humerus. Osteoporotic fractures in-
capacity and treatment in the 27 countries of the European Union, sum up to an estimated 
burden of 37 billion euros, costs that are expected to increase by 25% in 2025 (10). People 
who have low PBM are at higher risk of osteoporosis forasmuch as any further loss of bone 
with aging and as a result of hormonal changes will make the skeleton even more fragile 
and susceptible to fracture. In fact, it is estimated that PBM accounts for more than half of 
the variability observed in adult bone mass  (12), and an increase of PBM by one standard 
deviation would reduce fracture risk by 50% in women after menopause(13). Consequently, 
childhood and youth are crucial periods to determine bone health, and, thus, the knowl-
edge of determinants accounting for variations in bone accrual can be a key factor in the 
prevention of osteoporosis.
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Bone MinerAl DenSity (BMD) ASSeSSMent
Traditionally, bone health in children is assessed using BMD, which is also used to diagnose 
osteoporosis in adults. BMD is commonly measured by dual-energy X-ray absorptiometry 
(DXA), a non-invasive technique that directly measures BMD and derives bone area (BA); 
bone mineral content (BMC) can be quantified as the multiplication of the former param-
eters(15). In children, total-body less head (TBLH) and lumbar spine DXA scans are preferred 
over the hip to evaluate BMD(16) (Figure 3). The skull is excluded as its relative contribution 
to bone mass is proportionally larger with respect to the rest of the body, and its inclusion 
can mask gains or losses at other skeletal sites making diagnostic interpretation difficult (17). 
DXA measurements of the hip usually assessed in adults are not as reliable in children, 
as this region comprises a relatively small area influenced by changes in size during skel-
etal development and growth (i.e., bone modeling, remodeling, linear growth and bone 
expansion). Such limitation on bone age detection and the influence of changes in bone 
area have high repercussion in the BMD measurement leading to low reproducibility. The 
DXA lumbar spine measurement covers sufficient area to provide reliable information(15). 
Despite this, normative DXA data for the adolescent hip, especially in girls  (18), exist and 
this site might still be useful in addition to the TBLH and lumbar spine DXA measurements.
Figure 2. Change of bone mineral density in men and women through life.  Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Rheumatology 11, 462-474. Hendrickx, G. et al.  Copyright 2015(14)
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FACtorS inFluenCinG Bone GroWtH AnD PeDiAtriC BMD
A complex interplay of genetic and environmental factors determines skeletal growth. Fac-
tors as intrauterine exposures(19,20), hormones (e.g., sex steroids, insulin-like growth factor 
I(21,22)), ethnicity(23,24), nutrition (e.g., calcium, vitamin D, protein)(25), physical activity(26), body 
composition(27,28) have been implicated in pediatric bone growth and density.
There is considerable disagreement in the literature as to the magnitude of the effect of 
these factors, probably related to the predominance of cross-sectional studies and small 
sample sizes. Further, twin and family studies indicate that BMD is a highly heritable trait, 
with heritability estimates ranging between 50 - 85%(29-32). These estimates can vary due to 
the analytical model used in their calculation, the skeletal site measured and the popula-
tion under study. Gueguen and colleagues assessed the heritability of BMD in 129 families 
and found that heritability estimates increase during childhood and reach a maximum of 
Figure 3. DXA scans commonly used in pediatric and adolescent populations. A. DXA image of total body 
scan. Total body less head is the preferred measurement for BMD assessment in children. B.  DXA image of 
the lumbar spine. The scan shows regions of interest from L1 to L4. C. DXA image of the right hip. The scan 
shows regions of interest as the femoral neck.
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85% in early adulthood, being of 63% and 34% at 14 and 53 years, respectively(33). Hence, a 
substantial proportion of the variation in bone acquisition and peak bone mass is attribut-
able to genetic factors.
BeyonD BMD, Bone StrenGtH
Bone strength, defined as the capacity of bone to respond to mechanical demands, is 
ultimately determined by its material composition, quantity and dimension, bone distribu-
tion and microarchitecture. BMD typically explains 60–80% of bone strength when bone 
samples are compared in a laboratory setting under controlled loading conditions(34). Geo-
metrical bone parameters might explain why many individuals who fracture do not have 
BMD in the osteoporotic range. For example, a low BMD can be compensated by specific 
bone structural geometry with no, or minimal compromise to mechanical strength. As DXA-
derived images provide two-dimensional measurements, they have low spatial resolution, 
and no direct calculation of the three-dimensional structure can be made(35). However, a 
method applied to DXA scans using biomechanical engineering principles known as hip 
structural analysis (HSA), allows the measurement of geometric and strength parameters 
(e.g., cortical thickness, bone width, cross-sectional area, section modulus among others) 
of the proximal femur. Studies examining the influence of bone geometry and strength on 
fracture risk have focused primarily on older adults. Even though there are some studies 
targeting the evolution of these parameters at young ages, most are throughout puberty.
During growth, bone modeling and remodeling optimize strength, by depositing bone 
where it is needed, and minimize mass, by removing it from where it is not, always in re-
sponse to strain stimuli imposed by muscle forces. As stated by the Frost Mechanostat(36), 
the role of muscle in the development of bone strength is predominant, attesting to the 
importance of physical activity for bone health. In general, changes in bone structure rather 
than in bone mass have most often been associated with gains of bone strength as a re-
sponse to physical activity in growing individuals(37). Due to their rapid and highly dynamic 
changes, the peripubertal years are now recognized as the most critical period to modify 
bone structure and strength, traits that tend to track throughout life(38).
GenoMe-WiDe ASSoCiAtion StuDieS
Single Nucleotide Polymorphism (SNPs) are the most common type of genetic variation. 
Each SNP represents a difference in a single position on the DNA. The hypothesis-free 
genome-wide association study (GWAS) strategy enables population-based mapping of 
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genetic factors affecting complex traits and disease, whereby assessing the possible asso-
ciation of millions of genetic variants in one single experiment is made possible (39). GWAS 
methods rely on a dense map of bi-allelic SNP markers that are distributed relatively evenly 
across the genome to capture most of the common variation. Two major advances have en-
abled GWAS, namely 1) the knowledge derived from the International HapMap Project (40), 
and 2) the technological development of high-throughput genotyping with the use of 
microarrays with dense genotype content. The GWAS process starts with the collection of 
DNA samples from a large number of individuals, the determination of hundreds of thou-
sands of genotypes using the array technology, followed by methodical high standard steps 
of quality control. This is then followed by imputation of untyped genotypes. Imputation 
is a statistical process in which a reference panel of individuals genotyped (or sequenced) 
containing a dense set of SNPs is used to infer missing information of untyped genetic vari-
ants in individuals that have been genotyped for a subset of these SNPs (41). Then, by means 
of statistical models, all imputed genetic variants are surveyed for association with disease 
or quantitative traits. Finally, usually within the setting of consortia, summary-level data of 
each study is combined to perform a GWAS meta-analysis. (Figure 4)
The genetic architecture of complex traits implies that hundreds if not thousands of as-
sociated SNPs exist, each contributing just a small amount to the overall trait population 
variance. It is for this reason that investigators are forced to collect large sample sizes and 
Figure 4. Genome-wide association study scheme. Genotyping of samples is followed by QC and imputa-
tion. Then, statistical models are used to stablish association of the genetic variants. Replication of results in 
other cohorts and meta-analysis are a must. Finally, functional follow-up allows to unveil the action mecha-
nism of the positive fi ndings.
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collaborate in consortia bringing together research groups around the globe. So far, GWAS 
have focused on European populations nonetheless, the inclusion of other ethnic groups as 
well as admixed population studies is rapidly rising following the pressing need to increase 
statistical power and to extrapolate findings to non-European populations.
Genome-wide association studies of Bone Mineral Density
Up to date, more than 56 loci have been described as associated with BMD, as deter-
mined by GWAS, in adult North-European subjects  (42-44), confirming the high complexity 
of this trait. Before 2012, the genetic analysis of pediatric BMD was restricted to only one 
analysis lead by the Avon Longitudinal Study of Parents and Offspring (ALSPAC). In that 
study, association results from a sample of ~5,300 children of white British ancestry were 
combined with summary data from previously reported GWAS in adult studies. This lead 
to the identification of an association between TBLH-BMD and genetic variants in the os-
teoblast transcription factor gene Osterix, an early-acting developmental gene influencing 
osteoblast differentiation  (45). The pediatric BMD genetic studies from 2012 onwards are 
presented throughout this thesis.
evolutionAry StuDieS
GWAS-derived information enables the investigation of the relationship between recent 
human evolution and human diseases and/or complex phenotypes. The discovery of al-
leles influencing different traits and their geographical distribution have allowed inquiries 
into the evolutionary parameters shaping the human natural history. Indeed, many common 
SNPs present significantly different frequencies among human populations or even appear 
to be polymorphic just in certain populations (i.e., they are population-specific SNPs) (46), 
shedding a light into the etiology of different traits. It is clear that the skeletal system as a 
whole has been shaped by evolutionary forces of natural selection. A good example is the 
bipedalism of humans, where the ability to walk and run upright on two feet was made 
possible by virtue of specialized adaptations of the skeleton and muscles (47). Similarly, the 
analysis of ancient bones has unveiled important clues of the history of human evolution. 
Nature has selected materials and structural properties that meet the contradictory needs 
of strength and lightness, stiffness and flexibility (9). Modern skeletons appear to be gracile 
as compared with earlier hominins, plausibly due to a decrease in daily physical activity as 
a result of technological and cultural innovations (48). However, even modern populations 
show high skeletal diversity. Ancient migrations might have played a significant role in shap-
ing the ethnic differences in bone characteristics of modern humans. This diversity might 
have emerged as different populations worldwide faced different demographic and envi-
ronmental challenges once they left Africa  (47). Recent genetic and anthropologic studies 
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have provided evidence for positive selection driving high population differentiation in 
skeletal traits in modern human populations(47,49-51).
StuDy DeSiGn
The majority of studies presented in this thesis arise from data of the Generation R Study, 
a population-based multi-ethnic prospective cohort study from fetal life until young 
adulthood, designed to identify early environmental and genetic determinants of growth, 
development and health(52). The Generation R Study is conducted in Rotterdam, the Neth-
erlands, within a multi-cultural metropolitan area including inhabitants of approximately 
150 different ethnicities. In total, 9,778 women with a delivery date between April 2002 
and January 2006 were enrolled in the study. Assessments were planned in early pregnancy 
(<18 weeks of gestation), mid-pregnancy (18- 25 weeks of gestation) and late pregnancy (≥25 
weeks of gestation) and included parental physical examinations and self-administered 
questionnaires. Additionally, from birth to 6 years of age, data collection was performed 
in all children by questionnaires and visits to the routine child health centers. DXA scans 
of the total body and hip were performed on the participants at a mean age of 6 years. 
Measurements during this visit also included anthropometric assessments.
GenerAl AiM
This thesis contains studies that aimed to disentangle the multifactorial process of bone 
accretion in children including fetal exposures influencing early programming of the trait, 
possible effect of body size and composition during growth in bone status and innate ge-
netic factors influencing bone mineral density. I have focused a great part of my research on 
genetic factors influencing pediatric BMD. Nevertheless, I also encountered methodologi-
cal challenges intrinsic to running GWAS in general but particularly in multiethnic cohorts. 
Thus, I acknowledge several methodological aspects of the genetic association testing. In 
addition, I address major questions generated by the study of genetic variants as a source 
of phenotypic heterogeneity, taking up relevant issues as age- and site-specific effects, plei-
otropy, and ethnic differences on the genetic regulation of bone mass attainment. Finally, I 
also use an explorative analysis to trace the evolutionary forces that could have shaped the 
geographic distribution of bone mineral density across populations.
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outline oF tHiS tHeSiS
In Chapter 2 the methodological framework that allowed us to follow up genetic associa-
tion studies in an admixed population is described. In Chapter 2.1 an exhaustive descrip-
tion of the generation of the GWAS data and the challenges of the GWAS approach in 
admixed studies is provided. In Chapter 2.2 a novel approach to improve the quality of the 
imputation of rare variants, a crucial point in this new era in the genetic analysis of complex 
traits is presented. The potential of the genetic data of the multi-ethnic Generation R Study, 
as a resource in general for genetic studies is exemplified in Chapter 2.3, where it serves 
as control population to a collection of Behcet‘s cases from different ancestries in a GWAS 
study. Chapter 3 focuses on the effect of different factors, from fetus life to pre-school age, 
influencing BMD measured at 6 years of age in the Generation R Study participants. Chap-
ter 3.1 is dedicated to the effect of maternal diet on childhood bone mass, and Chapter 
3.2 assesses the effect of fetal and early childhood growth on bone accrual at school age 
while Chapter 3.3 describes sex differences in bone strength during childhood. Chapter 4 
is dedicated exclusively to genetic studies on pediatric BMD. In Chapter 4.1 the advantages 
of applying GWAS in pediatric populations is presented, and WNT16/CPED1 locus is used 
to show an example of age-specific genetic effects. In Chapter 4.2 we extend the analysis 
of pediatric populations to a general population context. We use DXA derived measures of 
the TB-BMD as a suitable phenotype for GWAS, discovering up to 18 novel loci associated 
with this trait in more than 50,000 individuals. We used the same data, meta-analyzed by 
age strata, to explore further the age-related heterogeneity in the effect of genetic variants 
on BMD in Chapter 4.3. Whereas in Chapter 4.4 we analyze another type of heterogeneity 
in the study of bone, i.e., the study of different skeletal sites which differ in their composi-
tion of cortical and trabecular bone and are subject to differential loading forces and its 
relevance for genetic investigations. In Chapter 4.5 the pleiotropic effects of genetic vari-
ants on both lean mass and BMD is studied. In Chapter 5.1 we go beyond the discovery 
of new variants by GWAS, and use the GWAS discoveries to characterize at a worldwide 
level the geographical patterns of BMD-associated SNPs, assessing the possible role of 
evolutionary selective pressures shaping the ethnic differences in this trait. Finally, Chapter 
6 provides a general discussion in which the studies described in this thesis are placed in 
a broader context, providing additional implications of these findings and suggestions for 
future research.
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ABStrACt
Genome-wide association studies (GWAS) have been successful in identifying loci associ-
ated with a wide range of complex human traits and diseases. Up to now, the majority 
of GWAS have focused on European populations. However, the inclusion of other ethnic 
groups as well as admixed populations in GWAS studies is rapidly rising following the 
pressing need to extrapolate findings to non-European populations and to increase statisti-
cal power. In this paper, we describe the methodological steps surrounding genetic data 
generation, quality control, study design and analytical procedures needed to ran GWAS 
in the multiethnic and highly admixed Generation R Study, a large prospective birth cohort 
in Rotterdam, the Netherlands. Furthermore, we highlight a number of practical consider-
ations and alternatives pertinent to the quality control and analysis of admixed GWAS data.
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introDuCtion
Genome-wide association studies (GWAS) analyze a large number of single nucleotide 
polymorphism (SNPs) across the genome in a large number of samples, aiming to identify 
loci associated with complex traits at the population level. Since 2007, well-designed stud-
ies have been able to comprehensively test common genetic variation across the genome (1). 
Up to now, at least 11,680 SNPs have been robustly associated with one or more complex 
traits, providing biological insight in traits as different as Alzheimer’s disease, prostate 
cancer, inflammatory bowel disease, obesity, stroke, diabetes, asthma, height, cholesterol 
levels and bone mineral density, to name only few examples of the successful performance 
of this approach (2).
Variants discovered by GWAS typically have small effects which is why minor sources of 
systematic or random error can lead to false positive associations or can mask real effects 
(false negative associations). In order to avoid bias, it is necessary to closely control the 
processes underlying the production of GWAS data, extending from laboratory processes 
(data generation) to imputation. It is also necessary to conduct statistical analyses, which 
incorporate factors into the models known to influence the trait of interest, as well as being 
appropriate to the characteristics of the study design.
Ethnicity is a confounder of epidemiological studies which incorporates cultural, geo-
graphical and biological dimensions. In the GWAS context spurious associations between 
genetic variants and a trait of interest occur when both allele frequencies and differences 
in trait distributions (disease prevalence or magnitude of quantitative traits), vary across 
ethnicities. From this perspective, adequate correction for potential population stratifica-
tion is required for successful identification of genetics determinants of complex traits and 
diseases.
To date, GWAS have mainly focused on populations of European ancestry. Consequently, 
having another ethnic background is a common reason for exclusion of GWAS samples. As 
an illustration, from the 1,734 GWAS papers indexed in the GWAS catalogue, 66% included 
only individuals from European ancestry, 34% included Non-Europeans only (most of those 
carried out in Asian populations), and 12% included both Europeans and Non-European 
individuals (3). Moreover, big consortia efforts such as Cohorts for Heart and Aging Research 
(CHARGE) or the Genetic Investigation of Anthropometric Traits (GIANT) have focused 
primarily on European populations, while efforts driven in populations of diverse ethnic 
background are of modest sample sizes. However, the inclusion of multiethnic and/or ad-
mixed populations in the analysis of GWAS can actually result in additional power. Firstly, 
larger datasets (representing higher power) can be assembled when the ancestry criterion 
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is not used for sample exclusion. Keeping such “ethnic outliers” in the study also represents 
a better use of resources considering the logistic and burden behind sample collection and 
genotyping, and their associated costs. Secondly, the European-only approach has little 
power to detect association for genetic variants segregating at low frequency in European 
populations and statistical power can be gained if those variants are more common in 
other ancestries included in the analysis (4). Some examples are provided by Fu et al., who 
describe variants associated with type 2 diabetes mapping to UBE2E2 and KCNQ1 that have 
higher frequencies in East Asians (minor allele frequency (MAF) of 0.22 and 0.38, respec-
tively) as compared with Europeans (MAF of 0.093 and 0.08, respectively) (5). Similarly, Wu 
et al. showed examples of ethnic specificity in variants associated with lipid levels map-
ping to APOA5 and APOB. These very rare variants identified in African-Americans were 
not detected in either East Asian or European populations(6). Further, (rare) variants specific 
to a subpopulation (e.g., a diabetes susceptibility variant arising in Native-Americans) can 
be identified in a derived highly admixed population (i.e., Mexicans) as having the larg-
est effect(7). In addition, population admixture, due to interbreeding of individuals from 
different origins, would have brought together genomes from continental populations, 
which are a product of genetic drift and different selective pressures. Following this line 
of reasoning, it is expected that recently admixed populations are likely to harbor a larger 
number of genetic variants than the original populations they come from(8). Theoretically, 
this will result in a higher yield in the discovery of genetic determinants of complex traits. 
Another important genetic approach, suitable in admixed population, to identify disease 
risk variants is admixture mapping, which is powerful when the ancestral populations differ 
both in allele frequencies and disease prevalence. Then, in the vicinity of a disease locus, 
an affected individual should have a higher proportion of alleles inherited from the most 
affected ancestral population(9).
As GWAS worldwide are expanding to include multi-ethnic and admixed populations, 
we describe here the steps used for genetic data generation, study design and analytical 
procedures applied in the Generation R Study. The Generation R Study is a population-
based prospective cohort following children and their mothers from fetal life onwards, 
which comprises a multiethnic population, including a high proportion of highly admixed 
individuals. We here mainly focus on how this approach can allow analyzing the whole set 
of individuals independent of genetic background as a mean to increase sample size and 
power to identify loci underlying complex traits and diseases. The different considerations 
described here can be applied to other multiethnic studies, particularly those of admix 
nature such as Hispanics or African Americans.
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MAteriAlS AnD MetHoDS
Study Population
The Generation R Study is a multi-ethnic population-based prospective cohort study, span-
ning from fetal life until young adulthood, designed to identify early environmental and 
genetic causes of normal and abnormal growth, development and health during fetal life, 
childhood and young adulthood. Study design, data collection in prenatal and postnatal 
phases, and ethical issues of this study have been previously described in detail  (10). The 
Generation R Study is conducted in Rotterdam, the Netherlands, within a multi-cultural 
metropolitan area. The study area includes inhabitants of approximately 150 different 
ethnicities (11). Pregnant women with a delivery date between April 2002 and January 2006 
were informed about the study and provided written informed consent through their pre-
natal care provider during their first visit of the pregnancy. The medical ethics committee 
of Erasmus University Medical Center approved the study. In total, 9,778 mothers were 
enrolled in the study.
The ethnic background of the children was defined by the parents’ country of birth, which 
was obtained by questionnaire. The participating child was defined as of non-Dutch ethnic 
origin if one of her/his parents was born abroad, and further classified using a socio-
demographic definition as described by Statistics Netherlands  (11). If both parents were 
born abroad, the country of birth of the mother decided the classification of the ethnic 
background of the child. The ethnic background of the mother and partner were obtained 
in the same manner, based on their parents’ (the child’s grandparents) country of birth.
Sample Collection, Biobanking and Genotyping
Blood samples of the children were collected from the umbilical cord at birth. Where an 
umbilical cord blood sample could not be collected at birth, a blood sample was obtained 
by venipuncture during the child’s visit to the research center at a mean age of 6 years. 
All samples were coded with a unique laboratory number. Umbilical cord samples were 
collected in 10 ml EDTA tubes and stored immediately at -80°C, while samples obtained 
by venipuncture were collected in 5 ml EDTA tubes and stored directly after transport at 
-20°C. DNA was extracted manually from white blood cells using the Qiagen FlexiGene Kit 
(Qiagen Hilden, Germany). Normalisation and further processing of the DNA samples were 
performed on a Caliper ALH3000 pipetting robot. A detailed description of the Genera-
tion R Biobank has been previously published (12).
Genotyping was performed using Illumina HumanHap 610 or 660 Quad chips -depending 
on collection time- following manufacturer protocols, and intensities were obtained from 
the BeadArray Reader. Genotype calling was performed on normalized intensities using 
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the Genecall module from the Illumina Genome Studio software version 1.1.0.28426. A 
no-call threshold of 0.15 was applied to a manufacturer-provided cluster file. Illumina Ge-
nome Studio provides a quality metric used to identify low-quality samples and, we used a 
threshold of 97.5% for exclusion of samples.
DnA Quality Control (QC)
The two Genome Studio projects (one each for the HumanHap 610 array and for the 660 
array), were merged using SNPs common to both arrays. The QC procedures were applied 
to the genotyped data using PLINK (13) in two phases: marker- and sample-based.
Marker QC included filters for: 1) marker call rate (calling <.2 - <0.05, --geno option), 
checked in two rounds, the initial with a threshold of 80% and the second one more 
stringent (95%), after inspection of sample quality, 2) minor allele frequency (MAF <=0.001, 
--maf option), 3) differential missingness between the two projects (P<1x10-7, --test-missing 
option) and 4) deviation from Hardy-Weinberg equilibrium proportion (P<10-7 --hwe op-
tion). Sample QC included: 1) duplicate detection (PLINK option IBS=1), 2) sex discordance 
rates (--check-sex option), comparing the reported sex of each participant with the sex 
predicted by the genetic data (expected chromosome X heterozygosity). When results 
Figure 1. Flowchart overview of the entire GWAS QC process. Quality control of all samples from Gen-
eration R-1 and Generation R-2 after merging of the projects. Red font denotes exclusion of either SNPs or 
samples from the dataset in the different QC steps.
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were inconclusive, the Genome Studio plots, log R ratios and B-allele frequencies, for both 
X and Y chromosomes were inspected. 3) Genotype call rate (<0.05 - <0.025--mind op-
tion) checked in two rounds, the initial with a threshold of 95% and the second one more 
stringent (97.5%), after inspection of marker quality and 4) high heterozygosity rate, over 
4 SD of the mean heterozygosity of all samples (--het option). The step by step summary 
of the applied QC pipeline is presented in Figure 1, and Online Resources Figures 1 and 2.
Population sub-structure and family relationships
Additional sample QC assessments were applied to determine genetic-based ethnic back-
ground and to identify potential family relationships.
Genetic ancestry
To characterize the genetic ancestry of the children in the Generation R Study, all samples 
passing QC procedures were merged with the three genotyped panels from the HapMap 
Phase II release 22 build 36 including: Northwestern Europeans (CEPH collection or CEU), 
Sub-saharan West Africans (Yoruba or YRI) and Asians (Han Chinese from Beijing or CHB, 
and Japanese from Tokyo or JPT)  (14,15) using only independent autosomal SNPs (r2>0.05). 
In the merged dataset, pairwise identity-by-state (IBS) relations were calculated for each 
pair of individuals (representing the average proportion of alleles shared by those indi-
viduals) using PLINK (–genome option). In addition, principal axes of variation (or so-called 
genomic components equivalent to Principal Components (PCs)) were derived from this 
IBS matrix by Multi-dimensional Scaling (MDS), to characterize the variability present in the 
data using few variables (PLINK –-cluster -–mds-plot). Participants were defined as being 
of non- Northwestern European ancestry when deviating more than 4 standard deviations 
(SD) from the CEU panel mean value in any of the first four genomic components.
Sample relatedness
To identify cryptic family relationships within the Generation R samples, we first removed the 
HapMap samples, recalculated the IBS matrix including only participants of the Generation 
R Study and then determined pairwise, the proportion of shared IBS alleles. By using this 
information and the population allele frequency, PLINK is able to estimate the number of 
these alleles coming from the same ancestor, known as IBD (identity-by-descent), using the 
methods of moments (13). These familial relationships detected using PLINK, were validated 
post-hoc using the recently released software REAP (Relatedness Estimation in Admixed 
Populations). REAP estimates IBD proportions in a similar way than PLINK. Nonetheless, it 
uses individual-specific allele frequencies that are calculated by conditioning on estimated 
individual genome-wide ancestry (16).
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Genotype imputation
A two-step genotype imputation, comprising a phasing step to resolve the haplotypes of 
the genotyped markers (using MACH software) and an imputation step in which unmapped 
SNPs are imputed to a reference panel (using Minimac software), was applied to the GWAS 
genotyped dataset after QC. Data was divided in marker sets across chromosomes to be 
processed using a parallel computing cluster. Thus far, two different reference panels have 
been used to impute the Generation R data: a) HapMap Project Phase II Release 22, build 
36 phasing and b) 1000 Genomes Project (phase III release version), build 37 phasing. For 
the phasing of the haplotypes we used the standard parameters recommended by the 
MACH/minimac developers (http://genome.sph.umich.edu/wiki/Minimac) consisting 
of 20 iterations of the Markov sampler and 200 states (number of haplotypes that should 
be considered when updating each individual). Parallelization was achieved by splitting 
jobs on chunks across chromosomes. The window size was 2,100 markers, of which 100 
were flanking markers, when using assembly build 36, and a window size of 2,500 markers, 
using 500 as flanking markers when using assembly build 37. Imputations were performed 
following the same chunking strategy of parallelization as mentioned for the phasing step. 
To evaluate genotype imputation quality we used the MACH r-squared (Rsq), metric based 
on the ratio of the empirically observed variance of the allele dosage to the expected bino-
mial variance f(1 − f ), assuming Hardy–Weinberg equilibrium, where f is the observed allele 
frequency. When imputations hold adequate information for predicting the unobserved 
genotypes from the observed haplotype backgrounds, this ratio should be distributed 
around unity(17). By consensus an Rsq>0.3 has been used to define sufficiently good quality 
for analysis (18).
HapMap Imputations
Imputations of autosomal chromosomes to HapMap used all haplotypes available from 
Phase 2 of the International HapMap Project reference panel, in the so-called “cosmopoli-
tan approach”. This combined reference panel includes 210 individuals from the CEU, YRI 
and CHB/JPT panels (15).
1000 Genomes Imputations
A second round of imputations was performed using 1000 Genomes (1KG) data - phase 
3 release (http://www.sph.umich.edu/csg/abecasis/MACH/download / 1000G.2012-
03-14.html), which comprises the genomes of 1,092 individuals from 14 populations  (19). 
We employed the same parameters as described for the phasing procedure in build 37, 
and included autosomal and chromosome X markers. Chromosome X imputations were 
performed separately for males and females.
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Genome Wide Association analysis in the Generation r Study
For illustration of possible pitfalls when using an admixed population, association analyses 
in the Generation R Study were performed with and without adjustment for population 
substructure. Additionally, we evaluated the distribution of the participant’s ethnicity along 
the genomic components, in order to assess the adequacy of questionnaire-based eth-
nicity to correct for population structure in the association models. Finally, we contrasted 
the two most common approaches used for correction of population stratification: 1) the 
traditional method of inclusion of genomic components as covariates in the association 
model, and 2) linear mixed models, as implemented in the publicly available software, 
Efficient Mixed-Model Association eXpedited (EMMAX) (20). The genome-wide significance 
(GWS) threshold for the association was established at P<5x10-8. For illustration, we present 
here examples of association results in the whole Generation R population obtained for 
two model phenotypes: 1) the dichotomous red hair pigmentation (a highly stratified trait) 
and 2) the continuous bone mineral density measured at the skull. For the former example 
(n=5,731), logistic association analyses ran on directly genotyped markers were corrected by 
four genomic components. Additionally, we used the two imputed datasets – HapMap and 
1KG- to show the fine mapping resolution improvement of the genome-wide signal. For the 
latter skull BMD analyses (n=4,086), linear association using HapMap imputed data includ-
ing twenty genomic components as covariates in the model. Further details on collection 
and analysis of this phenotype have been reported elsewhere (21). For further illustration, we 
ran GWAS for skull BMD with equal sample sizes (n=1,909) in both the non-European and a 
randomly selected sample of the European subgroup of the Generation R Study, adjusting 
for twenty genomic components and compared results for rs13223036, reported as the top-
hit in a meta-analysis of more than 9,000 kids mainly from European ancestry (21).
All linear and logistic models were ran using the MACH packages (http://www.unc.
edu/~yunmli/software.html) as available in the web-based tool GRIMP, which facilitates 
high-speed analysis of large imputed datasets making use of computational grid infrastruc-
tures (22).
reSultS
Study Population
A summary of the ethnic classification based upon questionnaire of the 9,749 children 
participating in the Generation R Study is presented on Online Resource 3. Ethnic classifica-
tion was missing in 6.7% of the population. The largest ethnic groups in the cohort were of 
Dutch (57%), other European (7.4%), Turkish (7.4%), Surinamese (7.3%), and Moroccan (6.4%).
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Sample Collection, Biobanking and Genotyping
At birth, 5,908 samples were obtained from 30 ml cord blood (Generation R-1). Ad-
ditionally, 320 samples were drawn during the visit to the research center at age 6 years 
(Generation R-2). Of the DNA samples from the collection of Generation R-1, 5,815 (98.4%) 
were genotyped using the Illumina HumanHap 610 Quad chip (including 620,901 markers, 
representing 592,532 SNPs and 28,369 copy number variation (CNV) probes). The 1.6% of 
samples not genotyped were discarded either for low quantity and/or low concentration 
of DNA in the stock solution as well as possible unresolved sample swaps. The extra 320 
DNA samples in Generation R-2, were genotyped with the Illumina HumanHap 660 Quad 
chip (comprising 657,366 markers, 561,490 SNPs and 95,876 CNV probes). The genotype 
data were exported on forward strand for both collections. A total of 178 samples with 
genotyping rates lower than 97.5 % (Genome Studio sample call rate), likely arising due to 
low DNA quality, array problems or poor performance of agents, were excluded from the 
final projects (Generation R-1 and Generation R-2 sets).
DnA Quality Control
Marker QC
CNVs reported in the manifests of the arrays, together with SNPs which could not be called 
in at least 95% of the samples or with a MAF <=0.001, were eliminated (Online Resources 1 
and 2) before merging the Generation R-1 and Generation R-2 sets. The combined dataset, 
merged using only SNPs common to both platforms (n=5,809), consisted of 549,511 SNPs. 
No SNP was excluded in any of the two call-rate inspections. One hundred and ninety-five 
SNPs were removed due to differential missingness, addressing possible bias induced by 
batch effects between the sets. Improvements to our quality control pipeline could be 
implemented, as to have more stringent standards. For example, although PLINK will report 
alleles incompatibilities when merging datasets, these would not be detectable in case of 
palindromic SNPs (A/T and G/C). Therefore, since strand issues would not be detected for 
these type of SNPs checking allele frequencies before merging is strongly recommended. 
In addition, 30,971 SNPs were excluded for deviations from Hardy-Weinberg Equilibrium 
(HWE) proportions (P<1x10-7). While other causes of deviation exist, failure of this test is 
highly indicative of genotyping errors at a given marker (23).
Sample QC
Unique laboratory codes together with an anonymous person-unique study code were 
compared in order to identify duplicates. Fifteen duplicated samples were removed from 
analysis (10 from the Generation R-1 set and 5 from the Generation R-2 set). Sex inconsisten-
cies were flagged by PLINK in 60 samples. Ten of them had incompatible sex data while 
the others were assessed as ambiguous. After revision of Genome Studio plots (Online 
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Resource 4), we identifi ed discrepancies for 15 of those samples. In total, 25 samples were 
excluded during this sex check. A Sample genotyped call rate test, based on the remain-
ing SNPs after merging projects, resulted in no samples exclusion. We found no individual 
samples with excess of heterozygosity of more than 4 SDs above the mean heterozygos-
ity value of all samples, thus the presence of sample cross-contamination was unlikely. 
However, reduced heterozygosity (- 4SDs) was identifi ed in 34 samples, possibly as result 
of the multiethnic background of the samples. Excess of homozygosity is typically seen in 
individuals from genetic isolates with large stretches of linkage disequilibrium (LD) or in 
populations with substructure, in which there is partial admixture as result of non-random 
mating, as is the case in the Generation R Study (24,25).
Population sub-structure
Genetic ancestry
Generation R and the three HapMap panels were merged based on a common set of 
36,845 independent (LD-pruned) autosomal SNPs. After calculation of pairwise IBS genetic 
distances between all individuals, we derived genomic components, summarizing the 
structure of the data into main genomic components explaining the genetic variation (Fig-
ure 2). Approximately 50.5% of the samples deviated more than 4 SDs from the mean CEU 
panel cluster on the main four components and were classifi ed as of “Non- Northwestern 
Figure 2. Genetic substructure of the Generation r Study. Two-dimensional plots from MDS analyses of the 
Generation R Study and the three initial Panels form the HapMap Project. Left panel: First two components 
explaining most of the variability of the data. Right panel: Third and Fourth components explaining some of 
the remaining variability.
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European” origin. A previous release of the Generation R data from 2009, included only 
individuals whose samples were collected at birth, and who were classified as of North-
western European origin (N=2,661) following the same steps mentioned above, and has 
been used in some publications (10,26,27).
Cryptic family relatedness
Two-hundred and eighty-nine possible pairwise sib-ships were found by IBS-sharing us-
ing PLINK (0.35<PI_HAT<1). Sixteen pairs of individuals shared two alleles at every locus 
corresponding either to monozygotic twins or a single sample processed twice. Twelve of 
these relations were conflicting with the registry, and thus most likely correspond to the 
same sample being processed twice. In these cases, both samples were removed from the 
dataset. The four remaining pairs were twins when traced back to registries. For these true 
twin pairs, the sample with a lower call rate was removed from the dataset. First-degree 
relationships discrepant with registry (13 samples) identified using PLINK were not initially 
excluded. Nevertheless, they were excluded after confirmation by REAP. Visualization of 
kinship coefficients obtained from REAP revealed that Generation R participants are (to 
a large extent) unrelated. Sibling pairs are represented by the small peak around a kin-
ship coefficient of 0.25. Yet another peak (0.025< kinship coefficient <0.0635) evidence 
the presence of third and fourth degree related individuals (Online Resource 5). Related 
individuals were not removed from the dataset to allow exclusion/inclusion in association 
analyses to be done specifically by phenotype availability. In addition, one more individual 
was recently removed for retracted informed consent. In summary, the current GWAS col-
lection for the Generation R Study consists of samples from 5,732 children.
Genotype imputation
HapMap imputations
Using the three HapMap panels combined 3,021,329 SNPs were imputed. The MAF distri-
bution of imputed SNPs is shown in Figure 3. The mean Rsq for all the imputed data was 
0.883, (median 0.972, IQR = 0.127); when markers with MAF<0.01 were excluded (com-
prising 313,593 SNPs or 10.38% of the markers), the mean Rsq was 0.914, (median 0.979, 
IQR=0.083). Figures 3A and 3B show how the increase of Rsq is proportional to the increase 
in the MAF of the markers. When grouping the markers into MAF bins, 83% of the SNPs 
with MAF<0.01 achieved sufficient quality, while for the other bins more than 95% of the 
SNPs were well imputed. Nonetheless, there is a broad range of quality scores for SNPs in 
each MAF bin. Statistical dispersion is decreasing with MAF as seen by the interquartile 
range represented by the size of the box in each bin. Patterns of imputation quality by 
chromosome are shown in Online Resource 6. In general, larger chromosomes tended 
to be better imputed. Imputation quality was visually checked across chromosomes and 
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the only notorious fall in Rsq was at centromeres and extremes of the telomeres, where 
the density of markers is low. Markers on the sex chromosomes were not imputed to the 
HapMap reference panel.
Figure 3. imputation Quality metrics evaluation HapMap. a. Boxplots of the MACH Rsq in function of the 
MAF of the imputed SNPs. b. Imputation quality distribution per MAF category. Blue and green denotes the 
poorly and well imputed SNPs based in a 0.3 quality score as threshold. 88,625 out of 3,021,329 (2,93%) are 
poorly imputed SNPs (Rsq<0.3).
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1KG Imputations
We were able to impute 30,072,738 autosomal variants using the 1KG reference panel, 
in which 28,681,763 are SNPs and 1,390,975 are insertion/deletions. The mean Rsq for 
all variants was 0.574 (median 0.622, IQR = 0.636); when markers with MAF<0.01 were 
Figure 4. imputation Quality metrics evaluation 1KG. a. Boxplots of the MACH Rsq in function of the MAF 
of the imputed SNPs. b. Imputation quality distribution per MAF category. Blue and green denotes the poorly 
and well imputed SNPs based in a 0.3 quality score as threshold. 8,263,752 out of 30,072,738 (27.4%) are 
poorly imputed SNPs (Rsq<0.3)
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excluded (comprising 18,804,120 SNPs or 62.52% of the markers), the mean Rsq increased 
to 0.815 (median 0.929, IQR= 0.244). Figure 4 shows an assessment of imputation accuracy 
by MAF. Although imputation quality was poor in the lower spectrum of allele frequencies 
(MAF<0.05), 15,164,960 markers had an Rsq >= 0.3 and were suitable for analysis. Moreover, 
the number of markers comprising bins of common frequency (6,894,397 markers with 
MAF>0.05) is much lower than the number of markers comprising bins of low frequency 
(23,178,341 markers with MAF<0.05), which usually have low imputation quality. Online 
Resource 6 summarizes the performance of the imputation per chromosome. The number 
of SNPs imputed on chromosome X was 1,264,877, of which 903,868 (71.5%) were rare 
(MAF<0.005). As expected, quality was not as high as for the autosomal chromosomes, as a 
consequence of the lower number of haplotypes contributed by men in this chromosome. 
Considering markers of sufficient imputation quality (Rsq>=0.3) on the autosomal chromo-
somes only, the 1KG imputation resulted in 18,874,123 more markers than those arising from 
the HapMap imputations including 7,892,440 markers with a MAF>0.01. There are minimal 
differences in imputation quality when comparing the 2,972,940 SNPs common across the 
two datasets (mean Rsq, 0.886 (median=0.972, IQR=0.123) for the HapMap imputed data-
set against 0.903 (median=0.978, IQR=0.097) in the 1KG imputed dataset). When further 
filtering markers for MAF>0.01 and Rsq>=0.3, (resulting in 2,671,742 SNPs) the concordance 
rate, based on best guess genotypes, between the Hapmap and the 1KG imputed datasets 
was 0.983 as calculated by PLINK (using the --merge-mode 7 option).
Correcting Genome Wide Association Analysis for ethnic background in the 
Generation r Study
The socio-demographic ethnic definition in the Generation R Study is based on country of 
birth of the parents of the participants. To evaluate the degree of potential misclassification 
between definitions, we assessed the agreement of the questionnaire definition with that 
of genetic ancestry, using genomic components (Online Resource 7). Groups classified as 
being of European and Dutch origin have historically undergone high waves of migration 
during the 1960s, 1970s or early 1980s. As a consequence, a scattered distribution across 
the genomic components axes was observed instead of a uniform one. A similar pattern 
was also observed for participants of Surinamese origin, arising from two clearly differenti-
ated ethnic groups, the Hindustani and the Creoles.
Statistical approaches based on EMMAX and genomic components were tested for two 
different traits. There is no evidence of major degrees of residual population stratification in 
the GWAS results for red hair color (Figure 5 and Online Resource 8), within the Generation 
R Study (196 children with red hair (3.4%) as gauged in the QQ-plots (no early deviation 
from the test statistic or p-value distribution) and genomic inflation factors (GIF) close to 
unity for both EMMAX (GIF= 0.994) and genomic components correction (GIF=0.999). In 
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contrast, when no adjustment for population stratification was employed, very early (ar-
tefactual) deviation was seen in the QQ plot, erroneously indicating that the vast majority 
of markers across the genome were associated with red hair pigmentation (Figure 5). After 
correction for population stratification, only the markers on chromosome 16q24.3 map-
ping in the vicinity of MCR1 reached GWS, variants in this gene largely explain the presence 
of red hair pigmentation (28). GWAS based on the imputed data gave rise to similar results, 
but showed an even higher number of SNPs underlying the MCR1 associated signal. Fur-
thermore, the leading SNP on these analyses was a missense variant rs1805007, P < 1x10-20, 
reported previously as associated with this trait (29), which was not present in the genotyped 
data (Online Resource 9). QQ-plots from the skull BMD GWAS show adequate correction 
for population stratification (Online Resource 10). Power for both EMMAX and genomic 
components is similar in the two tested traits, as gauged by the number of GWS signals and 
their significant level (Online Resources 8 and 11). Moreover, the effect size of skull BMD 
associated SNPs is practically identical across the two approaches.
Skull BMD analysis for equal sets of European and Non-European children shows a GWS 
signal in the WNT16/CPED1 locus only in the Non-European children, although similar 
direction for the leading SNPs was found in both sets (Online Resource 12). We compared 
the association results for rs13223036 in this locus. The frequency of the effect allele in 
Figure 5. Genome-wide association of red-hair pigmentation in the Generation r cohort. a. Q-Q plot 
showing the inflation of the test statistics when correction for data structure is not applied (black dots) and 
the slightly lower power when Genomic Components correction is applied (red dots) in comparison with the 
EMMAX model (green dots) and b. Manhattan Plots of the red-hair pigmentation GWAS in the Generation R 
Study using adjustment for Genomic Components c. Manhattan Plots of the red-hair pigmentation GWAS in 
the Generation R Study using a Linear Mixed Model as implemented in EMMAX
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Europeans was 0.622, while it was 0.695 in non-Europeans. The effect size differed by ~27% 
of the effect size in the European group (beta=0.15, P=6.8x10-6), being stronger and more 
significant in the non-European set (beta= 0.19, P=2.5x10-8).
DiSCuSSion
In summary, we have described the methodology used to genotype, impute, and analyze 
data for association with phenotypes in the multiethnic Generation R Study, addressing 
a number of practical issues that arise in implementing imputation-based association for 
a multiethnic cohort. Our genome-wide genotyped data, ready for analysis after quality 
control (QC), comprises information for 518,245 markers in 5,732 individuals of different 
ethnic backgrounds, which is available in the most common genome builds (i.e., 36 and 37). 
Enrichment by imputation of our genotypes, following a cosmopolitan approach, resulted 
in an increment of the number of markers of about 5.7 times for the HapMap imputed data 
and 46 times for the 1KG imputed data (Rsq>0.3).
The Generation R Study withholds a special setting determined by the admixed nature of its 
population confined within a restricted area. This encompasses analytical challenges as well 
as opportunities to design genetic studies, which take advantage of such characteristics. A 
joint analysis including all Generation R participants represents a considerable increase in 
power of the design, as about half of the study population is of non-Northwestern European 
background. While, increment in sample size will in principle boost the power of the study, 
differences in allele frequency or LD relationships between the variants merit further inter-
pretation, as shown in the example of skull BMD with equal number of individuals for both 
European and non-European sets. Decrease in power due to the use of an admixed popula-
tion can appear when the association is confined to one of the subpopulations (especially 
if small) either because of differential tagging or due to the effect of secondary signals (30).
GWAS meta-analyses are expanding to include Non-European populations (i.e., Latinos, 
African-Americans, etc) with adequate methodology lagging behind due to scarce avail-
able software for the processing and analysis of multiethnic data. For example, as the most 
used software, PLINK (13), relies on the assumption of homogeneous populations it cannot 
be applied directly to establish family relatedness in multiethnic cohorts. PLINK routine 
results in an overestimation of relatedness between ancestrally similar individuals. Alterna-
tively, REAP (16) employs a routine that considers the presence of more than one ancestral 
population and accounts for it in the calculation of IBD probabilities. Nevertheless, in our 
range of interest for QC purposes -greater than second degree relatives- we found no 
misclassification of the degree of relationship in the samples. Yet, in situations where high 
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sensitivity is required (e.g., for the assessment of distant relatedness and/or fine pedigree 
structure), REAP is recommended in studies with admixed populations.
Choosing the optimal panel to impute the GWAS data of a multiethnic population is criti-
cal. For the Generation R Study, we have employed the so-called “cosmopolitan approach”, 
which has become the preferred approach after the release of the 1000 Genomes Project 
panel (19). Notably, nowadays all studies are being imputed to the whole 1KG reference panel 
regardless of the background of the population. Introducing such a combination of refer-
ence panels, which achieve very large sample sizes of sequencing reference sets, has been 
shown to improve imputation accuracy (31-33). This is mainly beneficial for the imputation of 
rare variants, which have probably arisen recently and are highly population specific.
New denser reference panels for imputation are becoming available achieving a bet-
ter characterization of human genetic variation  (7,19,34). The 1KG project data significantly 
increased the genomic coverage providing more variants suitable to be analyzed in a new 
phase of the GWAS era (19), with already few reports of novel findings (6,35,36), yet to be em-
braced at a larger scale. Despite the higher density of markers in the 1KG, only ~63% of 
the markers achieved good quality as compared to 97% of the HapMap imputed markers. 
Nonetheless, the low imputation performance observed in 1KG markers is a consequence 
of the large amount of low-frequency and rare markers in the panel in low LD with the 
tagging SNPs in the array, which are thus, difficult to impute. When the analysis is limited to 
common variants (MAF>0.05) present in both datasets (n=2,144,906) the imputation qual-
ity was somewhat higher in the 1KG (mean Rsq=0.954, median=0.989, IQR=0.037) than 
the HapMap panel (mean Rsq=0.947, median=0.986, IQR=0.046), a slight improvement 
reflecting better imputation arising from a more dense set of markers and a larger reference 
panel. Special methods for imputation of admixed populations such as MACH-Admix, 
have also emerged (37), claiming better performance in admixed population and should be 
part of future studies.
Ethnic background, as assessed by questionnaire did not match the distribution of the sam-
ples in the genomic components, mainly because it does not allow for the identification of 
the third generation participants, i.e., the grand children of those who originally migrated 
to the country, and thus groups together children that are genetically divergent as shown in 
Online Resource 7. This comparison together with analysis of different traits, indicate that 
the genetic structure of studies, such as the Generation R Study, cannot be accounted for 
by considering the ethnic group definitions based on questionnaire data alone. Another 
practical advantage when using genomic components to adjust GWAS, is the possibility to 
include participants even when no information of the parents’ country of origin is available. 
Although in other studies this percentage might be larger, in the population under study, 
less than 7% of the information on ethnicity from the questionnaire was missing. The ethnic 
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distribution of the remaining children is in agreement with the ethnic demography of the 
city of Rotterdam (11) and thus we found no evidence of a systematic non-response.
We chose red hair pigmentation as an example of a highly stratified trait since it is more 
common in countries in the north of Europe and selected against in Africa due to higher 
sensitivity of its carriers to UV rays. As shown in Figure 5, if adjustment for population 
stratification is not used, alleles with different frequencies in Africa and the North of Europe 
would spuriously show an association with the trait. Instead our association results show 
that both genomic components and linear mixed models strategies cope well with the 
substructure of the data and yield similar results. This conclusion can also be derived from 
the skull BMD GWAS, where even magnitude of effect sizes can be reliably compared. 
Thus, across all tested scenarios subtle differences emerged not justifying the use of the 
more computational intensive EMMAX approach. Tests done on other traits such as height, 
fractional exhaled nitric oxide, site-specific BMD (total body, skull, arms and legs) produced 
similar results using EMMAX as those published before using genomic components (21,38,39).
It is important to emphasize possible drawbacks of both association strategies. Those 
of using EMMAX include: 1) for discrete traits obtained betas cannot be translated to odd 
ratios, given the statistical model applied and 2) its requirement for PLINK files, prevents 
the use of allelic dosages for analysis. On the other hand, since genomic components are 
calculated based on the variability of the input data, it is important to generate specific 
sets of components for particular subsets of the data when working with structured popu-
lations. Moreover, while using between two and four genomic components is common 
practice, the number of genomic components needed to control for population stratifica-
tion is trait-specific (i.e., dependent on the actual genetic architecture of the trait) (40). The 
GIF is an indicator of the degree of inflation of the test statistic due to true signals, cryptic 
relatedness, assay bias and/or population stratification. Hence, assessment of the GIF is 
instrumental to determine the needed number of genomic components to be used as 
covariates in the models. This strategy is not confined to admixed populations and should 
be assessed even in homogenous populations. In the examples mentioned above, both 
height and BMD needed up to ten genomic components (data not shown) to reach an 
acceptable GIF<1.1 (18).
Although the general problem of stratification, differential ethnic allele frequencies, has 
been successfully addressed in our cohort by the use of genomic components or linear 
mixed models, the ethnic differences in patterns of correlation between the underlying 
casual variant and the surrounding SNPs which are under study (LD), can still induce to 
false-negative findings (41).
As single-center GWAS are usually underpowered, the standard strategy in the field is 
meta-analysis, the combination of results from multiple independent studies, increasing 
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sample size and reducing false-positive findings. Frequently, pooling studies from ethni-
cally diverse populations within a single transethnic meta-analysis can be challenging. 
To cope with this, specialized software such as MANTRA, which allows effect size to vary 
across different populations, has been developed (42). The same strategy could also be ap-
plied to multiethnic studies such as Generation R, if clear boundaries between different 
ethnic groups forming part of the study population could be established. However, this is 
not plausible in our highly admixed population.
The complex structure of the Generation R Study, where admixture of individuals cannot 
be easily discerned just by assessing the combination of two ancestral populations, con-
strains the application of admixture mapping, which is an important limitation of our study. 
Further, in the current setting of the Generation R Study, the small sample size resulting from 
defining well characterized ethnic groups (of non-European background) is insufficient to 
allow fine mapping of variants underlying complex traits, typically withholding weak ge-
netic effects. Yet, with new approaches being developed (39), this analytical methodology 
should be further implemented.
The Generation R Study is unusual in the international arena due to its size, age range, 
quality of data and longitudinal study design, but particularly due to its multiethnic nature. 
These characteristics represent the main strengths of the cohort, allowing among others, the 
generalizability of findings and ethnic comparisons in epidemiological research, although 
complex routines might be required for genetic association analysis.
In summary, we have described the methods used for generating the GWAS data of the 
Generation R Study, as well as general strategies for imputation and analysis within a mul-
tiethnic setting. Such strategies have allowed the Generation R Study to take part in several 
consortia and collaborations, which have successfully identified genetic factors underlying 
an ample range of complex traits.
Detailed acknowledgements and online resources can be found in the published article 
online: http://link.springer.com/article/10.1007%2Fs10654-015-9998
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ABStrACt
Genotype imputation has been the pillar of the success of genome-wide association stud-
ies (GWAS) for identifying common variants associated with common diseases. However, 
most GWAS have been run using only 60 HapMap samples as reference for imputation, 
meaning less frequent and rare variants not being comprehensively scrutinized. Next-
generation arrays ensuring sufficient coverage together with new reference panels, as 
the 1000 Genomes panel, are emerging to facilitate imputation of low frequent single-
nucleotide polymorphisms (minor allele frequency (MAF) <5%). In this study, we present a 
two-step imputation approach improving the quality of the 1000 Genomes imputation by 
genotyping only a subset of samples to create a local reference population on a dense array 
with many low-frequency markers. In this approach, the study sample, genotyped with a 
first generation array, is imputed first to the local reference sample genotyped on a dense 
array and hereafter to the 1000 Genomes reference panel. We show that mean imputation 
quality, measured by the r2 using this approach, increases by 28% for variants with a MAF 
between 1 and 5% as compared with direct imputation to 1000 Genomes reference. Simi-
larly, the concordance rate between calls of imputed and true genotypes was found to be 
significantly higher for heterozygotes (P<1x10-15) and rare homozygote calls (P<x10-15) in this 
low frequency range. The two-step approach in our setting improves imputation quality 
compared with traditional direct imputation noteworthy in the low-frequency spectrum 
and is a cost-effective strategy in large epidemiological studies.
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introDuCtion
The genome-wide association studies (GWAS) approach has been useful in identifying 
thousands of single-nucleotide polymorphisms (SNPs) associated with hundreds of com-
plex traits and human diseases (1- 3). This has been made possible by the increase in power 
achieved by the meta-analysis of different studies where imputation of missing genotypes 
is essential to harmonize and share data (4, 5, 6). Low-frequency variants have not been scru-
tinized by most GWAS based on HapMap content  (7). Using newer reference panels for 
imputation will allow this (e.g., the 1000 Genomes project based on resequenced data 
sets) with more variants with lower frequencies for the association analysis with traits  (8) 
hereby increasing resolution and improving power (9, 10) within the so-called next-generation 
GWAS. Newer arrays have been designed including marker content in the low-frequency 
spectrum(11) These arrays are expensive (at the time of writing this paper, the approximate 
price for 5 M array was around 600$ per sample) and it is not clear so far if worth the invest-
ment in already GWAS’ed populations.
Here, we propose a two-step imputation approach seeking the optimization of imputations 
of low-frequency variants when using arrays based on HapMap content. This approach 
consists of first genotyping a local reference population with an array with dense marker 
content and a high coverage of markers in the low-frequency spectrum. Second, the whole 
study population on arrays with HapMap content is imputed to the array content of the 
local reference set, before imputing to the 1000 Genomes reference panel. This strategy 
results in improved imputation accuracy and quality in what constitutes a cost-effective 
strategy for genotyping very large populations.
MAteriAlS AnD MetHoDS
Design
This study was nested within the Rotterdam study, a prospective study of 14,926 partici-
pants over 45 years of age living in a suburb of Rotterdam. The study has been approved by 
the institutional review board (Medical Ethics Committee) of the Erasmus Medical Center 
and by the review board of The Netherlands Ministry of Health, Welfare and Sports. Over 
11000 samples have been genotyped either with Illumina (San Diego, CA, USA) HumanHap 
microarray beadchips 550 or 610 K (12).
Strategy overview
A subset of individuals from the Rotterdam study was chosen as the study sample for this 
project. This subset consisted of trios genotyped on two different platforms: the Illumnia 
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Figure 1. Study Diagram Flow. Panel A illustrates the baseline comparison of the local reference sample 
genotyped on both the 550K and Omni5 arrays imputed to the 1000 Genomes reference panel. Panel B il-
lustrates imputation of the study sample applying the two step approach and comparison to traditional one 
step imputation approach.
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Figure 2: two step imputation approach. Uppercase characters represent genotyped SNPs while lowercase 
characters represent imputed SNPs. Panel A illustrates the first step: imputation of the study sample using the 
local reference panel. Panel B illustrates the second imputation step: imputing the output best-guess imput-
ed genotypes from step 1 by using the 1000 Genome reference panel. The final output data set is illustrated in 
panel C. Illustration adapted from Li et al (6).
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550 K and the Omni2.5 (N=88). Another subset of individuals, consisting of women without 
major disease conditions during follow-up (N=397), was genotyped on the Illumnia Omni5 
array and used as the local reference panel as described below. These individuals were also 
genotyped using the Illumina 550 K array. For baseline comparison of the Omni5 and 550 K 
arrays, these two data sets were imputed to 1000 Genomes (1000 G) in a traditional direct 
one-step approach (Online Resource Figure S1).
For the two-step approach, we first used our local reference panel and imputed our study 
sample using the 550 K data, while the Omni2.5 data for the same individuals were used as 
gold standard for later accuracy analyses. After this first imputation, the best-guess imputed 
genotypes were hereafter used as input for imputation using the 1000 G reference panel 
(Version 3, 2010-11-23, European panel) (Figures 1 and 2). For comparison, we also directly 
imputed our study sample to 1000 G in a traditional direct one-step approach.
imputation software
We employed the MACH/Minimac software (13) using a pre-phasing step before the actual 
imputation as described at the Minimac website (http://genome.sph.umich.edu/wiki/
Minimac) adjusted with an extra intermediate imputation step as described above. The 
local reference sample was phased with MACH and hereafter used as a reference panel.
Samples QC
We used regular QC procedures before imputation steps as described in Online Resource 
Table S1, including removal of markers out of Hardy–Weinberg Equlibrium (P<1.0x10-6) with 
very low MAF (<0.001) and low SNP call rate (<0.98). We further removed individuals from 
the study sample related to individuals in the local reference population based on IBD 
estimation (proportion IBD >0.2). The study sample consisted of 88 samples genotyped 
on both Illumina 550 K and Omni2.5. The concordance rate between these two arrays was 
higher than 99.9%. The local reference sample consisted of 397 individuals genotyped on 
the Omni5 platform.
imputation quality assessment
The r2 statistic from Minimac was used as a quality measure with r2>0.3 considered as suf-
ficient imputation quality  (4) and high imputation quality defined as r2>0.8. After the first 
imputation step in the two-step strategy, SNPs were removed using three different filters for 
comparison: (1) no filter; (2) sufficient quality (r2 filter on 0.3) and (3) high quality (r2 filter on 
0.8). Accuracy was defined as the proportion of correct imputed genotypes over the total 
number of imputed genotypes and estimated by comparing the imputed best-guess data 
to the gold standard data (Omni2.5) using Calcmatch (http://genome.sph.umich.edu/
wiki/CalcMatch). This analysis was stratified per genotype class as the allelic concordance 
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rate for homozygotes major allele (major–major), heterozygotes (major–minor) and for 
homozygotes minor allele (minor–minor). Mendelian errors were calculated per study 
sample family in PLINK (14). Only imputed markers (i.e., those markers not genotyped in the 
550 K array) were taken into account while assessing and comparing the imputation quality. 
To evaluate the influence of number of individuals included in the local reference sample 
and its impact on imputation quality, we randomly selected two subsets of individuals with 
100 and 200 individuals, respectively and compared these with the full local reference 
using all 397 samples.
The performance of our approach using different imputation parameters was assessed by 
analyzing chromosomes 2 and 20. Information on samples genotyped across different plat-
forms and allele frequencies is presented in Table 1. After the evaluation of imputation pa-
rameters, we imputed all autosomal chromosomes using the two-step approach (r2 filter on 
first step 0.3) as well as using the direct approach. We then compared number of SNPs with 
sufficient imputation quality in the low-frequency spectrum by both approaches. Annota-
tion was done using publicly available data (ftp://share.sph.umich.edu/1000genomes/
fullProject/2010.11.23/20101123.annotation.v2.tgz).
When comparing quality between the two-step and the direct imputation strategy in 
means of r2 or concordance rates, we applied paired t-tests.
table 1. Description of number of markers and samples per array used in this study
local reference sample Study Sample
Array Omni5 550K Omni2.5
Samples 397 88
SNPs, CHR2+20 309320 51050 157924
SNPs, MAF >0-1% 61815 413 7738
SNPs, MAF 1-5% 83588 3130 25912
SNPs, MAF 5-10% 33718 5681 20814
SNPs, Overlap* - 119965
For the study sample the 550K data was used for imputation. *Overlap: refers to the common SNPs between 
550K imputed data and Omni2.5 genotypes used in gold standard analysis
reSultS
imputation Quality (as measured by r2 statistic)
Description of number of markers per array is presented in Table 1. We compared the effect 
of the array’s coverage in imputation quality by direct imputation of the local reference 
sample (N=397) using both the Omni5 and the 550 K array data (Online Resource Figure 
S1). This plot revealed improvement in imputation quality measured by r2 using the Omni5 
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array as compared with the 550 K with a mean r2=0.91 for the Omni5 and r2=0.71 for 550 K 
data in the minor allele frequency range between 1 and 5%.
To assess the effect of the two-step approach, we compared the imputation quality, 
as measured by the mean r2 across all imputed SNPs (chromosome 2 and 20), over the 
whole-allele frequency spectrum (Figure 3). First, our results indicate a gain in mean r2 
while using the two-step approach compared with the direct imputation, especially in the 
low-frequency ranges. Second, evaluating the results when applying different imputation 
quality (r2) cutoffs on the first imputation showed that using no filter and using a filter on 
r2>0.3 increased the quality as compared with applying the stricter filter on r2>0.8.
The comparison of the statistical differences in r2 values revealed highly significant im-
provement in imputation quality for the two-step approach using paired t-test (all P<1x10-15) 
(Table 2). In the 1–5% MAF range, the two-step approach using a r2 filter on 0.3 (mean 
r2=0.87) had a 28% higher mean r2 compared with the direct imputation (mean r2=0.68). For 
0.0 0.1 0.2 0.3 0.4 0.5
0.0
0.2
0.4
0.6
0.8
1.0
IMPUTATION RSQUARED
MAF
R
sq
ua
re
d
DIRECT
TWO STEP, no filter
TWO STEP, RSQ 0.3
TWO STEP, RSQ 0.8
0.0
0.2
0.4
0.6
0.8
1.0
MAF
R
sq
ua
re
d
10−3 10−2 10−1
Figure 3. imputation quality metric (r2). Imputation r2 per MAF for the two different imputation strategies, 
chromosome 2 and 20 for the study sample. The two step strategy further stratified by first imputation step 
filter. A grey horizontal dashed line at r2= 0.8 is included to indicate high imputation quality. Lines were cre-
ated by meaning r2 per 100 SNPs and applying local polynomial regression fitting (loess function in R-project).
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this analysis, filtering out SNPs genotyped in the local reference panel resulted in a slightly 
lower r2 increase between approaches on 21%.
Once we set a fixed threshold of r2>0.3 (sufficient quality) to remove badly imputed markers 
in the first imputation step, we imputed all autosomal chromosomes using both the two-
step and direct imputation approaches. This analysis revealed 2,528,598 SNPs (intergenic: 
78.49%, intronic: 20.47%, exonic: 1.04%) with MAF 1–5% and r2 above 0.3 using the two-
step approach (r2>0.3 on first step) compared with 2,147,168 (intergenic: 78.42%, intronic: 
20.58%, exonic: 1.00%) when imputing directly to the 1000 G. This represents an increment 
of 18% in the number of low-frequency SNPs using the two-step approach (synonymous: 
21.10%, non-synonymous: 25.89% and UTR 20.39% more variants). The r2 distribution of the 
extra imputed SNPs for the two-step approach in this low-frequency spectrum was highly 
right-skewed toward an r2 of 1 depicted in the supplement (Online Resource Figure S2).
Accuracy
Overall accuracy estimates are presented in Online Resource Table S2. The accuracy is also 
presented per genotype class in Table 3 and in Online Resource Figure S3 shows higher ac-
curacy for the heterozygotes and rare homozygotes when using the two-step approach in 
low frequencies (MAF<10%). Again, using a filter for the first step on r2>0.3 performed best. 
The mean accuracy was statistically significantly higher in the lower MAF (1–5% and 5–10%) 
bins when using the two-step approach (first-step filter r2>0.3) compared with the direct 
imputation. Comparing the accuracy of the heterozygotes-imputed genotypes from the 
two-step approach using the r2 filter on 0.3 with the approach without filter also revealed a 
significant difference (P<1x10-15) and better accuracy of applying a filter on 0.3.
Mendelian consistency
There were no differences between direct and two-step imputation in the number of Men-
delian errors per family in the imputed SNPs (Online Resource Table S3).
table 2. Quality comparison traditional one step and proposed two step approaches
MAF tWo SteP* DireCt
n r2, mean (SD) n r2, mean (SD)
>0-1%** 684334 0.16 (0.28) 839141 0.10 (0.20)
1-5%** 309759 0.87 (0.23) 303608 0.68 (0.31)
5-10%** 144718 0.94 (0.17) 143065 0.85 (0.24)
10-50%** 538142 0.97 (0.11) 539322 0.92 (0.17)
*First imputation filter on r2 <0.3
** Comparing two step and direct imputation in each MAF bin revealed p-values < 10-15
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evaluating the size of the local reference panel
Accuracy estimates are presented in Figure 4, and Online Resources Figures S4 and S5 
for different sizes of the local reference panel. As expected, the larger the local reference 
panel, the better the quality of the imputation. In the low-frequency spectrum with MAF 
from 1 to 5%, accuracy measures (two step, r2>0.3 at first step) dropped in the heterozygotes 
when lowering the number from all 397 samples (accuracy=0.915) to 200 (accuracy=0.901) 
and 100 (accuracy=0.879) individuals in the local reference panel. Similar drops were seen 
in the rare homozygotes in the same MAF bin from all 397 samples (accuracy=0.895) to 200 
(accuracy=0.868) and 100 (accuracy=0.838) individuals used in the local reference panel.
DiSCuSSion
Principal findings
In this study, we have compared the traditional direct one-step imputation procedure with 
a proposed two-step imputation approach to improve the quality of the imputed data 
obtained after the use of dense reference panels, as the ones emerging nowadays. Our 
most important finding was that the two-step approach increases both the quality and the 
accuracy of imputation, even increasing the number of high-quality markers in 18% for the 
lower frequency spectrum (MAF 1–5%) as compared with the traditional direct imputation 
table 3. Accuracy comparison traditional one step and proposed two step approaches
MAF n
tWo SteP*
Accuracy,
mean (SD)
DireCt
Accuracy, mean 
(SD)
P-value**
Common homozygotes (Major-Major)
>0-1% 25087 0.998 (0.005) 0.999 (0.004) -
1-5% 25087 0.998 (0.006) 0.998 (0.006) -
5-10% 18613 0.996 (0.009) 0.996 (0.01) -
Heterozygotes (Minor-Major)
>0-1% 25087 0.830 (0.237) 0.806 (0.244) 3.4e-6
1-5% 25071 0.915 (0.145) 0.886 (0.172) < 1e-15
5-10% 18613 0.955 (0.083) 0.942 (0.106) < 1e-15
Rare homozygotes (Minor-Minor)
>0-1% 0 - - -
1-5% 1248 0.895 (0.241) 0.826 (0.294) < 1e-15
5-10% 6746 0.925 (0.204) 0.888 (0.245) < 1e-15
*First imputation filter on r2>0.3
** Comparing groups, heterozygotes and rare homozygotes in each MAF bin
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approach. Accuracy improvement was primarily seen for the low-frequency variants and 
only in the heterozygotes and rare homozygotes genotype classes.
limitations and strengths
We evaluated the two-step imputation approach by means of different measures of quality, 
specifically r2 and imputation accuracy. Comparison to a gold standard data (in our case: 88 
samples genotyped with two different arrays) must be seen as one of the primary strengths 
of this study, enabling the evaluation of the approaches in low-frequency markers. None-
theless, one limitation is the relative low number of samples in our study sample.
To evaluate the gain of power and improvement in means of novel findings in the GWAS 
setting, a future effort should focus on applying the two-step approach to entire data sets, 
as earlier applied when analyzing the difference between HapMap and 1000 G imputa-
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Figure 4. imputation Accuracy for different local reference sizes. Imputation accuracy stratified per geno-
type for the different sizes of the local reference panel. This is presented using a first step r2 filter on 0.3.
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tion(9). This comparison would surely require large sample sizes and the combination of 
several studies before an assessment of its value at meta-analysis level can be done.
Further estimation of minimum marker content of the input for the study sample would 
also be necessary to evaluate and analyze by testing if this two-step approach would sur-
pass the quality of direct imputation in studies that are already genotyped in arrays with 
lower content than the 550 K array.
Meaning of the study
We found that the proposed two-step imputation approach excels the imputation quality 
(r2) and accuracy (concordance) as compared with the direct imputation to 1000 G. One 
of the main reasons for this could be that we used a dense array with many low-frequency 
markers at the intermediate imputation step. As these low-frequency markers can create 
population-specific haplotypes (8), we would expect that the markers imputed in our study 
sample using the local reference panel provide more precise haplotypes of both common 
and rare variants over which imputation to a more comprehensive panel such as the 1000 
G can be improved. The main reasoning to this improvement being that a local reference 
panel must be closer to the study sample in means of ancestry and that the overall number 
of haplotypes for some markers are doubled (794 haplotypes in the local reference panel in 
step 1 + 758 from the 1000 G panel in step 2). However, we did not apply the two-step ap-
proach imputing other European populations and using this Dutch local reference panel. 
The reasoning on closeness in ancestry between the study sample and local reference 
panel is therefore speculations.
It is possible that the increasing quality of future panels of the 1000 G (or other sequencing 
projects used as reference) may decrease the boost provided by our proposed two-step 
approach and thus be as efficient or even surpass the accuracy reached by the two-step 
approach suggested in this manuscript. Nevertheless, the rationale behind our approach is 
that by first imputing from a local reference panel can result in more accurate imputation 
of variants in the lower minor allele frequency spectrum, independent of the quality of the 
reference panel.
The size of the local reference panel influenced the imputation quality of the two-step 
approach. Nonetheless, for heterozygous genotypes of variants in the MAF 1–5% range, 
the increase in quality seems to level-off with increasing sample size, as observed from 
doubling the local reference panel from 100 to 200 samples. This increment showed a 
bigger leap in imputation quality, than the one after doubling the number from 200 to 397 
samples (Online Resource Figure S5). Probably, further increment in the local reference 
panel size (beyond the 397 samples) could still add to the imputation accuracy but in a less 
pronounced manner. Moreover, the current imputation quality metrics are within reason-
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able values expected across studies, raising the question if adding more samples will be a 
cost-efficient approach.
One other study by Sampson et al. (15) has assessed a two-platform approach, genotyping a sub-
set of samples on a denser array (Omni2.5). These samples were combined with the 1000 G 
reference set before imputation. Increasing the number of samples to combine with the 1000 
G improved r2 (15). However, by using standard imputation tools, the combination of reference 
panels is only implemented in IMPUTE2,5 software not used in the current study. We were 
therefore not able to compare the two-step approach to a direct one-step approach with the 
combined use of the 1000 G reference panel and our local reference panel. Nonetheless, in a 
recent study we showed that combining 1000 G with a Dutch sequenced panel (GoNL) only 
increased imputation r2 by 1.4% compared with the GoNL alone, for low-frequency markers 
imputing a Dutch GWA data set(16) . Thus, we would not expect that combining our local refer-
ence panel with the 1000 G panel would surpass the increase showed in our previous study.
Our study highlights a possible cost-effective strategy for large studies undertaking genome-
wide genotyping or a possible upgrade of existing genotyped data sets. We expect that 
in large studies (with thousands of individuals), a substantial reduction in costs would be 
achieved by genotyping only a subset of the samples on these relatively expensive arrays 
with many low-frequency markers (e.g., Omni5) and subsequently use these samples as 
a local reference set in a two-step imputation approach. This extra load will represent an 
increase in imputation quality and hence, the uncertainty of imputation calls will decrease, 
yielding more precise dosages what will be reflected in the power to detect associations 
in future GWAS on complex diseases. Nonetheless, discovering low-frequency variants 
associated with complex traits in GWAS does not depend only on imputation quality, but 
also on sufficiently powered settings (large sample sizes). Thus, the proposed two-step ap-
proach needs to be applied by all participating studies of a GWAS meta-analysis in order to 
observe an increase in the power needed to detect rare variants.
ConCluSion
Imputation is a useful approach to improve both coverage and power in genetic associa-
tion studies. The two-step approach in our setting increased imputation quality compared 
with direct imputation especially in the low-frequency spectrum. Further, this imputation 
methodology is a cost-effective strategy for improving imputation quality in large samples.
Detailed acknowledgements and online resources can be found in the published article 
online: http://www.nature.com/ejhg/journal/v23/n3/full/ejhg201491a.html
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ABStrACt
introduction: The etiology of Behçet’s disease (BD) is unknown, but widely considered an 
excessive T-cell mediated inflammatory response in a genetically susceptible host. Recent 
genome-wide association studies (GWAS) have shown limited number of novel loci-asso-
ciations. The rarity and unequal distribution of the disease prevalence amongst different 
ethnic backgrounds have hampered the use of GWAS in cohorts of mixed ethnicity and 
sufficient sample size. However, novel statistical approaches have now enabled GWAS in 
admixed cohorts. Methods: We ran a GWAS on 336 BD cases and 5,843 controls. The cases 
consisted of Western Europeans, Middle Eastern and Turkish individuals. Participants from 
the Generation R study, a multiethnic birth cohort in Rotterdam, The Netherlands were 
used as controls. All samples were genotyped and data was combined. Linear regression 
models were corrected for population stratification using Genomic Principal Components 
and Linear Mixed Modelling. Meta-analysis was performed on selected results previously 
published. results: We identified SNPs associated at genome-wide significant level map-
ping to the 6p21.33 (HLA) region. In addition to this known signal two potential novel asso-
ciations on chromosomes 6 and 18 were identified, yet with low minor allele frequencies. 
Extended meta-analysis revealed a GWS association with the IL12A variant rs17810546 on 
chromosome 3. Discussion: We demonstrate that new statistical techniques enable GWAS 
analyses in a limited sized cohort of mixed ethnicity. After implementation, we confirmed 
the central role of the HLA region in the disease and identified new regions of interest. 
Moreover, we validated the association of a variant in the IL2A gene by meta-analysis with 
previous work. These findings enhance our knowledge of genetic associations and BD, and 
provide further justification for pursuing collective initiatives in genetic studies given the 
low prevalence of this and other rare diseases.
67
Genome-wide association study in an admixed case series reveals IL12A as a new candidate
introDuCtion
Behçet’s disease (BD) is a systemic auto-inflammatory occlusive vasculitis presenting with 
oral and genital aphthous ulcers, skin lesions, ocular inflammation and a pathognomonic 
pathergy test (1-3). Although the etiology of the disease is largely unknown, it is considered 
to be an excessive inflammatory response possibly triggered by an infectious antigen in a 
genetically susceptible host. Prevalence varies from 110–420 per 100,000 in the Middle 
East (Turkey) to about 2 per 100,000 in Western countries (3, 4). In patients of Turkish origin 
there is a positive family history in 12% of the cases with a sibling risk ratio between 11–52 (3, 4). 
The heritability of BD has been estimated to range between 20 to 60%, with the strongest 
genetic association embracing variants in HLA-B51, explaining about 20% of the disease 
heritability  (3,4). The combination of epidemiological and genetic data suggest causal in-
volvement of both genetic and environmental factors (5).
Over the years, numerous single nucleotide polymorphisms (SNPs) have been found associ-
ated with BD (6-9). In 2010 the first genome-wide association study (GWAS) in BD cohorts of 
Turkish and Japanese origin demonstrated association of various variants in the known HLA-
B51 domain, and two new association signals, mapping to the interleukin-10 (IL10), and the IL-
23 receptor–IL-12 receptor Beta2 (IL23R–IL12RB2) locus (10,11). These associations later have been 
confirmed in an Iranian cohort (12). Yet another study in Algerian individuals only replicated 
the associations from the IL10 variants (13). GWAS in Chinese and Korean individuals reported 
associations of SNPs mapping to two other loci, with regions containing the signal transducer 
and activator of transcription 4 (STAT4) and GTPase of immune associated protein GIMAP 
genes, respectively. Polymorphisms in IL10 and IL23R–IL12RB2 were not found to be signifi-
cantly associated with BD in neither of those studies  (14,15). More recently, associations with 
CCR1, STAT4 and KLRC4 were identified by means of imputation and GWAS meta-analysis(14). 
This study also identified the IL12A region as suggestively associated with BD, but genome 
wide significance (GWS) was not reached. Discrepant association results, as those observed 
for variants mapping to the GIMAP locus, might be explained by the different ethnic origin 
of the cohorts studied(15,16). Therefore, studying cohorts of diverse ethnic background may be 
useful to understand the origin of these differences. Moreover, the inclusion of multiple eth-
nicities results in larger datasets (representing higher power) crucial for these analyses given 
the typically small effects of common genetic variants discovered by the GWAS approach(17). 
Nonetheless, GWAS results can be confounded by ancestry differences between cases and 
controls, potentially leading to spurious associations. This challenge in multi-ethnic studies 
has so far been approached by methods that take into account confounding by genetic 
ancestry, such as correction for Genomic Principal Components (GPC)  (18). More recently, 
linear mixed models (LMM) have been introduced as a reliable method to correct not only 
for ancestry differences, but also for family structure and/or cryptic relationships (19).
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We have therefore set up a multi-center GWAS including BD patients of both Middle Eastern 
and Western background. We demonstrate that by means of novel statistic approaches it is 
feasible to run a GWAS in a small multiethnic cohort and use these results for meta-analysis.
MAteriAlS AnD MetHoDS
Study populations
A total of 369 unrelated BD patients from 18 different geographic origins were included in 
our study (Table 1). The age range was 18 to 73 years (mean 47 years). All patients fulfilled 
the International Study Group (ISG) criteria of BD diagnoses (20). No exclusion criteria were 
applied.
table 1. Cases before and after QC. Collection at [1] Erasmus MC at Rotterdam, The Netherlands, [2] Univer-
sity Hospital of Cukurova, Turkey, [3] St John’s Ophthalmic Hospital, Jerusalem, Israel, [4] St Thomas’ Hospital, 
London, UK, [5] University Hospital, Damascus, Syria, Ethnicity of cases after QC.
ethnicity number of patients Collection number of patients after QC
Afghanistan 1 [1] 1
Iranian 4 [1] 4
Lebanese 1 [1] 1
Cape Verde 2 [1] 2
Curacao 1 [1] 1
Dominican Republic 1 [1] 1
Dutch caucasian 24 [1] 20
Greece 1 [1] 1
Israel 1 [1] 1
Jordan 1 [1] 1
Morocco 16 [1] 12
Surinam 2 [1] 1
Thailand 1 [1] 1
China 1 [1] 1
Turkey 35 [1] 32
Turkey 91 [2] 87
Arab Jerusalem ancestry 110 [3] 98
UK caucasian 38 [4] 33
Syrian 38 [5] 38
total 369 336
69
Genome-wide association study in an admixed case series reveals IL12A as a new candidate
As controls, 87 Syrian healthy volunteers (22-73 years, mean 51 years) and 5,756 participants 
from the Generation R study, a multi-ethnic birth cohort in Rotterdam (4-9 years, mean 6 
years), The Netherlands, were used (21). Replication was pursued in a cohort of 82 BD pa-
tients who met the ISG criteria, and 98 ethnically matched controls in Western European, 
collected from Birmingham and Midland Eye Centre, Birmingham, UK. The ethics commit-
tees of the involved centers (Erasmus MC (METC), Ethical Committe at Çukurova University 
and Sandwell and West Birmingham Hospitals Trust Ethics Committee) approved the study, 
and written informed consent was obtained from all participants.
Genome wide genotyping
Genotyping of cases and controls (including the Generation R Study) was performed using 
the Illumina HumanHap 610K and/or 660 K arrays, following manufacturers protocols. 
Quality Control (QC) was performed individually for each set following a standard protocol 
to exclude samples and SNPs with low quality genotyping. Markers with minor allele fre-
quency (MAF) ≤ 1%, missing genotypes ≥5% or which failed an exact test of Hardy-Weinberg 
equilibrium proportions in the controls (P<1x10-7) were excluded from the datasets. Samples 
with gender discrepancy, excess of heterozygosity, duplicates or samples with relatedness 
or other inconsistencies were also removed. In a subsequent stage, we extracted SNPs 
common to both platforms which passed individual QC and then applied the QC protocol 
for the combined dataset.
Phenotype-Genotype Analyses
Heritability
To characterize the extent to which common genetic variants play a role in BD suscep-
tibility, we applied a recently proposed approach for estimating heritability based on 
genome-wide sharing between distantly related individuals, as implemented in the GCTA 
software in combination with the determination of ancestry-aware kinship coefficients by 
REAP software (22, 23). No pairs exceeded the standard cutoff coefficient of 0.025 for genetic 
relatedness, confirming that no two individuals in the analysis were closer than third degree 
cousins. Relatedness coefficients calculated from REAP were used in the relatedness matrix 
before implementing GCTA. A disease prevalence of 0.42% was used in the modelling. (3, 4)
Genome-wide association analysis
Association between BD susceptibility and 553,224 genome-wide SNPs was carried out 
using a regression framework adjusting for population stratification. GWS threshold for the 
association was established at p<5x10-8. Two different strategies were followed to adjust for 
population sub-structure in the data.
Chapter 2.3
70
Genomic Principal Components
In the first approach, 20 GPC were obtained for all pairs of individuals in the combined 
dataset based on the similarities of individual genotypic profiles for 37,060 independent 
autosomal SNPs contained in the HapMap Phase II release 22 build 36  (24) using Multi-
Dimensional Scaling (MDS) as implemented in PLINK (http://pngu.mgh.harvard.edu/
purcell/plink/). Afterwards, we performed logistic regression adjusting for those 20 GPC.
Linear Mixed models
In the second approach we used LMM in order to account for possible population structure 
in the association analysis. This methodology estimates the level of relatedness even be-
tween independent individuals using the genotyped markers. By modeling the dissimilarity 
between genotypes of the subjects, it is able to correct the association results for stratifica-
tion. This approach is implemented in the publicly available EMMA eXpedited (EMMAX) 
software(25). Since the effect sizes reported by EMMAX are based on Mantel–Haenszel 
statistics, the odd ratios for associations of the significant SNPs were estimated from the 
regular logistic regression models performed in PLINK.
Meta-analysis
Meta-analysis of our own study results with published results for the BD suggestive associ-
ated SNP rs17810546 (14) was performed using an inverse variance fixed-effects approach in 
METAL(26).
Replication analysis
Four SNPs: rs8187722, rs439033, rs11969661 and rs17087141 were genotyped using TaqMan 
assays designed by Applied Biosystems, Warrington, UK in 82 BD patients and 98 control 
samples. In short, PCR was performed in 384-well plates with a 10 µl total reaction volume 
containing 20 pg/ml DNA (samples) or water (controls) and 2x LC-480 probe master 
(Roche, West Sussex UK) followed by endpoint genotyping analysis using the LC-480 
system (Roche, West Sussex UK). Genotypes were determined as either homozygous (e.g., 
AA or GG) or heterozygous (e.g., AG) according to the presence or absence of fluorescence 
for each genotype.
reSultS
An overview of the ethnicity of the included BD cases is presented in Table 1; all controls 
were collected in St John’s Ophthalmic Hospital, Jerusalem and had Arab ancestry. In order 
to gain power and match all remaining ethnicities, this dataset was combined with the 
genotyped samples from the multiethnic Generation R Study.
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Genome wide Genotyping
Genotyping was performed in 456 samples (369 cases and 87 controls) collected from the 
different participating hospitals (Erasmus MC at Rotterdam, The Netherlands, University 
Hospital of Cukurova, Turkey, St John’s Ophthalmic Hospital, Jerusalem, Israel and by St 
Thomas’ Hospital, London, UK). After quality control, 553,224 genotyped SNPs in 423 of 
these samples remained. We excluded 33 patients (including 1 control) because of low 
Illumina call rate (< 97.5%) and one more individual was excluded for gender mismatch. 
After QC of this combined dataset, 336 cases and 5,843 controls were available for analysis.
Genomic Principal Components
The representation of the fi rst GPC for the combined dataset projected together with the 
three reference panels of the International HapMap Project Phase II known as YRI, CEU 
and CHB/JPT representing populations of African, European and Asian background re-
spectively (27) is shown in Figure 1. As shown by the overlapping distribution across the four 
fi rst GPC, BD cases (represented in black) are well matched by genetic ancestry to controls 
(represented in yellow Syrian volunteers and grey for Generation R participants).
Figure 1. Genetic substructure of the Combined GWAS dataset. Two-dimensional scatterplots from multi-
dimensional scaling analyses of the Generation R Study and Behçet collected data together with the three 
initial Panels form the HapMap Project. Each dot represents an individual in the dataset. Color codes: 
Grey=Generation R, Black= Behcet Cases, Yellow = Jordan controls. Blue= CEU, Red=YRB, Green= CBH/JPT.
Phenotype Genotype Analyses
Heritability
The heritability estimate, based on the 505,454 genotyped SNPs and 4,855 unrelated indi-
viduals (296 cases) was 32.0% (95%CI 21.0-44.0%;P= 5.5x10-17). Thus a considerable percent 
of the BD risk is explained by the additive effect of the common SNPs analyzed.
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Figure 2. Behçet GWAS results using Genomic Principal Components (GPC) adjustment. each dot repre-
sents an SnP in the dataset. A. QQ-plot. Associated SNPs deviating from the null hypothesis of no association 
(identity line). B. Manhattan plot. SNPs showing association with the disease map to chromosome 6 and a 
singleton in chromosome 18.
table 2. GWS SnPs associated with Behçet’s disease susceptibility using GPC and eMMAX approaches. 
Results for the association analysis when correcting for 20 PCs to adjust for stratifi cation. In italic font the SNPs 
which show association only by one of the two approaches
CHr SnP BP A1 A2 MAF n 20PCs eMMAX*
Por P
6 rs9380215 31157634 A G 0.09 6178 2.132 1.32E-10 3.15E-15
6 rs4947296 31166157 C T 0.09 6178 2.131 1.38E-10 4.98E-15
6 rs9263509 31174398 T C 0.16 6179 1.82 6.62E-09 2.69E-10
6 rs2233984 31187243 A G 0.09 6179 2.064 3.35E-10 1.08E-15
6 rs4495304 31188697 C T 0.09 6028 2.069 7.92E-10 3.84E-14
6 rs4959053 31207556 A G 0.09 6175 2.348 1.20E-12 3.90E-17
6 rs2523589 31435313 C A 0.43 6177 0.5466 2.92E-09 5.83E-08
6 rs2844575 31442924 G A 0.48 6173 1.81 5.62E-10 5.92E-08
6 rs9266409 31444547 C T 0.25 6178 2.183 3.66E-16 2.62E-18
6 rs2253907 31444849 A G 0.48 6175 1.797 4.41E-10 1.46E-09
6 rs7770216 31448590 T G 0.26 6072 2.198 9.75E-17 2.25E-18
6 rs6933050 31451611 C T 0.25 6178 2.183 3.69E-16 2.59E-18
6 rs1131896 31487094 A G 0.31 6141 1.647 6.86E-08 2.66E-09
6 rs2256028 31487177 T G 0.21 6177 1.784 1.72E-09 7.49E-12
6 rs2848713 31492458 A G 0.1 6173 2.118 3.03E-12 7.08E-22
6 rs11969661 160626409 T C 0.02 6179 2.696 1.30E-03 5.15E-09
6 rs439033 160739406 C T 0.02 6163 2.016 2.30E-03 1.14E-08
6 rs8187722 160784748 G A 0.01 6179 1.696 1.00E-04 2.87E-15
18 rs17087141 69036707 C T 0.03 6167 4.925 1.08E-13 2.81E-18
* Odd ratios cannot be calculated by EMMAX approach
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Genome wide association analyses
Association analyses were performed for 505,454 SNPs. As expected in such structured 
population, results from analysis without any type of stratifi cation adjustment, showed 
association through the whole genome and a Genomic Infl ation Factor (λ) of 5.25 (Online 
Resource Figure S1). After GPC correction, the association analysis showed minimal infl a-
tion of the test statistics with a λ of 1.035 (Figure 2). The top associated SNPs mapped to 
the HLA region on chromosome 6 with rs7770216 being the most signifi cant (Table 2). Yet, 
another GWS signal in chromosome 18 driven by rs17087141 mapped to a region containing 
the uncharacterized miscRNA LOC400655.
Additional association analyses using different strategies including reduction of number 
of matching controls (to different case/control ratios) and incorporating different number 
of genomic principal components in the models yielded similar results for effect coeffi -
cients and genomic infl ation factors (data not shown).
Results from the GWAS analysis using EMMAX yielded three independent GWS signals (Table 
2). In addition to those mapping to the two previously described BD loci from chromosomes 
6 and 18, an additional signal was found on chromosome 6q25.3 6 in the solute carrier fam-
ily 22 member 3 (SLC22A3) gene region. The three most signifi cant markers underlying this 
GWAS signal included rs11969661, rs439033 and rs8187722 (Table 2). Using EMMAX resulted 
in adequate adjustment for population stratifi cation as corroborated by λ=1.0 (Table 2) and 
the absence of early deviation from the identity line in the QQplot (Figure 3).
The most signifi cant SNP identifi ed by the EMMAX approach maps also to the HLA 
region in chromosome 6. The regional association plot of this HLA-B region is shown in 
Online Resource Figure S2. This HLA-B region has been associated with BD susceptibility 
in previous GWAS analyses  (10,22). Figures 4 and 5 show the association plots for the other 
A B
Figure 3. Behcet GWAS results using linear Mixed Models Genomic approach. Each dot represents an SNP 
in the dataset. a. QQ-plot. Associated SNPs deviating from the null hypothesis of no association (identity line). 
b. Manhattan plot. SNPs showing association with the disease map to two different signals in chromosome 6 
and a singleton in chromosome 18.
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two GWS signals in 6q25.3 (SCLA22A3 locus) and 18q22.3, which have not been previously 
reported as associated with BD.
Meta-analysis
By scanning published BD GWAS, we identifi ed a variant suggestive of association 
(P=6.01x10-7)  (14), showing strong evidence for association with BD in our study, although 
not at GWS level. After meta-analysis of our results with those published by Kirino et al. (14) 
in two Turkish cohorts the leading SNP (rs17810546) in IL12A reached GWS. The G-allele 
conferred a 1.7 increased risk for BD (OR= 1.66; 95%CI [1.42,1.93]; P= 1.12x10-10 (Table 3)).
Figure 4. SnP association plot for Behçet’s susceptibility-associated region of chromosome 6q25.3. Dots 
represent GWAS P-values (EMMAX approach) and positions of SNPs found within the 6q25.3 locus. The top 
SNP, i.e., rs8187722, is denoted by a diamond. Different colors indicate varying degrees of pair-wise linkage 
disequilibrium (1000 Genomes Nov 2010 CEU) between the top SNP and all other genotyped SNPs. Genetic 
coordinates are per 1000 Genomes Nov 2010-CEU. Bottom: LD heat map based on D’ values from the com-
bined population under study including all SNPs in the 500Kb region.
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table 3. Meta-analysis of leading SnP in il12A. Association results for rs17810456 (G-allele) in two Turkish 
cohorts (14) and the current study.
Study n n cases or Ci 95% P value
Turkish replication* 2487 1209 1.64 [1.31 - 2.04] 1.20E-05
Turkish discovery* 1447 821 1.41 [1.06 - 1.89] 2.00E-02
Current study 6179 336 2.06 [1.49 - 2.84] 9.31E-06
Combined 10113 2366 1.66 [1.42 - 1.93] 1.12E-10
* From Table 1 Kirino et al. 2013
Figure 5. SnP association plot for Behçet’s susceptibility-associated region of Chromosome 18q22.3. Dots 
represent GWAS P-values (EMMAX approach) and positions of SNPs found within the 18q22.3 locus. The top 
SNP, i.e., rs17087141, is denoted by a diamond. Different colors indicate varying degrees of pair-wise linkage 
disequilibrium (1000 Genomes CEU) between the top SNP and all other genotyped SNPs. Genetic coordi-
nates are per 1000 Genomes Nov 2010-CEU. Bottom: LD heat map based on D’ values from the combined 
population under study including all SNPs in the 500Kb region.
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Replication Analysis
No significant evidence for replication of the leading SNPs from the GWAS signals of chro-
mosome 6 and 18 was found, while the MAF of the genotyped markers were very similar to 
those reported in healthy individuals.
DiSCuSSion
Enabled by innovative novel methodology we could run a GWAS in a rare condition like 
BD within a unique case collection of multiethnic background. We identified variants as-
sociated with BD mapping to the well-established MICA-HLA-B locus and to two regions on 
chromosome 6 in the SLC22A gene region and on chromosome 18 in an uncharacterized 
region. Moreover, meta-analysis with previous published results enabled the identification 
of a GWS association with variants in the IL12A region. All together, these common variants 
across these four loci explained up to 32% of the variance in BD risk.
Methods for the calculation of heritability estimates from SNP microarray data of popula-
tion-base studies have recently emerged (22,23). We could determine that the narrow sense 
heritability of BD explained by common variants in our study was 32%, estimate in line 
with those obtained by previous reports based on family data  (3,4,28), albeit smaller. This 
could be explained by the overestimation of heritability estimates in family-based design, 
as a result of biases due to epistatic interactions or shared environment. In addition, GCTA 
estimates should be interpreted as the lower bound of the true additive genomic influence 
on heritability, since the genetic variance is limited to the common SNPs present in the 
arrays (29). Therefore variance explained by rarer variants (MAF<0.01) and/or causal variants 
that were not genotyped or are not tagged by the SNPs on the genotyping array will be 
missed. As GCTA is intended for studies on homogeneous populations it is necessary to use 
appropriate methods to calculate the relatedness matrix in studies with admixed individu-
als to avoid overestimation of the heritability. Therefore, to obtain unbiased estimates we 
used REAP for the estimation of the kinship coefficient (30).
Methods based on LMM enabled the analysis of GWAS data in a cohort of mixed ethnicity 
of relative small sample size, maximizing power. The fact that our GWAS identified well-
established variants in the HLA-B locus, provides certainty that the methodological ap-
proach was sound and in fact applicable to other rare diseases. Expanding the current case 
collection or performing meta-analysis with other collections is warranted. Efforts including 
datasets of different ancestries, should be analyzed with methodologies which take into 
account different genomic architecture based on ethnic background. Such methods can 
also be applied at the meta-analysis level as implemented in MANTRA (31).
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In addition to the signal in the well-known HLA locus on chromosome 6, we also identi-
fied two genomic regions of interest. Nevertheless, all variants had relatively low MAF 
(2-3%) and thus their significance should be interpreted with caution. We could not find 
evidence for replication of the associations in an independent yet underpowered case/
control set. Considering the low MAF and the very limited power of the replication further 
scrutiny in an expanded dataset is required to confirm these variants as real or spurious 
associations.
Yet another GWS association with rs17810546 in the IL12A locus was identified by 
meta-analyses of our results with those reported previously in the literature. These results 
support the role of this locus in the susceptibility of BD. Kirino et al., described this locus as 
suggestive for association with BD. In that study the variants did not were reach GWS in the 
combined analysis likely due to the variant being monomorphic in the samples of Japanese 
origin included in the study. Variants in CCR1-CCR3, STAT4 and KLRC4 which were polymor-
phic in both Turkish and Japanese populations surpassed GWS thresholds, suggesting that 
the lower power likely contributed to the non-significant findings in the IL12A locus.
BD is a rare disease, even in countries with the highest prevalence. Collecting the patient 
material for large multi-ethnic genetic studies proved to be challenging. Not surprisingly, 
the first two GWAS studies reported in BD were in two separate cohorts with a single eth-
nicity, a Turkish and a Japanese cohort (10,11). After meta-analyses of the data of both studies, 
polymorphisms in IL10 and IL23R–IL12RB2 proved to be associated at GWS level. In our 
study, these two polymorphisms were not associated with BD, nor in two other recent 
studies in Chinese and Korean individuals (32,33). Moreover, the GIMAP variants presented 
in the Chinese and a Korean cohort were not identified in the other studies. Recently, 
Ortiz-Fernandez et al., reported no association of GIMAP variants in a Spanish study but 
also acknowledged lack of power as a likely cause for this negative results (16). Considering 
that most of our cases are of admixed ethnicity differences in ethnic background, specific 
pathology or clinical features of the cases are a more plausible explanation for the lack of 
replication of those variants in our study on top of limited power (32, 33).
In conclusion we have shown that appropriate methodological approaches enable per-
forming GWAS in cohorts of admixed ethnicity, combining cases of different ethnic origin 
as is often required in rare conditions like BD. As such, previously reported SNPs in the 
MICA-HLA-B locus reached GWS in the current approach. Additionally, we have shown 
that results of a mixed cohort can successfully be used in meta-analysis, by which we could 
establish the involvement of previously putative variant in the IL12A locus in the susceptibil-
ity of the disease.
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Our results emphasize the need of collaborative efforts intending to enlarge the collection 
of BD cases, which can enable a well-powered setting for detection of genetic associations 
with the disease, especially when interrogating low-frequency variants. Potentially novel 
loci need to be further explored in additional studies, and ultimately coupled with func-
tional studies, allowing a better understanding of the pathophysiology and the genetic 
architecture underlying the risk for BD.
Detailed acknowledgements and online resources can be found in the published article 
online: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119085
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ABStrACt
Background: Maternal diet during pregnancy has been suggested to influence bone health 
in later life. Objective: We assessed the association of maternal first-trimester dietary intake 
during pregnancy with childhood bone mass. Design: In a prospective cohort study in 
2,819 mothers and their children, we measured first-trimester daily energy, protein, fat, 
carbohydrate, calcium, phosphorus, and magnesium intakes by using a food-frequency 
questionnaire and homocysteine, folate, and vitamin B-12 concentrations in venous blood. 
We measured childhood total body bone mass by using dual-energy X-ray absorptiometry 
at the median age of 6 years. results: Higher first-trimester maternal protein, calcium, and 
phosphorus intakes and vitamin B-12 concentrations were associated with higher childhood 
bone mass, whereas carbohydrate intake and homocysteine concentrations were associat-
ed with lower childhood bone mass (all P-trend, 0.01). Maternal fat, magnesium intake, and 
folate concentrations were not associated with childhood bone mass. In the fully adjusted 
regression model that included all dietary factors significantly associated with childhood 
bone mass, maternal phosphorus intake and homocysteine concentrations most strongly 
predicted childhood bone mineral content (BMC) [β = 2.8 (95% CI: 1.1, 4.5) and β = 21.8 (95% 
CI: 23.6, 0.1) g per SD increase, respectively], whereas maternal protein intake and vitamin 
B-12 concentrations most strongly predicted BMC adjusted for bone area [β = 2.1 (95% CI: 
0.7, 3.5) and β = 1.8 (95% CI: 0.4, 3.2) g per SD increase, respectively]. Conclusion: Maternal 
first-trimester dietary factors are associated with childhood bone mass, suggesting that fetal 
nutritional exposures may permanently influence bone development.
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introDuCtion
Osteoporosis represents a major public health problem (1–3). Previous studies have shown 
the relevance of early life factors for the development of bone health and osteoporosis dur-
ing the life course (4). The maternal diet during pregnancy, which is the main determinant 
of fetal nutrition, has been suggested to influence childhood bone mass  (5–9). In mother-
offspring cohorts in Tasmania, India, and the United Kingdom, maternal milk, magnesium, 
calcium, and folate intakes during pregnancy were positively associated with bone mass in 
their offspring (5–8), whereas fat intake showed an inverse association (8).
Although these finding may reflect an effect of shared genetic or environmental deter-
minants, they support the hypothesis of bone-health programming via direct or indirect 
effects of nutrient availability in early life. It is unknown which mechanisms may underlie 
such a programming effect. Nutrients such as calcium and phosphorus, which are the main 
bone-forming minerals, may enhance fetal bone accrual in a direct manner (10). In addition, 
indirect effects of nutrient availability may act through changes in the growth hormone/
insulin-like growth factor I axis or alterations in glucocorticoid concentrations, such as 
cortisol  (11,12). Two other candidate hormonal mediators of bone-diet interactions are the 
adipokine leptin and osteocalcin (13, 14). In addition, epigenetic changes that are a result of 
altered DNA methylation or histone modification have been suggested to be key players in 
this programming process and should also be considered (15).
Maternal folate intake and blood concentrations were positively associated with child-
hood bone mass in 2 studies that focused on this nutrient (5,7). Folate and other B vitamins 
(riboflavin, vitamin B-6, and vitamin B-12) are involved in the homocysteine metabolism (16) 
and may reduce adverse effects of hyperhomocysteinemia, which is a strong risk factor 
for osteoporotic fractures in older adults  (17). Alternatively, by acting as methyl donors, a 
beneficial effect of high maternal folate and B-vitamin concentrations on childhood bone 
mass may support the hypothesis of epigenetic changes that program later bone health. 
Because homocysteine and B-vitamin concentrations are potentially modifiable, we inves-
tigated the influence of maternal dietary factors on the bone health of their children with 
particular focus on the homocysteine metabolism. We assessed associations of maternal 
first-trimester dietary nutrient intake and homocysteine, folate, and vitamin B-12 concen-
trations with childhood bone mass in a population-based prospective cohort study that 
included 2,819 Dutch mothers and 6-y-old children.
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MAteriAlS AnD MetHoDS
Study population
This study was embedded in the Generation R Study, which is a population-based prospec-
tive cohort study from fetal life onwards in Rotterdam, Netherlands  (18). All mothers who 
were resident in the study area at their delivery dates and had a delivery date from April 
2,002 until January 2,006 were eligible. We aimed for enrollment in fi rst trimester, but 
we allowed enrollment until the delivery of the child. In total, 75% of all mothers enrolled 
before a gestational age of 18 wk. Of all eligible children in the study area, 61% of children 
participated at birth in the study. We conducted the study according to the guidelines of 
the Helsinki Declaration, and it was approved by the Medical Ethics Committee of the Eras-
mus Medical Center, Rotterdam (MEC 198.782/2001/31). We obtained written informed 
consent from all participants. We restricted the study population to 4,097 mothers of 
Dutch ethnicity because the food-frequency questionnaire (FFQ) was validated for the as-
sessment of dietary intake in a Dutch population (19). We defi ned the ethnicity of the mother 
according to the classifi cation of Statistics Netherlands (20,21). Of these Dutch mothers, 4,016 
mothers enrolled in the fi rst or second trimester of pregnancy. We measured dietary intake 
Figure 1. Flowchart of participants included for analysis in the Generation r Study, rotterdam, nether-
lands. DXA, dual-energy X-ray absorptiometry; FFQ, food-frequency questionnaire; IUFD, intrauterine fetal 
death.
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and/or homocysteine, folate, or vitamin B-12 concentrations in 3,859 of these mothers. 
Their pregnancies resulted in 3,780 singleton live births. Of these births, 2,901 children par-
ticipated in the 6-y visit, and we performed dual-energy X-ray absorptiometry (DXA) scans 
in 2,819 children (69%). Because the exclusion of mothers with a second (n = 241) or third 
(n = 2) pregnancy in the study did not change our results, we included these pregnancies in 
the analyses (Figure 1).
Maternal dietary intake
We assessed maternal dietary intake at enrollment in the study (median: 13.5 wk of ges-
tation, IQR: 3.3 wk) by using a modified version of the validated semiquantitative FFQ of 
Klipstein-Grobusch et al (19). We validated this modified version of the FFQ against 3-d 24-h 
recalls in 82 Dutch pregnant women visiting their midwives in Rotterdam, Netherlands. We 
considered the FFQ valid for studying macronutrient and micronutrient intakes in Dutch 
pregnant women because the intraclass correlation coefficients for the (energy-adjusted) 
nutrients were 0.65 for protein, 0.54 for fat, 0.54 for carbohydrate, 0.75 for calcium, and 
0.78 for phosphorus intakes, whereas for total energy intake, it was only 0.33. The FFQ 
considered food intake over the previous 3 mo, which mostly covered dietary intake within 
the first trimester of pregnancy. The FFQ consisted of 293 items structured according to 
the meal pattern. Questions included consumption frequency, portion size, preparation 
method, and additions. We estimated portion sizes by using Dutch household measures 
and photographs of foods that showed different portion sizes (22). To calculate average daily 
nutritional values, we used the Dutch Food-Composition Table 2006  (23). In the current 
study, we analyzed intakes of macronutrients and intakes of calcium, phosphorus, and 
magnesium following results of earlier studies (5–8).
Maternal homocysteine, folate, and vitamin B-12 concentrations
Venous blood samples were drawn at enrollment in early pregnancy (median: 12.9 wk 
of gestation; IQR: 2.3 wk) and stored at room temperature for a maximum of 3 h. Blood 
samples were transported to a dedicated laboratory facility of the regional laboratory in 
Rotterdam, Netherlands (Star-Medisch Diagnostisch Centrum) for additional processing 
and storage at −80°C (24). To analyze homocysteine, folate, and vitamin B-12 concentra-
tion, we picked and transported the serum (vitamin B-12) and plasma (homocysteine and 
folate) samples to the Department of Clinical Chemistry at the Erasmus University Medical 
Centre, Rotterdam in 2008. After thawing, we analyzed homocysteine, folate, and vitamin 
B-12 concentrations by using an immunoelectrochemoluminence assay on the Architect 
System (Abbott Diagnostics BV). Between-run CVs for plasma measurements were as fol-
lows 3.1% at 7.2 µmol/L, 3.1% at 12.9 µmol/L, and 2.1% at 26.1 µmol/L with an analytic range 
of 1–50 µmol/L for homocysteine; 8.9% at 5.6 nmol/L, 2.5% at 16.6 nmol/L, and 1.5% at 33.6 
nmol/L with an analytic range of 1.8–45.3 nmol/L for plasma folate; and 3.6% at 142 pmol/L, 
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7.5% at 308 pmol/L, and 3.1% at 633 pmol/L with an analytic range of 44–1,476 pmol/L for 
serum vitamin B-12.
Bone mass measurements
We measured the total body bone mineral density (BMD), bone mineral content (BMC), 
and bone area by using a dual-energy X-ray absorptiometry (DXA) scan (iDXA; General 
Electrics–Lunar) at the median age of 6.0 y (IQR: 0.37 y). Well-trained research assistants 
obtained DXA scans by using the same device and software (enCORE, version 13; GE 
Healthcare) following standard manufacturer protocols. We performed daily quality assur-
ance by using a spine phantom. In 2,011, the longitudinal CV for BMD was 0.23. Before the 
scan procedure, we asked participants to take off their shoes, heavy clothes, and metal 
accessories. We measured weight to the nearest 0.2 kg by using an electronic personal 
scale (Seca) and height to the nearest 0.1 cm by using a Harpenden stadiometer (Holtain 
Ltd). Thereafter, we placed participants in a supine position on the scan and instructed 
them to hold their hands flat with the palms down on the scanner table and arms alongside 
the body. To ensure that the lines between adjacent subregions of the body were placed 
correctly, scans were evaluated twice, directly after the scanning procedure and at a later 
time point by a second well-trained research assistant.
In our analyses, we used areal total-body-less-head BMD and BMC as recommended by 
the International Society for Clinical Densitometry (25). Bone-size effects should be consid-
ered in studies focused on BMC and areal BMD measured during periods of growth  (26). 
In subjects with large bones, areal BMD alone can overestimate the volumetric BMD. In 
studies focused on BMD, Prentice et al (27) suggested to use BMC corrected for bone area, 
weight, and height to correctly adjust for size effects. Therefore, in a sensitivity analysis, 
we further adjusted BMC models for bone area because weight and height were already 
included.
Covariates
We registered maternal age and measured height and weight without shoes and heavy 
clothing at enrollment. We also collected information about weight just before pregnancy, 
maternal education, marital status, parity, ethnicity, and ethnicity of the grandparents and 
father by using a questionnaire at enrollment in the study. Because the enrollment in our 
study was during pregnancy, we were not able to measure maternal weight before preg-
nancy. However, the correlation of pre-pregnancy weight obtained by questionnaire and 
weight measured at enrollment was high (ρ = 0.97, P < 0.01). Maternal smoking and alcohol 
habits were assessed by questionnaires in each trimester. We obtained information about 
offspring sex, gestational age, and birth weight from medical records and hospital registries 
and about breastfeeding from questionnaires at 2, 6, and 12 mo after delivery (28). We as-
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sessed the child’s diet around the age of 14 mo by using a modified version of a validated 
semi-quantitative FFQ  (29) that consisted of 211 food items. This FFQ has been validated 
against 3-d 24-h recalls in Dutch children aged 14 mo and showed the following intraclass 
correlation coefficients: 0.7 for total protein; 0.4 for total fat; 0.4 for carbohydrate, and 0.5 
for calcium intakes. Because this FFQ was implemented in a later stage in the study, it was 
only available in a subgroup of the population (59%).We obtained information about the 
frequency of participation in sports from a questionnaire at 6 y of age.
Statistical analysis
We used t-tests and chi-square tests to compare differences in subject characteristics 
between boys and girls. We categorized dietary nutrient intake (fat, protein, carbohydrate, 
calcium, phosphorus, and magnesium) and blood concentrations (homocysteine, folate, 
and vitamin B-12) into quintiles and used the lowest category as the reference category in all 
models. We performed multiple linear regression analyses to assess associations of dietary 
factors with childhood bone measures at the age of 6 y. We performed tests for trends by 
using dietary intakes and blood concentrations as continuous variables in the models. We 
log- and square root–transformed blood concentrations that were not normally distributed 
and lacked goodness of fit. On the basis of previous studies, we adjusted models for mater-
nal age, weight, height, parity, educational level, marital status, alcohol use, and smoking 
and sex, birth weight, ethnicity, breastfeeding, participation in sports, and age and height 
at the time of the measurement of the child (5–8). We adjusted for weight at the time of the 
measurement by adding lean mass plus fat mass to the model, which thereby excluded the 
contribution of bone mass to the child’s weight. Because maternal total energy intake and 
macronutrient intakes were strongly correlated (Online Resource Table S1), we used the 
energy-partition method to adjust for total energy intake in the macronutrient analyses (30). 
In the micronutrient analysis, we used the residual nutrient method. We entered dietary 
factors shown to be associated with childhood bone mass at a P < 0.10 significance level in a 
backward-selection regression model to identify the major dietary factors of bone mineral 
accrual in childhood (P < 0.10). We assessed potential multicollinearity between nutrients 
by exploring the change in effect estimates and calculating the variance inflation factor (31). 
We performed a sensitivity analysis to assess whether associations of maternal nutrient in-
take with childhood bone mass could be explained by the later diet of the child rather than 
maternal diet. We added available information on protein, fat, carbohydrate, or calcium in-
take of the child at 14 mo to each corresponding model. We did not add the nutrient intake 
of the child to our final models because data were missing in 41% of the study population 
because nutrient intake of the child was only assessed in a subgroup (18). In another sensitiv-
ity analysis, we further adjusted models that concerned BMC for the total-body bone area 
to assure the correct size adjustment (27). To prevent bias associated with missing data, we 
used multiple imputations (5 imputations) for covariates with missing values on the basis 
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of the correlation of missing variables with other participant characteristics, according 
to the Markov Chain Monte Carlo method (32). In addition, we added variables related to 
covariates as predictors to the imputation model to increase the plausibility of the missing-
at-random assumption. The amount of missing values ranged from 1% to 14%, except for 
breastfeeding duration (26%). We report the pooled results of the analyses performed in 
each of the 5 imputed datasets. P values (P) were 2-sided. We performed analyses with the 
Predictive Analytic Software (version 17.0 for Windows; PASW Inc).
reSultS
Characteristics of study participants
Boys were born with a higher birth weight, were taller, and more often participated fre-
quently in sports at age 6 y than did girls (Table 1). Bone measures did not differ between 
boys and girls. The average maternal nutrient intake and homocysteine, folate, and vitamin 
B-12 concentrations in the first trimester of pregnancy are shown in Table 2. See Online 
Resource Table S2 for characteristics of the imputed study population.
table 1. Characteristics of study participants in the Generation r Study Cohort, rotterdam, netherlands. 
All values are means ± SDs for continuous variables and absolute numbers (percentages) for categorical vari-
ables. P values were obtained by using Student’s t tests for continuous variables and chi-square tests for cat-
egorical variables.
Boys (n = 1409) Girls (n = 1410) P
Maternal characteristics
 Height (cm) 170.9 ± 6.2 170.9 ± 6.6 0.99
 Prepregnancy weight (kg) 68.1 ± 12.5 68.3 ± 12.2 0.59
 BMI (kg/m2) 23.3 ± 4.0 23.4 ± 4.0 0.5
 Age (y) 31.6 ± 4.3 31.5 ± 4.1 0.41
 Parity ≥1
  No 877 (62) 866 (61) 0.25
  Yes 531 (38) 539 (38)
 Missing 1 (0) 5 (0)
 Single motherhood
  No 1279 (92) 1296 (93) 0.56
  Yes 85 (6) 74 (5)
  Missing 45 (3) 40 (3)
 Educational status
  Primary 24 (2) 38 (3) 0.16
  Secondary 495 (35) 519 (37)
  Higher 866 (62) 835 (59)
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table 1. (continued)
Boys (n = 1409) Girls (n = 1410) P
  Missing 24 (2) 18 (1)
 Smoking during pregnancy
  Never 958 (68) 988 (70) 0.1
  Until pregnancy was known 116 (8) 136 (10)
  Continued 207 (15) 184 (13)
  Missing 128 (9) 102 (7)
 Alcohol use during pregnancy
  No 597 (42) 640 (45) 0.07
  Yes 694 (49) 680 (48)
  Missing 118 (8) 90 (6)
Paternal characteristic
 Ethnicity
  Dutch 1115 (79) 1108 (79) 0.9
  Other 266 (19) 271 (19)
  Missing 28 (2) 31 (20)
infant characteristics
 Gestational age at birth (wk) 40.0 ± 1.6 40.0 ± 1.8 0.26
 Birth weight (g) 3564 ± 540 3434 ± 539 <0.001
 Birth length (cm) 50.9 ± 2.4 50.1 ± 2.3 <0.001
 Breastfeeding
  Never 103 (7) 106 (8) 0.8
  ≤3 mo 365 (26) 347 (25)
  >3 mo 583 (41) 587 (42)
 Missing 358 (25) 370 (26)
Child characteristics at 6-y visit
 Age (y) 6.15 ± 0.46 6.14 ± 0.42 0.37
 Height (cm) 119.9 ± 5.7 119.2 ± 5.7 <0.001
 Weight (kg) 23.0 ± 3.4 22.7 ± 3.7 0.05
 BMI (kg/cm2) 15.9 ± 1.4 15.9 ± 1.6 0.91
 Participation in sports
  Never 683 (49) 636 (45) <0.001
  1/wk 445 (32) 613 (44)
  ≥2/wk 183 (13) 52 (4)
 Missing 98 (7) 109 (8)
 Bone mineral density (g/cm2) 0.551 ± 0.046 0.548 ± 0.045 0.12
 Bone mineral content (g) 520 ± 95 519 ± 93 0.78
 Bone area (cm2) 940 ± 111 942 ± 107 0.56
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Maternal dietary intakes and childhood bone mass
Higher maternal protein intake in the first trimester of pregnancy was associated with a 
higher childhood BMC (P-trend = 0.02) and density (P-trend < 0.001). As shown in Table 
3, the difference in BMC between highest and lowest (reference) quintiles of maternal 
protein intake was 7.0 g (95% CI: 0.1, 13.9 g). Maternal carbohydrate intake was inversely 
associated with childhood BMC and density (both P-trend = 0.02). The difference in BMC 
between highest and lowest quintiles was −6.9 g (95% CI: −12.8, −0.9 g). Neither maternal 
total energy intake nor fat intake were associated with the bone mass of the child (P-trend > 
0.05) (data for total energy not shown).
Maternal homocysteine, folate, and vitamin B-12 concentrations and childhood 
bone mass
Higher maternal first-trimester homocysteine concentrations were associated with a lower 
childhood BMC (P-trend = 0.03) and showed a borderline significant association with BMD 
(P-trend = 0.06) (Table 5). The difference in BMC between highest and lowest quintiles was 
−5.2 g (95% CI: −10.4, 0.1 g). Maternal folate concentrations were not associated with child-
hood bone outcomes. Higher maternal vitamin B-12 concentrations were not associated 
with absolute bone mineral accrual but were associated with BMD (P-trend < 0.001), which 
suggested an effect on bone size rather than bone mineral accrual.
The first sensitivity analysis showed that effect estimates did not change when corre-
sponding nutrient intakes of the child at 14 mo were added to each of the models (see 
Online Resource Table S3). Likewise, when we further adjusted BMC models for bone area 
in a second sensitivity analysis, results hardly changed (see Online Resource Table S4).
table 2. Maternal first-trimester dietary intake and blood concentrations in the Generation r Study Co-
hort, rotterdam, netherlands. Dietary intake has been energy adjusted.
Dietary intake n
Values
Mean ± SD
Energy (kcal/d) 2580 2152 ± 5042
Fat (g/d) 2580 73.6 ± 10.7
Protein (g/d) 2580 78.5 ± 11.7
Carbohydrate (g/d) 2580 236 ± 30
Calcium (mg/d) 2580 1108 ± 311
Phosphorus (mg/d) 2580 1443 ± 241
Magnesium (mg/d) 2580 339 ± 56
Median; iQr
Blood concentrations
Homocysteine (µmol/L) 2260 7.0 (13.3)
Folate (nmol/L) 2282 19.5 (1.9)
Vitamin B-12 (pmol/L) 2173 175 (100)
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To identify the major dietary factors that influencing bone mineral accrual in childhood and 
take into account the effect of other dietary factors, we entered all dietary factors associated 
with childhood bone mass at the P < 0.10 significance level in a backward-selection regres-
sion model. When simultaneously analyzed, maternal phosphorus intake was the only 
dietary factor significantly associated with childhood BMC (P-trend = 0.002), whereas ma-
ternal homocysteine concentrations showed a borderline significant association (P-trend = 
0.058) (Table 6). Maternal protein intake (P-trend = 0.003) and vitamin B-12 concentrations 
(P-trend = 0.01) showed the strongest association with childhood BMD. The other mater-
nal dietary factors did not add significantly to the explained variation. Multicollinearity 
table 3. Associations of maternal first-trimester daily macronutrient intake with childhood bone mass in 
the Generation r Study Cohort, rotterdam, netherlands. Values are based on multiple linear regression 
models and reflect the difference (95% CI) for each quintile of daily macronutrient intake compared with the 
lowest reference quintile. Models were adjusted for maternal age, weight, height, parity, educational level, 
marital status, alcohol use, and smoking; paternal ethnicity; and sex, birth weight, birth length, breastfeeding, 
participation in sports, and age, weight measured as lean mass plus fat mass, and height at measurement of 
the child and mutually for other macronutrients following the energy-partition method (30). *P < 0.05, **P < 
0.01, ***P < 0.001.
Macronutrient intake (kcal/d) n
Bone mineral content
g
ß (95% Ci)
Bone mineral density
mg/cm2
ß (95% Ci)
Energy from proteins
Quintile 1 516 Reference Reference
Quintile 2 516 6.4 (1.3, 11.4)* 6.1 (2.0, 10.2)**
Quintile 3 516 6.3 (0.9, 11.7)* 8.8 (4.4, 13.2)***
Quintile 4 516 10.1 (4.0, 16.1)** 11.4 (6.5, 16.3)***
Quintile 5 516 7.0 (0.1, 13.9)* 11.9 (6.3, 17.5)***
P-trend — 0.02 <0.001
Energy from fat
Quintile 1 516 Reference Reference
Quintile 2 516 −0.1 (−5.1, 4.9) −2.9 (−7.0, 1.1)
Quintile 3 516 −0.1 (−5.5, 5.3) 0.0 (−4.4, 4.3)
Quintile 4 516 −1.3 (−7.1, 4.5) −3.7 (−8.3, 1.0)
Quintile 5 516 0.9 (−5.7, 7.5) −3.8 (−9.1, 1.5)
P-trend — 0.46 0.31
Energy from carbohydrate
Quintile 1 516 Reference Reference
Quintile 2 516 −2.6 (−7.6, 2.3) −1.8 (−5.8, 2.2)
Quintile 3 516 -5.4 (-10.6, −0.2)* −3.7 (−7.9, 0.5)
Quintile 4 516 −3.9 (−9.5, 1.6) -4.9 (-9.3, −0.5)*
Quintile 5 516 -6.9 (-12.8, −0.9)* −4.6 (−9.4, 0.2)
P-trend — 0.02 0.02
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between maternal protein, phosphorus, and calcium intakes seemed present. Therefore, 
we explored potential collinearity between nutrients in the final model. We observed that 
effect estimates for the associations of protein, phosphorus, and calcium intakes with bone 
outcomes varied largely when mutually adjusted for one another, and the variance inflation 
factors were 4.8, 3.8, and 8.0 for protein, calcium, and phosphorus intakes. These findings 
suggested that collinearity between these nutrients is present.
table 4. Associations of maternal first-trimester daily calcium, phosphorus, and magnesium intakes with 
childhood bone mass, the Generation r Study Cohort, rotterdam, netherlands. Values are based on multi-
ple linear regression models and reflect the difference (95% CI) for each quintile of daily micronutrient intake 
compared with the lowest reference quintile. Models were adjusted for maternal total daily energy intake, 
age, weight, height, parity, educational level, marital status, alcohol use, and smoking; paternal ethnicity; and 
sex, birth weight, birth length, breastfeeding, participation in sports, and age, weight measured as lean mass 
plus fat mass, and height at measurement of the child. *P < 0.05, **P < 0.01, ***P < 0.001.
Micronutrient intake (g/d) n
Bone mineral content g
ß (95% Ci)
Bone mineral density mg/cm2
ß (95% Ci)
Calcium
 Quintile 1 516 Reference Reference
 Quintile 2 516 5.4 (0.6, 10.3)* 4.1 (0.2, 8.0)*
 Quintile 3 516 5.7 (0.8, 10.6)* 5.6 (1.7, 9.6)**
 Quintile 4 516 5.6 (0.7, 10.6)* 4.0 (0.0, 8.0)*
 Quintile 5 516 9.1 (4.1, 14.1)*** 6.4 (2.4, 10.4)**
 P-trend — <0.001 0.005
Phosphorus
 Quintile 1 516 Reference Reference
 Quintile 2 516 8.6 (3.6, 13.5)*** 6.5 (2.5, 10.5)**
 Quintile 3 516 4.3 (−0.7, 9.3) 3.8 (−0.2, 7.8)
 Quintile 4 516 7.0 (2.0, 12.1)** 6.1 (2.0, 10.1)**
 Quintile 5 516 8.6 (3.5, 13.6)*** 7.5 (3.4, 11.5)***
 P-trend — <0.001 <0.001
Magnesium
 Quintile 1 516 Reference Reference
 Quintile 2 516 −0.8 (−5.7, 4.2) −0.1 (−4.0, 3.9)
 Quintile 3 516 −0.4 (−5.4, 4.7) 0.5 (−3.6, 4.5)
 Quintile 4 516 4.4 (−0.7, 9.5) 0.6 (−3.5, 4.7)
 Quintile 5 516 2.3 (−3.0, 7.6) 0.4 (−3.9, 4.6)
 P-trend — 0.23 0.76
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DiSCuSSion
Main Findings
In this large, population-based, prospective cohort study of pregnant women in Nether-
lands, we showed that maternal dietary factors during pregnancy were associated with 
childhood bone mass. Maternal daily intake of proteins, calcium, and phosphorus and con-
centrations of vitamin B-12 were positively associated with childhood bone mass, whereas 
carbohydrates intake and homocysteine concentrations were negatively associated with 
childhood bone mass. Multiple regression analysis, including all dietary factors associated 
with childhood bone mass, showed that maternal phosphorus intake and homocysteine 
table 5. Associations of maternal first-trimester homocysteine, folate, and vitamin B-12 concentrations 
with childhood bone mass in the Generation r Study Cohort, rotterdam, netherlands. Values are based 
on multiple linear regression models and reflect the difference (95% CI) for each quintile of blood concentra-
tion compared with the lowest reference quintile. Models are adjusted for maternal age, weight, height, par-
ity, educational level, marital status, alcohol use, smoking, and gestational age at blood collection; paternal 
ethnicity; and sex, birth weight, birth length, breastfeeding, participation in sports, and age, weight measured 
as lean mass plus fat mass, and height at measurement of the child. *P < 0.05, **P < 0.01, ***P < 0.001.
Micronutrient intake (g/d) n
Bone mineral content g
ß (95% Ci)
Bone mineral density mg/cm2
ß (95% Ci)
Homocysteine
 Quintile 1 485 Reference Reference
 Quintile 2 454 -0.9 (-6.0, 4.2) -3.3 (-7.4, 0.8)
 Quintile 3 441 -3.1 (-8.3, 2.0) -2.1 (-6.3, 2.1)
 Quintile 4 436 -3.8 (-9.0, 1.3) -7.1 (-11.3, -2.9)***
 Quintile 5 444 -5.2 (-10.4, 0.1) -4.7 (-9.0, -0.5)*
 P-trend — 0.03 0.06
Folate
 Quintile 1 457 Reference Reference
 Quintile 2 458 -0.1 (-5.4, 5.1) 0.9 (-3.4, 5.2)
 Quintile 3 456 0.7 (-4.6, 6.1) 0.4 (-3.9, 4.7)
 Quintile 4 456 2.9 (-2.5, 8.4) 0.6 (-3.8, 5.0)
 Quintile 5 455 -0.1 (-5.6, 5.3) 1.1 (-3.3, 5.6)
 P-trend — 0.95 0.52
Vitamin B-12
 Quintile 1 439 Reference Reference
 Quintile 2 430 -1.6 (-6.9, 3.7) -0.7 (-5.0, 3.6)
 Quintile 3 442 1.8 (-3.5, 7.1) 2.3 (-1.9, 6.6)
 Quintile 4 434 -1.4 (-6.7, 3.9) 3.6 (-0.7, 7.9)
 Quintile 5 428 2.5 (-2.9, 7.8) 8.9 (4.6, 13.3)***
 P-trend — 0.39 <0.001
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concentrations most-strongly affected absolute bone mineral accrual, whereas maternal 
protein intake and vitamin B-12 concentrations were the strongest predictors of bone mass 
adjusted for bone size in childhood.
interpretation of main results
Maternal phosphorus intake showed the strongest association with childhood bone mass 
when simultaneously analyzed with other significant dietary factors. However, results from 
the simultaneous analysis must be carefully interpreted because collinearity between some 
nutrients was present. Although multicollinearity did not affect the validity of the model as 
a whole, it complicated the estimation of the individual contribution of predictors in the 
model. Maternal protein, calcium, and phosphorus intake were highly correlated (Online 
Resource Table S1), which likely reflected their shared dietary sources  (33). As a result, we 
were unable to indicate which of the independent nutrients may be most essential for 
childhood bone health.
Accordingly, in previous studies regarding the association of maternal dietary intakes 
with offspring bone health, discrepant associations have been described; in the study of 
Jones et al  (6) in 330 Tasmanian mothers and their 8-y old children, maternal phosphorus 
intake most-strongly predicted childhood bone mass, whereas in the study of Ganpule et 
al (5) in 797 Indian mothers and their 6-y old children, the intake of calcium-rich foods most-
strongly predicted childhood bone mass. From animal studies, phosphorus and calcium 
are known to be codependent for bone health (34). Likewise, both may be essential to fetal 
bone mineral accrual.
table 6. Associations of simultaneously analyzed dietary factors with childhood bone mass in the Gen-
eration r Study Cohort, rotterdam, netherlands. Values are based on multiple linear regression models by 
using backward selection and reflect the difference (95% CI) for each SD increase in daily nutrient intake or 
ln-transformed blood concentration.
Dietary factors
Bone mineral content (g)
(n=2,029)*
Bone mineral density (mg/cm2) 
(n=1945)**
ß (95% Ci) P-trend ß (95% Ci) P-trend
Protein (SD) - - 2.6 (1.2, 4.0) <0.001
Carbohydrate (SD) - - - -
Phosphorus (SD) 2.8 (1.1, 4.5) 0.002 - -
Homocysteine – SD -1.8 (-3.6, 0.1) 0.058 - -
Vitamin B12 – SD - - 2.3 (0.8, 3.7) 0.002
*Model was adjusted for covariates that remained in the model as follows: maternal parity, marital status, and 
gestational age at blood collection; and sex, birth weight, breastfeeding duration, participation in sports, and 
age, weight measured as lean mass plus fat mass, and height at measurement of the child.’
**Model was adjusted for covariates that remained in the model as follows: maternal smoking; birth weight, 
birth length, participation in sports, and age, weight measured as lean mass plus fat mass, and height at mea-
surement of the child.
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In a British study in 4,451 mothers and their 9-y-old children, maternal protein intake 
showed a positive association with childhood bone mass, which attenuated after a simulta-
neous analysis with mineral and vitamin intakes (7). In the studies of Jones et al (6) at 8-y-old 
and Yin et al (8) in the same population at the age of 16 y, of all macronutrients, maternal fat 
intake was the strongest negative predictor of childhood bone mass. In our study, maternal 
fat intake did not show an association. However, because intakes of macronutrients are 
highly correlated (Online Resource Table S1), it may be that, instead of a higher or lower 
intake of one specific macronutrient, a certain balance between intakes of macronutrients 
is the most optimal for childhood bone development. The existence of an optimal balance 
needs to be further studied.
Maternal homocysteine concentrations showed a negative association with childhood 
BMC, whereas vitamin B-12 concentrations showed a positive association with BMD. Ho-
mocysteine and vitamin B-12 concentrations did not show an association in the previous 
dian study (5). The population differed from our study population in size, and moreover, it 
was reported that 60% of the mothers had low vitamin B-12 concentrations (<150 pmol/L) 
compared with 26% in our population. Furthermore, the children in this study had very low 
weight and were short and thin according to NHANES references (35).
Potential Mechanism
Diet during pregnancy has been shown to be associated with epigenetic changes alter-
ing postnatal transcriptional activity of genes that affect childhood body composition (36) 
and possibly bone mass  (11, 12). Protein restriction in pregnant rats has been associated 
with reduced methylation of the glucocorticoid receptor promoter  (37), and increased 
expression of this receptor could sensitize osteoblasts to cortisol and thereby reduce 
offspring bone mass (12). Recently, in umbilical cord tissue, the methylation of the eNOS 
gene, which is the key to osteocyte, osteoblast, and osteoclast function, was shown to 
be associated with childhood bone mass (38). Additional studies are needed to confirm a 
direct link between maternal diet, epigenetic changes, and offspring bone development. 
Alternatively, higher intakes of protein, which is a component of the organic bone matrix, 
and calcium and phosphorus, which are the main bone-forming minerals, may lead to 
increased fetal bone mineral accrual through direct effects (10,39). In adults, higher protein 
intake has been shown to increase concentrations of insulin-like growth factor I, which is 
an osteotrophic factor, as well as intestinal calcium uptake (40, 41). Vitamin B-12 and folate 
may play a crucial role in fetal bone health by providing methyl donors for DNA methyla-
tion according to the mechanisms suggested above, or it may exert a direct effect by act-
ing as a cofactor for osteoblast function (42,43) or for the metabolism of homocysteine (44,45). 
Elevated homocysteine concentrations have been shown to be a strong risk factor for 
osteoporotic fractures in adulthood  (17,46). The deleterious effect of homocysteine may 
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involve the disturbance of the bone matrix or a shift of bone metabolism toward bone 
resorption (47).
Methodological Considerations
Strengths of this study lie in the setting and design. We measured maternal dietary intakes 
and concentrations combined with childhood bone mass in a large population. In addition, 
we collected detailed information on many potential confounding variables. However, as 
in any observational study, residual confounding as a result of unmeasured sociodemo-
graphic and lifestyle factors should still be considered, especially because a healthy diet is 
likely to be associated with a health-conscious lifestyle.
In total, 88% of all eligible mothers fully completed the FFQ, and 79% of mothers partici-
pated in the blood sample collection. The bone mass in children of mothers who did not 
have complete data on dietary factors was not different from the bone mass in children 
of mothers who had. However, missing information may have led to a loss of power. In 
mothers whose children did not have DXA data available, intakes of protein, calcium, 
phosphorus, and magnesium and concentrations of folate and vitamin B-12 were lower, 
whereas homocysteine concentrations were higher (P < 0.05). Our results would be biased 
if effect estimates differed between those included and not included in the analyses. This 
bias seems unlikely because a loss to follow-up in a cohort study is unlikely to be related to 
the research question (48) but cannot be excluded.
Although the FFQ yielded valid estimates of nutrient intakes when validated against 3-d 
24-h recalls, measurement error may still have occurred. Because measurement error in 
nutrient intake is probably random, it might have led to an underestimation of associations. 
The sensitivity analysis did not suggest that the infant diet explained the associations of the 
maternal diet with childhood bone mass. Nevertheless, we could not fully exclude that 
the diet of the child in later life, which may be more strongly related to the maternal diet 
and bone mass in childhood, has influenced the results. Last, as discussed above, collin-
earity between protein, calcium, and phosphorus intakes complicated the interpretation 
of specific effects of individual nutrients. As a result, we were unable to disentangle the 
independent contributions of these nutrients to childhood bone health.
In conclusion, in a Dutch population-based cohort, we observed that the maternal diet 
during pregnancy is associated with bone mineral accrual in childhood. In addition to the 
previously identified role of maternal phosphorus and calcium intakes, this study indicates 
a role for maternal protein intake as well as homocysteine and vitamin B-12 blood concen-
trations in childhood bone development. Additional studies are needed to further explore 
the components of the most-optimal nutrition favoring bone development and to explore 
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whether nutrition during pregnancy may be a potential target for improving bone health 
during the life course.
Detailed acknowledgements and online resources can be found in the published article 
online: http://ajcn.nutrition.org/content/98/1/224.long
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ABStrACt
Low birth weight is associated with lower bone accrual in children and peak bone mass in 
adults. We assessed how different patterns of longitudinal fetal and early childhood growth 
influence bone properties at school age. In 5431 children participating in a population-
based prospective cohort study, we measured fetal growth by ultrasound at 20 and 30 
weeks gestation, and childhood growth at birth, 1, 2, 3, and 4 years of age. We analyzed 
these growth measurements in relation to total body (less head) BMD measured by DXA 
at age 6. We used conditional growth modeling; a technique which takes into account 
correlation between repeatedly measured growth measures. Our results showed that 
estimated fetal weight gain, femur length growth between 20 and 30 weeks of gestation, 
femur length growth between 30 weeks and birth, as well as all height and weight growth 
measurements from birth to 4 years of age were all positively associated with BMC, bone 
area (BA), and BMD (all P < 0.01). Fetal femur length growth between 30 weeks and birth 
was positively associated with BMC and BA (both P < 0.001), but not with BMD. Overall, 
childhood growth measurements exerted a larger influence on bone measures than fetal 
growth measures. The strongest effect estimate was observed during the first year of life. 
Children born small (<10th percentile) for gestational age (SGA) had lower BMC and BA, but 
not BMD, than children born appropriate for gestational age (AGA), whereas children born 
large (>90th percentile) for gestational age (LGA) had higher BMC and BA (all P < 0.001). 
These differences were no longer present in children showing subsequent accelerated and 
decelerated infant growth, respectively. We conclude that both fetal and childhood growth 
patterns are associated with bone mineral accrual, showing the strongest effect estimates 
in infancy. Compensatory infant growth counteracts the adverse consequences of fetal 
growth restriction on bone development.
109
Fetal and Childhood Growth Patterns Associated with Bone Mass in School-Age Children
introDuCtion
Early life factors influence the development of bone health and osteoporosis during the life-
course (1). Several studies have consistently shown that low birth weight leads to lower bone 
accrual in children and peak bone mass acquisition in adults (2,3). However, birth weight is 
an inappropriate measure of fetal growth, because different adverse fetal growth patterns 
may still result in the same birth weight (4). Also, birth weight is strongly correlated with infant 
growth. A low or high birth weight is frequently compensated for by catch-up growth or 
catch-down growth during the first 2 years of life (5). Studies assessing the effects of directly 
measured fetal growth in different trimesters along with early postnatal growth on bone 
mineral accrual in later life are scarce. Nevertheless, these studies are important to identify 
specific early critical periods for bone development. A previous study among 380 children 
suggested that fetal growth from 19 to 34 weeks of gestation affected childhood bone de-
velopment at age 4 years (6). In another study, among the same population, including 628 
children, fetal as well as early postnatal growth contributed to bone development at age 4 
years (7). On the other hand, a study among 123 adolescents, found fetal growth and early 
postnatal growth to be a less crucial determinant of adolescent bone development than 
prepubertal growth (8). These findings suggest that bone accrual is influenced by different 
critical periods, though diverse methodological challenges interfere with identifying effects 
across time in a conclusive manner; when growth measurements are widely separated in 
time, pinpointing the most influential period of growth is very difficult (8). Furthermore, the 
identification of a critical period of growth on subsequent bone development is challenged 
by the correlation existing between repeatedly collected growth measures (9), and the un-
known influence of growth realignment following an earlier period of growth deviation.
We investigated the independent associations of repeatedly measured fetal and childhood 
growth characteristics and bone mineral density (BMD) measured by DXA at age 6 years 
in 5,431 children participating in a population-based birth cohort. We applied conditional 
growth modeling  (10), which enables the simultaneous assessment of correlated growth 
measures to identify independent critical periods, to further elucidate the independent 
role of fetal and childhood growth on bone development.
MAteriAlS AnD MetHoDS
Study population
This study is embedded in the Generation R Study, a population-based prospective cohort 
study from fetal life onward in Rotterdam, the Netherlands (11). All mothers who were resi-
dent in the study area and had an expected delivery date between April 2,002 and January 
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2,006 were eligible. The study aimed toward enrollment in the fi rst trimester but allowed 
enrollment until delivery of the child. In total, 75% of all mothers enrolled before 18 weeks 
of gestation. Of all eligible children in the study area, 61% participated at birth in the study. 
The study was approved by the Medical Ethics Committee of the Erasmus Medical Centre, 
Rotterdam (MEC 198.782/2001/31), and conducted according to the guidelines of the 
Helsinki Declaration. Written informed consent was obtained from all participants.
In total, 7,893 children of mothers who gave consent for follow-up in the preschool 
phase (0 to 4 years) were eligible for this study. Of the 7,696 singleton born children, growth 
was measured at least once in 7,683 children. Of these children, 5,602 visited our research 
center around the age of 6 years. DXA scanning was successfully performed in 5,431 children 
(69% of the eligible population). A fl owchart of included participants is shown in Figure 1.
FetAl AnD CHilDHooD GroWtH CHArACteriStiCS
Fetal ultrasound examinations were performed in each trimester of pregnancy. Medians 
(interquartile ranges [IQRs]) of these visits were 13.1 (2.4), 20.5 (1.3), and 30.4 (1.1) weeks 
of gestation for the fi rst, second, and third trimester, respectively. In total, 88% of the 
examinations took place at either of the two research centers of the study. The remaining 
examinations were carried out in one of fi ve hospitals in the vicinity under guidance of our 
research staff. In order to achieve optimal reproducibility all sonographers were experi-
Figure 1. Flowchart of participants included for analysis, from the Generation r Study, rotterdam, the 
netherlands.
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enced and underwent additional training according to guidelines from The Fetal Medicine 
Foundation  (12). Gestational age was determined at the first fetal ultrasound examination, 
because 39% of pregnant women had unknown or irregular last menstrual periods and 
because using last menstrual period for this purpose has several described limitations (12). In 
the second and third trimesters, fetal head circumference (HC), abdominal circumference 
(AC), and femur length (FL) were measured to the nearest millimeter using standardized 
ultrasound procedures  (13-16). A brief description of the techniques applied is available in 
the Supporting Information. Fetal weight (EFW) was estimated using HC, AC, and FL in the 
formula from Hadlock: log10 EFW = 1.5662 − 0.0108 (HC) + 0.0468 (AC) + 0.171 (FL) + 0.00034 
(HC)2 − 0.003685 (AC * FL)  (17). In a previous study within the Generation R Study, refer-
ence curves were developed based on fetal growth characteristics of the whole study 
population (12). In the current study, we used these reference curves to calculate gestational 
age–adjusted SD scores.
Information about offspring sex, gestational age, and weight at birth was obtained from 
medical records and hospital registries. Very preterm birth was defined as birth occurring 
before 32.0 weeks of gestation, and preterm birth as birth between 32.0 and 37.0 weeks of 
table 1. Parental, fetal and child characteristics, the Generation r study, rotterdam, the netherlands.
Characteristic
Boys Girls
P-value1
n=2,718 n=2,732
Maternal characteristics
Age (years) 30.9 (5.1) 30.8 (5.0) 0.38
Height (cm) 167.9 (7.2) 167.8 (7.5) 0.62
Pre-pregnancy weight (kg) 66.2 (12.1) 66.8 (12.5) 0.19
Pre-pregnancy BMI (kg/m²) 23.4 (4.1) 23.6 (4.2) 0.13
Parity ≥1
No 1466 (54) 1499 (55) 0.39
Yes 1150 (42) 1129 (42)
Missing 106 (4) 90 (3)
Single motherhood
No 2192 (81) 2203 (81) 0.8
Yes 285 (11) 284 (10)
Missing 245 (9) 231 (9)
Educational status
Primary 199 (7) 214 (8) 0.76
Secondary 1021 (38) 1038 (38)
Higher 1259 (46) 1234 (45)
Missing 243 (9) 232 (9)
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table 1 (continued)
Characteristic
Boys Girls
P-value1
n=2,718 n=2,732
Smoking during pregnancy
Never 1766 (65) 1797 (66) 0.08
Until pregnancy was known 199 (7) 233 (9)
Continued 382 (14) 333 (12)
Missing 375 (14) 355 (13)
Alcohol use during pregnancy
No 1200 (44) 1226 (45)
Yes 930 (34) 952 (35) 0.23
Missing 592 (22) 1045 (36)
Start folic acid supplement use
Preconception 812 (30) 886 (33) 0.18
First 10 weeks 588 (22) 571 (21)
No 439 (16) 418 (15)
Missing 883 (32) 843 (31)
Paternal characteristics
Age (years) 33.4 (5.4) 33.5 (5.5) 0.44
Height (cm) 182.4 (7.9) 182.4 (7.8) 0.39
Weight (kg) 83.8 (12.8) 84.2 (12.9) 0.95
Body mass index (kg/m²) 25.2 (3.3) 25.3 (3.4) 0.26
Child characteristics
Gestational age at birth (weeks) 39.9 (1.7) 39.8 (1.7) 0.17
Ethnicity
European 2026 (74) 2022 (74) 0.89
African 413 (15) 403 (15)
Asian 146 (5) 144 (5)
Missing 137 (5) 149 (6)
Breast feeding
Never 186 (7) 188 (7) 0.64
>0-3 months 655 (23) 656 (23)
>3 months 1021 (38) 1055 (39)
Missing 819 (30) 777 (29)
Participation in sports at age 6
Never 1291 (47) 1226 (45) <0.001
1/week 739 (27) 976 (36)
≥2/week 289 (11) 88 (3)
Missing 403 (15) 428 (16)
1P-values obtained by Students t-tests for continuous variables and chi-square tests for categorical variables.
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gestation. Small for gestational age (SGA) and large for gestational age (LGA) was defined 
as sex- and gestational age–adjusted birth weight below the 10th percentile and above the 
90th percentile, respectively. Childhood growth was routinely measured at the Community 
Health Centres at the median ages of 6.2 (IQR 0.4), 11.1 (IQR 0.7), 24.8 (IQR 1.6), 36.7 (IQR 
1.4), and 45.8 (IQR 1.3) months following standardized protocols. Sex- and age-adjusted SD 
scores were calculated using Growth Analyser 3.5 (Dutch Growth Research Foundation, 
Rotterdam, the Netherlands; http://www.growthanalyser.org)  (18,19). In accordance with 
earlier studies, we defined an increase or decrease in weight greater than 0.67 SD from 
birth to the age of 24 months as accelerated or decelerated growth, respectively.(20,21) At 
the age of 6 years, we measured weight in our research center using an electronic personal 
scale (Seca, Almere, The Netherlands) and height using a Harpenden stadiometer (Holtain 
Limited, Dyfed, UK) following standardized protocols.
BMD measurements
Total body BMD (g/cm2), bone mineral content (BMC; g), and bone area (BA; cm2) were 
measured at a median age of 6.0 (IQR 0.37) years using a DXA scanner (iDXA; GE Lunar, 
Madison, WI, USA). As described in detail earlier  (22), well-trained research assistants ob-
tained the DXA scans using the same device and software (enCORE) following standard 
manufacturer protocols. In our analyses, we used areal total body less head (TBLH) BMD, 
BMC, and BA as recommended by the International Society for Clinical Densitometry for 
pediatric evaluations of bone health (23) All measures were adjusted for skeletal size by us-
ing body height or weight as covariate in the models to correct for artifacts arising from 
periods of rapid growth (24); this is needed because areal BMD measured on larger bones 
overestimates true (volumetric) BMD, whereas on smaller bones it can underestimate BMD 
across individuals (25, 26). In subsequent comparative analyses, we, in addition to the other 
covariates, corrected BMC for BA to further adjust for size effects (25).
Covariates
We registered maternal age at enrollment and collected information about maternal edu-
cation, marital status, parity, and country of birth, and country of birth of the father and 
grandparents by questionnaire at enrollment in the study. Maternal smoking and alcohol 
habits were assessed in each trimester. We measured parental height and weight at the re-
search center and obtained information about maternal weight before pregnancy by ques-
tionnaire. Because the enrollment in our study was during pregnancy, we were not able to 
measure maternal weight before pregnancy; however, correlation of pre-pregnancy weight 
obtained by questionnaire and weight measured at enrollment was high (P = 0.95; P < 0.01). 
We categorized ethnicity into three main groups: Western (Dutch, Turkish, other European, 
American, and Oceanic), African (Moroccan, other African, Antillean, Surinamese-Creole, 
and Cape Verdean), and Asian (Indonesian, other Asian, and Surinamese-Hindu) descent 
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according to the three largest transcontinental ancestral groups. Information about breast 
feeding (27) and participation in sports was obtained from postnatal questionnaires.
Statistical analysis
We used t tests and chi-square tests to compare differences in subject characteristics be-
tween boys and girls. We calculated age-adjusted SD scores for all bone measures based 
on their distribution in the whole study population and analyzed them following four 
strategies. First, we performed multiple linear regression analyses to assess the individual 
associations of fetal and childhood growth measures with bone measures at the age of 6 
years. Second, we assessed the associations of these growth measures with bone measures 
using conditional change modeling (10). In conditional growth modeling, a growth measure 
at a specific time point is adjusted for growth predicted by prior growth measures. Accord-
ingly, we calculated standardized residuals by regression of the growth measure of interest 
on prior growth measures  (10), obtaining growth measures independent of prior growth 
measures and statistically independent of each other across time. This approach enabled 
a simultaneous analysis of all growth measures with bone measures in order to identify the 
period of growth most critical to bone development. In an attempt to eliminate potential 
artifacts caused by bone size and to further distinguish potential effects on bone size from 
bone mineral accrual, we additionally corrected BMC for BA in a sensitivity analysis. Third, 
we assessed associations of birth outcomes (gestational age, birth weight, gestational age–
adjusted birth weight) with bone measures at the age of 6 years. Fourth, we explored the 
associations of gestational age–adjusted birth weight with bone measures stratified for the 
postnatal growth pattern. Based on previous literature, all models were adjusted for mater-
nal age, weight, height, parity, educational level, marital status, alcohol use, smoking, use of 
folic acid supplements, paternal weight and height, and child’s sex, ethnicity, breastfeeding 
duration, and participation in sports  (28-31). Models concerning weight measures were ad-
ditionally adjusted for current height, whereas models concerning height were adjusted for 
current soft tissue weight calculated as “lean + fat mass” (thereby excluding the contribution 
of bone mass to the child’s weight). Because missing values add up in conditional model-
ing and to prevent bias associated with missing data, we used multiple imputations (five 
imputations) to impute missing values in growth measures and covariates. Missing values 
for growth measures and covariates were imputed based on the correlation of the missing 
variables with other participant characteristics and other available growth measures, ac-
cording to the Markov Chain Monte Carlo method (32). The percentage of missing values for 
any fetal growth measure was lower than 16%, and for any childhood growth measure it was 
lower than 38%. Of all children, 6% did not have any data on growth from 1 to 4 years of age. 
Results from the complete case analyses were similar to results from the imputed analyses. 
We only present results for the imputed analyses. Comparing infants born SGA and not 
born SGA, we would be able to detect statistically significant difference in childhood BMD 
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of 0.13 SD (type I error of 5% and a type II error of 20% [power 80%]) (33). Analyses were 
performed using the SPSS Predictive Analytic Software version 17.0 for Windows (PASW Inc, 
Chicago, IL, USA).
Fetal growth, childhood growth, and bone measures
The associations of individually modeled growth measures with bone parameters at age 6 
are shown in Online Resource Table S1. In short, all fetal length and weight measures were 
positively associated with BMC and BA (all P < 0.05), whereas all childhood growth height 
and weight measures were positively associated with BMC, BA, and BMD (all P < 0.01). The 
magnitude of the effect estimates increased with advancing age. When applying a condi-
tional model, estimated fetal weight gain between 20 and 30 weeks gestation, 30 weeks 
and birth, as well as childhood weight gain from birth to 4 years of age were all positively 
associated with BMC, BA, and BMD (all P < 0.001) (Figure 2). Fetal femur length growth be-
tween 20 and 30 weeks gestation and height growth from birth to 4 years were all positively 
associated with BMC, BA, and BMD (all P < 0.01). Fetal femur length growth between 30 
weeks gestation and birth was positively associated with BMC and BA (both P < 0.001), but 
not with BMD. Effect estimates (in SD) for childhood height and weight growth measures 
were larger than for fetal growth. The largest effect estimates were found for the associa-
tions of height growth during the first year with BMC and BA, and weight gain during the 
first year with BMC, BA, and BMD. The size of the effect estimates decreased after the first 
year of age, except for the association of height growth with BMD, which peaked at 2 to 3 
years of age. The corresponding effect estimates are shown in Online Resource Table S2.
We further explored whether the associations of height and weight growth during the 
first year with bone measures were driven by growth during the first 6 months by replacing 
growth from birth to age 1 year by two separate measures for growth from birth to 6 months 
and from 6 to 12 months in our models. Height and weight growth during the first 6 months 
showed stronger associations with bone measures than growth from 6 to 12 months, yet 
effect estimates were not larger than those observed for growth during the first year as a 
whole (data not shown).
Size is a major determinant of bone mass. To demonstrate its impact on the conditional 
growth analysis, Online Resource Table S3 shows the results from the analyses unadjusted 
for size. Size adjustment reduced effect sizes approximately by one third. In a second sen-
sitivity analysis, to further distinguish an increase in bone mineral accrual from bone size, 
we additionally adjusted BMC models for BA. As a result, fetal femur growth measures were 
no longer associated with BMC. However, estimated fetal weight measures, and postnatal 
height and weight growth measures remained positively associated with BMC, although 
effect estimates were less than half the size of the effect estimates for BMC not adjusted for 
BA (shown in Online Resource Table S4).
Chapter 3.2
116
Figure 2. (A–F) Associations of conditional fetal and childhood growth with bone measures at age 6 years, 
from the Generation r Study Cohort, rotterdam, the netherlands. Values are based on multiple linear re-
gression models and reflect the coefficients and 95% CI per standardized residual of conditionally modeled 
growth. Conditional growth variables are independent of prior growth. Models are adjusted for maternal 
age, weight, height, parity, educational level, marital status, alcohol use, smoking, daily protein intake, use of 
folic acid supplements, paternal weight and height, and sex, ethnicity, breastfeeding duration, participation in 
sports, and for current height (weight models) or weight measured as “lean + fat mass” (height models) of the 
child and mutually for the other growth measures.
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Birth outcomes and bone measures
Gestational age at birth showed a weak positive association with BMC (P for trend 0.05) 
and BA (P for trend 0.02) at 6 years of age, not with BMD (Table 3). Children born preterm 
had a −0.09 SD lower BMC (95% CI, −0.19, 0.00) and a −0.08 SD lower BA (95% CI, −0.18, 
0.01) at school age. Birth weight showed a stronger positive association with both BMC and 
BA (both P for trend <0.001) and a weak positive association with BMD (P for trend 0.06). 
When birth weight was adjusted for gestational age at birth, it was still positively associated 
with BMC and BA, but not with BMD. As compared to children born AGA, children born 
SGA had a −0.07 SD (95% CI, −0.14, 0.00) lower BMC and a −0.11 SD (95% CI, −0.18, −0.05) 
lower BA, whereas children born LGA had a 0.12 SD (95% CI, 0.06, 0.18) higher BMC and a 
0.16 SD (95% CI, 0.10, 0.23) higher BA.
table 2. Average fetal growth, childhood growth and bone mass measures at age 6, the Generation r 
study, rotterdam, the netherlands.
Period (Gestational) 
age
median (iQr)
Growth 
character-
istic
unit Boys Girls P-value1
n mean (SD) n mean (SD)
Trimes-
ter 2
20.5 (1.3) weeks Femur 
length
mm 2292 33.4 (3.5) 2316 33.4 (3.4) 0.72
Estimated 
fetal weight
g 2281 385 (94) 2309 376 (87) <0.001
Trimes-
ter 3
30.4 (1.1) weeks Femur 
length
mm 2368 57.3 (3.0) 2394 57.6 (3.0) 0.007
Estimated 
fetal weight
g 2364 1635 (258) 2383 1619 (260) 0.03
Birth 40.1 (1.9) weeks Birth length cm 1698 50.6 (2.4) 1703 49.9 (2.2) <0.001
Birth weight g 2719 3503 (562) 2716 3372 (527) <0.001
1 year 11.1 (0.7) months Height cm 2141 75.1 (2.5) 2116 73.5 (2.5) <0.001
Weight kg 2143 10.0 (1.1) 2123 9.3 (1.0) <0.001
2 years 24.8 (1.6) months Height cm 1987 88.9 (3.4) 1984 87.7 (3.4) <0.001
Weight kg 2023 13.2 (1.5) 2006 12.7 (1.5) <0.001
3 years 36.7 (1.4) months Height cm 1884 97.9 (3.8) 1911 96.8 (3.8) <0.001
Weight kg 1908 15.5 (1.8) 1929 15.0 (1.9) <0.001
4 years 45.8 (1.3) months Height cm 1687 103.7 (4.1) 1666 102.8 (4.2) <0.001
Weight kg 1697 17.1 (2.2) 1669 16.8 (2.3) <0.001
6 years 72.2 (4.1) months Height cm 2719 119.5 (5.7) 2713 118.7 (5.7) <0.001
Weight kg 2719 23.2 (3.8) 2713 22.9 (4.1) 0.008
BMC g 2722 523 (100) 2718 519 (98) 0.01
Bone area cm² 2722 942 (115) 2718 941 (109) 0.17
BMD g/cm² 2722 0.552 (0.051) 2718 0.549 (0.052) 0.66
1P-values obtained by Students t-tests for continuous variables and chi-square tests for categorical variables. 
SD denotes standard deviation. BMC= Bone Mineral Content, BMD= Bone Mineral Density
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Birth weight, infant growth, and bone measures
As compared to children born AGA with normal infant growth, children born SGA without 
growth realignment between 0 and 2 years of age had a −0.30 SD (95% CI, −0.42, −0.18) 
lower BMC, a −0.35 SD (95% CI, −0.47, −0.24) lower BA, and a −0.21 SD (95% CI, −0.36, 
−0.06) lower BMD at age 6 years (Fig. 3A–C). Children born LGA without growth realign-
ment during infancy had a 0.44 SD (95% CI, 0.33, 0.55) higher BMC, a 0.44 SD (95% CI, 
0.34, 0.55) higher BA, and a 0.28 SD (95% CI, 0.14, 0.41) higher BMD at age 6 years than 
children born AGA with normal infant growth. Children born SGA and LGA who did show 
growth realignment during infancy had a similar BMD, BMC, and BA to that of children 
born AGA with normal growth. The corresponding effect estimates are shown in Online 
Resource Table S5.
table 3. Associations of birth outcomes with bone mass at age 6, the Generation r Study Cohort, rot-
terdam, the netherlands. Values are based on multiple linear regression models and reflect the coefficients 
and 95% CI for each category. Models are adjusted for maternal age, weight, height, parity, educational level, 
marital status, alcohol use, smoking, use of folic acid supplements, paternal weight and height, and gender, 
ethnicity, breastfeeding duration, participation in sports and current height of the child. SGA denotes small 
for gestational age, AGA denotes appropriate for gestational age, LGA denotes large for gestational age.
Fetal growth n Bone mineral content
(SD)
Bone area
(SD)
Bone mineral density
(SD)
β 95% Ci β 95% Ci β 95% Ci
Gestational age adjusted for birth weight (weeks)
 <32 28 −0.09 −0.35, 0.17 −0.06 −0.31, 0.19 −0.08 −0.40, 0.23
 ≥32–37 225 −0.09 −0.19, 0.00 −0.08 −0.18, 0.01 −0.06 −0.18, 0.05
 ≥37–42 4761 0 0 0
 ≥42 380 0.01 −0.06, 0.09 0.01 −0.06, 0.08 0.01 −0.08, 0.10
 P for trend 0.05 0.03 0.35
Birth weight (g)
 <2000 64 −0.11 −0.29, 0.07 −0.06 −0.23, 0.11 −0.12 −0.34, 0.09
 ≥2000–2500 170 −0.10 −0.21, 0.01 −0.15 −0.26, −0.05a −0.01 −0.15, 0.12
 ≥2500–3000 808 −0.08 −0.14, −0.02b −0.07 −0.13, −0.01b −0.07 −0.15, 0.00a
 ≥3000–3500 1912 0 0 0
 ≥3500–4000 1755 0.04 −0.01, 0.09 0.1 0.05, 0.14c −0.03 −0.09, 0.02
 ≥4000–4500 602 0.11 0.04, 0.18b 0.15 0.08, 0.21c 0.05 −0.04, 0.13
 ≥4500 124 0.19 0.06, 0.32b 0.29 0.16, 0.41c −0.02 −0.18, 0.14
 P for trend <0.001 <0.001 0.06
Birth weight adjusted for gestational age (SD)
 SGA 501 −0.07 −0.14, 0.00a −0.11 −0.18, −0.05c −0.01 −0.09, 0.07
 AGA 4311 0 0 0
 LGA 576 0.12 0.06, 0.18c 0.16 0.10, 0.23c 0.02 −0.05, 0.10
aP value <0.05 bP value <0.01 cP value <0.001
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Figure 3. (A–C) Associations of birth weight with bone measures at age 6 years, stratifi ed for postnatal 
growth patterns, from the Generation r Study Cohort, rotterdam, the netherlands. Values are based on 
multiple linear regression models and the bars and lines refl ect the coeffi cients and 95% CI for each cat-
egory of birth weight and postnatal growth pattern. Models are adjusted for maternal age, weight, height, 
parity, educational level, marital status, alcohol use, smoking, use of folic acid supplements, paternal weight 
and height, and sex, ethnicity, breastfeeding duration, participation in sports, and current height of the child. 
SGA = small for gestational age; AGA = appropriate for gestational age; LGA = large for gestational age.
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DiSCuSSion
Main findings
In this large population-based prospective cohort study of pregnant women and their 
children in the Netherlands, we found that both fetal and childhood growth, as reflected by 
height and weight gain, were positively associated with bone accrual at school age. Child-
hood growth showed larger effect estimates than fetal growth, whereas growth occurring 
in the first year of life showed the strongest positive association with bone mass accrual 
in later childhood. Gestational duration and birth weight were positively associated with 
bone parameters at 6 years of age. However, growth realignment between birth and 2 years 
of age in children born SGA or LGA led to similar bone measures at the age of 6 years to 
children born AGA who showed normal postnatal growth.
Methodological considerations
One of the major strengths of the study is that it is a large-scale, population-based, prospec-
tive cohort study rich in assessments of prenatal and early childhood growth. This unique 
setting of repeated measures of fetal growth, childhood anthropometrics, and bone 
measures enabled us to evaluate the independent associations of early growth with bone 
health. We used DXA, a well-validated technique to assess bone mass accrual in children. 
Nevertheless, our study is not free of limitations. Of the eligible children, 69% participated 
in the 6-year visit at our research center. Children who did not participate grew slower 
during fetal life and, accordingly, had lower birth weight and length than those participating 
in the study. They more often showed accelerated growth in the first 2 years of life, were 
of non-European descent, and had mothers with a lower educational level (all P < 0.05). 
Further, because in the Netherlands it is not obligatory to attend the routine Community 
Health Centre visits, only 40% of the children had complete data on growth from 1 to 4 
years of age and 6% did not have data from these routine visits at all. Children with incom-
plete data on average had a higher weight and BMC, and larger BA at the age of 6 years (all 
P < 0.05), but overall similar BMD levels. Although we used multiple imputation, we cannot 
exclude that missing information may still have led to loss of power or biased estimates. 
Nevertheless, this will only be the case if effect estimates would have differed systematically 
between those children included and not included in the analyses. This is unlikely, because 
loss to follow-up in our cohort is not expected to be related to the studied research ques-
tion (34), but cannot be fully excluded.
Establishing gestational age by ultrasound is considered superior to the use of the last men-
strual period (LMP)(35) because almost 40% of pregnant women have unknown or irregular 
last menstrual periods (12). However, use of first trimester ultrasounds assumes the variation 
in fetal growth before that ultrasound to be zero, possibly leading to underestimated effect 
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estimates in early pregnancy. We minimized this unwanted side effect by using crown-rump 
length and biparietal diameter for pregnancy dating (36,37) , but not for assessing fetal growth. 
Yet as a result of the correlation between fetal growth measures, underestimation of effect 
estimates may still have occurred. Nonetheless, because we studied relative change in 
size within time periods by conditional modeling, we do not expect our pregnancy dating 
strategy to have substantially influenced our results. The validity of ultrasound estimation 
of fetal weight has often been debated. A systematic review assessed the validity of esti-
mated fetal weight measurements by reviewing measurement errors across 42 studies (38). 
In this review, the authors found that all methods used to estimate fetal weight, including 
the method of Hadlock, have insignificant systematic error. Random error, on the other 
hand, averaged 10%. Another limitation possibly leading to random error may be the fact 
that growth measures from age 1 to 4 years were acquired from routine Community Health 
Centres. Nevertheless, measurements within these clinics were performed using standard-
ized protocols. Even though routinely collected measurements of this type have previously 
been shown to have good accuracy by lacking systematic error (39), random error may still 
have been introduced. Random error may reduce power and lead to underestimation of 
effects. Furthermore, the 0.67 SD cut-off that we used to define “accelerated growth” has 
been internationally recognized to represent clinically significant catch-up growth, but 
does not necessarily represent, and should not be interpreted as a biological phenom-
enon. Last, although we collected detailed information on many potential confounding 
variables, residual confounding due to unmeasured sociodemographic and lifestyle factors 
could still be influencing the results.
interpretation of main results
Our results confirmed that early growth is associated with both bone size (BA) and bone 
mineral (BMC) accrual at school age. Overall, effect estimates for models including BMD 
were consistent in direction, yet smaller in magnitude. This attenuation of the effect on 
BMD is likely consequence of the influence of changes in bone area on BMD (eg, larger 
bone areas result in comparatively lower BMD). Further, as DXA is a two-dimensional 
assessment of a three-dimensional structure, the overestimation of areal BMD in larger 
bones compared to volumetric BMD may also, although to a lesser extent, reduce the ef-
fect estimates. However, the prominent, yet incomplete, attenuation of effect estimates by 
additional correction of BMC for BA supports the idea that early growth is associated with 
both increased bone size as well as mineral accrual. The attenuation of effect estimates by 
size correction seemed to be larger for height than for weight measures. Possibly, height 
growth, and in particular increase in fetal femur length, are more closely related to the 
actual skeletal frame size, whereas weight gain is only indicative of the loading effects on 
the skeleton during postnatal life.
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Evidence supporting an influence of early growth on adult peak bone mass acquisition is 
increasing (2). Recently, fast weight and height gain during childhood and adolescence were 
positively associated with bone strength among 1,658 adults 60 to 64 years old (40). Only a 
few studies have assessed the association of fetal growth with bone development by actu-
ally measuring fetal growth instead of using birth weight as a proxy for fetal growth (6-8, 41). 
In line with our results, Beltrand and colleagues (41) found that fetal growth restriction (≥20 
percentile reduction in estimated fetal weight between 22 weeks of gestation and birth) led 
to lower BMC in 185 newborns, independent of birth weight. Among 380 British children, 
fetal femur length and abdominal circumference growth during 19 to 34 weeks of gestation 
were positively associated with BMC and BMD at age 6 years. The effect of fetal abdominal 
growth was independent of current height, weight, or bone size (6). Among 119 adolescents 
living in Denmark, third trimester fetal growth velocity, birth weight, and growth in the first 
year were positively associated with BMC (8). However, these associations fully disappeared 
when adjusted for current height and weight. For that reason, the authors concluded that 
growth in later life, rather than early growth, may be crucial to bone health in adolescence. 
However, pinpointing the most influential period of growth is less precise when assess-
ments are so widely separated in time.
Assessment of repeatedly measured growth is challenged by some methodological issues. 
In fact, “early size” adjusted for “later size” in regression analysis is a measure of change 
in size between the earlier and later measurement, rather than a measure of absolute 
growth (9). To overcome these issues, only one previous study used conditional modeling (10) 
to study the associations of linear and abdominal growth measured at 11, 19, and 34 weeks 
of gestation, birth, and 1, 2, 3, and 4 years with bone measures among 628 4-year-olds (7). 
The results were consistent with our observations, showing that both fetal and childhood 
growth are positively associated with bone development at age 4 years, whereas growth in 
the first 2 postnatal years contributed most strongly. These results are also in line with our 
results indicating that children born with a low birth weight who showed growth realign-
ment in the first 2 years had similar bone mass to children with a normal birth weight and 
normal postnatal growth. Our findings highlight the importance of early growth patterns 
determining bone health later in childhood.
Potential underlying mechanisms
Bone growth during fetal development and postnatal life involves complex regulatory pro-
cesses mediated by growth factors, cytokines, hormones, mechanical stimuli, and diverse 
environmental influences. These processes are largely controlled by genetics, epigenetic 
regulation, and availability of nutrients and diverse exposures during fetal life, childhood, 
and adolescence  (42). By adaptation to environmental cues, early growth even from fetal 
life may already program later bone development (43). Among others, hormones like leptin, 
123
Fetal and Childhood Growth Patterns Associated with Bone Mass in School-Age Children
growth hormone (GH), and cortisol have been suggested to play a prominent role in this 
“programming” of bone mineral accrual  (44,45). However, the exact mechanisms underly-
ing the process remain unclear. Altered leptin levels, resulting from low or high nutrient 
availability, are proposed to program bone development by stimulating differentiation of 
mesenchymal stem cells into bone (osteoblasts) precursors, over adipogenic lineages, as 
well as stimulating cortical bone over trabecular bone formation (44,46). Further, leptin levels 
are negatively correlated with fetal growth retardation  (47) and positively with postnatal 
catch-up growth and neonatal BA and BMC (48,49). Similarly, the GH/IGF-I axis has long been 
considered a major determinant of bone mass acquisition. The axis is negatively affected by 
fetal growth restriction (42) and essential to achieve catch-up growth in fetal growth–retarded 
infants (50). IGF-I levels in neonates as well as in children are positively correlated with bone 
mass (51,52). On the other hand, endogenous cortisol inhibits osteoblast function (53). Serum 
cortisol levels are higher in infants born SGA  (54), especially in those who do not achieve 
catch-up growth (55). High normal endogenous cortisol levels have been negatively associ-
ated with bone mass, predominantly in boys (56,57). Nutritional aspects such as breastfeeding, 
calcium and vitamin D intake, and environmental exposures such as sunlight and physical 
activity may also exert an effect on these associations. Nevertheless, the fact that effect es-
timates remained essentially unchanged upon correction for a large number of nutritional 
and environmental factors does not seem to corroborate this contention.
Conclusion
Both fetal and childhood growth predict bone development at 6 years of age. Weight and 
height growth in the first year of life appeared to have the largest impact on bone mineral 
accrual. Compensatory growth in the first 2 postnatal years reduced the adverse conse-
quences of slower growth velocity in fetal life on childhood bone mass. Because childhood 
bone mass tends to track into adulthood, fetal life and infancy may be critical periods to 
attain optimal bone health and possibly reduce the risk of osteoporosis in later life. The 
mechanisms underlying these findings are largely unknown and warrant further study.
Detailed acknowledgements and online resources can be found in the published article 
online: http://onlinelibrary.wiley.com/doi/10.1002/jbmr.2299/full
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ABStrACt
Bone strength, a key determinant of fracture risk, has been shown to display clear sexual 
dimorphism after puberty. We sought to determine whether sex differences in bone mass 
and hip bone geometry as an index of strength, exist in school age pre-pubertal children 
and the degree to which the differences are independent of body size and lean mass. We 
studied 3,514 children whose whole body and hip scans were measured using the same 
densitometer (GE-Lunar iDXA) at a mean age of 6.2 years. Hip DXA scans underwent hip 
structural analysis (HSA) with derivation of bone strength indices. Sex-differences in these 
parameters were assessed by regression models adjusted for age, height, ethnicity, weight 
and lean mass fraction (LMF).Whole body BMD and BMC levels were 1.3% and 4.3% higher 
in girls after adjustment by LMF. Independent of LMF, boys had 1.5% shorter femurs, 1.9% and 
2.2% narrower shaft and femoral neck with 1.6-3.4% thicker cortices than girls. Consequent 
with this geometry configuration, girls observed 6.6% higher stresses in the medial femoral 
neck than boys. When considering LMF, the sexual differences on the derived bone strength 
indices were attenuated, suggesting that differences in muscle loads may reflect an innate 
disadvantage in bone strength in girls, as consequence of their lower muscular acquisition. 
In summary, we show that bone sexual dimorphism is already present at 6 years of age, with 
boys having stronger bones than girls, relation which is influenced by body composition 
and likely due to differential adaption to mechanical loading. Our results support the view 
that early life interventions (i.e., increased physical activity) targeted during the pre- and 
peri-pubertal stages may be of high importance particularly in girls as before puberty onset, 
muscle mass is strongly associated with bone density and geometry in children.
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introDuCtion
Bone strength is determined by bone material properties and by how this material is dis-
tributed to resist applied mechanical forces (structural geometry). These factors are adap-
tive in nature and believed to evolve differently between sexes through adolescence and 
adulthood (1-3). Such sexual dimorphism of bone and its susceptibility to fracture has been 
attributed to the distinctive hormonal changes pinnacling in adolescence, as well as those 
occurring in women during menopause. An important aspect of skeletal growth is that the 
structural geometry of bone continually adapts to muscle forces applied during physical 
activity. The theoretical background for such adaptation is expressed in the Frost Mechano-
stat, which basically states that throughout life and especially during skeletal growth, bone 
tissue is placed where it is needed and removed from where it is not, always in response 
to strain stimuli imposed by muscle forces and detected by cells within and upon bone 
surfaces(4). Previous work has shown that during puberty, girls accrue more bone mass rela-
tive to muscle mass than boys, presumably due to the higher release of estrogen (5,6). Before 
puberty, the presence and origin of sex differences in bone accrual are less clear (1,5,7).
Bone development processes alter the amount of bone tissue within bones as well as its 
spatial placement, with implications evident in bone density and bone structural aspects 
(geometry); different bone configurations with the same BMD can have very different me-
chanical strengths (8). Forces acting along the bone axis are supported by its cross-sectional 
area (CSA), while bending is resisted by the distribution of bone from its center of mass and 
quantified by the section modulus (Z) (9). Presumably at any point in skeletal growth, bone 
cross-sections will have adapted to prevalent loading conditions so that stresses would be 
expected to be equal regardless of body size and other factors (10).
Previous research suggests that the skeleton is most sensitive to mechanical loading during 
childhood and adolescence(11,12). The mechanical stimuli applied to bone are induced by 
muscle contractions that move the body in opposition to gravitational forces. Yet, the rela-
tive contribution of each of these sources (including ground, substrate and joint reaction 
forces), to the adaptive response of bone remains controversial given their interdepen-
dence(13,14). These osteogenic stimuli may differ between boys and girls, but are difficult to 
quantify as they depend on factors like: body size and weight, physical activity intensity 
and type of activity among others. In the present study, we aimed to examine pre-pubertal 
sex differences in bone accrual and hip structure in children of 6 years of age. Specifically, 
we investigated if sex differences in children of school age observed across bone mass, 
density and geometry parameters are explained by distinct patterns of scaling to loading 
and differences in bone stresses.
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Study Population
The Generation R Study is a prospective prenatal cohort study in which 9,778 pregnant 
women living in Rotterdam and with delivery date between April 2002 and January 2006 
were enrolled. Details of study design and data collection can be found elsewhere (15). Eth-
nic background of the children was assessed by country of birth of her/his parents using a 
questionnaire. The participating child was deemed to be of non-Dutch ethnic origin if one 
parent was born abroad (definition Statistics Netherlands (16,17)). If both parents were born 
abroad, the country of birth of the participant’s mother defined the ethnic background. Fif-
teen different ethnicities based on parental country of birth, were narrowed to three main 
ancestry groups including: Europeans: all European countries, together with Americans, 
Oceanics and North Africans (with parents from: Algeria, Egypt, Libya, Morocco, Sudan, 
Tunisia, and Western Sahara) (18); Africans: including Sub Saharan Africans, Dutch Antilleans 
and Surinamese Creoles; and Asians: including all Asian countries and Surinamese Hindu-
stanis. The study was approved by the Medical Ethics Committee of the Erasmus Medical 
Center, Rotterdam (MEC 198.782/2001/31), and conducted according to the guidelines of 
the Helsinki Declaration with written informed consent obtained from all participants.
Bone mineral density and anthropometric measurements
Participants underwent dual-energy X-ray absorptiometry (DXA), following standard 
manufacturer protocols, using the same GE-Lunar iDXA device (GE Healthcare Lunar, 
Madison, WI) during their visit to the research centre at a mean age of 6 years. The co-
efficient of variation of whole-body scans was determined earlier to be 0.23% (19). Of the 
6,508 children with whole body scans, 3,976 (61.1%) also had total hip scans measured. All 
scans were analysed by well-trained research assistants using the enCORE software by the 
same manufacturer. After quality control, 107 hip and 62 whole body scans were discarded 
due to incorrect positioning, movement during the scan or device errors. Weight, whole 
body lean and fat mass were derived from the DXA scans. Lean mass fraction (LMF) was 
calculated as whole body lean mass divided by weight. Femur length (FL) was measured 
from whole body DXA scans using the ruler tool of the enCORE software along a straight 
line extending from the highest point of the greater trochanter to the distal midpoint be-
tween the femoral condyles. Participant height was measured to the nearest 0.1 cm using a 
Harpenden stadiometer (Holtain Limited, Dyfed, U.K.).
Hip Structural Analysis
Structural parameters were derived from the total hip scans using hip structural analysis 
(HSA) software developed by Beck and colleagues  (20). Precision studies done in adults 
(postmenopausal women) using older generation scanners yielded coefficients of variation 
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between 1- 5%  (21). Parameters are calculated from the proximal femur in three different 
regions: Narrow Neck (NN), across the narrowest diameter of the femoral neck, Intertro-
chanteric (IT), along the bisector of the neck-shaft angle, and the femur shaft (FS), at a point 
1.5 times minimum femoral neck width distal to the intersection of the neck and shaft axes. 
The latter region is considered to be 100% cortical bone (requiring no assumptions on 
trabecular/cortical bone content) and is relatively axially symmetric.
In this study we focused on the cross-sectional bone surface area (CSA), section modu-
lus (Z) as well as BMD, estimated cortical thickness (CT), the outer diameter (W) at the shaft 
and narrow neck regions. We also compared Neck- Shaft Angle, and neck length which 
influence the bending moments at the proximal end of the femur.
Derived strength indices
We used two types of measurements to assess strength, namely: strength-to-load index at 
the shaft and net stress at the femoral neck using a mechanical model (22). As bending bone 
strength scales to Z, we calculated a composite index of bone strength relative to skeletal 
loading, comparing the effect of weight and LMF in both boys and girls, using the following 
equations.
Strength-to-load Index (SLI):
FS_SLIweight =
FS_Z/FL
Weight
And additionally adjusting for LMF,
FS_SLILMF =
FS_Z/FL
Weight*LMF
whereas, the stress analysis incorporates the forces acting on the femur at its narrowest 
point using engineering beam theory. As,
Net stress (NS) on the medial surface of the femoral neck from both bending and axial 
forces is given by
δMedial =
MS*yMedial
+
PS
I A
where Ms and Ps are the bending moment and axial load on the neck cross-section. I and 
A are the moment of inertia and cross-sectional area of the narrow neck, and ymedial is the 
perpendicular distance between the medial surface and the neutral axis. Correction for 
lean mass was done by multiplying the resulting stress by LMF. A detailed description of the 
derivation of medial femoral neck stance stress has been described elsewhere (22).
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Statistical analysis
The analyses reported here are based on a sample of 3,514 children within an age range of 
4.9 – 9.1 years (where <5% of the population was over 8 years old), who had good quality 
DXA scans, underwent HSA analysis and had valid information on height and ethnicity.
Whole body and Femoral Neck DXA parameters
As recommended for paediatric populations by the International Society for Clinical Den-
sitometry whole body less head (WBLH) was used to assess bone density and content in 
the children (23). Femoral Neck (FN) BMD was measured on the right leg for all participants. 
Multivariate regression analyses were performed followed by the calculation of least 
square (LS)-means of WBLH-BMC and WBLH- and FN-BMD for each sex. We determined 
sex differences after accounting for the effect of age, height, weight and ethnic background 
(first model). Next, we adjusted further for LMF (second model), and compared again the 
sex derived LS-means.
Hip Structural Analysis
We compared BMD, CT, W, CSA, and Z -both at the NN and FS regions-between boys and 
girls by LS-means using the basic (first) model and further adjusting for LMF, as explained 
above. In addition, we corrected the models using femur length rather than height. Sex 
comparisons for the derived strength indices were adjusted only by age and ethnicity, as 
in their formulation they include a size parameter. Pearson correlations of these indices 
corrected by LMF, and DXA bone parameters adjusted by age, height, gender and ethnicity 
were also calculated.
Based on previous studies, we performed all described analyses adjusting further for gesta-
tional age, birthweight, breastfeeding history TV watching, participation in sports and hours 
playing outside, as well as maternal height and weight before pregnancy. To avoid loss of 
power or potential biases associated with missing data we used multivariate imputation 
by chained equations (MICE) procedure (24). The amount of missing values ranged from 1% 
to 40% across these variables. We pooled results of the analyses performed in each of 10 
imputed datasets. All statistical analyses were checked for multicollinearity using variation 
inflation factors (VIF) and performed using R statistical software (25).
reSultS
Descriptive characteristics of the 3,514 children under study are shown in table 1. Within 
the three defined ethnicities there were approximately the same number of boys and girls. 
Between boys and girls there were no differences in age, weight, WBLH-BMD, or WBLH-
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table 1. Descriptive Characteristics of Study Participants
Boys (n=1,732) Girls (n=1,782) Δ %a P
Ethnicity
European Ancestry 1432 1483 0.165
Asian Ancestry 108 101 0.493
African Ancestry 192 198 0.667
Anthopometrics
Age (years) 6.175 ± 0.633 6.147 ± 0.587 0.45% 0.167
Height (m) 1.197 ± 0.628 1.189 ±0.618 0.67% 5.37E-05
Weight (Kg) 23.21 ± 4.36 22.99 ± 4.62 0.95% 0.15
Lean mass (Kg) 16.95 ± 2.44 15.75 ± 2.29 7.08% <2.20E-16
Lean mass fraction 0.736 ± 0.048 0.692 ± 0.053 5.98% <2.20E-16
Fat mass (Kg) 5.42 ± 2.28 6.42 ± 2.67 -18.45% <2.20E-16
Fat mass fraction 0.227 ± 0.050 0.272 ± 0.055 -19.82% <2.20E-16
Femur length (cm) 27.28 ± 1.98 27.68 ± 2.02 -1.47% 3.25E-09
DXA parameters
WBLH-BMC (g) 533.14 ± 114.50 528.71 ± 110.94 0.83% 0.240
WBLH-BMD (g/cm2) 0.55 ± 0.056 0.549 ± 0.053 0.18% 0.510
FN-BMD (g/cm2) 0.727 ± 0.095 0.681 ± 0.090 6.33% <2.20E-16
HSA parameters
FS_BMD (g/cm2) 0.419 ± 0.059 0.396 ±0.058 5.49% <2.20E-16
NN_BMD (g/cm2) 0.391 ± 0.056 0.362 ± 0.052 7.42% <2.20E-16
FS_CSA (cm2) 0.747 ± 0.128 0.707 ± 0.123 5.35% <2.20E-16
NN_CSA (cm2) 0.751 ± 0.143 0.706 ± 0.133 5.99% <2.20E-16
FS_width (cm) 1.872 ± 0.163 1.876 ± 0.160 -0.21% 0.452
NN_width (cm) 2.019 ± 0.228 2.048 ± 0.234 -1.44% 2.00E-04
FS_Z (cm3) 0.252 ± 0.060 0.240 ± 0.057 4.76% 1.43E-10
NN_Z (cm3) 0.254 ± 0.072 0.236 ± 0.066 7.09% 1.49E-14
FS_CT (mm) 1.377 ± 0.211 1.295 ± 0.205 5.95% <2.20E-16
NN_CT (mm) 0.742 ± 0.011 0.686 ± 0.105 7.55% <2.20E-16
Neck-shaft angle 143.34 ± 6.18 140.12 ± 6.14 2.25% <2.20E-16
Necklength 3.50 ± 0.57 3.30 ± 0.52 5.71% <2.20E-16
a Δ %= 
(Pboys − Pgirls)
* 100
Pboys
, where P represent the parameter of interest
WBLH= whole body less head; BMC=bone mineral content; BMD=bone mineral density; FN=femoral neck; 
FS=femur shaft; NN=narrow neck; CSA=cross-sectional area; Z=section modulus; CT=cortical thickness; 
LMF=lean mass fraction.
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BMC. Boys had greater height, lean mass, LMF, and FN-BMD, but shorter femur lengths and 
lower body fat as compared to girls. With regard to the HSA variables, boys had greater 
NSA and longer neck lengths. In both the narrow neck and shaft regions, BMD was higher in 
boys consistent with their thicker cortices and greater bone cross sectional area; nonethe-
less, girls showed wider narrow necks than boys. Even though wider bones have greater 
bending resistance, the index of bending strength was still greater in boys. No signifi cant 
differences between sexes were observed in shaft width or centroid position.
Results of the applied models for all studied variables are shown in detail in table 2. In 
general, after adjustment by age, height, weight and ethnicity no differences in WBLH-
BMD were observed across sexes, although boys had 0.96% lower BMC. Additional ad-
justment for LMF resulted in boys having 1.28% and 4.30% lower WBLH-BMD and WBLH-
BMC than girls (Figure 2). Moreover in analyses not adjusted for LMF (fi rst model), boys 
had 5.96% higher FN-BMD, 5.06% higher shaft and 6.96% higher narrow neck BMD than 
girls. Likewise, boys had thicker cortices (5.56% in the shaft and 7.22% in the narrow neck), 
larger CSA (4.19% in the shaft and 4.98% in the narrow neck), and higher section modulus 
(3.61% in the shaft and 5.20% in the narrow neck) than girls. In contrast, girls had wider 
shaft (0.86%) and narrow neck (1.99%) diameters. After correction for LMF, the differences 
in BMD were less pronounced, with boys still having 2.67% higher FN-BMD, 3.66% higher 
shaft BMD and 1.22% higher narrow neck BMD than girls. This was still the consequence of 
thicker cortices in the boys (1.64% greater in the shaft and 3.44% in the narrow neck). The 
Figure 1. Sex differences in femur geometry at the narrow neck and femoral shaft after adjustment by age, 
height, weight, lean mass fraction and ethnicity. Reported percentages correspond to the sex difference 
in the parameters taking the boys as the reference group. Asterisks represent level of signifi cance of the dis-
played differences (*P<0.05) and (**P<0.01). Boys have thicker cortices and narrower femur width than girls. 
Please note the drawing is for illustration purposes only and is not to scale.
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differences in bone dimensions were accentuated after LMF correction (Figure 1), with 
girls having 1.93% higher shaft and 2.22% narrow neck width. Similarly, after LMF correction 
the indices of axial strength (CSA) were now similar at the shaft (-0.79%, not signifi cant) but 
still remained higher in boys at the narrow neck (1.11%); the index of bending strength (Z) 
became lower in boys than in girls (-2.88%) at the shaft while at the narrow neck was at-
tenuated yet higher on boys (0.41%). As it is plausible that differences in temporality in the 
development and growth between the peripheral and axial skeleton exist and infl uence 
the results, we used femur length rather than height in our models as sensitivity analysis 
(Online Resource Table S1). Nonetheless, results and derived conclusions did basically not 
change.
Before adjustment for LMF the strength-to-load index calculated at the shaft based on 
weight only was 5.54% greater in boys, while stress of the femoral neck was 13.37% lower, 
as compared to girls. These differences were largely attenuated when LMF was considered 
in the derivation of both parameters. After LMF correction, the strength-to-load index was 
0.64% higher in girls, yet no longer signifi cant. The calculated stress was still higher in girls 
but with the difference reduced to 6.58% (Figure 2 and table 3). Correlation between these 
two strength parameters including LMF was moderate (ρ= -0.42). Adjusted WBLH-BMD 
had a correlation of 0.38 with strength-to-load index of the shaft and of -0.28 with the 
axial stress index at the narrow neck. Similarly, WBLH-BMC had a correlation of 0.40 with 
strength-to-load index of the shaft and of -0.25 with the axial stress at the narrow neck. After 
Figure 2. Sex differences in bone mass and strength parameters depending on the load applied. The 
strength-to-load index (SLI) was calculated at the shaft evaluating bone strength relative to skeletal loading. 
The stress (NS) index was calculated at the narrowest point of the femur neck, incorporating both bending 
and axial forces. Differences between boys and girls are presented as percentages in order to make them 
comparable across parameters
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correction for LMF, FN-BMD showed correlations of 0.45 and of -0.53 with these indices, 
respectively. All reported correlations had P<0.0001.
Adjustment for further potential cofounders essentially did not modify these observa-
tions and all effect estimates did not statistically differ from those reported in tables 2 and 3. 
All reported models had a VIF under 10.
DiSCuSSion
This study assessed sex differences in hip structure and femur strength in 3,514 pre-pubertal 
children with a mean age of 6.2 years. No differences in whole-body BMD or BMC were 
found between sexes. Nevertheless, after correction for LMF, it became apparent that 
girls have higher whole-body BMD and BMC per unit of lean mass. At the hip, BMD was 
higher in boys regardless of any applied adjustment. Additionally, boys had shorter femur 
length than girls. Hip bone geometry parameters showed that boys had thicker cortices and 
narrower femur widths at both the narrow neck and shaft regions, underlying their higher 
indices of axial (CSA) and bending (Z) strength. Likewise, girls observe greater stresses and 
lower or similar strength per load unit at the analysed sites when considering body weight. 
These results indicate that on average the femur of boys have better resistance to axial and 
bending forces at both the narrow-neck and proximal shaft. Yet, these sex differences are 
largely attenuated by lean mass adjustment, suggesting adaptation to differences in the 
amount of muscle mass and presumably to the forces it generates, while other mechanisms 
(i.e., genetic, hormonal and environmental determinants) could still play a role.
In agreement with previous reports we observed that pre-pubertal girls of our study had 
significantly higher whole body fat mass and lower lean mass than boys  (5,26,27). We found 
that sex differences in bone mass greatly depended on lean mass. After adjustment for LMF 
both WBLH-BMD and WBLH-BMC were higher in girls than in boys; while differences in 
BMC were more evident than differences in BMD (Figure 2). Higher BMC accrual per lean 
table 3. Strength indices and stress sex comparisons for the Generation R Study
Boys Girls Differencea P
FS_SLI_Weight 3.96e-4 [3.92e-4, 4.00e-4] 3.74E-4 [3.70E-4, 3.78E-4] 2.19E-5 [1.81E-5, 2.58E-5] <0.0001
FS_SLI_WeightLMF 5.41E-4 [5.36E-4, 5.46E-4] 5.44E-4 [5.39E-4, 5.49E-4] 3.44E-6 [-8.26E-6, 1.38E-6] 0.181
FN_NS_Weight (Mpa) 8.758 [8.653, 8.864] 9.928 [9.823,10.033] -1.17 [-1.066,-1.276] <0.0001
FN_NS_WeightLMF (Mpa) 6.361 [6.296, 6.427] 6.779 [6.713, 6.844] -0.418 [-0.353,-0.484] <0.0001
aDifference is the regression coefficient for sex taking boys as reference [95% Confidence interval]
All results adjusted means [95% confidence intervals]. FS=Femur Shaft; SLI=strength-to-load index; LMF=lean 
mass fraction, NS= net stress
All models adjusted by: ethnicity and age
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mass unit in girls during puberty has been reported earlier  (1,3,28), and here we show this 
difference appears to be already evident at six years of age.
In our study we describe strong sexual dimorphism at children of pre-pubertal school age. 
Sexual dimorphism of skeletal geometry is known to accentuate during puberty, where 
periosteal diameter expands to a greater extent in boys as compared with girls (29-32). Among 
these studies, Sayers et al. reported the largest one performed in 3,914 English children 
of peri-pubertal age (mean age 13.8 years), also using geometrical and strength param-
eters derived from DXA showing that boys have thicker cortices and higher hip-bending 
strength (3). Nonetheless, in that study they observed wider femurs in boys than girls, which 
is in contradiction to our findings. This may well reflect the different ages between ours and 
their study population at the time of measurement. Similarly, a Canadian study conducted 
in 138 adolescents also showed that boys develop greater periosteal apposition, resulting 
in greater femoral neck width and higher bending strength than girls. Nevertheless, in line 
with the findings of our study, measurements performed before the start of the growth 
spurt (peak height velocity), depicted narrower femoral width values in boys (29). Another, 
interesting yet intriguing finding is that, we found girls to have longer femurs than boys 
despite having no differences in overall height. To the extent of our knowledge there are no 
previous studies describing differences in femur length between sexes during childhood. 
Replication of this finding in other populations should be attempted. Altogether, pre-
pubertal girls have on average wider and longer bones, which may represent an adaption 
to the constraint on periosteal apposition to occur after onset of puberty.
While hormones play a key role on the bone sexual dimorphism arising during puberty 
their influence at earlier ages is less clear. Garnett et al. showed that sex differences in IGF-1, 
estradiol, testosterone, and leptin levels were already present in children of 7-8 years of age 
and were associated with LS-BMD (5). Since we did not measure hormone levels, we cannot 
exclude that relevant hormonal influences (i.e., androgens) could also modulate bone me-
tabolism directly and/or indirectly through bone composition and underlie the differences 
observed in our study. On the other hand, site specific regulation has also been described 
for both periosteal and endosteal apposition (3,33), even at the genetic level (34). Therefore, 
it is possible that local regulation such as differential mechanical loading between bones, 
predominate over systemic effects like the influence of hormonal and nutritional factors in 
definition of bone characteristics (33).
Our study showed that the sexual dimorphism of the skeleton observed during the pre-
pubertal period already reflects differences in bone strength, including higher stresses of 
the femoral neck and lower strength per unit load at the shaft in girls as compared to boys 
(table 3). These two indices are moderately correlated hence providing complementary 
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information across femoral sites of measurement (shaft vs narrow-neck). In addition, they 
are modestly correlated with BMD indicating that they reflect mechanical properties which 
are not fully captured by areal BMD measurements. The higher stresses observed in the 
femoral neck of girls as compared to boys, are undoubtedly complex but may be due in 
part to thinner cortices in wider bones (Figure 1). The implications of these findings for the 
risk of osteoporosis and fracture in adult life remain to be determined. Nevertheless, the 
magnitude of these sex differences are not negligible (e.g., 5% lower femoral neck BMD 
in girls); considering the 1% yearly average decrease in BMD in the elderly and that a BMD 
decrease of 1 standard deviation represents between 1.5 to 3 times increased risk of fracture 
(all types and hip, respectively) (35).
As postulated earlier by other studies, we also observe that the described sexual dimor-
phism of bone is attenuated when considering differences in lean mass. This is expected 
as muscle-induced mechanical loads have an important role determining the three dimen-
sional distribution of tissue within bones, as strains generated by muscle contraction have 
been reported to be more osteogenic than static gravitational loading, exerted by body 
weight alone  (36). Nonetheless, there is a high interdependence among both stimuli and 
their role in bone functional adaptation is by no means mutually exclusive (37). In our analy-
ses however, the magnitude of these forces, are only crudely represented by the indices we 
used, which consider body weight, lean body mass and fraction. Previous work has shown 
that in young women, bending strength of the hip (Z) scales with the proportion of lean 
mass in their bodies (38). In our study, we also show this is the case and that in fact this rela-
tion is already evident in pre-pubertal children of school age. Differences in the strength-
to-load index are no longer significant while the differences in stress reduce in more than 
50% when including LMF, therefore lean mass has a great impact on bone mechanical 
resistance (Figure 2). The similar strength reached at the shaft after lean mass adjustment is 
not reflected in similar FS-BMD between boys and girls suggesting an stronger association 
of muscular stimuli with bone geometry than with bone density at this site. These results 
indicate that a program of physical activity at early ages could have positive effects on bone 
stability, as has been demonstrated by several studies (39-44). Girls in particular would benefit 
the most from these interventions as in the general population they have lower levels of 
physical activity than boys  (40) and their bone formation on the periosteal surface greatly 
decreases during puberty (45).
Our study arises in a powerful setting where research subjects are relatively standardized 
as they are all residents of the city of Rotterdam, The Netherlands, and were measured 
using the same dual-energy X-ray absorptiometry (DXA) device at a similar age. This study 
design reduces the impact of inter-machine variance, as well as local environmental and 
lifestyle exposures influencing bone health variation such as, major differences in access 
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to medical care, sunlight exposure, diet or physical activity. Eventually this also explains 
why correction for a large set of these confounders did not essentially modify the observed 
associations. Further, despite the multi-ethnic background of our cohort, ethnicity is not 
expected to play a role in these relationships, as we observed a very similar distribution of 
ethnic groups across sexes.
This study has some limitations. The three dimensional model makes assumptions as to 
the distribution of bone mineral at the narrow neck. The estimation of cortical thickness 
at the narrow neck (NN_CT) is the only parameter assuming a fixed proportion of cortical 
vs trabecular bone (which has not been validated in children). All other HSA parameters 
are derived at both sites (NN and shaft) directly from measured mineral mass (g/cm2) 
and do not involve the estimate of cortical thickness (cm) or its distribution assumption 
at the femoral neck. Further, the shaft site is purely cortical so no assumption is required. 
In addition, an intrinsic error of the HSA method may arise when applied to children as 
their mineralization density is lower than that of adults, thus resulting in underestimation 
of Z and CSA  (29) and potentially less precise measurements than in adults. Nonetheless, 
as the same error is introduced to the measurements regardless of sex of the participant, 
this or any other systematic errors are not expected to affect the absolute sex differences 
we observed. Further, given the consistency of the observed differences between sexes 
it is unlikely they can be explained by random error alone derived from less precise HSA 
assessments. It is unlikely that studies using three dimensional imaging techniques with 
greater radiation exposure (i.e., quantitative computerized tomography) can assess the hip 
structure parameters in a similar large set of healthy children to verify our findings. Never-
theless, studies (including our own) incorporating pQCT measurements are increasingly 
being performed in children, using cross-sections of the tibia and/or radius that could be 
used to verify and extrapolate our findings. Further, although we ran sensitivity analyses 
including other possible confounders found in literature, there is still the possibility of 
residual confounding due to measurement error in explanatory variables influencing our 
results. In addition, stimuli from muscle contractions were not directly assessed by our 
approach, under the assumption these influences are partially captured by lean mass. 
Moreover, given the observational nature of our study causal relationships between the 
observed differences in body composition (lean mass) and BMD or strength parameters 
cannot be unequivocally assessed.
In summary, we have shown here that sexual dimorphism in both bone mass and density 
measured at the whole body and femur, together with bone distribution at the femoral shaft 
and narrow neck, is already present at a pre-pubertal age; and that these sex differences 
are closely related to lean (muscle) mass. Given the relative “weaker” bone configuration 
of girls already present at an early age and the influence of lean mass fraction on these 
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relationship, establishment of exercise programs during the pre- and peri-pubertal years 
may be an effective way to decrease fracture risk later in life.
Detailed acknowledgements and online resources can be found in the published article 
online: http://onlinelibrary.wiley.com/doi/10.1002/jbmr.2755/full
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ABStrACt
To identify genetic loci influencing bone accrual we performed a genome-wide association 
scan for total-body bone mineral density (TB-BMD) variation in 2,660 children of different 
ethnicities. We discovered variants in 7q31.31 associated with BMD measurements with the 
lowest P=4.1x10-11 observed for rs917727 with minor allele frequency of 0.37. We sought rep-
lication for all SNPs located +/-500 kb from rs917727 in 11,052 additional individuals from 
five independent studies including children and adults; together with de-novo genotyping 
of rs3801387 (in perfect linkage disequilibrium (LD) with rs917727) in 1,014 mothers of 
children from the discovery cohort. The top signal mapping in the surroundings of WNT16 
was replicated across studies with a meta-analysis P=2.6x10-31 and an effect size explain-
ing between 0.6-1.8% of TB-BMD variance. Conditional analyses on this signal revealed a 
secondary signal for total body BMD (P=1.42x10-10) for rs4609139 and mapping to C7orf58. 
We also examined the genomic region for association with skull BMD to test if the asso-
ciations were independent of skeletal loading. We identified two signals influencing skull 
BMD variation including rs917727 (P=1.9x10-16) and rs7801723 (P=8.9x10-28) also mapping 
to C7orf58 (r2=0.50 with rs4609139). Wnt16 knockout (KO) mice with reduced total body 
BMD and gene expression profiles in human bone biopsies support a role of C7orf58 and 
WNT16 on the BMD phenotypes observed at the human population level. In summary, 
we detected two independent signals influencing total body and skull BMD variation in 
children and adults, thus demonstrating the presence of allelic heterogeneity at the WNT16 
locus. One of the skull BMD signals mapping to C7orf58 is mostly driven by children sug-
gesting temporal determination on peak bone mass acquisition. Our life-course approach 
postulates that these genetic effects influencing peak bone mass accrual may impact the 
risk of osteoporosis later in life.
AutHor SuMMAry
Genetic investigations on bone mineral density (BMD) variation in children allows the 
identification of factors determining peak bone mass and their influence on developing 
osteoporosis later in life. We ran a genome-wide association study (GWAS) for total body 
BMD based on 2,660 children of different ethnic background, followed by replication in an 
additional 12,066 individuals comprising children, young adults and elderly populations. 
Our GWAS meta-analysis identified two independent signals in the 7q31.31 locus, arising 
from SNPs in the vicinity of WNT16, FAM3C and C7orf58. These variants were also associ-
ated with skull BMD, a skeletal trait with much less environmental influence for which one 
of the signals displayed age-specific effects. Integration of functional studies in a Wnt16 
knockout mouse model and gene expression profiles in human bone tissue provided 
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additional evidence for WNT16 and C7orf58 to be underlying the described associations. 
All together our findings demonstrate the relevance of these factors for bone biology, the 
attainment of peak bone mass and their likely impact on bone fragility later in life.
introDuCtion
Roughly 30 to 50% of women and 15 to 30% of men experience an osteoporosis-related 
fracture during their lifetime  (1). In adults, bone mineral density (BMD) measured at skel-
etal sites where osteoporotic fractures occur more frequently (i.e., lumbar spine, hip and 
forearm) is used for the diagnosis of osteoporosis and assessment of fracture risk. BMD 
measured at a given point in time is the result of peak-bone mass acquisition and subse-
quent bone loss in later life.
Due to the rapid changes in bone area in early life, the total body measurement (less head) 
is the preferred measurement to evaluate bone health in children (2). The total body BMD 
measurement (in both children and adults) incorporates components of both cortical 
(~80%) and to a lesser extent trabecular (~20%) bone (3). Moreover, it is likely that the genes 
underlying skeletal growth and bone loss differ in importance across the lifespan and can 
act in a site specific manner (4-6). Peak bone mass is an important determinant of the risk of 
osteoporosis later in life (7,8). Early identification of individuals prone to low peak BMD may 
allow implementing strategies (interventions) which can delay the onset of osteoporosis.
From a genetic perspective, the discovery of loci influencing peak bone mass should be 
based on younger populations to avoid the noise introduced by bone loss later in life. A 
relatively recent Genome Wide Association Study (GWAS) in native British children suc-
cessfully identified an association between total body derived BMD and variants in the 
osteoblast transcription factor gene Osterix (9), an early acting developmental gene shown 
to influence peak bone mass accrual but also BMD in adults (10,11) .
The purpose of this study was to identify genetic variants associated with total body BMD 
(TB-BMD) in children, thus targeting variants involved in bone accrual. We ran a GWAS on 
children from the multiethnic Generation R Study and then replicated our findings in five 
additional cohorts including Northern European individuals covering different age groups 
ranging from children to elderly adults, allowing any life-course effect of the discovered 
variants to be evaluated
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Association with total Body BMD in the Discovery Cohort
To search for loci influencing total body BMD variation we performed genome-wide 
association analysis in a subset of 2,660 children from the Generation R Study with DXA 
scans and GWAS data. The Generation R Study is a population-based multiethnic birth 
cohort currently assessing children at an average age of 6.1 (SD 0.28) years. Table S1 shows 
population characteristics of these children overall and stratified by ethnicity. To increase 
the genome coverage of common variants we imputed genotypes for 3,021,329 SNPs in 
reference to the combined CEU, CHB/JPT and YRI HapMap Phase II panels using MACH/
minimac software taking into account the admixed nature of the Generation R popula-
tion (12). The GWAS for TB-BMD in these individuals adjusted for age, gender, weight and 20 
principal components, showed appropriate control for population structure with genomic 
inflation factors (λ) approaching unity (Figure 1A), and revealed a genome-wide significant 
association (lowest P=4.1x10-11 for rs917727) mapping to the 7q.31 locus (Figure 1B).
Figure 1. Genome-wide association of tB-BMD in the discovery cohort. A. Q-Q plot showing the inflation 
of the test statistics when correction for data structure is not applied (green dots) and the loss of power when 
no weight correction is applied (red dots) in comparison with the applied model (black dots) and B. Manhat-
tan Plot of the genome wide association analysis of TB-BMD in the Generation R (discovery) cohort of model 
correcting by age, gender and body weight.
replication of the 7q31.31 association signal
We sought replication of 721 SNPs spanning the region comprised by +/- 500 kb from the 
top associated SNP (rs917727). We did this across five populations with total body DXA 
scans and GWAS data including: the Avon Longitudinal Study of Parents and their Children 
(ALSPAC), the Gothenburg Osteoporosis and Obesity Determinants (GOOD) and the Rot-
terdam Study (RS-I, RS-II and RS-III) cohorts. These replication cohorts were selected to 
153
Meta-analysis of Genome-Wide Scans for Total Body BMD in Children and Adults
cover a wide spectrum of age groups to assess the genetic association with total body 
BMD variation throughout different life periods (Figure 2A) comprising: ALSPAC children 
(n=5,334; mean age 9.9 years), GOOD young adults (n=938; mean age 18.9 years) and a set 
of individuals over age 45 years RS-III (n=1,594; mean age 56.1 years), RS-II (n=750; mean 
67.2 years); and RS-I, (n=2,436, mean age 75.3 years). In addition, a sample of young women 
of Northern European descent (mothers of the Generation R participants) lacking GWAS 
scans, MoGENR, (n=1,014; mean age 38 years) were de-novo genotyped for rs3801387, a 
perfect proxy (r2=1, based on the Hapmap phase II-CEU panel) of the top associated SNP. 
Detailed population characteristics of these cohorts can be found in Table S2. From the 721 
SNPs used in the meta-analysis 20 surpassed the genome-wide significant threshold (Table 
1) whilst a further 22 were suggestive of association (P<1x10-5). These SNPs had a minor allele 
frequency (MAF) ranging between 0.23-0.30 across studies (Table 1). The top associated 
SNP was rs917727 (P=1.28x10-27 and P=2.6x10-31 when including Generation R mothers), 
which had a combined effect of 0.16 SD increment per copy of the minor allele (Figure 
2B). The effect of the rs917727 explained on average 0.9% of the phenotypic variance in 
standardized BMD and had no significant evidence for statistical heterogeneity across the 
meta-analyzed cohorts (I2=17%, P=0.306). The GWAS signal mapped to a 66.3 Kb region of 
high LD (r2>0.8) between the FAM3C and WNT16 genes (Figure 3A).
Conditional analyses for secondary signals
To assess the presence of allelic heterogeneity at the locus we carried out a conditional 
analysis conditioning on the top signal. After meta-analysis we identified a secondary 
independent signal mapping to C7orf58 (Figure 3B) including 67 SNPs surpassing (P<5x10-8) 
genome-wide significant level (Table S3). In general, most of these 67 SNPs were in high 
Figure 2. tB-BMD across cohorts and meta-analysis. A. Mean Total Body BMD in each cohort by gender 
showing the highest BMD levels in young adults and overall higher levels in male than in female partici-
pants. B. Forest plot of the association of TB-BMD and rs917727. Results are reported per copy of the G-allele 
(MAF=0.27).
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LD with each other (r2: 0.80-1.00, based on the Hapmap phase II-CEU panel), displayed 
moderate heterogeneity across cohorts (I2 between 11 and 47%) and had smaller effect sizes 
(standardized SD -0.067 to -0.081) as compared to those observed for the main signal. The 
lead SNP rs4609139 associated at P=1.42x10-10 (Figure S1) had an average MAF of 0.35 across 
studies and a combined effect of -0.08 BMD standard deviations (SE:0.0126) per copy of 
the minor allele, explaining on average 0.2% of the phenotypic variance in standardized 
BMD.
evaluation of covariates
In the discovery cohort we observed prominent effects of the covariates on the SNP-pheno-
type relationships. To illustrate this we present beta estimates as standardized coefficients 
from null-intercept centered models in Table S4 (T-S4). As expected, lack of correction for 
principal components of the sex- and age- adjusted model (Model 0 in T-S4 and Figure 
1A) generated important inflation of the test statistic, which is severely reduced by inclu-
sion of twenty principal components (Model 1 in T-S4 and Figure 1A). Inclusion of weight 
in the sex-, age- and PCs- corrected model (Final Model in T-S4 and Figure 1A) increased 
the significance of the putative signal by reducing the standard error of the SNP effect 
estimate (from 0.030 to 0.022). Such reduction of the error variance led to genome-wide 
significance after weight correction. Weight is an important determinant of peak bone mass 
accrual related to both loading and size effects as illustrated by the positive relationship 
with total body BMD also evident across our SNP-Phenotype models (Table S4).
Association with skull BMD
The impact of weight correction on the standard errors of the association led us to hypoth-
esize that, at least in children, the effect of variants in the WNT16 region on total-body BMD 
was independent of skeletal loading (of which body weight is a proxy). For this reason, 
Figure 3. Association plots for tB-BMD. A. SNP association plot for TB-BMD-associated region of Chromo-
some 7q31.31. B. SNP association plot for TB-BMD-associated region of Chromosome 7q31.31 after condition-
ing on rs3801382. Genetic coordinates are as per HapMap phase II-CEU. *Data from the mothers of Genera-
tion R is not included.
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we analyzed the 721 SNPs of the same genomic region in relation to skull BMD across all 
five cohorts with GWAS data and total body BMD (without Generation R mothers). Skull 
BMD measured by the total body DXA scan constitutes an independent measurement in 
children since the head region is excluded from the total body BMD assessment. This is 
done given the large variation in density and area inflicted by the skull on the head region, 
which is particularly evident in paediatric populations (13). The head DXA region is suitable 
to evaluate the relationships with skeletal loading considering that its direct influence on 
the mineralization process of the skull is negligible. Despite being a skeletal region com-
posed of laminar bones, the proportion of mostly cortical (95% for the inner and outer 
layers) but also trabecular (inner lamella) bone in the skull is similarly high to that of the 
overall skeleton (80% cortical) as compared to other skeletal sites. In addition, the BMD of 
the skull is subject to the same patterns of peak bone mass accrual and decrease with aging 
observed across the lifetime (Figure 4A). Since, as expected, weight was not a significant 
covariate in the analysis of skull BMD (P=0.09) we performed the meta-analysis using a 
sex-, age-, height- and PCs-corrected model across the five cohorts with GWAS data. The 
strongest association signal with skull BMD mapped to C7orf58 (the gene underlying the 
secondary signal of TB-BMD). The most significantly associated SNP was rs7801723 with 
MAF between 0.33 and 0.39 across cohorts and in moderate LD (r2=0.56) with rs4609139 
(secondary signal in TB-BMD). The combined effect of rs7801723 was -0.14 BMD standard 
deviations (SE:0.012) per copy of the minor allele (P=8.9x10-28) showing a high heterogene-
ity I2 of 60.7% and Phet=0.03 (Figure 4B). Moreover, we identified 147 variants in the 7q31.31 
locus achieving genome-wide significance (Table S5) and suggesting the existence of two 
independent signals (Figure 5) in the regional meta-analysis of skull BMD. The rs917727 
Figure 4. Skull-BMD across cohorts and meta-analysis A. Gender-specific mean Skull BMD for each cohort. 
B. Forrest plot of the association of skull BMD with rs7801723. The results are reported per copy of the T-allele 
(MAF=0.37).
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SNP (primary signal of total body BMD) was also associated at genome-wide significant 
level (P=1.9x10-16) with skull BMD with an effect estimate of 0.12 BMD standard deviations 
(SE:0.014) per copy of the minor allele and no evidence for significant heterogeneity (I2=0%).
The heterogeneity at rs7801723 appeared to be driven by different effects in younger 
and older populations (Figure 4B). For this reason, we stratified the analysis according to 
whether individuals within the cohorts had achieved total skeletal maturation (RS-I, RS-II, 
RS-III) or were still in the process of peak bone accrual (GOOD, ALSPAC, GEN-R). The 
rs7801723 signal seemed to be strongest in the younger populations (B=-0.16; P=2.06x10-27) 
since the effect was considerably weaker in older populations (B=-0.08; P=2.7x10-4), though 
differences in power due to lower sample size may also play a role (Figure S2). Meta-regres-
sion across studies showed a significant relation between mean age and absolute effect 
sizes observed for rs7801723 (Figure S3) on skull BMD (Betaage meta-regression= 0.0015; 
P=0.006) but not on total BMD (Betaage meta-regression= 0.0008; P=0.12). In contrast, the 
effect of rs917727 on skull BMD seems to be uniform across older (B=0.14; P=4.16x10-9) and 
younger (B=0.10; P=4.28x10-9) populations, displaying no evidence of effect heterogene-
ity nor a significant relation with the mean age across studies (Betaage meta-regression= 
-0.0006; P=0.19). Similarly, the effect size of rs917727 on total body BMD was not related to 
the mean age of the studies (Betaage meta-regression= -0.0004; P=0.57).
Functional evaluation of the 7q31.31 locus
The effect of variants from the 7q31.31 locus on both total body and skull BMD cannot 
be unequivocally attributed to any of the closest three genes in the GWAS signal region 
Figure 5. Association plots for skull-BMD. SNP association plot for the skull BMD-associated region in chro-
mosome 7q31.31, based on 13,712 individuals from the five different cohorts with GWAS information.
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(WNT16, FAM3C and C7orf58). This is also complicated by the high LD across the region. 
Based on current knowledge, WNT16 is the best candidate at the locus considering that 
it belongs to the Wnt family of proteins. The Wnt signaling pathway plays ubiquitous key 
roles in fundamental biological processes, including those critical for bone biology and 
specifically for bone formation  (14,15). FAM3C is a widely expressed gene (including in os-
teoblasts) which belongs to a cytokine-like gene family without homology to any known 
cytokines (16). Minimal information exits about the functional aspects of C7orf58. Consider-
ing the hypothesis-free nature of our GWAS approach we cannot exclude the possibility 
that any of these genes may code for proteins involved in BMD regulation.
Wnt16 and Fam3c KO mouse models
Further evidence implicating WNT16 as the gene underlying these associations with total 
body BMD at the population level is provided by functional studies on Wnt16 knockout 
(KO) mice generated at Lexicon Pharmaceuticals (Table 2). These KO mice have reduced 
total body BMD at 24 weeks of age, resulting from both reduced total body bone mineral 
content (BMC) and bone area. BMC and aBMD measured at the spine (a skeletal site more 
strongly influenced by trabecular bone than total body or femur measurements) were 
slightly reduced in KO mice but this reduction did not achieve statistical significance. Male 
and female knockout mice appeared healthy with no discernible morphological or growth 
defects, and normal femur length, body weight and body composition. We also examined 
mice from three Fam3c KO models testing for differences across DXA phenotypes with 
table 2. Summary statistics for densitometric properties of control (+/+) and Wnt16 deficient (-/-) mice
Parameter Male
Wt Mice
Male
Wnt16
Ko Mice
Statistics Female
Wt Mice
Female
Wnt16
Ko Mice
Statistics
Number of mice 9 12 24 16
Body Weight (grs) 36.4 ± 1.8 38.5 ± 1.2 Δ = ↑5%, P = 0.42 28.2 ± 0.8 26.8 ± 1.2 Δ = ↓5%, P = 0.30
Lean Body Mass (grs) 27.0± 0.9 27.9 ± 0.7 Δ = ↑4%, P = 0.42 20.5 ± 0.4 19.6 ± 0.6 Δ = ↓4%, P = 0.20
Body Fat (percent) 23.1 ± 2.1 24.9 ± 1.4 Δ =↑8%, P = 0.48 24.2 ± 1.2 23.2 ± 1.6 Δ = ↓4%, P = 0.63
Femur Length (mm) 16.3 ± 0.2 16.2 ± 0.2 Δ = ↑1%, P = 0.58 16.2 ± 0.1 16.1 ± 0.1 Δ = 0%, P = 0.86
Body aBMD (mg/cm2) 56.9 ± 1.1 54.8 ± 0.7 Δ = ↓4%, P = 0.11 53.9 ± 0.6 48.7 ± 0.6 Δ = ↓10%, P < 0.001
Body Bone Area (cm2) 9.4 ± 0.2 8.6 ± 0.3 Δ = ↓9%, P = 0.03 8.9 ± 0.2 8.1 ± 0.1 Δ = ↓8%, P = 0.002
Body BMC (mg) 532 ± 16 470 ± 18 Δ = ↓12%, P = 0.02 479 ± 11 396 ± 10 Δ = ↓17%, P < 0.001
Femur aBMD (mg/cm2) 89.4 ± 3.3 83.6 ± 1.5 Δ = ↓7%, P = 0.10 78.5 ± 1.3 62.8 ± 1.2 Δ = ↓20%, P < 0.001
Femur Bone Area (cm2) 0.36 ± 0.01 0.34 ± 0.01 Δ =↓7%, P = 0.13 0.35 ± 0.01 0.31 ± 0.01 Δ = ↓13%, P < 0.001
Femur BMC (mg) 32.6 ± 1.8 28.0 ± 1.0 Δ = ↓17%, P = 0.03 27.8 ± 0.6 19.5 ± 0.7 Δ = ↓30%, P < 0.001
Spine aBMD (mg/cm2) 61.9 ± 1.5 58.8 ± 3.7 Δ = ↓5%, P = 0.50 62.8 ± 1.8 58.2 ± 1.6 Δ = ↓7%, P = 0.08
Spine BMC (mg) 25.8 ± 0.9 23.2 ± 2.0 Δ =↓10%, P = 0.29 26.3 ± 0.9 24.3 ± 0.9 Δ = ↓8%, P = 0.16
Results provided as [mean +/- SEM]
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wild type animals. We failed to observe any significant differences across the skeletal 
phenotypes in each independent Fam3c KO strategy (Table S6). Even though these data 
suggest Fam3c does not influence bone mass in mice, the possibility of a false negative due 
to power limitations cannot be excluded.
Gene transcript - phenotype correlations
We examined the correlation of gene expression transcript levels derived from iliac bone 
crest biopsies in relation to BMD levels in a distinct cohort of 78 unrelated-Norwegian 
women with total body scans (of which 51% have osteoporosis) and who are part of a set 
(n=84) described in detail previously (17). The investigated region comprised +/-500 Kb of 
rs917727 and contained seven different genes including TSPAN12 (3 transcripts), ING3 (4 
transcripts), C7orf58 (2 transcripts), WNT16 (2 transcripts), FAM3C (3 transcripts), PTPRZ1 (1 
transcript) and one represented by the Affymetrix probe with ID 217206_at lacking annota-
tion. We only identified significant correlations with BMD measurements of the donors in 
transcripts from C7orf58 and WNT16 (Table 3). Expression levels in one of the transcripts in 
WNT16 (224022_x_at) was significantly associated with BMD measured at several skeletal 
sites including the total body, skull, legs, total hip and lumbar spine (L1-L4 vertebrae). The 
correlation was positive and of similar magnitude across sites, ranging between 0.25 and 
0.31, indicating that higher expression of this gene is correlated with higher BMD, results 
which are in line with the Wnt16 KO mice data. Significant correlation with total body lean 
mass was also observed (r2=0.31) for this transcript. This suggests a pleiotropic effect on 
muscle considering that correction for BMI did not importantly influence the correlation 
of the transcript with total body BMD. There is even a stronger (inverse) correlation of total 
body and skull BMD with expression levels of one of the C7orf58 transcripts (228728_at), 
even approaching a correlation of -0.50 with total body BMD. This suggests high C7orf58 
expression levels of this transcript are related to lower BMD. This transcript was inversely 
correlated with body weight as well, but still maintained a strong (inverse) correlation (r2=-
0.45) with skull BMD (which as discussed above, is not readily affected by body weight) 
and also with BMI-adjusted total body BMD (r2=-0.42). In addition, levels of both C7orf58 
transcripts were significantly correlated with age, which further supports the age-specific 
effects seen for the GWAS variants mapping to C7orf58.
DiSCuSSion
In this study we carried out a genome-wide association scan of total body BMD in 2,660 
children with regional replication of the top hit in 12,066 children and adults from six ad-
ditional studies, including de novo genotyping of a sample of 1,014 Northwestern European 
pre-menopausal women, mothers of the children from the discovery cohort. We identified 
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at least two independent signals (primary rs917727 and secondary rs4609139) associated 
with total body BMD mapping to the 7q31.31 locus harboring (among others) two genes 
and an open reading frame sequence including WNT16, FAM3C and C7orf58. To examine 
whether the observed associations were independent of skeletal loading we tested vari-
ants in the 7q31.31 region for association with skull BMD, a non-weight bearing skeletal 
site. We found the rs917727 influencing skull BMD and an even stronger signal arising from 
rs7801723 (in partial LD with rs4609139) which unlike the total body signals was largely 
driven by the younger (children) populations. A DXA-based assessment of the Wnt16 KO 
mice showed a lower total body BMD phenotype which is compatible with an effect of 
WNT16 variants playing a role on total body BMD at the human population level. Moreover, 
the analysis of gene transcript expression profiles supports the involvement of variants from 
both WNT16 and C7orf58. Together, these findings postulate that the WNT16/C7orf58 locus 
contains complex patterns of genetic variation, which play an important role in peak bone 
mass accrual and may likely impact BMD determination at later life.
Genetic variants in the region mapping to FAM3C as the closest gene, have been previously 
reported in the literature as associated with speed of sound as analyzed by quantitative 
ultrasound in radius and calcaneous in a Korean population (18) and in a recent follow-up 
study the same SNPs were genotyped de novo and were found to be associated with bone 
mineral density at different sites in individuals of European descent (19). Nonetheless, to our 
knowledge this is the first time this locus is associated with total body BMD in children. 
Total body BMD measured in children corresponds only to the amount of bone accrued up 
to that point in time; consequently the variants described here have a definite role in the ge-
netic determination of bone acquisition. Furthermore, considering the previously reported 
association in East Asians, the multiethnic background of our discovery population and the 
lack of heterogeneity in the total-body signal, one can conclude the effect of these variants 
is present across populations of different genetic background. To assess this in more detail 
we examined in the multiethnic Generation R discovery cohort the top associated SNPs of 
the meta-analysis across clusters of different ethnic backgrounds (Table S7). We confirmed 
that the effect of the top associated variants was not confined to individuals of European 
descent. Effect directions and magnitude of the markers were largely similar across groups, 
despite some evident differences in linkage disequilibrium patterns between markers.
Without additional functional evaluation it is not feasible to undisputedly distinguish which 
genes in the 7q31.31 region could be underlying the observed GWAS signals. The analysis 
of gene expression profiles provides supporting evidence for the involvement of variants 
from WNT16 and C7orf58, while not for FAM3C in relation to total body BMD and skull 
BMD. Similarly, the lower likelihood of an effect arising from FAM3C is supported by the 
absence of an abnormal skeletal phenotype in the Fam3c KO mice, although we cannot 
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exclude the possibility that variants resulting in gain of function of Fam3c affect bone. In 
contrast, functional evidence of the involvement of WNT16 is well supported by the analy-
sis of expression profiles and the observation of reduced BMD in the Wnt16 KO mice. The 
WNT16 human/mouse sequence alignment shows 93% identity favoring the plausibility of 
similarity in phenotypic effects across both species. Even though the Wnt16 KO mice had 
reductions of both BMC (strongest) and bone area, in humans we found no indication of 
an effect on bone size (area) in either children or adults. This is consistent with the lack of 
any observed association between common genetic variation in this region and adult body 
height as assessed in a sufficiently powered GWAS  (20). We can infer a prominent effect 
of WNT16 on cortical bone in humans considering the close resemblance of the cortical 
phenotype observed in the Wnt16 KO mice to that reported in humans by Zheng et al. 
based on pQCT (accompanying submission). This prominent genetic effect on cortical 
bone is also manifested by the associations of WNT16 variants with BMD traits measured 
at skeletal sites rich in cortical bone including the total body, the skull and the forearm as 
also shown by Zheng et al. (accompanying submission). In addition, Zheng et al. show that 
this effect on cortical bone influences bone strength in mice and fracture risk in humans. 
Nevertheless, the KO mouse data should be interpreted with caution since our functional 
validation sought the confirmation of the KO strategy but did not assess the integrity of 
the surrounding genomic region (i.e. intact FAM3C and/or C7orf58 function). Further, total 
body BMD also involves components of trabecular bone which, together with the associa-
tions previously reported with ultrasound of the heel (18) and lumbar spine (19) (sites of rich 
trabecular content), do not fully exclude an effect of WNT16 (or FAM3C) variants on this 
type of bone.
Both the secondary signal unveiled by our total body BMD GWAS and the strongest signal in 
the skull BMD GWAS analyses map to an open reading frame sequence (C7orf58) in the re-
gion. The effect size for rs4609139 on total body BMD (mapping to C7orf58) was up to 50% 
lower in magnitude than that of rs917727 (mapping in the vicinity of WNT16). In contrast, 
the associations with skull BMD were stronger for variants from the C7orf58 signal than for 
those arising from WNT16. Further study of the mechanisms by which C7orf58 exerts its role 
either independently or together with WNT16 is warranted.
Several aspects derived from the analysis of skull BMD merit further discussion. Skull 
BMD is minimally influenced by loading, muscular activity, and in general less masked by 
environmental influences. From this perspective, fine-tuned mechanosensing mechanisms 
involved in the regulation of bone metabolism can be better dissected examining skull 
BMD. The skull BMD associations arising from the C7orf58 signal are substantially more 
prominent in the younger populations. Such age dependency was not seen for the signals 
arising from WNT16, which also shows effects already evident at young age, but that do 
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persist through adulthood until very old age, as corroborated by the replication studies 
in the older population cohorts. Also, from the strong associations with skull BMD we 
can infer that these effects likely to be arising from WNT16 and C7orf58 are not mediated 
by a mechanosensing response to skeletal loading. A recent study examining expression 
patterns at different skeletal sites in rats has shown differential gene expression patterns 
between the skull, the limbs and the total body, which likely reflects different responses to 
loading and mechanosensing between skeletal sites (21). In the latter study, WNT16 showed 
opposite expression patterns in arms than in skull. While in rats only one isoform is active, 
in humans different WNT16 isoforms could play distinct regulatory roles on skeletal devel-
opment and/or metabolism (22). Alternatively, modulation by other signaling factors could 
also modify the (up-/down-) streaming effects of WNT16. Recently, it has been shown that 
WNT16 influences hematopoietic stem cell differentiation via non-canonical Wnt signaling 
in zebra fish  (23). Whether this is also the case in bone biology remains to be confirmed, 
since its effect through canonical (beta-catenin mediated) activation has already been 
established in cartilage (24).
The allelic heterogeneity demonstrated by the conditional analysis on total body BMD is 
indicative of multiple (at least 2) causal variants in the region within and across phenotypes. 
The associations with TB-BMD observed for the top hits reported in the accompanying 
submission by Zheng et al. (namely rs2707466 for pQCT, rs2536189 for forearm BMD 
and rs7776725 for wrist fracture) are affected differently by conditional analysis on the 
top signal. As predicted by the complete linkage disequilibrium between rs917727 (top 
total body BMD SNP) and rs777625 (top wrist fracture SNP associated with TB-BMD with 
B=0.156; P=2.36x10-27), after conditioning, the effect of rs777625 on TB-BMD is largely gone 
(B=-0.0013; P=0.93). In contrast, the effects on TB-BMD of rs2536189 (forearm BMD from 
B=0.135 P=3.06x10-27 to B=0.042; P=6.7x10-4) and rs2707466 (pQCT from B=0.133 P=5.13x10-25 
to B=0.043 P=6.8x10-4) are not completely explained by their moderate LD (with r2 values 
between 0.51 and 0.55) with the top associated SNP of the TB-BMD GWAS signal.
In addition to the top associated pQCT SNP (rs2707466), there is yet another non-synony-
mous variant (rs2908004) annotated within the coding region of WNT16 which is genome 
wide significant in our meta-analysis of total body BMD. After conditional analysis the effect 
sizes of these non-synonymous SNPs show considerable reduction suggesting there are not 
likely causal to the stronger top GWAS signal. Nevertheless, the residual effect is still signifi-
cant after conditioning (indicating independence and) implying a weaker effect on TB-BMD 
or (more likely) partial linkage disequilibrium with yet other causal variants. Such relation-
ships between genetic variants can follow diverse types of complex relationships as recently 
described for loci displaying allelic heterogeneity (25) for which follow-up investigations are 
warranted to elucidate the definitive involvement of the genes in this 7q31.31 region.
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Finally, this region harbors one or more genes revealing critical effects on bone biology. 
While we have shown that genetic variants in this locus influence total body BMD variation 
in children of multiple ethnic background, the relevance of our findings are manifested 
by the persistence and consistency of the associations observed later in life. Further, the 
prominent effect on total body BMD we describe agrees with associations observed in 
adults across diverse skeletal traits  (18,19) (see also Zheng et al. accompanying submission), 
but most importantly, by their effect on risk of fracture (see also Zheng et al. accompanying 
submission), the most deleterious consequence of osteoporosis.
In summary, this study detected at least two independent GWAS signals influencing total 
body and skull BMD variation in children, thus confirming the presence of allelic heteroge-
neity in this WNT16 locus. In addition, we showed how the effects observed in children are 
consistently replicated in adults. Specific genetic determination of peak bone mass (rather 
than bone loss later in life) is suggested by more prominent effects of some markers in 
children than in adults. These genetic effects likely influence the attainment of peak bone 
mass accrual and impact the risk of osteoporosis and fracture later in life.
MetHoDS
ethics Statement
All research aims and the specific measurements in the participating studies involving hu-
man beings have been approved by the correspondent Medical Ethical Committee. Writ-
ten informed consent was provided by all subjects or their parents in the case of children. 
Mouse studies were performed in accordance with institutional and regulatory guidelines 
for animal care and use at Lexicon Pharmaceuticals.
Subjects
Generation R Study
The Generation R Study is a prospective cohort study in which 9,778 pregnant women liv-
ing in Rotterdam and with delivery date from April 2002 until January 2006 were enrolled. 
Details of study design and data collection can be found elsewhere (26). The current study 
comprised 2,660 children (mean age 6.16, SD=0.39 years), of which 1,511 are of Dutch 
Northern European origin, who had both GWAS and DXA-based BMD measurements. DXA 
measurements were recorded on children visiting a unique research centre at around 5 years 
old accompanied by their mothers. All research aims and the specific measurements in the 
Generation R Study have been approved by the Medical Ethical Committee of the Erasmus 
Medical Center, Rotterdam and written informed consent was provided by all parents.
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Avon Longitudinal Study of Parents and their Children (ALSPAC)
In-silico replication of the GWAS signals was initially pursued in The Avon Longitudinal 
Study of Parents and their Children (ALSPAC). This is a longitudinal population-based birth 
cohort that recruited pregnant women residing in Avon, UK, with an expected delivery date 
between 1st April 1991 and 31st December 1992. This cohort is described in detail on the 
website (http://www.alspac.bris.ac.uk) and elsewhere (27,28). Total body BMD and genome-
wide SNP data were available for 5,334 unrelated children (mean age=9.9, SD=0.32 years) 
all of Northern-European descent. Ethical approval was obtained from the ALSPAC Law and 
Ethics committee and relevant local ethics committees, and written informed consent was 
provided by all parents.
The Gothenburg Osteoporosis and Obesity Determinants (GOOD)
The GOOD Study is a population-based cohort in which male subjects from between 
18 and 20 years of age in the Gothenburg area in Sweden were randomly selected using 
national population registers and invited to participate in this initiative by phone. From the 
selected candidates 1,068 agreed to participate providing oral and written informed con-
sent  (29,30). The GOOD Study was approved by the local ethics committee at Gothenburg 
University. A subset of 938 individuals from this study with DXA measurements and GWAS 
data were included in this analysis.
Rotterdam Study (RS I, II & III)
Additional in-silico replication in elderly adults was pursued in participants of the Rotter-
dam Study, a large prospective population-based cohort study of white subjects aged 45 
years and older living in the Ommoord District of Rotterdam, The Netherlands who are 
studied for the occurrence of chronic diseases and disability (31). Subjects were derived from 
the three different cohorts of the Rotterdam Study including RS-I (n=2,436), RS-II (n=750) 
and RS-III (n=1,594) comprising individuals of Northwestern European Ancestry with avail-
able BMD-DXA measurements and GWAS data. Approval of the Medical Ethics Committee 
of the Erasmus University Rotterdam was obtained for the three cohorts of the Rotterdam 
Study. From all participants written informed consent was acquired.
Bone mineral density measurements
Total body and Head BMD were measured in all participants using dual-energy X-ray ab-
sorptiometry (DXA) following standard manufacturer protocols. GE-Lunar iDXA was the de-
vise used in the Generation R Study while the other cohorts employed GE Lunar (GE-Lunar 
Prodigy; GE Healthcare, Chalfont St Giles, UK). Bone mineral content (BMC) was derived 
from the projected bone area (BA) as BMC (mg) = BMD g/cm2 X BA (cm2). As recommended 
by the International Society for Clinical Densitometry total body less head (TBLH) was the 
measurement used in the Generation R Study and ALSPAC instead of total body BMD (2).
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Genotype assessment
Genotyping was performed using the Illumina HumanHap 610 QUAD microarray in The 
Generation R, GOOD and RS-III cohorts while Illumina HumanHap 550 was the platform 
used for ALSPAC, RS-I and RS-II cohorts. Stringent quality control of the genotype and impu-
tation process was performed in each study (Table S8). Samples with gender discrepancy, 
excess of heterozygosity or duplicates were excluded from analysis. De novo genotyping for 
the Generation R mothers was performed as part of a GEFOS initiative at Kbiosciences for 
specific SNPs of interest in the Osteoporosis field among those rs3801387.
imputation
For the imputation in the discovery Generation R cohort, we built a panel of reference 
haplotypes using HapMap phase II (release 22, build 36) CEU, YRI and CHB/JPT data. A 
two-step imputation process was performed, haplotype phasing and genotype imputa-
tion were carried out using MACH and minimac software, respectively. Imputation of the 
replication cohorts was done using MACH v1 based on the Phase II CEU HapMap data 
(release 22, build 36). Detailed descriptions of quality control and imputation procedures 
are summarized in Table S8.
Statistical Methods
Association between Total Body BMD and GWAS SNPs was carried out using a regression 
framework adjusting for age, gender, weight and population stratification in the Generation 
R discovery cohort using MACH2QTL as implemented in GRIMP(32). Since this is a popu-
lation-based study on unrelated individuals of different ethnic background, 20 genomic 
principal components obtained after SNP quality exclusion criteria and LD pruning were 
used to adjust for population sub-structure reaching a Genomic Inflation Factor (λ) of 1. 
We selected the most associated SNP and SNPs located at +/- 500 kb from the top SNP for 
replication including all markers with a MAF>0.01 and an r2 imputation quality score >0.3 in 
all the participating studies. Additionally, rs3801387 a proxy of the ‘top hit’ (r2=1 in HapMap 
CEU populations) was genotyped in a subset of mothers of the Generation R Study of 
Dutch Northern European background. All replication cohorts included only individuals of 
North European ancestry and thus the correction for stratification was not as astringent as 
for the discovery cohort.
In the genome-wide association study, the association test of SNPs with standardized 
residuals of total body (skull) BMD after adjusting for age, gender, population stratification 
and weight (height) was implemented via Mach2QTL for all cohorts. Moreover, association 
in the mature adults and elderly cohorts, in which ample ranges of age are seen (Rotterdam 
Studies I, II, III and Mothers of Generation R) allowed for a non-linear relationship between 
age and BMD by inclusion of a squared term. On the conditional analysis we selected the 
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most associated genotyped SNP (rs3801382) and applied a regression model including that 
marker besides the mentioned covariates in order to evaluate its effect in the originally 
detected signal(s).
We carried out regional meta-analyses in METAL using the minor allele from HapMap CEU 
genotypes as the coding allele, and applying inverse-variance methodology assuming fixed 
effects. A P value less than 5x10-8 was considered genome-wide significant (GWS). Hetero-
geneity was evaluated using Cochran’s Q statistic and was quantified by I2. (http://www.
sph.umich.edu/csg/abecasis/Metal/). For the meta-regression the absolute value of the 
effect size of the selected SNP (i.e. rs7801723, rs917727) in each trait was regressed on mean 
age of each of the six studies. These analyses were weighted by the inverse of variance of 
the effect; in line with the methodology applied for the meta-analyses.
Knockout mice
Wnt16 and Fam3c knockout (KO) mice were obtained from a program scrutinizing targets 
for drug discovery at Lexicon Pharmaceuticals. F2 hybrid littermates were derived from 
C57BL/6J and 129 SvEv parental strains. The 28 knockout mice (16 females) were gener-
ated by homologous recombination removing the first three exons of Wnt16. A three-fold 
strategy was used to generate Fam3c KO mice including a gene-trap (G-T) disrupting the 
intron between the first two exons of 6 mice (3 females); homologous recombination 
removing the first two exons (HR#1) of 8 mice (4 females); and homologous recombination 
replacing the whole gene of 8 mice (4 females) by the human gene (HR#2) resulting in loss 
of function. Confirmation of the exon disruption in Wnt16 and Fam3c (HR#1) was achieved 
with Southern blot hybridization analysis while RT-PCR was used to confirm lack of gene 
expression of Fam3c (G-T) in KO mice (see Zheng et al. for details). Successful disruption of 
the Fam3c gene in all three KO strategies was demonstrated by a consistent hematological 
phenotype (data not shown). Male and female mice were scanned using a PIXImus DXA at 
24 weeks (Wnt16 KO comparison) and 14 weeks (Fam3c KO comparison) of age. BMD (and 
body composition) measurements were obtained from total body (excluding skull), femur 
and spine scans. Bone mineral content (BMC) was derived from the projected bone area 
(BA) as BMC (mg) = BMD mg/cm2 X BA (cm2). Student’s t-tests were used to assess statistical 
significance (P<0.05) of the differences within each sex.
Gene transcripts expression levels from trans-iliacal bone biopsies
Gene expression profiles from all transcripts located within +/- 500kb of the rs917727 
SNP in locus 7q31.31 were analyzed within an eQTL dataset of 78 Norwegian women, who 
make part of the set published by Reppe and colleagues (17). Of these 78 women, 40 had 
osteoporosis (T-score less than -2.5), 7 had osteopenia (T-score between -2.5 and -1) and 31 
were normal (T-score greater than -1) as ascertained by the BMD measurement at the total 
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hip or lumbar spine (L1-L4 verterbrae). The Affymetrix HG U133 2.0 plus array was used for 
the expression analysis. The Affymetrix Cel files were imported into Partek Genomics Suite 
(Partek Inc., St Louis, MO, USA), and normalized using the RMA (Robust Multichip Average) 
algorithm. Further normalization was done by removing batch effects and patterns of gene 
expression levels due to differences in synthesis times across samples.
Detailed acknowledgements and online resources can be found in the published article 
online: http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1002718
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ABStrACt
Background: Bone mineral density (BMD) is used for the assessment of bone health in 
children and diagnose osteoporosis in the elderly population. While in pediatric popula-
tions, BMD is preferably measured from total body scans (TB-BMD); in adults, lumbar spine 
(LS) and femoral neck (FN) are traditionally used. Genetic factors explain 50-80% of BMD, 
depending on the site of measurement and study design. To date, more than sixty genetic 
loci have been associated with this trait, most of them associated with LS and FN-BMD 
in the elderly population. Here, we investigated if TB-BMD may constitute an adequate 
phenotype for genetic studies when applied to the whole population. Methods: We 
performed a meta-analysis of 26 genome-wide association studies (GWAS) on TB-BMD 
including 52,680 individuals. Also, we applied conditional analysis to determine indepen-
dent association signals and evaluate their novelty. results: We identified genome-wide 
significant variants in 55 loci of which 18 are novel and enriched for genes with a proven 
role in bone biology mainly as factors in the Wnt signalling pathways. Also, we identified 
independent signals in nine known loci associated with bone traits. Conclusion: TB-BMD 
is a relevant trait for genetic studies of osteoporosis, capable of identifying (novel) variants 
influencing different bone compartments at different skeletal sites. We identified 18 novel 
genetic loci influencing BMD variation, including several with factors embedded in Wnt 
signaling and a handful unknown to bone biology. These results notoriously contribute to 
our knowledge of BMD genetic determination and highlight the efficiency of increasing 
sample size for the discovery of new genetic variants.
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introDuCtion
Osteoporosis is a disease characterized by low bone mass and microarchitectural dete-
rioration of bone tissue leading to increased risk(1). Clinically, osteoporosis is diagnosed 
through the measurement of bone mineral density (BMD) utilizing dual-energy X-ray 
absorptiometry (DXA), which remains the single best predictor of fracture(2,3 ). A recent 
study included BMD in the global burden estimates as a risk factor for fractures after fall 
and concluded that low BMD is responsible for a growing global health burden, probably 
related to the global growth of the aged population(4).
Bone is a dynamic tissue that is constantly undergoing bone resorption and bone forma-
tion. BMD at any age is the result of bone accrued during growth, until the third decade of 
life and the subsequent bone loss thereafter. The International Society for Clinical Densi-
tometry recommend DXA measurements at the lumbar spine (LS), femoral neck (FN) and 
total hip to predict osteoporosis in postmenopausal women and men 50 years or older (5). 
Consequently, studies of modifiable and non-modifiable factors affecting BMD are based 
on measurements at these skeletal sites. On the other hand, for the assessment of bone 
health in children, from infancy to adolescence, total body less head and LS are the pre-
ferred sites for measurement (6). As DXA is a projection of a 3-D structure into a 2-D image, 
the continual growth of bone in children introduce an error in this assessment and thus, 
larger skeletal sites with large areas are preferred(7). Nevertheless, also in adults, total body 
DXA scans are commonly available, as they are used to measure total body composition 
and fat content with a high degree of accuracy.
In twin and family studies, the heritability of BMD has been estimated to be 50%-85%(8-10). 
These estimates can vary due to the analytical model used, the skeletal site measured and 
the population under study (11). Up to date, around 60 different loci have been shown to be 
robustly associated with BMD variability in adults  (12-15). Several of the associated variants 
display significant effects on a site-specific manner. It is plausible that these differences can 
be the result of bone composition dissimilarities across different skeletal sites (e.g. cortical 
bone vs. trabecular bone) or response to mechanical loading, which also varies across 
skeletal sites(15).
The purpose of this study was to identify gene variants associated with total body BMD 
(TB-BMD). The selection of TB-BMD as phenotype of interest allowed us to reach the 
largest GWAS of BMD to date. Also, as the total body BMD measurement incorporates 
components of both cortical and to a lesser extent trabecular bone, we expected to be 
able to identify variants which would not be necessarily discovered in a site-specific study.
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Study Populations
Subjects
This study comprised 26 GWA studies comprising ~52,680 individuals from populations 
across America, Europe, and Australia, with a variety of epidemiological designs (Supple-
mentary table 1) and participant characteristics (Supplementary table 2). All research aims 
and the specific measurements in the participating studies have been approved by the 
correspondent Medical Ethical Committee of each participating study. Written informed 
consent was provided by all subjects or their parents in the case of children.
BMD measurement
Total body BMD (g/cm2) was measured in all participants using dual-energy X-ray ab-
sorptiometry (DXA) following standard manufacturer protocols. As recommended by 
the International Society for Clinical Densitometry total body less head (TBLH) was the 
measurement used in pediatric cohorts  (16) (e.g., 0-15 years). Detailed information on this 
assessment per study can be found in Supplementary table 1.
GWAS data and imputation
All individuals included in this study had genome-wide array data, except for the PANIC 
study genotyped with the Metabochip. Quality control of the obtained genotypes is sum-
marized in Supplementary table 1. To enable meta-analysis, each study performed geno-
type imputation using the cosmopolitan (all ethnicities combined) 1000 genomes phase 1 
version 3 (March 2012) reference panel (17), via MACH/Minimac(18,19) or SHAPEIT/Impute2(20) 
suites yielding ~ 30,000,000 SNPs for analysis.
Association Analyses
TB(LH)-BMD was corrected for age, weight, height and the genomic principal components 
(derived from GWAS data), as well as any additional study-specific covariates (e.g. recruit-
ing center), in a linear regression model. For studies with non-related individuals, residuals 
were computed separately by sex, whereas for family-based studies sex was included as 
a covariate in the model. Finally, residuals were subject to inverse normal transformation. 
SNP association was tested for autosomal variants, in which the additive effect of each SNP 
on the normalized BMD-residual was estimated via linear regression using MACH2QTL(18), 
SNPtest(21), PLINK(22) or ProbABEL(23).
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Quality control of TB-BMD association summary statistics
A centralized quality-control procedure implemented in EasyQC (24) was applied to all study-
specific association files to identify cohort-specific problems: (1) assessment of possible 
problems in BMD-residuals normalization by inspection of standard error vs. sample size 
plots; (2) comparison of allele frequency alignment against 1000 Genomes Project phase 1 
reference data to pinpoint any potential strand issues; (3) examination of quantile-quantile 
(QQ) plots and genomic inflation factors per study to identify problems arising from popu-
lation stratification, cryptic relatedness and genotype biases; (4) analytical problems in the 
computation of beta estimates, standard errors and P-values by evaluation of P-Z plots.
In addition, we excluded variants if they had missing information (e.g., missing asso-
ciation P-value, effect size (beta) estimate, alleles, allele frequency), or nonsensical values 
(e.g., absolute beta estimates or standard errors >10, association P-values (P) >1 or <0; or 
imputation quality < 0; infinite beta estimates or standard errors); minor allele frequency 
(MAF) less than 0.5%; Imputation quality <0.4 (when Impute2 was used for imputation) and 
<0.3 (when Minimac was used for imputation). Moreover, markers were flagged if they had 
large allele frequency deviations from reference populations (>0.6 for admixed studies and 
>0.3 for ancestry-specific studies).
The meta-analysis of all individuals per participant cohort consisted of 26 studies compris-
ing ~52,680 individuals. Although no exclusion criteria were applied based on the ethnicity 
of the individuals included in each study, more than 80% of them were reported as of 
European ancestry (Supplementary table 1). We discarded markers present in less than 
three studies; approximately 23,700,000 markers (both SNPs and INDELS) were assessed 
for association. We used the conventional genome-wide significance level (GWS, P<5x10-8) 
for SNP discovery.
Conditional meta-analyses
Conditional analyses were undertaken based on the combined meta-analysis of the studies 
of European ancestry only (N=42,352). To note, only those loci which reached GWS in the de-
scribed meta-analysis of cohorts of European ancestry were assessed. The Rotterdam Study 
I (n=6,291) was used as a referent for precise calculation of the linkage disequilibrium (LD) 
between the analyzed markers. We used an iterative strategy as implemented in GCTA(25,26) 
(P<5x10-8) to determine: 1) independence of association signals within loci discovered in our 
study, by means of stepwise model selection procedure per chromosome (--massoc-slct 
routine. 2) the novelty of the association signals discovered by our meta-analysis with regard 
to variants reported in previous well-powered GWAS of different bone traits (Supplementa-
ry table 3). To this end, we performed the association analysis conditional on 74 bone-traits 
associated variants (--massoc-cond routine). These 74 SNPs were selected from different 
GWAS publications (12-15,27-29), assuring their inter-independence to avoid collinearity issues.
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Search for biological and functional knowledge of the identified association 
regions
For all those SNPs not within 500Kb of the bone GWAS SNPs (hereinafter referred as novel) 
we checked in PubMed and Web of Science if nearby genes (within 500Kb) were known 
to play a role in bone metabolism. Also, we determined if the annotated genes underlie 
any human Mendelian disorder with a skeletal manifestation, had KO mouse models with 
a skeletal phenotype or were annotated to pathways critical to bone metabolism. Genomic 
annotation for all SNPs was made based on UCSC hg19 assessed through Bioconductor (30).
Pathway analysis
We used a recently developed method, DEPICT(31) to identify enriched genes-sets as well 
as tissues/cell types where genes from associated loci are highly expressed. The methodol-
ogy first selects all lead SNPs below a certain threshold with respect to a target P-value 
(GWS SNPs, P<5x10-8). Additionally, we used clusterProfiler (32)developed in R(33) for a Gene 
Ontology (GO) enrichment analysis(34). This analysis opposite to DEPICT included not only 
the genes in LD r>0.5 with the index SNP but also the nearest transcribed element as input. 
Given the redundancy of GO terms, we have used the REVIGO tool to prune the results 
employing the simRel algorithm and a threshold of 0.5 for allowed similarity (35). Adjusted 
P-value of all enrichment analysis were obtained by False Discovery Rate (FDR) method.
reSultS
GWAS meta-analysis the overall population
Meta-analysis of all cohorts resulted in 52 different loci associated with TB-BMD at GWS 
level (Figure 1). Genomic inflation factor for the meta-analysis was 1.06 providing no evi-
dence for population stratification, cryptic relatedness or technical artifacts as illustrated in 
the Q-Q plots. The highest inflation of the test statistic was observed for the common SNPs 
(0.2<MAF<0.5) reaching 1.14. From the 52 identified loci, 16 (31%) were not located within 
500 kb from index SNPs previously associated with any bone trait through GWAS nor in 
regions of extended LD with them (table 1). Sixty-seven out of the 74 index SNPs in loci 
known to be associated with bone traits, were associated with TB-BMD in our study at a 
nominal level (P<0.05) (Supplementary table 3).
Index SNPs of association signals located in the 16 novel loci were, in general, common non-
coding markers. Twelve of them map nearby genes likely to influence bone metabolism 
(table 1, Supplementary Figure 1). Fourteen of these sixteen index SNPs had concordant 
effect direction and were nominally associated with either LS-BMD or FN-BMD in the last 
published GEFOS meta-analysis for these traits(13) (table 1).
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N= 52,000; GIF=1.06
Figure 1. Manhattan plot of association statistics (-log10(P values)) for tB-BMD trans-ethnic meta-analysis. 
Each dot represents an SNP and the x-axis indicates its chromosomal position (built 37 NCBI). Red dots rep-
resent SNPs not within ±500Kb of leading SNPs in previous GWAS with different bone traits. Dashed horizon-
tal red and yellow lines mark the GWS threshold (P<5x10-8) and suggestive threshold (P<1x10-6), respectively. 
Novel loci in the only-CEU analysis are not shown.
Figure 2. Manhattan plots of association statistics (-log10(P values)) for tB-BMD only-european meta-anal-
ysis. Each dot represents an SNP and the x-axis indicates its chromosomal position (Build 37 NCBI). Dashed 
horizontal red and yellow lines mark the GWS threshold (P<5x10-8) and suggestive threshold (P<1x10-6), re-
spectively. top: The association Pvalue (on –log10 scale) in the meta-analysis including only studies comprising 
individuals of European ancestry. Bottom: The association Pvalue (on –log10 scale) after conditional analy-
sis on all variants described in Supplementary Table 3. Highlighted in blue already known loci (SNPs within 
±500Kb of leading SNPs in previous GWAS with different bone traits).
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Genetic studies of TB-BMD yield eighteen novel loci involved in bone biology
Meta-analysis based in studies with european ancestry
We conducted a step-wise conditional approach in order to determine the independent 
SNPs associated with TB-BMD including studies comprising only individuals of European 
ancestry. The first step consisted of a meta-analysis based only in these 20 cohorts. We 
identified 45 loci associated with the trait (Figure 2). Of these, three loci surpassed the GWS 
threshold in the only-European analysis despite only being suggestive in the larger trans-
ethnic meta-analysis. Two of them (e.g., 10q26.13 (BTBD16) and 12q21.33 (BTG1)) were novel 
(table 1, Supplementary Figure 1). Whereas the remaining signal mapped to the already 
known PKDCC locus.
Conditional analysis based in studies with european ancestry
To perform adequate conditional analysis, we opted to exclude non-European cohorts 
leaving for this analysis ~80% of the original sample size (N=42,352). As a consequence of 
this lower sample size, 9 of the 52 initially discovered loci in the trans-ethnic meta-analysis 
did not reach the GWS threshold and were excluded from the conditional analysis. All 
of the excluded signals were novel and included 2p11.2 (TCF7L1), 5q22.2 (APC), 5q23.2 
(CNK1G3), 11p13 (LDLRAD3), 15q14 (TMCO5A), 15q22.33 (SMAD3), 16q22.3 (ZFHX3), 17q24.1 
(CEP112) and 20q12 (MAFB). Yet, index SNPs from eight of these loci were all suggestively 
associated with TB-BMD in this meta-analysis (5x10-8<P<5x10-6).
We performed an approximate conditional analysis which resulted in the identification of 
55 independent SNPs mapping to 45 different loci. Loci harboring 1p36 (WNT4/ZBTB40), 
6q22.33 (RSPO3), 6q25.1 (ESR1/CCDC170), 7q31.31 (WNT16/CPED1), 13q14.11 (AKAP11/
TNFSF11), 17q21.31 (SOST/UBTF), 11p14.1 (CCDC34/LINC7), and 11p15.2 (SOX6) depicted 
multiple distinct signals attaining GWS (table 2). The TB-BMD variance explained by these 
55 variants reached 8.1%.
We next investigated if variants reaching GWS in our analysis were independent of previous 
variants associated with bone traits in well-powered GWAS meta-analysis (Supplementary 
table 3). Our analysis revealed that in nine of the loci previously reported as associated 
with bone traits, we identified statistically independent signals (Figure 2). None of the 
subset of new loci inquired in the approximate conditional analyses: 2q33.1 (FZD7), 7p14.3 
(AQP1), 10q26.13 (BTBD16), 11p15.5 (RIC8A), 12q21.33 (ATP2B1), 12q21.33 (BTG1), 21q22.12 
(RUNX1) and 1p13.3 (CSF1), showed secondary signals, and only CSF1 did not reach GWS 
when conditioning for known variants (Pbefore_cond=3.7x10-8, Pafter_cond=1.1x10-7).
Biological and functional knowledge of the identified association regions
Novel loci and their potential role in bone metabolism are summarized in table 1. 
Across these novel loci, we identified only one coding marker associated with TB-BMD, 
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table 2. independent SnPs associated with BMD in the only –european meta-analysis. Each locus is named 
according to either the most biologically relevant candidate gene in the region, or the gene that is physically 
closest to the most strongly associated SNP. Note that in the vast majority of instances neither the identity of 
the true functional variant(s), nor the particular gene responsible for the association is known with certainty
Chr BP rsiD A1 freq1 effect P effect_joint P_joint ± 500 Kb locus
1 22484575 rs3971300 T 0.70 0.072 1.33E-18 0.075 1.02E-19 yes WNT4
1 22692315 rs12728589 C 0.18 0.102 1.05E-26 0.104 5.77E-28 yes ZBTB40
1 68656697 rs2566752 T 0.61 -0.074 2.71E-23 -0.074 5.61E-23 yes WLS
1 2.41E+08 rs12044944 T 0.19 0.052 1.48E-08 0.052 1.78E-08 yes FMN2
2 40630678 rs10490046 A 0.76 0.047 3.69E-08 0.048 2.70E-08 no SLC8A1
2 42194758 rs2374385 A 0.22 -0.049 4.72E-08 -0.050 3.23E-08 yes PKDCC
2 1.2E+08 rs62159873 T 0.21 -0.061 7.39E-10 -0.061 8.32E-10 yes EN1
2 1.67E+08 rs7586085 A 0.52 0.052 6.89E-13 0.052 5.82E-13 yes GALNT3
2 2.03E+08 rs6716216 A 0.88 -0.069 3.70E-10 -0.069 3.20E-10 no FZD7
3 41118898 rs419918 C 0.52 0.065 2.62E-19 0.065 3.51E-19 yes CTNNB1
3 1.57E+08 rs11717138 T 0.23 -0.048 2.32E-08 -0.048 2.32E-08 yes LEKR1
4 1008972 rs74569579 A 0.15 -0.070 2.87E-10 -0.070 3.33E-10 yes IDUA
4 88831249 rs11934731 A 0.68 -0.061 3.00E-15 -0.061 3.68E-15 yes MEPE
5 88376061 rs1366594 A 0.52 0.047 1.03E-10 0.047 1.23E-10 yes MEF2C
6 44639184 rs11755164 T 0.40 -0.047 5.42E-10 -0.047 4.45E-10 yes SUPT3H/RUNX2
6 1.27E+08 rs13220518 A 0.22 -0.060 1.66E-12 -0.055 7.99E-11 yes RSPO3
6 1.27E+08 rs4580892 T 0.30 0.060 1.01E-13 0.055 5.72E-12 yes RSPO3
6 1.52E+08 rs6557155 T 0.42 -0.073 3.64E-22 -0.075 2.31E-23 yes ESR1/CCDC170
6 1.52E+08 rs7765040 A 0.84 0.056 2.76E-08 0.061 1.48E-09 yes ESR1/CCDC170
7 30957702 rs28362721 T 0.18 -0.065 1.48E-10 -0.065 1.09E-10 no AQP1
7 38136277 rs1524058 T 0.40 -0.051 2.21E-12 -0.052 1.39E-12 yes STARD3NL
7 96133319 rs6965122 A 0.69 0.076 3.05E-23 0.076 4.76E-23 yes SLC25A13
7 1.21E+08 rs6950680 A 0.63 0.055 1.29E-13 0.072 8.84E-22 yes CPED1
7 1.21E+08 rs3801387 A 0.74 -0.135 4.27E-63 -0.165 5.81E-82 yes WNT16
7 1.21E+08 rs2041490 C 0.18 0.018 0.06782 0.067 2.90E-11 yes WNT16
7 1.21E+08 rs6952513 T 0.07 0.104 4.71E-12 0.104 4.34E-12 yes FAM3C
7 1.51E+08 rs113810201 A 0.88 -0.071 7.68E-11 -0.071 6.60E-11 yes ABCF2
8 1.2E+08 rs1485307 T 0.44 0.075 8.52E-25 0.075 1.58E-24 yes TNFRSF11B
9 1.33E+08 rs10901216 A 0.35 -0.048 3.56E-10 -0.048 3.61E-10 yes FUBP3
10 54420223 rs7070913 A 0.12 -0.078 9.89E-12 -0.078 1.01E-11 yes MBL2/DKK1
10 1.24E+08 rs6585812 T 0.52 0.040 2.24E-08 0.040 2.58E-08 no BTBD16
11 249408 rs17655188 A 0.22 0.056 3.36E-11 0.056 3.30E-11 no RIC8A
11 15695331 rs9787942 T 0.21 0.054 9.69E-10 0.056 1.77E-10 yes SOX6
11 15814794 rs11023718 T 0.04 0.128 7.61E-10 0.119 1.17E-08 yes SOX6
11 16249659 rs10766308 A 0.26 0.054 2.14E-11 0.052 2.22E-10 no SOX6
11 27308483 rs10450586 C 0.61 -0.051 4.69E-12 -0.053 5.66E-13 yes CCDC34
183
Genetic studies of TB-BMD yield eighteen novel loci involved in bone biology
rs77447196/G (11:280464, MAF=0.21) in the NLRP6 gene (Pro244Ala), which is cataloged 
as benign both by SIFT and polyphen2. Also, we report 32 GWS coding variants in known 
loci from which 20 are non-synonymous. A low-frequency variant in LRP5, rs4988321/A 
(11:68174189, MAF=0.04), is predicted to be damaging by both polyphen2 and SIFT (Val-
667Met). Moreover, a homozygous G-to-A transition of this variant was identified in a 
patient with osteoporosis-pseudoglioma syndrome (36). Another common variant in ESPL1 
rs1318648/C (12: 53670545, MAF=0.36) is also cataloged as probably damaging and damag-
ing in polyphen2 and SIFT, respectively; nevertheless, this variant has no clinical annotation. 
Mice and rat knockout models of several genes in the implicated loci, show an impaired 
skeletal phenotype (e.g., Csf1(37), Aqp1(38), Apc(39), Ric8a(40), Runx1(41), Smad3(42), Btg1(43)).
Pathway analysis
To prioritize genes at the associated regions, define possible pathways by enrichment test-
ing and identify tissue and cell types in which genes from loci associated with TB-BMD were 
highly expressed we used DEPICT. DEPICT prioritized 43 genes and 271 pathways (Supple-
mentary table 4). Also, there was significant enrichment expression of genes within loci 
associated with TB-BMD (FDR<0.05) in muscular and cartilaginous tissues and cells. 
table 2 (continued)
Chr BP rsiD A1 freq1 effect P effect_joint P_joint ± 500 Kb locus
11 27593899 rs1352479 A 0.28 0.043 3.32E-07 0.046 4.13E-08 yes LINC7
11 46856536 rs10838622 T 0.37 0.053 1.66E-11 0.053 1.69E-11 yes CKAP5
11 68218290 rs11228240 T 0.26 -0.086 1.00E-23 -0.086 9.37E-24 yes LRP5
11 86887931 rs634277 A 0.67 0.058 2.18E-13 0.058 1.74E-13 yes TMEM135
12 49385679 rs10875906 T 0.27 0.048 3.42E-08 0.049 1.68E-08 yes DDN
12 53743064 rs10735851 A 0.71 -0.057 1.62E-12 -0.057 7.98E-13 yes SP7
12 90334829 rs10777212 T 0.35 0.045 3.25E-09 0.045 3.22E-09 no ATP2B1
12 92597520 rs11106464 A 0.23 0.049 1.14E-08 0.049 1.37E-08 no BTG1
12 1.07E+08 rs759603 T 0.50 0.042 5.92E-09 0.042 4.65E-09 yes RIC8B/TMEM263
13 42952145 rs9594738 T 0.47 -0.071 1.30E-22 -0.064 8.38E-19 yes AKAP11
13 43077245 rs116926994 A 0.97 -0.173 5.12E-14 -0.145 4.67E-10 yes TNFSF11
14 91445162 rs1286079 T 0.19 0.055 3.39E-09 0.055 3.85E-09 yes RPS6KA5
16 392318 rs8047501 A 0.49 0.054 9.58E-13 0.054 1.02E-12 yes AXIN1
17 2064702 rs2873195 A 0.32 -0.043 3.15E-08 -0.043 3.56E-08 yes SNG6
17 41798621 rs66838809 A 0.08 0.125 1.36E-17 0.127 7.01E-18 yes SOST
17 42281282 rs4473241 T 0.31 0.045 3.30E-08 0.046 1.71E-08 yes UBTF
18 60054857 rs884205 A 0.25 -0.053 5.51E-10 -0.053 5.73E-10 yes TNFRSF11A
20 10640877 rs6040063 A 0.50 0.042 3.90E-09 0.042 3.07E-09 yes JAG1
21 36963137 rs118052194 T 0.59 0.043 2.30E-08 0.043 1.89E-08 no RUNX1
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Based only on the novel variants DEPICT defi ned 17 loci -the LDLRAD3 locus was not in-
cluded as reference data derived from European ancestry- and genes mapping to these 
loci showed enrichment of expression only in eight cells and tissues, from which fi ve are 
related to the musculoskeletal system (Figure 3). No signifi cant enrichment for pathways or 
prioritized genes were uncovered (FDR<0.05). Nevertheless, C15orf61, ZFHX3, REEP5 and 
FZD7 were nominally prioritized. Additionally, we used the transcribed elements defi ned 
by DEPICT per locus to assess GO enrichment. The ATP2B1, BTG1 and TMCO5 genes in table 
1 were not included as they failed both conditions regardless of being less than 500Kb from 
the index SNP. LDLRAD3 was added to the list as the index SNP is intronic to this gene. 
Figure 3. Pathway enrichment and tissue expression of genes at the novel tB-BMD-associated loci 
(FDr<0.05). top panel: Gene Ontology (GO) enrichment analysis for 27 genes only the top 10 results are 
shown. Bottom panel: Enrichment and tissue expression of genes on the basis of expression patterns in 37,427 
human microarray samples, annotations found to be signifi cantly enriched by DEPICT are shown, grouped by 
type and signifi cance. Specifi c genes at the loci were signifi cantly enriched for expression in musculoskeletal-
related cells and tissues (highlighted in black).
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Pruned analysis of GO enrichment resulted in 55 enriched GOterms at an FDR<0.05 thresh-
old (Supplementary table 5). The GOterm with the highest enrichment was “negative 
regulation of cell differentiation” (APC, SMAD3, ZFHX3, AXIN2, FZD7, TCF7L1, RUNX1,and 
MAFB). Among the ten GO terms more significantly enriched three were related to Wnt 
signaling pathways including: “Catenin import into the nucleus” (SMAD3, AXIN2 and FZD7), 
“Wnt signaling pathway” (CSNK1G3, APC, SMAD3, AXIN2, FZD7 and TCF7L1) and “canonical 
Wnt signaling” (APC, SMAD3, AXIN2, FZD7 and TCF7L1). Also, the term “regulation of os-
sification” (CSF1, APC, SMAD3 and AXIN2) was significantly enriched (Figure 3).
DiSCuSSion
This meta-analysis of TB-BMD in up to 52,000 individuals emerges as the largest discovery 
GWAS ran for BMD to date. We have identified 18 novel loci and replicated at GWS several 
known association signals with diverse bone phenotypes. Loci identified for the first time by 
our study comprised genes enriched for expression, almost exclusively, in musculoskeletal-
related cells and tissues, and solidly represented in the Wnt Signaling pathway. Conditional 
analysis confined to studies of European ancestry identified secondary signals in 9 of the 
known associated loci. We have identified six loci unknown to bone biology whose role in 
BMD variation reminds to be elucidated. These results emphasize the suitability of TB-BMD 
as a phenotype to study the genetic factors influencing bone quality.
Traditionally, DXA-BMD measurements at sites of high fracture risk (i.e., femoral neck, lum-
bar spine and forearm) have been used in genetic epidemiological investigations of bone 
health in adults. Instead, we have used BMD derived from total body scans, widely avail-
able because of their appropriateness to study body composition. Not only we show a high 
overlap of association signals with previous GWAS of different bone traits but also identi-
fied novel loci, demonstrating that TB-BMD offers a powerful alternative to identify genetic 
variants associated with bone metabolism. We have scrutinized 74 previously reported 
signals of association with diverse bone traits and 39 of them surpassed GWS threshold in 
our meta-analysis. From these, 36 were previously associated with DXA-derived measure-
ments of BMD at specific skeletal sites: 23 with both FN-BMD and LS-BMD(12), 5 only with 
FN-BMD(12), another 5 only with LS-BMD(12,13), 1 with Hip-BMD(29), and other 2 with pediatric 
skull BMD(15) and TB-BMD(14). Moreover, we also replicated association signals obtained 
from bone phenotypes acquired with techniques other than DXA, as ultrasound BUA and 
VOS measures(28) or cortical and trabecular vBMD derived from pQCT(27) (Supplementary 
table 3). Additionally, other 28 reported association signals, have consistent effect direc-
tion and a nominally significant evidence of association in our analysis.
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Association signals at seven loci failed to replicate in our study (index SNPs: rs148771817 
(7q31.31), rs754388 (14q32.12), rs7017914 (8q13.3), rs7071206 (10q22.3), rs7953528 (12p11.22), 
rs1878526 (2q14.2), rs3905706 (10p.11.23)). The last four markers reported significant site 
effect heterogeneity in Estrada et al. (12). Of note, these markers were only nominally associ-
ated in the latest GEFOS discovery meta-analysis of FN-BMD and LS-BMD (13) with the same 
BMD trait for which they were discovered. These results suggest that variants whose effect 
is highly site-specific cannot be detected in our TB-BMD meta-analysis. Whilst, this event 
involved a limited number of the tested known variants (<10%), it is plausible that more 
variants of this type exist and will be discovered as site-specific BMD meta-analysis increase 
in size. Furthermore, the rs7017914 mapping to the XRK9 locus was identified as associated 
with FN-BMD only in females(12), while our study is sex-combined. Also, the rs754388 map-
ping to the RIN3 locus has only been associated with pediatric BMD (15). This particular SNP 
shows high effect heterogeneity in our meta-analysis (Phet=3x10-5) probably as a result of the 
different age ranges of the participating cohorts. Also, even if rs148771817 (WNT16/CPED1) 
and rs1878526 (INSIG2) did not replicate in our study, neighboring variants (within 500Kb), 
not in LD with them, reached GWS evidence of association.
The transethnic meta-analysis presented no evidence of population stratification and 
identified 52 loci associated with BMD. Index SNPs from these loci were in a vast majority 
common non-coding variants. In six of these loci, index SNPs show high effect heterogene-
ity (Phet<0.05), however, neighboring variants also reaching GWS exist in all these but the 
LDLRAD3 locus. The index SNP of this association signal, the rs113964474 variant, located in 
the first LDLRAD3 intron, is monomorphic in all our European studies, ergo the association 
was confined to four studies. The low allele frequency (MAF= 0.025) of this variant and our 
limited statistical power (N=6,748), allude this might be a false-positive association signal, 
and replication of this finding is necessary. Nevertheless, plasma lipids have been previ-
ously associated with BMD(44), and several other low-density lipoprotein receptors have 
been described as playing a role in the maintenance of bone (e.g., LRP4, LRP5 and LRP6)(45).
Index SNPs in the remaining discovered loci, all but one had consistent effect direction and 
nominally significant association with FN-BMD or LS-BMD, implying a low probability for 
false-positives among these findings (table 1). The association signal in 5q21, whose index 
SNP rs438252 maps to SREP19, although, in high linkage disequilibrium with variants in REEP5 
and APC was not significantly associated with LS- or FN-BMD. None of the variants reaching 
GWS in this locus is functional, complicating the identification of the gene underlying the 
association. DEPICT nominally significantly prioritize REEP5 in this locus. Nevertheless, APC 
can affect osteoblast viability and signaling  (46) and its KO mouse model shows impaired 
skeletogenesis (all endochondral bones were misshaped and lacked structural integrity)(39), 
making it a strong candidate to drive the unveiled association.
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We also performed a meta-analysis including only studies from European ancestry iden-
tifying three loci which did not reach GWS in the trans-ethnic meta-analysis. Moreover, 
ten of the novel BMD-loci did not reach GWS in the European only meta-analysis. Both 
differences in MAF or effect size for these variants suggest that the differences observed 
between these analyses is a consequence of the change in sample size and not to the dif-
ferent population structure embedded in each of them. The conditional analysis identified 
55 independent SNPs associated with TB-BMD mapping to 45 different loci which together 
explained 8.03% of the TB-BMD variance. Loci harboring CCDC34/LINC7, RSPO3, WNT4/
ZBTB40, ESR1/CCDC170, WNT16/CPED1/FAM3C, AKAP11/TNFSF11, SOST/UBTF, and SOX6 
depicted multiple distinct signals attaining GWS.
Allelic heterogeneity in the latter six loci has already been established by previous meta-
analyses(12,13), Conditioning on the known variants associated with bone traits demonstrated 
the existence of allelic heterogeneity additionally in loci harboring WLS, EN1 and WNT1/
DHH were we report new secondary signals. Noteworthy, WNT1 has never previously been 
implied in bone phenotypes through GWAS. Although, variant rs12821008, previously 
associated with LS-BMD is only 98.2 Kb downstream of the gene. The independent vari-
ant reported in our study is only 3 Kb downstream of WNT1. Yet, functional studies will be 
needed in order to confirm the involvement of WNT1 in normal BMD variation. This gene 
is responsible for rare monogenetic forms of early-onset osteoporosis and osteogenesis 
imperfecta(47).
We have shown that the genes mapping to the novel loci identified as associated with TB-
BMD in our analysis are enriched for expression in cells and tissues relevant to the muscu-
loskeletal system, whereas enrichment in cells or tissues, particularly coming from smooth 
muscle are less clearly connected to the studied phenotype. DEPICT did not identify any 
enriched geneset. Using the same genes considered by DEPICT but including always the 
closest transcripted element to each index SNPs we assessed several GOterms to be en-
riched. Our GWS results were overrepresented by genes involved in Wnt signaling pathway. 
On top of markers mapping to Wnt factors known to be associated with BMD (e.g., WNT4, 
WNT16, WLS, CTNNB1, SOST, DKK1, MEF2C, AXIN1, LRP4, LRP5) our analysis implicated addi-
tional Wnt signaling factors (e.g., TCF7L1, FZD7, APC, SMAD3, AXIN2, CSNK1G3). In addition, 
CSF1, APC, SMAD3 and AXIN2 are annotated in the GO term of regulation of ossification. To 
note, enrichment analysis are biased towards what it is already known.
Our study has limitations. The identified SNPs are in their vast majority, not coding variants, 
increasing the probability that the causal genes are different from the candidate genes we 
have prioritized here, based on the current biological knowledge and prediction bioinfor-
matic tools. Further functional studies are required to unveil the potential role of the genes 
in the identified loci. Despite the large sample size of our study, we did not identify several 
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variants in the low-frequency spectrum pointing out that comprehensive surveys of rare 
variation influencing BMD would need an even larger sample size. Results in other traits as 
height or BMI, have already shown that GWAS with better coverage and in larger popula-
tions nearly all the proportion of genetic variability of a trait can be accounted for (48).
Altogether, this study is the largest-scale genome-wide survey for association with BMD 
to date. Opposite to previous studies, we used TB-BMD and not DXA measurements on 
skeletal sites prone to fracture to identify genetic factors influencing BMD variation. We 
demonstrate that TB-BMD is a suitable phenotype to study, as more than 90% of previously 
reported signals, regardless of site or compartment specificity, are nominally associated 
with TB-BMD in our meta-analysis. Most importantly, we identified 55 different loci associ-
ated with TB-BMD from which 18 have not been previously reported in GWAS of bone 
phenotypes. Our association signals in 45 of the identified loci explained 8% of TB-BMD 
variation. The novel loci are enriched for genes highly expressed in chondrocytes and af-
fecting bone metabolism, mainly through WNT signaling pathways. On the basis of our 
results, we anticipate that increasing the sample size of GWAS of bone phenotypes will 
yield important insights in bone biology.
Additional detailed methods, results and acknowledgements are to be provided in the 
online Supplement of the journal containing this publication.
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Supplementary Figure 1. Regional association plots for each of the novel BMD loci. SNPS are plotted by 
position on hg19. Blue peaks indicate recombination rates. The SNPs surrounding the most significant SNP 
are color coded to reflect their LD with this SNP, pairwise r2 values from the CEU 1000 Genomes population 
except for figure I. based on the YRI population. Figures Q. and R. represent GWS in the only CEU meta-
analysis A. 1p13.3, B. 2p22.1, C. 2p11.2, D. 2q33.1, e. 5q22.2, F. 5q23.2, G. 7p14.2, H. 11p15.5, i. 11p13, J. 12q21.3, 
K. 15q14, l. 15q22.33, M. 16q22.3, n. 17q24.1, o. 20q12, P. 21q22.12, Q.10q26.13, r. 12q21.33
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Supplementary table 1. Descriptives of the participating cohorts
StuDy rS1 rS2 rS3 AlSPAC deCode oPrA 
cohort
HABC BProoF GooD erF FHS neo 
StuDy
CoP-
SAC2000
CoP-
SAC2010
Gen-
erAtion r 
StuDy
twinsuK 1982 Pelotas PAniC rAine 
StuDy
orCADeS CHoP’s MroS SoF
GWAS 
SAMPle 
nuMBer
6,291 2,157 3,048 8,165 90,298 993 2,658 2,789 938 2,786 8,481 5,744 271 446 5733 
individuals 
with GWAS 
data
5654 
individuals 
with GWAS 
data
3736 individuals 
with GWAS data
469 1494 
individuals 
with GWAS 
data
2215 
individuals 
with GWAS 
data
1885 
individuals 
with GWAS 
data
5130 3625
ethnicity Caucasian Caucasian Caucasian Caucasian Icelandic Caucasian European 
Ancestry 
(EA) and 
African 
American 
(AA)
Caucasian Caucasian Caucasian Caucasian Caucasian Danish, 
European 
Descent
Danish, 
European 
Descent
Multiethnic North-
Western 
European
Multiethnic Caucasian Mainly 
Caucasian, 
a small 
number of 
admixed
European 
descent
Multiethnic Non-hispanic 
white
Non-hispanic 
white
GenotyPinG
Geno-
typing 
platform 
& SnP 
panel
Ilumina 
HapMap 
550
Ilumina 
HapMap 
550
Ilumina 
HapMap 
550 & 610
Illumina 
HumanHap 
550K
Illumina 
Hapmap 
and Omni 
chips
Illu-
mina Omni 
Express 
Exome 
chip
Illumina 1M Omniex-
press
Ilumina 
HapMap 
550
Illumina 
310, 370, 
610K
Affymetrix 
Nsp, Sty and 
50K gene 
centric
Illumina 
Human-
CoreExom-
e24v1-0
Illumina 
Omni-
Expres-
sExome
Illumina 
Omni-
Expres-
sExome
Illumina 
Hapmap 
610K
Illumina 
Human-
Hap300, 
Human-
Hap610Q 
and 
1M-Duo
Human Omni2.5-
8v1
Illumina 
Custom Infinium 
chemistry, Array 
- Cardio-Metabo_
Chip_11395247_A, 
Illumina Hu-
manCoreExome-
12v1-0_B
Illu-
mina Hu-
man660W 
Quad Array
Illumina 
Hap300, 
Omni1, 
OmniX
Illumina 
Infinium™ 
II OMNI 
Express 
plus Exome 
BeadChip
Illumina Hu-
manOmni1_
Quad_v1-0 B
Illumina Hu-
manOmni1_
Quad_v1-0 B
Genotyp-
ing calling 
algorithm
Genome-
Studio
Genome-
Studio
Genome-
Studio
Laboratory 
Corporation 
of America
Genome-
Studio
Genome 
Studio
Genome-
Studio
Genome-
Studio
Genome-
Studio
Bead-
studio/
Genome-
Studio
Genome 
Studio
Genome 
Studio
Genome 
Studio
Genome 
Studio
Illuminus Genome Studio BeadStudio 
version 3.3.7, 
Gentrain version 
1.0 (Metabochip), 
Genome Studio 
(CoreExome)
Bead Studio Bead 
Studio, 
Genome 
Studio
Genome 
Studio
BeadStudio BeadStudio
SAMPle QC
Call rate ≤97.5% 
Excluded
≤97.5% 
Excluded
≤97.5% 
Excluded
≤97% 
Excluded
<97% 
excluded
<95% 
Excluded
≤95% 
Excluded
≤97.5% 
Excluded
≤97.5% 
Excluded
≤95% 
Excluded
≤95% 
Excluded
≤98% 
Excluded
Individu-
als with 
call rate 
<95% were 
excluded
Individu-
als with 
call rate 
<95% were 
excluded
≤97.5% 
Excluded
<98% 
excluded
≤97% Excluded ≤95% excluded ≤97% 
Excluded
≤98% 
Excluded
≤95% 
Excluded
≤97% 
Excluded
<97% 
excluded
Heterozy-
gosity
 F-values < 
-0.096
 F-values < 
-0.096
 F-values < 
-0.096
(F< .32) or  
(F> .345)
None None 6sd from 
population 
mean
 F-values < 
-0.096
 F-values < 
-0.096
FDR < 1% None F>0.35-0.45 F<0.0375 
&F >0.27
F<0.0375 
&F >0.27
Individuals 
with  F-
values < 
-0.096 
were 
excluded
Individuals 
with  het-
erozygosity 
across all 
SNPs >2SD 
from the 
sample 
mean 
excluded
Individuals with 
heterozygos-
ity rates outside 
the range of 
median±1.5*IQR 
were excluded
All included. h-values 
<0.3
NA No exclu-
sion under 
this criteria
Not applied Not applied
ethnic 
outliers 
excluded
4SD CEU 
HapMap
4SD CEU 
HapMap
4SD CEU 
HapMap
 Individuals 
with non 
European 
Ancestry
Non-
icelandic 
individuals 
excluded
No exclu-
sion under 
this criteria
6sd from 
reference 
popualtion 
mean for C1 
and C2
4SD CEU 
HapMap
4SD CEU 
HapMap
ethnic 
outliers 
removed
None  +/- 3.5 SD 
of NEO 
mean
Yes Yes No exclu-
sion under 
this criteria
Indi-
viduals with 
evidence 
of non-
European 
ancestry 
excluded
No exclusion un-
der this criteria
Non-caucasians 
were excluded
No exclu-
sion
No exclu-
sion under 
this criteria
No exclu-
sion under 
this criteria
4 SD from 
mean of PC1 
or PC2
4 SD from 
mean of PC1 
or PC2
Stratifi-
cation 
Adjust-
ment
4 PCs 4 PCs 4 PCs None None None 2 (EA) / 10 
(AA) PCs
4 PCs 4 PCs  Relation-
ship matrix 
in probabel
None 3 PCs No No Correction 
for 20 PCs 
generated 
by MDS in 
Plink
Corrected 
for 2 PCs 
gener-
ated using 
Eigenstrat
20 PCs None 10PCs 10 PCs 4 PCs 4 PCs
incorrect 
Gender 
Alloca-
tion
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
None Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. 
X chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. 
X chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self reported 
gender vs. X 
chromosome 
heterozygosity
Self reported 
gender vs. X 
chromosome 
heterozygosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self reported 
gender vs. X 
chromosome 
heterozy-
gosity
Self reported 
gender vs. X 
chromosome 
heterozy-
gosity
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Supplementary table 1. Descriptives of the participating cohorts
StuDy rS1 rS2 rS3 AlSPAC deCode oPrA 
cohort
HABC BProoF GooD erF FHS neo 
StuDy
CoP-
SAC2000
CoP-
SAC2010
Gen-
erAtion r 
StuDy
twinsuK 1982 Pelotas PAniC rAine 
StuDy
orCADeS CHoP’s MroS SoF
GWAS 
SAMPle 
nuMBer
6,291 2,157 3,048 8,165 90,298 993 2,658 2,789 938 2,786 8,481 5,744 271 446 5733 
individuals 
with GWAS 
data
5654 
individuals 
with GWAS 
data
3736 individuals 
with GWAS data
469 1494 
individuals 
with GWAS 
data
2215 
individuals 
with GWAS 
data
1885 
individuals 
with GWAS 
data
5130 3625
ethnicity Caucasian Caucasian Caucasian Caucasian Icelandic Caucasian European 
Ancestry 
(EA) and 
African 
American 
(AA)
Caucasian Caucasian Caucasian Caucasian Caucasian Danish, 
European 
Descent
Danish, 
European 
Descent
Multiethnic North-
Western 
European
Multiethnic Caucasian Mainly 
Caucasian, 
a small 
number of 
admixed
European 
descent
Multiethnic Non-hispanic 
white
Non-hispanic 
white
GenotyPinG
Geno-
typing 
platform 
& SnP 
panel
Ilumina 
HapMap 
550
Ilumina 
HapMap 
550
Ilumina 
HapMap 
550 & 610
Illumina 
HumanHap 
550K
Illumina 
Hapmap 
and Omni 
chips
Illu-
mina Omni 
Express 
Exome 
chip
Illumina 1M Omniex-
press
Ilumina 
HapMap 
550
Illumina 
310, 370, 
610K
Affymetrix 
Nsp, Sty and 
50K gene 
centric
Illumina 
Human-
CoreExom-
e24v1-0
Illumina 
Omni-
Expres-
sExome
Illumina 
Omni-
Expres-
sExome
Illumina 
Hapmap 
610K
Illumina 
Human-
Hap300, 
Human-
Hap610Q 
and 
1M-Duo
Human Omni2.5-
8v1
Illumina 
Custom Infinium 
chemistry, Array 
- Cardio-Metabo_
Chip_11395247_A, 
Illumina Hu-
manCoreExome-
12v1-0_B
Illu-
mina Hu-
man660W 
Quad Array
Illumina 
Hap300, 
Omni1, 
OmniX
Illumina 
Infinium™ 
II OMNI 
Express 
plus Exome 
BeadChip
Illumina Hu-
manOmni1_
Quad_v1-0 B
Illumina Hu-
manOmni1_
Quad_v1-0 B
Genotyp-
ing calling 
algorithm
Genome-
Studio
Genome-
Studio
Genome-
Studio
Laboratory 
Corporation 
of America
Genome-
Studio
Genome 
Studio
Genome-
Studio
Genome-
Studio
Genome-
Studio
Bead-
studio/
Genome-
Studio
Genome 
Studio
Genome 
Studio
Genome 
Studio
Genome 
Studio
Illuminus Genome Studio BeadStudio 
version 3.3.7, 
Gentrain version 
1.0 (Metabochip), 
Genome Studio 
(CoreExome)
Bead Studio Bead 
Studio, 
Genome 
Studio
Genome 
Studio
BeadStudio BeadStudio
SAMPle QC
Call rate ≤97.5% 
Excluded
≤97.5% 
Excluded
≤97.5% 
Excluded
≤97% 
Excluded
<97% 
excluded
<95% 
Excluded
≤95% 
Excluded
≤97.5% 
Excluded
≤97.5% 
Excluded
≤95% 
Excluded
≤95% 
Excluded
≤98% 
Excluded
Individu-
als with 
call rate 
<95% were 
excluded
Individu-
als with 
call rate 
<95% were 
excluded
≤97.5% 
Excluded
<98% 
excluded
≤97% Excluded ≤95% excluded ≤97% 
Excluded
≤98% 
Excluded
≤95% 
Excluded
≤97% 
Excluded
<97% 
excluded
Heterozy-
gosity
 F-values < 
-0.096
 F-values < 
-0.096
 F-values < 
-0.096
(F< .32) or  
(F> .345)
None None 6sd from 
population 
mean
 F-values < 
-0.096
 F-values < 
-0.096
FDR < 1% None F>0.35-0.45 F<0.0375 
&F >0.27
F<0.0375 
&F >0.27
Individuals 
with  F-
values < 
-0.096 
were 
excluded
Individuals 
with  het-
erozygosity 
across all 
SNPs >2SD 
from the 
sample 
mean 
excluded
Individuals with 
heterozygos-
ity rates outside 
the range of 
median±1.5*IQR 
were excluded
All included. h-values 
<0.3
NA No exclu-
sion under 
this criteria
Not applied Not applied
ethnic 
outliers 
excluded
4SD CEU 
HapMap
4SD CEU 
HapMap
4SD CEU 
HapMap
 Individuals 
with non 
European 
Ancestry
Non-
icelandic 
individuals 
excluded
No exclu-
sion under 
this criteria
6sd from 
reference 
popualtion 
mean for C1 
and C2
4SD CEU 
HapMap
4SD CEU 
HapMap
ethnic 
outliers 
removed
None  +/- 3.5 SD 
of NEO 
mean
Yes Yes No exclu-
sion under 
this criteria
Indi-
viduals with 
evidence 
of non-
European 
ancestry 
excluded
No exclusion un-
der this criteria
Non-caucasians 
were excluded
No exclu-
sion
No exclu-
sion under 
this criteria
No exclu-
sion under 
this criteria
4 SD from 
mean of PC1 
or PC2
4 SD from 
mean of PC1 
or PC2
Stratifi-
cation 
Adjust-
ment
4 PCs 4 PCs 4 PCs None None None 2 (EA) / 10 
(AA) PCs
4 PCs 4 PCs  Relation-
ship matrix 
in probabel
None 3 PCs No No Correction 
for 20 PCs 
generated 
by MDS in 
Plink
Corrected 
for 2 PCs 
gener-
ated using 
Eigenstrat
20 PCs None 10PCs 10 PCs 4 PCs 4 PCs
incorrect 
Gender 
Alloca-
tion
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
None Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. 
X chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. 
X chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self reported 
gender vs. X 
chromosome 
heterozygosity
Self reported 
gender vs. X 
chromosome 
heterozygosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self 
reported 
gender vs. X 
chromo-
some 
heterozy-
gosity
Self reported 
gender vs. X 
chromosome 
heterozy-
gosity
Self reported 
gender vs. X 
chromosome 
heterozy-
gosity
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StuDy rS1 rS2 rS3 AlSPAC deCode oPrA 
cohort
HABC BProoF GooD erF FHS neo 
StuDy
CoP-
SAC2000
CoP-
SAC2010
Gen-
erAtion r 
StuDy
twinsuK 1982 Pelotas PAniC rAine 
StuDy
orCADeS CHoP’s MroS SoF
Cryptic 
related-
ness
PI HAT>0.3 PI HAT>0.3 PI HAT>0.3 PI HAT> 0.11 Related 
individuals 
included
PI HAT > 0.2 exclusion 
at 12.5% 
sharing
PI HAT>0.3 PI HAT>0.3 Related 
individuals 
included
Related 
individuals 
included
PI HAT 
(>0.25)
removed 
with IBM 
calcula-
tion
removed 
with IBM 
calcula-
tion
287 close 
related 
individuals 
(pi^>0.3), 
from which 
28  indi-
viduals with 
a twin in the 
dataset was 
excluded
Unre-
lated but 
estimated 
pi hat > 0.12 
(19 samples 
excluded)
IBD≥0.1 Twins were 
excluded
PI HAT> 
0.19
excess IBS 
incompat-
ible with 
pedigree
PI HAT> 
0.45
Only one 
member of a 
family
Only one 
member of a 
family
SnP QC (prior to imputation)
MAF SNPs with ≤ 
0.1 % MAF
SNPs with ≤ 
0.1 % MAF
SNPs with ≤ 
0.1 % MAF
SNPs with ≤ 
0.1 % MAF
SNPs with ≤ 
1 % MAF
No 
exclusion 
on MAF 
performed
SNPs with ≤ 
1 % MAF
SNPs with ≤ 
0.1 % MAF
SNPs with ≤ 
0.1 % MAF
SNPs with ≤ 
0.5 % MAF
SNPs with ≤ 
0.5 % MAF
NA SNPs with 
≤ 1 % MAF
SNPs with 
≤ 1 % MAF
SNPs with ≤ 
1 % MAF
SNPs 
with MAF 
<1% were 
excluded
SNPs with ≤ 0.1 
% MAF
SNPs with ≤ 1 
% MAF
SNPs with ≤ 
1 % MAF
SNPs with ≤ 
1 % MAF
SNPs with ≤ 
0.5% MAF
SNPs with ≤ 1 
% MAF
SNPs with ≤ 1 
% MAF
HWe SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
0.001
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with P value 
< 1E-7
SNPs with P value 
< 1E-6
SNPs with 
P value < 
6E-7
SNPs with 
P value < 
1E-6
No exclu-
sion under 
this criteria
SNPs with P 
value < 1E-4
SNPs with P 
value < 1E-4
Call rate SNPs with 
a callrate ≤ 
98%
SNPs with 
a callrate ≤ 
98%
SNPs with 
a callrate ≤ 
98%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
98%
SNPs with 
a callrate ≤ 
98%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
97%
SNPs with 
a callrate ≤ 
98%
SNPs with 
a call rate 
< 95%
SNPs with 
a call rate 
< 95%
SNPs with 
a callrate ≤ 
98%
MAF >5% 
C.R <97% or 
MAF 1-5% 
C>R <99%
SNPs with a call 
rate < 95%
SNPs with a 
callrate ≤ 95%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
97%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
97%
SNPs with 
a callrate ≤ 
97%
iMPutAtion AutoSoMAl
imputa-
tion 
software
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
In-house 
software
IMPUTE 
version 
2.1.2
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
IMPUTE2 SHA-
PEIT2 & 
IMPUTE2
SHA-
PEIT2 & 
IMPUTE2
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
SHAPEIT2 & 
IMPUTE2
IMPUTE2 v2.3.1 SHAPEIT, IM-
PUTE2.
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(ShapeIt2) 
Imputation 
(Impute2)
Phasing 
genotypes 
(SHAPEIT)   
Imputation 
(IMPUTE2)
IMPUTE2 IMPUTE2
Phased 
reference 
Data
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I 
V. 3
1000G 
Phase I 
V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G Phase 
I V. 3
1000G Phase I V. 3 1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
UK10K/1000G 
Phase I  V.3
UK10K/1000G 
Phase I  V.3
SnPs used 
for impu-
tation
502,668 490,409 517,658 464,311 699,107 899,818 730,525 502,668 678,524 389,956 349,605 657,699 657,699 489,878 303,940 
-878,319
2,073,816 390,669 521,554 287,208 
(Hap300) 
615658 
(Omni)
739,284 740,713 740,713
total 
number of 
imputed 
SnPs
30,072,738 30,072,738 30,072,738 30,072,738 21106834 36,890,632 30,072,738 30,072,738 29,974,334 8,221,074 28,427,527 27,446,975 27,446,975 30,072,738 37,428,090 37,759,470 12,250,634 29,540,342 37,500,000 15,689,930 41,992,162 41,992,162
AnAlySiS oF SnP ASSoCiAtionS
Asso-
ciation 
Software
MACH2qtl MACH2qtl MACH2qtl MACH2qtl SNPTEST GEMMA MACH2qtl MACH2qtl MACH2qtl ProbABEL In House SNPTEST Quicktest 
v0.94
Quicktest 
v0.94
MACHqtl Genome-
wide Effi-
cient Mixed 
Model 
Association 
(GEMMA)
SNPTEST v2.5 SNPTEST2 ProbAbel ProbABEL SNPTEST2 GEMMA GEMMA
DXA MACHine SPeCiFiCAtion
Device GE-Lunar  
(Lunar 
Prodigy)
GE-Lunar  
(Lunar 
Prodigy)
GE-Lunar  
(Lunar 
Prodigy)
GE-Lunar  
(Lunar 
Prodigy)
HologicQ-
DR4500A
GE-Lunar 
DPX-L
Hologic 
QDR 4500
GE-Lunar  
(Lunar 
Prodigy)
GE-Lunar  
(Lunar 
Prodigy)
GE-Lunar-
DPX-L
GE-Lunar-
DPX-L
Hologic 
Discovery 
A, Tromp 
Medical BV, 
Castricum, 
The Nether-
lands
Lunar 
iDXA 
densitom-
eter (GE 
Health-
care, 
Fairfield, 
Connecti-
cut, USA)
Lunar 
iDXA 
densitom-
eter
GE-Lunar 
iDXA (Lunar 
Prodigy)
Ho-
logic QDR 
4500W
Lunar GE® 
(Prodigy)
Lunar GE® 
(Prodigy)
Norland 
XR-36 den-
sitometer
Hologic 
QDR-4500
Hologic 
bone densi-
tometers
Hologic QDR 
4500
Hologic QDR 
1000
total 
number 
Scanned
2436 758 2488 5,434 24,397 931 2658 968 938 2,786 5,627 802 271 446 6,490 7,711 3,438 469 1183 1,302 1885 5955 609
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StuDy rS1 rS2 rS3 AlSPAC deCode oPrA 
cohort
HABC BProoF GooD erF FHS neo 
StuDy
CoP-
SAC2000
CoP-
SAC2010
Gen-
erAtion r 
StuDy
twinsuK 1982 Pelotas PAniC rAine 
StuDy
orCADeS CHoP’s MroS SoF
Cryptic 
related-
ness
PI HAT>0.3 PI HAT>0.3 PI HAT>0.3 PI HAT> 0.11 Related 
individuals 
included
PI HAT > 0.2 exclusion 
at 12.5% 
sharing
PI HAT>0.3 PI HAT>0.3 Related 
individuals 
included
Related 
individuals 
included
PI HAT 
(>0.25)
removed 
with IBM 
calcula-
tion
removed 
with IBM 
calcula-
tion
287 close 
related 
individuals 
(pi^>0.3), 
from which 
28  indi-
viduals with 
a twin in the 
dataset was 
excluded
Unre-
lated but 
estimated 
pi hat > 0.12 
(19 samples 
excluded)
IBD≥0.1 Twins were 
excluded
PI HAT> 
0.19
excess IBS 
incompat-
ible with 
pedigree
PI HAT> 
0.45
Only one 
member of a 
family
Only one 
member of a 
family
SnP QC (prior to imputation)
MAF SNPs with ≤ 
0.1 % MAF
SNPs with ≤ 
0.1 % MAF
SNPs with ≤ 
0.1 % MAF
SNPs with ≤ 
0.1 % MAF
SNPs with ≤ 
1 % MAF
No 
exclusion 
on MAF 
performed
SNPs with ≤ 
1 % MAF
SNPs with ≤ 
0.1 % MAF
SNPs with ≤ 
0.1 % MAF
SNPs with ≤ 
0.5 % MAF
SNPs with ≤ 
0.5 % MAF
NA SNPs with 
≤ 1 % MAF
SNPs with 
≤ 1 % MAF
SNPs with ≤ 
1 % MAF
SNPs 
with MAF 
<1% were 
excluded
SNPs with ≤ 0.1 
% MAF
SNPs with ≤ 1 
% MAF
SNPs with ≤ 
1 % MAF
SNPs with ≤ 
1 % MAF
SNPs with ≤ 
0.5% MAF
SNPs with ≤ 1 
% MAF
SNPs with ≤ 1 
% MAF
HWe SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
0.001
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with 
P value < 
1E-6
SNPs with P value 
< 1E-7
SNPs with P value 
< 1E-6
SNPs with 
P value < 
6E-7
SNPs with 
P value < 
1E-6
No exclu-
sion under 
this criteria
SNPs with P 
value < 1E-4
SNPs with P 
value < 1E-4
Call rate SNPs with 
a callrate ≤ 
98%
SNPs with 
a callrate ≤ 
98%
SNPs with 
a callrate ≤ 
98%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
98%
SNPs with 
a callrate ≤ 
98%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
97%
SNPs with 
a callrate ≤ 
98%
SNPs with 
a call rate 
< 95%
SNPs with 
a call rate 
< 95%
SNPs with 
a callrate ≤ 
98%
MAF >5% 
C.R <97% or 
MAF 1-5% 
C>R <99%
SNPs with a call 
rate < 95%
SNPs with a 
callrate ≤ 95%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
97%
SNPs with 
a callrate ≤ 
95%
SNPs with 
a callrate ≤ 
97%
SNPs with 
a callrate ≤ 
97%
iMPutAtion AutoSoMAl
imputa-
tion 
software
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
In-house 
software
IMPUTE 
version 
2.1.2
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
IMPUTE2 SHA-
PEIT2 & 
IMPUTE2
SHA-
PEIT2 & 
IMPUTE2
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
SHAPEIT2 & 
IMPUTE2
IMPUTE2 v2.3.1 SHAPEIT, IM-
PUTE2.
Phasing 
genotypes 
(MACH)   
Imputation 
(Minimac)
Phasing 
genotypes 
(ShapeIt2) 
Imputation 
(Impute2)
Phasing 
genotypes 
(SHAPEIT)   
Imputation 
(IMPUTE2)
IMPUTE2 IMPUTE2
Phased 
reference 
Data
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I 
V. 3
1000G 
Phase I 
V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G Phase 
I V. 3
1000G Phase I V. 3 1000G 
Phase I V. 3
1000G 
Phase I V. 3
1000G 
Phase I V. 3
UK10K/1000G 
Phase I  V.3
UK10K/1000G 
Phase I  V.3
SnPs used 
for impu-
tation
502,668 490,409 517,658 464,311 699,107 899,818 730,525 502,668 678,524 389,956 349,605 657,699 657,699 489,878 303,940 
-878,319
2,073,816 390,669 521,554 287,208 
(Hap300) 
615658 
(Omni)
739,284 740,713 740,713
total 
number of 
imputed 
SnPs
30,072,738 30,072,738 30,072,738 30,072,738 21106834 36,890,632 30,072,738 30,072,738 29,974,334 8,221,074 28,427,527 27,446,975 27,446,975 30,072,738 37,428,090 37,759,470 12,250,634 29,540,342 37,500,000 15,689,930 41,992,162 41,992,162
AnAlySiS oF SnP ASSoCiAtionS
Asso-
ciation 
Software
MACH2qtl MACH2qtl MACH2qtl MACH2qtl SNPTEST GEMMA MACH2qtl MACH2qtl MACH2qtl ProbABEL In House SNPTEST Quicktest 
v0.94
Quicktest 
v0.94
MACHqtl Genome-
wide Effi-
cient Mixed 
Model 
Association 
(GEMMA)
SNPTEST v2.5 SNPTEST2 ProbAbel ProbABEL SNPTEST2 GEMMA GEMMA
DXA MACHine SPeCiFiCAtion
Device GE-Lunar  
(Lunar 
Prodigy)
GE-Lunar  
(Lunar 
Prodigy)
GE-Lunar  
(Lunar 
Prodigy)
GE-Lunar  
(Lunar 
Prodigy)
HologicQ-
DR4500A
GE-Lunar 
DPX-L
Hologic 
QDR 4500
GE-Lunar  
(Lunar 
Prodigy)
GE-Lunar  
(Lunar 
Prodigy)
GE-Lunar-
DPX-L
GE-Lunar-
DPX-L
Hologic 
Discovery 
A, Tromp 
Medical BV, 
Castricum, 
The Nether-
lands
Lunar 
iDXA 
densitom-
eter (GE 
Health-
care, 
Fairfield, 
Connecti-
cut, USA)
Lunar 
iDXA 
densitom-
eter
GE-Lunar 
iDXA (Lunar 
Prodigy)
Ho-
logic QDR 
4500W
Lunar GE® 
(Prodigy)
Lunar GE® 
(Prodigy)
Norland 
XR-36 den-
sitometer
Hologic 
QDR-4500
Hologic 
bone densi-
tometers
Hologic QDR 
4500
Hologic QDR 
1000
total 
number 
Scanned
2436 758 2488 5,434 24,397 931 2658 968 938 2,786 5,627 802 271 446 6,490 7,711 3,438 469 1183 1,302 1885 5955 609
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Supplementary table 2 Anthopometric description of the individuals in each of the participating studies
Study trait All
n mean SD median min max
DeCoDe Age (yrs) 6794 54.825 16.745 55.400 15.100 92.100
Weight (kg) 6794 74.520 15.042 73.000 35.700 129.300
Height (cm) 6794 168.782 8.756 168.000 116.500 203.000
(TB/TBLH)BMD (g/cm2) 6794 1.067 0.129 1.072 0.669 1.710
BProoF Age (yrs) 968 74.594 5.547 74.000 66.000 96.000
Weight (kg) 968 78.094 13.152 77.500 46.700 133.500
Height (cm) 968 170.024 8.879 169.650 145.600 194.700
(TB/TBLH)BMD (g/cm2) 968 1.117 0.152 1.119 0.675 1.638
FHS Age (yrs) 2386 53.532 12.836 52.000 24.000 92.000
Weight (kg) 2386 86.193 14.270 84.370 48.535 148.327
Height (cm) 2386 175.674 7.033 175.895 151.765 199.390
(TB/TBLH)BMD (g/cm2) 2386 1.264 0.098 1.264 0.905 1.598
MroS Age (yrs) 4670 73.951 5.955 73.000 65.000 100.000
Weight (kg) 4670 83.421 13.003 82.000 50.800 136.400
Height (cm) 4670 174.494 6.633 174.450 147.150 198.900
(TB/TBLH)BMD (g/cm2) 4670 1.167 0.127 1.158 0.765 2.047
SoF Age (yrs) 314 79.557 3.949 79.000 74.000 97.000
Weight (kg) 314 66.716 12.443 65.650 37.000 115.700
Height (cm) 314 158.223 5.902 158.575 143.050 175.350
(TB/TBLH)BMD (g/cm2) 314 1.014 0.122 1.011 0.749 1.531
CHoP Age (yrs) 1320 9.568 3.013 9.496 5.000 14.995
Weight (kg) 1320 35.244 14.001 31.800 15.300 78.400
Height (cm) 1320 137.261 18.588 136.216 101.867 182.400
(TB/TBLH)BMD (g/cm2) 1320 0.712 0.148 0.693 0.416 1.168
orcades Age (yrs) 1162 56.408 13.076 58.040 25.720 87.340
Weight (kg) 1162 77.329 15.435 75.450 45.600 148.400
Height (cm) 1162 166.473 9.160 165.600 140.600 199.400
(TB/TBLH)BMD (g/cm2) 1162 1.059 0.130 1.064 0.688 1.468
PAniC Age (yrs) 447 7.640 0.375 7.630 6.770 9.000
Weight (kg) 447 26.830 4.815 26.020 15.240 51.440
Height (cm) 447 128.700 5.597 129.200 110.700 144.700
(TB/TBLH)BMD (g/cm2) 447 0.720 0.048 0.717 0.610 0.960
PelotAS Age (yrs) 2688 30.079 0.188 30.076 29.430 31.136
Weight (kg) 2688 74.533 16.016 72.350 33.700 119.500
Height (cm) 2688 167.232 8.969 166.800 140.600 191.800
(TB/TBLH)BMD (g/cm2) 2688 1.217 0.101 1.212 0.917 1.568
CoPSAC2000 Age (yrs) 271 6.894 0.718 6.550 6.354 10.227
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Supplementary table 2 (continued)
Study trait All
n mean SD median min max
Weight (kg) 271 24.590 4.251 24.000 15.500 40.600
Height (cm) 271 124.400 6.162 124.000 108.200 143.100
(TB/TBLH)BMD (g/cm2) 271 0.583 0.053 0.577 0.462 0.777
CoPSAC2010 Age (yrs) 436 3.458 0.320 3.400 2.650 4.760
Weight (kg) 436 15.880 1.930 15.800 11.700 23.500
Height (cm) 436 99.650 5.064 99.650 59.900 115.800
(TB/TBLH)BMD (g/cm2) 436 0.450 0.033 0.449 0.344 0.546
Generation r Age (yrs) 4070 6.215 0.501 6.072 4.890 9.080
Weight (kg) 4070 23.080 4.085 22.370 13.660 54.950
Height (cm) 4070 119.600 5.909 119.200 99.000 147.000
(TB/TBLH)BMD (g/cm2) 4070 0.555 0.049 0.551 0.392 0.784
tuK Age (yrs) 4650 48.075 13.885 50.000 16.000 84.000
Weight (kg) 4650 68.100 13.046 66.000 35.100 128.100
Height (cm) 4650 163.309 7.224 163.000 141.000 204.000
(TB/TBLH)BMD (g/cm2) 4650 1.151 0.117 1.152 0.732 1.602
rAine Age (yrs) 4070 6.215 0.501 6.072 4.890 9.080
Weight (kg) 4070 23.080 4.085 22.370 13.660 54.950
Height (cm) 4070 119.600 5.909 119.200 99.000 147.000
(TB/TBLH)BMD (g/cm2) 4070 0.555 0.049 0.551 0.392 0.784
oPrA Age (yrs) 887 75.220 0.140 75.189 75.030 76.000
Weight (kg) 887 66.881 10.596 66.000 41.000 109.000
Height (cm) 887 160.490 5.670 160.000 140.000 179.000
(TB/TBLH)BMD (g/cm2) 887 1.007 0.098 1.002 0.718 1.422
HABC_eu Age (yrs) 1585 73.750 2.838 73.000 69.000 80.000
Weight (kg) 1585 74.270 14.328 73.200 40.800 134.500
Height (cm) 1585 166.900 9.307 166.600 141.600 194.800
(TB/TBLH)BMD (g/cm2) 1585 1.071 0.135 1.068 0.730 1.605
HABC_AA Age (yrs) 1073 73.420 2.872 73.000 68.000 80.000
Weight (kg) 1073 77.660 14.898 77.100 33.500 133.800
Height (cm) 1073 165.300 9.478 164.600 137.000 200.700
(TB/TBLH)BMD (g/cm2) 1073 1.115 0.146 1.105 0.763 1.706
erF Age (yrs) 2786 48.958 14.345 49.518 16.653 86.501
Weight (kg) 2631 75.457 15.414 74.200 41.900 161.000
Height (cm) 2631 167.591 9.398 167.000 141.000 196.500
(TB/TBLH)BMD (g/cm2) 2786 1.151 0.113 1.148 0.745 1.557
rS1 Age (yrs) 2436 75.270 5.930 74.400 65.230 98.490
Weight (kg) 2436 76.080 13.170 75.300 36.800 138.000
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Supplementary table 2 (continued)
Study trait All
n mean SD median min max
Height (cm) 2436 166.600 9.219 166.000 135.300 196.000
(TB/TBLH)BMD (g/cm2) 2436 1.109 0.124 1.108 0.726 1.473
rS2 Age (yrs) 750 67.160 6.457 65.170 49.470 91.190
Weight (kg) 750 77.230 12.770 77.200 46.400 123.200
Height (cm) 750 168.800 8.830 168.400 146.900 192.400
(TB/TBLH)BMD (g/cm2) 750 1.146 0.114 1.147 0.770 1.467
rS3 Age (yrs) 2483 57.310 6.940 57.100 45.740 97.220
Weight (kg) 2483 80.230 15.439 78.900 31.500 153.200
Height (cm) 2483 170.500 9.511 169.800 145.000 201.000
(TB/TBLH)BMD (g/cm2) 2483 1.178 0.107 1.176 0.845 1.515
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Supplementary table 4. Prioritized genes in the associated tB-BMD loci. Analysis was carried out including 
all markers GWS associated with TB-BMD (P<5x10-8) using DEPICT.
no.
Genes
locus location Gene 
Prioritized
top cis eQtl SnP False discovery 
rate
5 chr1:22350487-22470462 WNT4 rs6688182 <0.05
1 chr1:22778344-22857650 ZBTB40 - <0.05
1 chr1:68564142-68698803 WLS rs11209243; rs11209243; 
rs11209243; rs2039153; rs6691613
<0.05
3 chr11:15987995-17035990 SOX6 - <=0.01
3 chr11:15987995-17035990 PLEKHA7 - <0.05
2 chr11:27068733-27385415 CCDC34 rs3781677 <0.05
3 chr11:27387508-27719721 LGR4 rs725015 <0.05
3 chr11:27387508-27719721 BDNF-AS1 - <0.05
31 chr11:46299212-47736941 CREB3L1 - <=0.01
31 chr11:46299212-47736941 AMBRA1 - <0.05
31 chr11:46299212-47736941 LRP4 - <0.05
31 chr11:46299212-47736941 SLC39A13 - <0.05
31 chr11:46299212-47736941 CELF1 rs12419692;rs10838708 <0.05
31 chr11:46299212-47736941 CKAP5 - <0.05
2 chr11:68080077-68382802 LRP5 rs10750821 <0.05
1 chr12:49372398-49375459 WNT1 - <0.05
4 chr12:49388932-49463808 MLL2 - <=0.01
8 chr12:53662083-53874945 SP7 - <=0.01
8 chr12:53662083-53874945 SP1 - <=0.01
8 chr12:53662083-53874945 PCBP2 - <0.05
8 chr12:53662083-53874945 ESPL1 - <0.05
1 chr12:90501516-90506066 - - <=0.01
4 chr15:67356101-67819628 SMAD3 rs12443279 <=0.01
1 chr16:238968-279462 LUC7L rs1203974;rs8466 <0.05
1 chr16:72816784-73093597 ZFHX3 - <=0.01
4 chr17:1963133-2240678 SMG6 - <0.05
5 chr17:41831103-41940994 SOST rs1731902 <=0.01
7 chr17:42154121-42298994 UBTF rs11079983;rs7222501 <=0.01
1 chr2:119599766-119605254 EN1 - <=0.01
1 chr2:202899310-202903160 FZD7 - <0.05
1 chr2:85360533-85537511 TCF7L1 - <=0.01
1 chr20:10618332-10654608 JAG1 rs8708 <=0.01
1 chr20:39314488-39317880 MAFB rs2902941 <0.05
1 chr21:36160098-37357047 RUNX1 - <0.05
3 chr3:156391024-156697347 TIPARP rs13070271;rs7644005 <=0.01
1 chr3:41236328-41301587 CTNNB1 rs11711946 <0.05
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Supplementary table 4 (continued)
no.
Genes
locus location Gene 
Prioritized
top cis eQtl SnP False discovery 
rate
1 chr4:88742550-88767969 MEPE - <=0.01
2 chr4:980785-1020685 FGFRL1 - <0.05
1 chr6:127439749-127518910 RSPO3 - <=0.01
2 chr6:44777054-45518818 RUNX2 rs2772395 <=0.01
4 chr7:120628731-121038821 CPED1 rs1949803 <=0.01
1 chr7:37945543-38065297 SFRP4 rs6953908 <=0.01
3 chr8:119935796-120257913 TNFRSF11B rs1389541 <0.05
Supplementary table 5. Gene ontology (Go) enrichment analysis. Genes in the 18 novel loci as defined by 
DEPICT where used to perform a GO enrichment (p-adjust, FDR<0.05).
iD Description p.adjust geneiD
GO:0045596 negative regulation of cell 
differentiation
5.78E-04 APC/SMAD3/ZFHX3/AXIN2/FZD7/
TCF7L1/RUNX1/MAFB
GO:0009887 organ morphogenesis 7.86E-04 CSF1/APC/AQP1/SMAD3/PLEKHA1/
SLC8A1/AXIN2/RUNX1/MAFB
GO:0035412 regulation of catenin import into 
nucleus
0.001 SMAD3/AXIN2/FZD7
GO:0016055 Wnt signaling pathway 0.001 CSNK1G3/APC/SMAD3/AXIN2/FZD7/
TCF7L1
GO:0035282 segmentation 0.001 SMAD3/AXIN2/TCF7L1/MAFB
GO:0051239 regulation of multicellular 
organismal process
0.001 CSF1/GHRHR/APC/AQP1/SMAD3/
ZFHX3/SLC8A1/AXIN2/FZD7/TCF7L1/
RUNX1/MAFB
GO:0060070 canonical Wnt signaling pathway 0.001 APC/SMAD3/AXIN2/FZD7/TCF7L1
GO:0030278 regulation of ossification 0.004 CSF1/APC/SMAD3/AXIN2
GO:0032879 regulation of localization 0.005 CSF1/CEP120/GHRHR/APC/AQP1/
SMAD3/SLC8A1/AXIN2/FZD7/RUNX1
GO:0022414 reproductive process 0.005 ODF3/CSF1/GHRHR/APC/PLEKHA1/
SLC8A1/FZD7/RUNX1
GO:0003006 developmental process involved in 
reproduction
0.005 CSF1/APC/PLEKHA1/SLC8A1/FZD7/
RUNX1
GO:0051179 localization 0.006 LDLRAD3/CSF1/CEP120/CEP112/GHRHR/
APC/AQP1/SMAD3/BET1L/PLEKHA1/
RIC8A/SLC8A1/AAGAB/AXIN2/FZD7/
RUNX1
GO:0032502 developmental process 0.007 ODF3/CSF1/CEP120/GHRHR/APC/
AQP1/SMAD3/ZFHX3/PLEKHA1/RIC8A/
SLC8A1/AXIN2/FZD7/TCF7L1/RUNX1/
MAFB
GO:0007050 cell cycle arrest 0.008 APC/SMAD3/ZFHX3/PSMD13
GO:0007389 pattern specification process 0.008 APC/SMAD3/AXIN2/TCF7L1/MAFB
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Supplementary table 5 (continued)
iD Description p.adjust geneiD
GO:0042127 regulation of cell proliferation 0.008 CSF1/GHRHR/APC/AQP1/SMAD3/
AXIN2/FZD7/RUNX1
GO:0008283 cell proliferation 0.009 CSF1/CEP120/GHRHR/APC/AQP1/
SMAD3/AXIN2/FZD7/RUNX1
GO:0033036 macromolecule localization 0.009 CEP120/CEP112/APC/SMAD3/BET1L/
PLEKHA1/AAGAB/AXIN2/FZD7/RUNX1
GO:0034614 cellular response to reactive 
oxygen species
0.009 AQP1/PLEKHA1/SLC8A1
GO:0048518 positive regulation of biological 
process
0.010 CSF1/NLRP6/GHRHR/APC/AQP1/
SMAD3/ZFHX3/PSMD13/PLEKHA1/
AXIN2/FZD7/TCF7L1/RUNX1/MAFB
GO:0048519 negative regulation of biological 
process
0.010 NLRP6/APC/AQP1/SMAD3/ZFHX3/
PSMD13/PLEKHA1/SLC8A1/AXIN2/FZD7/
TCF7L1/RUNX1/MAFB
GO:0008104 protein localization 0.012 CEP120/CEP112/APC/SMAD3/BET1L/
PLEKHA1/AAGAB/AXIN2/FZD7
GO:0031122 cytoplasmic microtubule 
organization
0.012 CEP120/APC
GO:0002682 regulation of immune system 
process
0.014 CSF1/NLRP6/APC/SMAD3/PLEKHA1/
RUNX1/MAFB
GO:0051983 regulation of chromosome 
segregation
0.015 APC/AXIN2
GO:0009893 positive regulation of metabolic 
process
0.015 CSF1/GHRHR/APC/SMAD3/PSMD13/
AXIN2/FZD7/TCF7L1/RUNX1/MAFB
GO:0035264 multicellular organism growth 0.018 CSF1/GHRHR/PLEKHA1
GO:0051641 cellular localization 0.018 CEP120/GHRHR/APC/AQP1/SMAD3/
BET1L/SLC8A1/AXIN2/FZD7/RUNX1
GO:0030155 regulation of cell adhesion 0.018 CSF1/APC/SMAD3/FZD7
GO:0007187 G-protein coupled receptor 
signaling pathway, coupled 
to cyclic nucleotide second 
messenger
0.020 GHRHR/RIC8A/FZD7
GO:0060986 endocrine hormone secretion 0.020 AQP1/RUNX1
GO:0043009 chordate embryonic development 0.020 SMAD3/RIC8A/SLC8A1/AXIN2/RUNX1
GO:0001503 ossification 0.020 CSF1/APC/SMAD3/AXIN2
GO:0048538 thymus development 0.021 APC/MAFB
GO:0035556 intracellular signal transduction 0.023 CSF1/NLRP6/GHRHR/APC/SMAD3/
PSMD13/PLEKHA1/SLC8A1/FZD7
GO:0030104 water homeostasis 0.023 GHRHR/AQP1
GO:0010604 positive regulation of 
macromolecule metabolic process
0.023 CSF1/APC/SMAD3/PSMD13/AXIN2/
FZD7/TCF7L1/RUNX1/MAFB
GO:0042060 wound healing 0.025 NLRP6/AQP1/SMAD3/SLC8A1/FZD7
GO:0019220 regulation of phosphate metabolic 
process
0.026 CSF1/NLRP6/GHRHR/APC/SMAD3/
RIC8A/AXIN2/FZD7
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Supplementary table 5 (continued)
iD Description p.adjust geneiD
GO:0002376 immune system process 0.026 CSF1/NLRP6/APC/SMAD3/PSMD13/
PLEKHA1/FZD7/RUNX1/MAFB
GO:0048522 positive regulation of cellular 
process
0.026 CSF1/GHRHR/APC/AQP1/SMAD3/
ZFHX3/PSMD13/AXIN2/FZD7/TCF7L1/
RUNX1/MAFB
GO:0006950 response to stress 0.031 CSF1/NLRP6/APC/AQP1/SMAD3/
PSMD13/PLEKHA1/SLC8A1/AXIN2/FZD7/
RUNX1
GO:0023052 signaling 0.031 CSF1/CSNK1G3/NLRP6/GHRHR/APC/
AQP1/SMAD3/PSMD13/PLEKHA1/RIC8A/
SLC8A1/AXIN2/FZD7/TCF7L1/RUNX1
GO:0010817 regulation of hormone levels 0.031 GHRHR/AQP1/PLEKHA1/RUNX1
GO:0051817 modification of morphology or 
physiology of other organism 
involved in symbiotic interaction
0.033 AQP1/SMAD3
GO:0007154 cell communication 0.034 CSF1/CSNK1G3/NLRP6/GHRHR/APC/
AQP1/SMAD3/PSMD13/PLEKHA1/RIC8A/
SLC8A1/AXIN2/FZD7/TCF7L1/RUNX1
GO:0032501 multicellular organismal process 0.036 ODF3/CSF1/CEP120/GHRHR/APC/
AQP1/SMAD3/ZFHX3/PLEKHA1/RIC8A/
SLC8A1/AXIN2/FZD7/TCF7L1/RUNX1/
MAFB
GO:0050886 endocrine process 0.041 AQP1/RUNX1
GO:0065008 regulation of biological quality 0.041 CSF1/GHRHR/APC/AQP1/SMAD3/
PLEKHA1/SLC8A1/AXIN2/RUNX1/MAFB
GO:0050790 regulation of catalytic activity 0.041 CSF1/GHRHR/APC/AQP1/SMAD3/
PSMD13/RIC8A/AXIN2
GO:0035821 modification of morphology or 
physiology of other organism
0.044 AQP1/SMAD3
GO:0019222 regulation of metabolic process 0.044 LDLRAD3/CSF1/NLRP6/GHRHR/APC/
AQP1/SMAD3/ZFHX3/PSMD13/RIC8A/
AXIN2/FZD7/TCF7L1/RUNX1/MAFB
GO:0048583 regulation of response to stimulus 0.044 CSF1/NLRP6/GHRHR/APC/SMAD3/
PLEKHA1/AXIN2/FZD7/TCF7L1/RUNX1
GO:0040007 Growth 0.044 CSF1/GHRHR/SMAD3/PLEKHA1/FZD7
GO:0001775 cell activation 0.046 CSF1/APC/SMAD3/FZD7/MAFB
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ABStrACt
The skeleton is a dynamic organ increasing in mass and density until approximately the 
third decade of life, and subsequently after the age of fifty-yearsbeing resorpt, particularly 
in women after menopause. Bone Mineral Density (BMD) a highly heritable trait is used 
to assess skeletal health in children and risk of osteoporosis later in life. To date >60 loci 
associated with BMD have been described arising from studies focusing primary in old 
adults. Nevertheless, age-specific regulation of BMD might drive the dynamic nature of 
this trait. To evaluate possible age-dependent effects of genetic variants on BMD, we con-
ducted a genome-wide association study (GWAS) meta-analysis of total body (TB-)BMD by 
age-strata of 15 years, in more than 50,000 individuals across the life span. We identified 
variants in 24 loci, associated with TB-BMD at different age-strata (P<5x10-8), including 
variants in three loci not identified in an overall meta-analysis, including RIN3, ZNF789/
ZSCAN5, and PTPN5. In addition, we identified variants in 18 loci exerting age dependent 
effects on BMD. The strongest age specific effects were found for variants in the ESR1 locus 
only exerting a GWS effect (β=0.07 SD, P=2.6x10-12) in adults (betaage=|1.5x10-3|, P=2.42x10-10); 
and variants in RIN3 with GWS effect (β=0.1 SD, P=1x10-8) only in children (betaage=|1.8x10-3|, 
P=1x10-8). In conclusion, applying an age-stratified GWAS approach allowed us to identify 
novel loci and further characterize variants exerting effects that change with aging, helping 
to unveil further the complex genetic mechanisms underlying bone health and partly the 
risk of osteoporosis.
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introDuCtion
The skeleton is a rigid yet dynamic organ that provides support to the body, protects vital 
organs, serves as a reservoir for calcium, growth factors and cytokines. One of the most 
important properties of bone is its ability to regenerate and repair; bones continuously 
adjusts skeletal mass and architecture to changing mechanical environments (1). Generation 
and maintenance of the shape of bone during skeletal growth depends on bone modeling; 
although throughout life, bones also undergo remodeling to remove old, microdamaged 
bone and replace it with new, mechanically stronger tissue in order to help preserve bone 
strength (2). In fact, this process is so dynamic that it is estimated that the entire adult human 
skeleton is replaced every ten years (3).
Bone mass increases steadily during childhood and markedly during adolescence growth (4). 
Peak bone mass is attained at approximately the third decade of life. Thereafter, until an age of 
about fifty years, bone mineral density (BMD) levels remain more or less stable, preserving the 
coupling between bone formation and resorption (e.g., bone remodeling). From there, bone 
loss occurs at a higher rate after fifty-years of age(5), particularly in women after menopause.
Twin and family studies indicate that BMD is a highly heritable trait, with heritability estimates 
ranging between 50 - 85%(6-8). These estimates can vary due to the analytical model used in 
their calculation, the skeletal site measured and the population under study. Importantly, the 
porportion of variance explained by genetic factors, also hanges with age. Gueguen and col-
leagues assessed the heritability of BMD in 129 families and found that heritability estimates 
increase during childhood and reach a maximum of 85% in early adulthood, being of 63% 
and 34% at 14 and 53 years, respectively(9). In addition, Moayyeri and colleagues showed that 
heritability estimates decreased with aging based on a large twin-based longitudinal study 
with participants 35 years or older and average follow up of ten years(10). To date more than 60 
loci have been described as associated with this trait (11). The vast majority of these discover-
ies come from genome-wide association studies (GWAS) in elderly individuals (12,13), while in 
children 14 loci have been identified (14,15). Previous studies have shown for specific variants in 
CPED1 (14), ESR1 and ESR2 (16) the magnitude of the genetic effect varies with age. Nevertheless, 
it is plausible that several genetic variants would exert differential age effects considering that 
BMD shows an age-dependent pattern of an initial increase in bone accrual until achieving 
peak bone mass followed by a subsequent decline in later life, driven by different metabolic 
processes (e.g. menopause in women). In this study, we applied a comprehensive approach 
to investigate the possible modulation of genetic effects by age, through the use of aggregated 
GWAS summary results from cross-sectional studies analyzed across age-bins. Besides the 
specific meta-analyses, we assesed the changes of magitud of genetic effects with respect to 
age, by coparing the extreme age groups and by employing a meta-regression methodology.
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MetHoDS
Study Populations
Subjects
This study included 26 GWAS comprising ~53,427 individuals from populations across 
America, Europe, and Australia, with a variety of epidemiological designs (Chapter 4.2, 
Supplementary table 1) and participant characteristics (Chapter 4.2, Supplementary 
table 2). The correspondent Medical Ethical Committee of each participating study ap-
proved all research aims and the specific measurements performed on human subjects. 
Written informed consent was provided by all subjects or their parents (or legal guardian) 
in the case of children.
BMD measurement
Total body BMD (g/cm2) was measured in all participants using dual-energy X-ray ab-
sorptiometry (DXA) following standard manufacturer protocols. As recommended by 
the International Society for Clinical Densitometry (17) total body less head (TBLH) was the 
measurement used in pediatric cohorts. Detailed information on this assessment per study 
can be found in Chapter 4.2, Supplementary table 1.
GWAS data and imputation
All individuals included in this study had genome-wide array data, except for the PANIC 
study genotyped with the Metabochip. Quality control of the obtained genotypes is 
summarized in Chapter 4.2, Supplementary table 1. To enable meta-analysis, each study 
performed genotype imputation using the cosmopolitan (all ethnic panels combined) 
1000 genomes phase 1 version 3 (March 2012) reference panel (18), via MACH/Minimac(19,20) 
or SHAPEIT/Impute2(21) suites yielding ~30,000,000 SNPs.
Association Analyses
TB(LH)-BMD was corrected for age, weight, height and the genomic principal components 
(derived from GWAS data), as well as any additional study-specific covariates (e.g. recruiting 
center) using linear regression models. For studies with non-related individuals, residuals were 
calculated separately by sex, whereas for family-based studies sex was included as a covariate 
in the model. Finally, residuals were subject to inverse normal transformation to diminish the 
impact of BMD extreme values in the analysis. The analyses were performed in each study for 
subgroups of individuals by age-strata, defined by bins of 15 years (i.e., 0-15 years, 15-30 years, 
30-45 years, 45-60 years, and 60 or more years). SNP association was tested for autosomal 
variants, in which the additive effect of each SNP on the normalized BMD-residual was esti-
mated via linear regression using MACH2QTL(19), SNPtest(22), PLINK(23) or ProbABEL(24).
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Quality control of TB-BMD association summary statistics
A centralized quality-control procedure implemented in EasyQC  (25) was applied to all 
study-specific association files to identify cohort-specific problems: (1) assessment of pos-
sible problems in BMD-residuals normalization by inspection of standard error vs. sample 
size plots; (2) comparison of allele frequency alignment against the 1000 Genomes Project 
phase1 reference data to pinpoint any potential strand issues; (3) examination of quantile-
quantile (QQ) plots and genomic inflation factors per study to identify problems arising 
from population stratification, cryptic relatedness and genotype biases; (4) Analytical is-
sues in the computation of beta estimates, standard errors and P-values by evaluation of 
(P-value – Test statistic) P-Z plots.
In addition, we excluded variants if they had missing information (e.g., missing association 
P-value, effect size (beta) estimate, alleles, allele frequency), or nonsensical values (e.g., 
absolute beta estimates or standard errors >10, association P-values (P) >1 or <0; or imputa-
tion quality < 0; infinite beta estimates or standard errors); minor allele frequency (MAF) 
less than 0.5%; Imputation quality <0.4 (when Impute2 was used for imputation) and <0.3 
(when Minimac was used for imputation). Moreover, markers were flagged if they had large 
allele frequency deviations from reference populations (>0.6 for admixed studies and >0.3 
for ancestry-specific studies).
GWAS meta-analyses
Analyses were performed in each study and meta-analyzed by age strata (minimum sample 
size per bin N=200) resulting in: 1) 0-15 years (N=11,807), 15-30 years (N=4,180), 30-45 years 
(N=6,604), 45-60 years (N=10,482), and 60 or more years (N=20,354). Although there was 
not exclusion based on the ethnicity of the individuals included in each study, more than 
80% of them were reported as of European ancestry (Chapter 4.2, Supplementary table 
1). We discarded markers per age-bin analysis if they were present in less than three studies 
or the overall MAF was less than 1%; approximately 23,700,000 markers were assessed for 
association. We used the conventional genome-wide significance level (GWS, P<5x10-8) for 
SNP discovery.
Age-dependent effects screening
We selected SNPs which were suggestively (P<5x10-6) associated with BMD either in the 
children or the elderly population, whose MAF difference across these meta-analyses was 
lower than 0.5, assigning to each SNP the lowest P-value reached in any of these two as-
sociation meta-analyses. Then, in PLINK(23), we clumped the dataset with an r2 ≥ 0.8, so that 
variants in the final set will not be correlated at this high level. Linkage disequilibrium (LD) 
calculations were based on the RS1 study best guess data (Chapter 4.2, Supplementary 
table 1), using as reference the most BMD-associated SNPs and finally, pruning remaining 
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SNPs within 0.5 Mb of each other. The assessment of an age-dependent effect was per-
formed by testing for these SNPs, the difference between beta-estimates in children vs. 
elderly meta-analyses (Pdiff) using Easy-strata(26). We used a Bonferroni-corrected P-value 
to determine the significance of the differences. Also, we evaluated the gene-age interac-
tion of these SNPs with significant differences in effect in children and elderly, through a 
linear regression of the SNP effect estimates onto an intercept and the median age of each 
subgroup (e.g., each study stratified in age-bins). Standard errors of the effect estimates of 
each subgroup were multiplied by the square root of the genomic inflation factor, if this 
was higher than 1, as proposed before(27). We performed this meta-regression in R(28) using 
the Metafor package(29), statistical evidence of linear association was adjusted for multiple 
testing. For those markers whose effect displayed evidence for age-dependency, we as-
sessed the 2 degrees of freedom results, meaning the significance of intercept (basal effect 
of the SNP) and interaction effect, in order to test whether the inclusion of an interaction 
term would enhance the discovery of associated variants in an overall meta-analysis.
DePiCt Pathway analysis
We used the recently developed DEPICT(30) method to identify enriched genes-sets as well 
as tissues/cell types where genes from associated loci are highly expressed. DEPICT first 
selects all lead SNPs below a certain threshold with respect to a target P-value. We tested 
the set of GWS SNPs in the elderly, and those reaching the suggestive threshold (P<5x10-6) 
on the other subgroups, where statistical power was more limited.
Search for biological and functional knowledge of the identified association regions
We examined whether GWS SNPs are in regions known to be associated with previous 
GWAS of bone traits. In addition, for all those SNPs not within 500Kb of the bone GWAS-
SNPs we checked in PubMed and Web of Science if nearby genes (within 500Kb) were 
known to play a role in bone metabolism. Genomic annotation for all SNPs was made 
based on UCSC HG19 assessed through Bioconductor (31).
reSultS
GWAS meta-analyses
Meta-analyses across age strata resulted in 24 different loci associated with TB-BMD as sum-
marized in Figure 1. Most of the loci were GWS associated in the elderly population, where 
the statistical power for discovery was the highest (i.e., largest sample size). Genomic inflation 
factors in the five age bins were all close to unity, providing no substantial evidence for popu-
lation stratification issues. Markers surpassing the GWS threshold were in the vast majority 
common non-coding SNPs (Supplementary table 1). Missense variants in RIN3 (rs117068593, 
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GWS in children), TNFRSF11B (rs2073618, GWS in elderly), LRP4 (rs2306029 and rs6485702, 
GWS in elderly), CCDC170 (rs12205837 and rs3734804, GWS in elderly, and rs6929137 GWS 
in the 45-60 years and elderly groups), and WNT16 (rs2707466 and rs2908004 associated 
in all age-strata but 15-30 years); associated with TB-BMD are all classifi ed as benign both in 
SIFT(32) and polyphen2(33) algorithms. Additionally, a low-frequency variant in LRP5, GWS in 
the elderly strata - rs4988321/A (11:68174189, MAF=0.04)- is annotated in ClinVar, as a patient 
with osteoporosis-pseudoglioma syndrome was a homozygous carrier of this mutation(34).
When comparing the results obtained in the age-specifi c meta-analyses with those re-
ported in the overall meta-analysis, including all age category sub-populations (Chapter 
4.2), three additional novel loci were identifi ed (Figure 1, Supplementary table 1). In chil-
dren (i.e., 0-15 age bin), the 14q32.12 locus, harboring RIN3, had seven common (MAF=17%) 
variants, including one missense marker, which reached the GWS threshold. In the 30-45 
years age-bin, one rare variant rs71486878 (MAF=1.5%) mapping intronic in the PTPN5 gene 
was GWS associated. Moreover, in the elderly, three variants (MAF ~5%) mapping to 7q22.1, 
containing ZNF789 and ZSCAN5 among others were also associated with TB-BMD.
Age-dependent effects screening
Association signals, rising from the meta-analyses of the children and elderly individuals 
were different, with the elderly meta-analysis showing more association peaks even if 
signals in chromosome 2 and 14 were absent (Figure 2). We sought to investigate if these 
distinct signals were a consequence of variation in sample size across these age-strata 
Figure 1. loci GWS associated with tB-BMD at the primary meta-analysis per age-bin. Each locus is charac-
terized by one or two representative genes chosen either because of their biological relevance or physically 
proximity to the most strongly associated SNP. The colored squares represent the different age bins enclosing 
the genes from loci harboring GWS variants: 60 yrs or more (N=20,354) in red; 45-60 yrs, (N=10,482) in green; 
30-45 yrs (N=6,604) in purple; 15-30 yrs (N=4,180) in pink; and 0-15 yrs (N=11,807) in blue.
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(i.e., children vs. elderly) or rather due to age-dependency of the effect of the associated 
variants on BMD. We selected 3,529 SNPs suggestively associated (P<10-6) with BMD either 
in the children or in the elderly population meta-analyses, from which 377 were pruned 
by LD (r2<0.8). These 377 variants were tested for differences in effect size between the 
children and elderly groups. We chose suggestive (rather than GWS) SNPs, to allow 
capturing potentially true genetic associations with BMD either in the children or the 
elderly population meta-analyses, without particularly favoring the markers identified 
in the elderly, where the statistical power was the highest. Fifty-two markers, mapping 
to 18 different loci (table 1), displayed significant effect differences after multiple testing 
adjustment (P=0.05/377=1.33x10-4). Markers within ten loci presented with larger effects 
in children (i.e., 2p21, 5p14.3, 5q11.2, 7p15.3, 7q31.31, 11p12, 12p11.22, 17q25.1, 20p12 and 
21q21.3). Whereas, larger effects in the elderly were observed for markers in six loci (i.e., 
2q37, 6q21.1, 6q25.1, 7q22.1, 11p15.3 and 17q12). The remaining two loci exhibited allelic 
heterogeneity, with markers exerting greater effects on the children while others exerted 
greater effects in the elderly individuals. In locus 14q32.12, two RIN3 intronic variants were 
tested. While a common variant (rs72699866 with MAF=17%) had greater effect on the chil-
dren (betaA:0-15yrs=-0.09 P0-15yrs=1x10-8) than in the elderly (betaA:60>yrs=0.03 P60>yrs=0.08), a low 
frequency variant (rs77002573 with MAF=3.6%) located 11Kb away, had greater effect on the 
elderly (betaA:60>yrs=-0.15 P60>yrs=3.8x10-6) than on the children (betaA:0-15yrs=0.09 P0-15yrs=0.02). 
Likewise, in the 13q14 locus rs7318320, rs9525638 and rs875625 in moderate LD with each 
Figure 2. Miami plot of association statistics (-log10(P values)) for tB-BMD contrasting children (top) and 
elderly (bottom) populations. Each dot represents an SNP and the x-axis indicates its chromosomal position. 
Dashed horizontal red and yellow lines mark the GWS threshold (P<5x10-8) and suggestive threshold
(P<1x10-6), respectively.
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other (r2~0.6) and mapping in close vicinity or in TNFSF11, presented significant effect in 
the children (e.g., rs9525638, betaA:0-15yrs=0.08 P0-15yrs=1.9x10-10) but not in the elderly (e.g., 
rs9525638, betaA:>60yrs=0.005, P>60yrs=0.60). On the contrary, the rs9533094 located 14-20 
Kb upstream and closer to AKAP11 showed significant effect in the elderly (betaA:60>yrs=0.07 
P60>yrs=1.8x10-12) but not in the children (betaA:0-15yrs=-0.008 P0-15yrs=0.52).
In the meta-regression, we evidenced a linear association of age with effect estimates for 
48 out of these 52 markers, significant after correction (P=0.05/52=9.61x10-4). By taking into 
consideration the interaction term in the joint modeling of the SNP effect (e.g., 2df test), 
we identified association signals, at GWS level, in 32 of these 52 SNPs. Of these, 16 were 
not identified in the meta-analysis of the same populations without age-stratified subgroup 
analysis (i.e., overall meta-analysis, Chapter 4.2). Although most of these 16 SNPs map to 
loci already identified in the overall meta-analysis, rs148982377 and rs72699866, (located 
in 7q22.1 and 14q32.12, respectively), reach GWS only in our meta-regression approach 
(Supplementary table 2).
The strongest statistical evidence for age interaction was provided by rs2982559, an intronic 
variant mapping to ESR1, which was not GWS in the overall meta-analysis (P=1.3x10-7) and 
presented high heterogeneity (Phet =4x10-5) (Chapter 4.2). The effect of age accounted for 
75% of the rs2982559-effect heterogeneity across cohorts (betaage=|1.5x10-3|, P=2.42x10-10) 
(Figure 3). Nevertheless, other SNPs in the same locus reached GWS already in the overall 
meta-analysis. In contrast, the intronic variant rs72699866 in RIN3, provided a similar level 
of statistical evidence of effect dependency on age (betaage=|1.8x10-3|, P=1x10-8), reaching a 
2df P-value of 3.2x10-8 even when no evidence of association in the overall meta-analysis 
was found for this region (Figure 3). Variants with lower frequency (MAF<0.05) attained the 
largest modulation of TB-BMD by age, as expected due to power limitations. In most of 
the cases in which age modulated the effect of the genetic variant, the amount of residual 
heterogeneity was negligible after its inclusion as moderator. Nevertheless, this was not the 
case for specific variants in 13q14, 20p12, and 6q25.1, for which residual effect heterogeneity 
was still nominally significant after inclusion of age in the model, probably indicating that 
other moderators besides age are also influencing their effect.
DePiCt Pathway analysis
DEPICT was used to test for enrichment and define pathways and networks between the 
genes harbored by the GWS associated loci in elderly, and suggestively associated in each 
of the other age bins. Genes were prioritized only in the 45-60 years (SP7, BICC1, WNT4, 
CD300LG, TNFRF11B, LGR4, PDZRN4, SOST, PKDCC, LRP5, TNFSF11, FRMD6, IDUA, and 
FGFRL1) and in the elderly (EN1, ESR1, CPED1, LRP5, SOST, SFRP4, ZNF498) groups. DEPICT 
based on the suggestive associated markers with BMD  identified enrichment for the  GO 
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term “cell-matrix adhesion” in the age group from 15-30 years and the genesets “abnormal 
long bone epiphyseal plate proliferative zone”, “abnormal chondrocyte morphology”, 
“regulation of growth”, “ossifi cation, cell growth”, “abnormal long bone epiphyseal plate 
morphology” in the 45-60 years group. The limited power of our analysis may be due to the 
relatively small number of loci identifi ed in the meta-analyses across age-strata or to limited 
existing knowledge surrounding bone metabolism.
DiSCuSSion
Our meta-analysis of data from more than 50,000 individuals distributed across fi ve differ-
ent age-strata comprising the whole life-course identifi ed 24 loci signifi cantly associated 
with TB-BMD. While an overall GWAS including the same populations without age stratifi -
cation reported 52 different loci associated with TB-BMD, three (7q22.1 [ZNF789/ZSCAN5], 
14q32.12 [RIN3], 11p15.1 [PTPN5]) of the 25 associated loci in the different age-strata did not 
Figure 3. the two loci exhibiting the largest effect of age in the modulation of genetic variant effect in the 
meta-regression. The panels display the SNP effect as a function of age. At the right, each circle represents an 
study subgroup (i.e., study divided in age strata), with the circle size proportional to the inverse variance of 
the SNP main effect. At the left, estimates from each age-bin meta-analysis, with the symbol size proportional 
to the inverse variance of the SNP main effect.
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reach GWS for the TB-BMD overall meta-analysis, despite its larger sample size. This obser-
vation supports the contention that genetic effects in these associated loci, influence BMD 
mainly within an age specific range. In addition, we identified variants in 18 loci with dif-
ferential effects in children as compared to elderly individuals. Of these, variants in at least 
13 loci evidenced a linear trend of change throughout the life-course and the majority of 
the remaining loci seemed to be only important at an early age. Although preliminary and 
requiring additional evidence to support this assertion, prominence of different biological 
pathways across age strata do appear to follow age-specific patterns.
Our findings indicate that there are age-specific genetic effects, maybe as signature of the 
dynamic nature of gene expression or post-translational protein modifications (35-37).Three 
different BMD novel loci were detected in the age-bin meta-analyses. The 14q32, harboring 
the RIN3 gene that showed only association in children and had previously been identified 
as influencing pediatric BMD both at the TB- and at the lower limbs  (15). The minor allele 
of the leading SNP rs726999866/A associated with higher BMD levels in children also 
shows statistical evidence of an effect decreasing by of 0.001-0.002 per year in the studied 
cohorts. This change in effect size with aging likely explains why BMD GWAS meta-analyses 
in adults have not previously detected this association signal. This same rs726999866/A 
allele has been associated with higher risk of Paget’s disease(38). RIN3 is known to affect os-
teoclast function(39), yet the reason for the strong association of variants within this gene and 
BMD in pediatric populations is still unknown.The rs71486878 intronic in PTPN5 showed 
GWS association only in the 30-45 years age-bin. Nevertheless, the studies on this age-bin 
are of modest sample size (N<1,500) and given the MAF of 1.5%, there is a high likelihood for 
this finding to be spourius and replication in a larger sample size should confirm it. On the 
ontrary, the rs148982377 (MAF of 4%) mapping to 7q22.1, identified in the elderly popula-
tion leads an association signal expanding approximately 300Kb where other variants in 
LD also show evidence of association. Although, this locus has never been associated in 
previous more powerful GWAS analyses for both lumbar spine (LS) and femoral neck BMD, 
in the last GEFOS meta-analysis(12), the leading SNP for this association was suggestively 
associated with LS-BMD (P=1.9x10-6). Moreover, rs11761528 (r2=0.42, P60>yrs=1.9x10-5) has 
been previously associated with dehydroepiandrosterone sulphate (DHEAS) levels in the 
blood (40). The minor allele associated with lower DHEAS concentration was also associated 
with lower TB-BMD. The positive correlation between DHEAS and BMD in adult and post-
menopausal women have previously been described  (41,42). A longitudinal study showed 
that this effect might be explained by a decreased rate of bone loss(42).
By comparing summary statistic results from children and elderly subgroups, we found 18 
different loci whose effects change with aging. The 6q25.1 locus demonstrated the most 
compelling evidence for age-dependent effects. Even if this locus, comprising ESR1 and 
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CCDC170, has been shown to harbor complex allele heterogeneity, with at least three inde-
pendent signals associated with BMD (43) and also heel bone properties(44), all the variants 
studied here showed larger effects in the elderly as compared to the pediatric populations. 
In the bin 0-15 years, the largest cohorts (i.e., Avon Longitudinal Study of Parents and 
Children (ALSPAC) and Generation R) comprise predominantly pre-pubertal children. As 
levels of estradiol in infancy are low (45), a negligible effect of ESR1 variants on BMD is ex-
pected. The rs2982559 showed the strongest association with BMD of this locus in children 
(P=0.002), the minor allele of this SNP showed a marked increase of magnitude effect on 
BMD with age, particularly after 45 years, the age of menopause in women. Estrogen and 
BMD are positively correlated from late puberty onwards (46,47), being estrogen production 
a key factor in the maintenance of bone mineralization and prevention of osteoporosis 
in men and women  (48). Nevertheless, before, the influence of estrogen on longitudinal 
bone growth depends on maturational stage and its serum levels (49). In line with estrogen 
exerting an effect in bone longitudinal growth two independent signals in ESR1 have been 
identified to be associated with adult height(50).
On top of RIN3, detailed above in this section, variants within or in the neighborhood of 
other known bone-related genes as BMP2, SUPT3H or SOX6 also demonstrated differential 
effects throughout the life course. Bone morphogenetic protein 2 (BMP2) is a growth factor 
that initiates osteoblast differentiation(51), which even if not GWS in the children meta-anal-
ysis, show a larger effect size in this population. BMP2 variants have been previously associ-
ated with risk of osteoporosis in Icelandic and Danish families(51), an association that has not 
been replicated by later GWAS meta-analyses(12,13,52). Nonetheless, BMP2 signaling seems 
to regulate peak bone mass in mice(53). Variants in BMP2 have additionally been associated 
with body mass index(54), waist-to-hip ratio(55) and height(50) through GWAS, underlying the 
role of this protein in development. Variants in SUPT3H, on the other hand, showed a 
greater effect on old adults, and indeed, it is in this population that association with lumbar 
spine BMD has been established(13) as well as with height(50). It has been suggested that mark-
ers in this gene could regulate RUNX2 expression in bone(56). Together with RUNX2, SOX6 
plays a pivotal role in endochondrial ossification, through the regulation of chondroblast 
differentiation(57). The reason for the larger effect of variants in these key factors of skeletal 
development on the elderly population rather than at an early age remains to be elucidated. 
The WNT16/CPED1 age-effect dependency was not confirmed in our study. Nevertheless, 
this interaction was described for skull-BMD, and not TB-BMD  (14). Site-heterogeneity for 
variants within this locus have been previously shown in pediatric populations (15).
Variants with age-dependent effects have been detected at a genome-wide significant 
level for other complex traits using similar approaches (27,58). By the implementation of the 
meta-regression, we have demonstrated here that age is a fundamental factor in explaining 
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the heterogeneity of the genetic effect for variants associated with BMD in our previous 
study (Chapter 4.2), and should also be investigated as a source of heterogeneity in other 
BMD meta-analyses. As described earlier, the age-stratification approach provides a chief 
advantage over the inclusion of an agexSNP interaction term on the study-specific GWAS 
analysis. Studies typically have a narrow age range (i.e., less of ten or fifteen years) and, 
therefore, contribute little information by using the interaction as a covariate  (27). This is 
mainly the case of the participant studies in our overall metanalysis.
However, some methodological issues could have influenced our findings. First of all, we 
may have introduced a cohort effect, meaning that environmental condition for cohorts at 
different age ranges might be different, particularly when comparing groups at the extremes 
of the age distribution. Second, a recent publication has raised the possibility that adjustment 
for correlated heritable covariates could lead to a (Collider) bias in the assessment of the ge-
netic effect estimate, and this bias would be a function of the correlation of the outcome and 
the covariate (59). Our analysis included as covariates height and weight, which are heritable 
complex traits and whose correlation with BMD varies across the lifespan. Additionally, SNP-
by-age interaction for BMI has been shown, and could complicate further the evaluation of 
the possible effect bias in the reported differences(58). Third, the linear correlation between age 
and the SNP effect could have been affected by the relative larger influence of studies in the 
two extremes of the age distribution (i.e., children and elderly strata), where indeed the larg-
est cohorts included in the meta-analysis are located. This aggregation could have pulled the 
significance of the identified trends, without the contribution of the smaller set of studies in 
the middle age-bins. Nevertheless, the different effects of these variants will still be seen in the 
extremes, but that aggregation makes it difficult to be certain if non-linear effects are present.
In summary, our study provides the first insight into genetic effects changing with aging, at 
a genome-wide level, on BMD spanning from childhood through late adulthood. Our cur-
rent knowledge of genetic factors influencing BMD come mostly from large meta-analyses 
of BMD performed in elderly adults. Our results suggest that increasing the sample size of 
GWAS in younger populations would be an effective strategy for identification of novel 
variants affecting bone metabolism at early ages. Several of the age-dependent loci present 
stronger effects in children as compared to adults, which may reflect a higher accumulation 
of environmental factors on bone density in older adults, probably masking the genetic 
effects. Variants with BMD-effects that either increase or decrease during adult age might 
provide additional knowledge on bone biology mechanisms, which could lead to new 
strategies for the prevention or treatment of osteoporosis.
Additional detailed methods, results and acknowledgements are to be provided in the 
online Supplement of the journal containing this publication.
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ABStrACt
Heritability of bone mineral density (BMD) varies across skeletal sites, reflecting different 
relative contributions of genetic and environmental influences. To quantify the degree to 
which common genetic variants tag and environmental factors influence BMD, at different 
sites, we estimated the genetic (rg) and residual (re) correlations between BMD measured at 
the upper limbs (UL-BMD), lower limbs (LL-BMD) and skull (SK-BMD), using total-body DXA 
scans of ~4,890 participants recruited by the Avon Longitudinal Study of Parents and their 
Children (ALSPAC). Point estimates of rg indicated that appendicular sites have a greater 
proportion of shared genetic architecture (LL-/UL-BMD rg=0.78) between them, than with 
the skull (UL-/SK-BMD rg=0.58 and LL-/SK-BMD rg=0.43). Likewise, the residual correlation 
between BMD at appendicular sites (re=0.55) was higher than the residual correlation be-
tween SK-BMD and BMD at appendicular sites (re=0.20 – 0.24). To explore the basis for the 
observed differences in rg and re, genome-wide association meta-analyses were performed 
(n~9,395), combining data from ALSPAC and the Generation R Study identifying 15 inde-
pendent signals from 13 loci associated at genome-wide significant level across different 
skeletal regions. Results suggested that previously identified BMD-associated variants may 
exert site-specific effects (i.e., differ in the strength of their association and magnitude of 
effect across different skeletal sites). In particular, variants at CPED1 exerted a larger influ-
ence on SK-BMD and UL-BMD when compared to LL-BMD (P=2.01×10-37), whilst variants 
at WNT16 influenced UL-BMD to a greater degree when compared to SK- and LL-BMD 
(P=2.31×10-14). In addition, we report a novel association between RIN3 (previously associ-
ated with Paget’s disease) and LL-BMD (rs754388: β=0.13, SE=0.02, P=1.4×10-10). Our results 
suggest that BMD at different skeletal sites is under a mixture of shared and specific genetic 
and environmental influences. Allowing for these differences by performing genome-wide 
association at different skeletal sites may help uncover new genetic influences on BMD.
AutHor SuMMAry
The heritability of bone mineral density (BMD) varies across skeletal sites, reflecting differ-
ent relative contributions of genetic and environmental influences. To investigate whether 
the genes underlying bone acquisition act in a site-specific manner, we quantified the 
shared genetic influences across axial and appendicular skeletal sites by estimating the 
genetic and residual correlation of BMD at the upper limb, lower limb and the skull. Our 
results suggest that different skeletal sites as measured by total-body Dual-Energy X-Ray Ab-
sorptiometry are to a certain extent under distinct genetic and environmental influences. 
To further explore the basis for these differences, genome-wide association meta-analyses 
were performed to identify genetic loci that are preferentially associated with one or more 
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skeletal regions. Variants at 13 loci (including RIN3, a novel BMD associated locus) reached 
genome-wide significance and several displayed evidence of differential association with 
BMD across the different skeletal sites in particular CPED1 and WNT16. Our results suggest 
that it may be advantageous to decompose the total-body BMD measures and perform 
GWAS at separate skeletal regions. By allowing for site-specific differences, new genetic 
variants affecting BMD and future risk of osteoporosis may be uncovered.
introDuCtion
Bone mineral density (BMD) at the femoral neck and lumbar spine [as measured by dual-
energy X-ray absorptiometry, (DXA)], represents the primary diagnostic marker for osteo-
porosis as it serves as a good predictor of bone strength and fracture risk in adults (1). Bone 
strength and fracture risk are influenced by: i) bone acquisition in childhood, adolescence 
and young adulthood ii) the subsequent maintenance of bone mass over the life course 
and iii) the progressive loss of bone in later life (2,3). Large-scale genome-wide association 
studies (GWAS) using adult-BMD measured at the femoral neck (FN) and lumbar spine (LS) 
have successfully identified variants in 56 loci explaining 4-5% of the phenotypic variance 
in adult-BMD (4-6). However, it is possible that the genetic variants influencing bone acquisi-
tion are different from the ones involved in bone maintenance and bone loss across the 
life course. Consequently, GWAS using paediatric-BMD measurements have recently been 
performed with the goal of identifying novel genetic variants primarily associated with 
bone acquisition, whilst limiting the noise introduced by bone maintenance and bone 
loss (7). This approach has resulted in the successful identification of novel BMD associated 
variants in the WNT16 (7) and Osterix (SP7) loci (8) and it is highly likely that more variants will 
be discovered as the sample size of these paediatric studies increases.
In growing children, changes in bone area create artefacts influencing the reproducibility, 
comparability and interpretation of DXA measurements. For this reason, regions of interest 
(ROI) containing larger bone areas [i.e., total-body, (TB)], which are less prone to these arte-
facts, are preferred for paediatric evaluations of bone health (9). The skull region is generally 
excluded from TB-DXA scans as its relative contribution to bone mass is proportionally 
larger with respect to the rest of the body in children, and its inclusion has been shown to 
make diagnostic interpretation difficult (10). However, from a locus discovery perspective, it 
may be advantageous to partition TB-DXA further into different regions, such as the upper 
and lower limbs and the skull. This is important if genetic heterogeneity exists in terms of 
loci differentially affecting BMD at different skeletal sites, or whose effect is greater at some 
locations than in others. Considering that environmental factors (i.e., mechanical loading) 
influence skeletal sites differently, analysis of skull-BMD may be particularly informative and 
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even provide greater power to identify genetic variants. This is the case given that the skull is 
less influenced by mechanical loading than appendicular and other axial sites. Further, the 
skull is frequently affected in monogenic conditions involving the skeleton. For example, 
craniofacial abnormalities such as thickening of the cranium and skull base are cardinal 
features of van Buchems disease, Sclerosteosis and other sclerosing bone dysplasias (11,12).
In the current study we examined whether genetic factors influence bone mass accrual in 
a site-specific manner, by performing regional analysis of TB-DXA scans, focusing on the 
total-body less head (TBLH), lower limb (LL), upper limb (UL), and skull (SK) regions. Using 
genome-wide complex trait analysis (GCTA) on participants from the Avon Longitudinal 
Study of Parents and their Children (ALSPAC), we assessed the proportion of BMD vari-
ance explained by common genetic variants, across each sub-region and additionally 
determined the shared genetic and residual correlation between each sub-region. Subse-
quently, we performed a genome-wide association (GWA) meta-analysis of BMD at each 
skeletal site in the ALSPAC and Generation R studies and went on to identify factors, which 
preferentially influence one or more skeletal regions.
reSultS
Phenotypic correlation and genome-wide complex trait analysis of BMD at 
different regions
Univariate GCTA analysis revealed that common genotyped variants explained a greater 
proportion of the variance in SK-BMD (vg = 0.51, SE = 0.07, P = 2.0×10-13) than LL- (vg = 0.40, SE 
= 0.07, P = 8.0×10-9) or UL- (vg = 0.39, SE = 0.07, P = 2.0×10-8) BMD. Higher phenotypic correla-
tions were observed when comparing LL- and UL-BMD than with SK-BMD (Table 1). Simi-
table 1. Bivariate GCtA estimates of the genetic and residual correlations for bone mineral density mea-
surements at the total-body less head, lower limb, upper limb and skull for the AlSPAC cohort.  TBLH-BMD 
= total body less head BMD, (LL-BMD) = lower limb BMD, (UL-BMD) = upper limb BMD, (SK-BMD) = skull BMD, 
rg = genetic correlation between trait 1 and trait 2. re = residual correlation between trait 1 and trait 2. All traits, ex-
cluding SK-BMD were adjusted for age, gender and weight. SK-BMD was adjusted for age, gender and height. 
P-refers to the P-value for the likelihood ratio test of whether rg = 0. Phenotypic correlations (rp) were as follows: 
SK-BMD/TBLH-BMD (rp = 0.40, SE = 0.013, P < 0.001), SK-BMD/LL-BMD (rp = 0.31, SE = 0.013, P < 0.001), SK-
BMD/UL-BMD (rp = 0.40, SE = 0.013, P < 0.001) and LL-BMD/UL-BMD (rp = 0.64, SE = 0.010, P < 0.001).
trAit 1 trAit2 SAMPle SiZe rg Se re Se P
SK-BMD tBlH-BMD 9732 0.52 0.088 0.29 0.086 4.1×10-6
ll-BMD 9732 0.44 0.099 0.20 0.088 1.2×10-3
ul-BMD 9732 0.58 0.090 0.24 0.085 9.1×10-7
ll-BMD ul-BMD 9782 0.78 0.067 0.55 0.055 1.4×10-7
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larly, bivariate GCTA analysis indicated that the strongest genetic correlation was between 
BMD at the two appendicular sites, whereas the genetic correlations involving SK-BMD 
were more moderate. The residual correlation between the different sites was in general 
smaller than the genetic correlation, and was higher for BMD between the appendicular 
sites than for comparisons involving the skull (Table 1). Highly similar magnitudes and pat-
terns of residual correlations were obtained for a sensitivity analysis in which BMD at all 
skeletal sites was corrected for age, gender, weight and height (Online Resource Table S1).
Genome Wide Meta-Analysis of BMD across different skeletal regions in AlSPAC 
and Generation r
Genome-wide association meta-analyses were performed on TBLH-, LL-, UL- and SK-BMD, 
using regional BMD data derived from ~9,395 TB-DXA scans. Detailed population charac-
teristics of the ALSPAC and Generation R cohorts are summarised in Tables S2 and S3. Sum-
mary statistics from each GWAS (after meta-analysis) indicated that negligible systematic 
inflation of test statistics was observed (META λGC = 1.01 – 1.03). In contrast, a marked devia-
tion from the null was observed in the tail of the distribution amongst the lowest observed 
P-values of the meta-association analyses (Online Resource Figure S1). SNPs in thirteen 
published BMD-associated loci exceeded the genome-wide significance (GWS) threshold 
for association (P ≤ 5×10-8, Table 2). They included variants which mapped close to, or 
within: WNT4 (1p36.12), WNT16/FAM3C/CPED1 (7q31.31) for all skeletal sites measured, EYA4 
(6q23.2), COLEC10/TNFRS11B (8q24.12), LIN7C/LGR4 (11p14.1), PPP6R3/LRP5 (11q13.2) and 
TNFRSF11A (18q21.33) for SK-BMD, CENPW/RSPO3 (6q22.32) for UL- and SK-BMD, TNFSF11 
(13q14.11) and GALNT3 (2q24.3) for UL- and TBLH-BMD. In addition, variants proximal to 
or within FUBP3 (9q34.11) and KLHDC5/PTHLH (12p11.22) were associated with TBLH- and 
LL-BMD. Furthermore, a novel signal (top SNP rs754388, 14q32.12), located within Ras and 
Rab interactor 3 (RIN3) achieved genome-wide significance after meta-analysis of LL-BMD 
(β = 0.13, SE = 0.02, P = 1.4×10-10, Figure 1-I, Table 2) and TBLH-BMD (β = 0.12, SE = 0.02, P = 
3.0×10-9, Table 2 and Online Resource Figure S2). The full list of all genome-wide significant 
SNPs and regional association plots for each locus and skeletal site are presented in Online 
Resources Tables S4 – S7 and Figures S2 - S5.
A followup of 66 independent SNPs at 58 loci, previously associated with BMD  (4,13), in-
dicated that 31 loci showed nominal evidence of association (P < 0.05) with TBLH-BMD, 
28 with LL-BMD, 26 with UL-BMD and 26 with SK-BMD (versus an expectation of 3.3. per 
phenotype) (Online Resource Table S8). A similar distribution of associations was also 
observed when a more conservative threshold considering multiple hypothesis testing was 
adopted that took into account the fact that 66 variants and four phenotypes had been 
tested (i.e., α < 1.9×10-4). Using this threshold nine variants showed evidence of association 
with TBLH-BMD, seven with LL-BMD, six with UL-BMD and 10 with SK-BMD (versus an 
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expectation of 0.1 per phenotype). We note that in all cases where nominal significance 
was reached, the direction of effect was consistent with previous studies.
To ensure that our results were robust to the possible effects of population stratification 
and our choice of covariates, we performed sensitivity analyses where we either restricted 
our analysis to white European individuals only, or adjusted for the same set of covariates 
across all analyses (i.e., age, gender, height, and weight). Similar effect sizes and patterns 
of association were observed for the top SNPs when adjusting BMD measures of all four 
regions for age, gender, height and weight (Model 1a, Online Resource Table S9) and when 
limiting the GWAS meta-analysis to individuals of European ancestry (Model 1b, Online 
Resource Table S9). In both sensitivity analyses, no additional loci reached the threshold of 
genome-wide association (Online Resource Figure S6 and S7).
identification of novel BMD-associated signals
We assessed the presence of novel secondary association signals at loci that contained ge-
nome-wide associated variants. Meta-analysis of conditional association analyses resulted 
in the attenuation of the majority of our top association signals (Online Resource Table S10, 
Figures S2 - S5), indicating that these loci were not independent from signals previously 
reported by other BMD GWAS. However, the top signal for SK-BMD (rs2130604, β = 0.11, 
SE = 0.02, P = 3.3×10-11), mapping near RSPO3, but closest to CENPW (previously known as 
C6orf173, 6q22.32, Figure 2A-I, Table 2) was only marginally attenuated after conditional 
Figure 1: regional association plot of the primary signal (rs754388) associate with lower limb-BMD at 
14q32.12, in addition to a comparison of the effect of rs754388 on bone mineral density at three different 
skeletal sites. For I and II: Circles show GWA meta-analysis P-values and positions of SNPs found within the 
14q32.12 locus. The top SNP, i.e., rs754388, is denoted by a diamond. Different colors indicate varying degrees 
of pair-wise linkage disequilibrium (HapMap 2 CEPH) between the top SNP and all other SNPs. For II: The 
per-allele effect in standard deviations (SD) (red dot) and the 95% confidence interval (error bar) of rs754388 
for lower limb (LL), upper limb (UL) and skull (SK) BMD, plotted with the strength of evidence against the null 
hypothesis of no association.
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analysis (rs2130604, β = 0.10, SE = 0.02, P = 7.1×10-9, Figure 2A-II, Online Resource Table 
S10). This suggests that rs2130604 is largely independent from the previously reported 
signal at RSPO3 (rs13204965, 6q22.32), which was identified in a GWAS of individuals with 
extremely high or low BMD at the hip [12] and later replicated in the second GEnetic Factors 
for OSteoporosis Consortium (GEFOS-II) BMD meta-analysis (4). This observation is further 
supported by low estimates of LD (r2 = 0.14) between rs2130604 and rs13204965. Further-
more, the secondary signal (after conditional analysis) reached the estimated significance 
threshold of association after multiple testing correction (i.e., P ≤ 7.2×10-5).
Interestingly, after conditioning rs4418209 (another SNP in the same locus) on the pub-
lished BMD-associated SNP rs13204965, we observed a marked increase in its evidence of 
association [(β = 0.07, SE = 0.02, P = 1.1×10-6) before and (β = 0.09, SE = 0.01, P = 7.9×10-10) after], 
(Figure 2A-II, Online Resource Table S10). The rs4418209 variant maps closest to CENPW 
(6q22.32) and is in moderate LD with the secondary independent signal (rs2130604, r2 = 
0.43) and in low LD with the published RSPO3 SNP (rs13204965, r2 = 0.12). Whilst no other 
Figure 2: regional association plots of the top skull- and upper limb-BMD associated SnPs at the 6q22.32 
locus before and after conditioning on published SnP (rs13204965*) in addition to a comparison of the 
effect sizes of the top skull- (rs2130604) and upper limb-BMD (rs1262476) associated SnP (before condi-
tional analysis) on BMD at three different skeletal sites. For I and II: Circles show GWA meta-analysis P-val-
ues and positions of SNPs found within each locus. Top SNPs are denoted by diamonds. Different colors indi-
cate varying degrees of pairwise linkage disequilibrium (HapMap 2 CEPH) between the top SNP and all other 
SNPs. Blue vertical shaded areas indicate the position of rs2130604 (top SNP A-I) and rs1262476 (top SNP B-I) 
for each analysis. The red vertical shaded area represents the position of the published SNP (rs13204965*). 
Rsids of relevant SNPs (blue dots) have been provided. For III: The per allele effect in SD (red dot) and 95% 
confidence intervals (error bar) of each top SNP (before conditional analysis) for lower limb (LL), upper limb 
(UL) and skull (SK) BMD are plotted with their specific strength of evidence against the null hypothesis of no 
association. Please note: RSPO3 is also found in the 6q.22.32 locus containing CENPW
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SNPs reached the threshold for declaring genome-wide significance (P < 5×10-8), variants 
from three loci still yielded suggestive evidence for association (P < 1×10-5) after conditional 
analyses (Online Resource Table S10 and Figures S2 - S5). They included: i) KLHDC5/PTHLH 
(rs4420311, 12p11.22) associated with TBLH- (β = 0.08, SE = 0.016, P = 7.6×10-7) and LL-BMD (β 
= 0.08, SE = 0.016, P = 1.9×10-6), ii) TNFSF11 (rs17536328 and rs2148072, 13q14.11) associated 
with TBLH- (β = 0.08, SE = 0.015, P = 5.6×10-7) and UL-BMD (β = 0.07, SE = 0.015, P = 2.1×10-6) 
respectively and iii) LIN7C/LGR4 [rs10160456, 11p14.1, (β = 0.07, SE = 0.015, P = 7.8×10-6)] with 
SK-BMD. After conditional analysis, the secondary signal at LIN7C/LGR4 (i.e., rs10160456) 
mapped closest to CCDC34 and not to LIN7C, the gene closest to the primary signal. All 
these three loci might represent novel secondary signals as the residual signal reached the 
predicted locus specific threshold of association after multiple testing correction (Online 
Resource Table S10). However, we cannot exclude that both associations (i.e., the pri-
mary and secondary signals) could potentially arise from their association with one or more 
causal variants, which could occur, on the same haplotype background. For example, one 
such BMD-associated rare variant has recently been identified in LGR4 in Icelandic popula-
tions although this mutation appears specific to this population and therefore is unlikely to 
account for the LIN7C/LGR4 signal we observe (14).
Comparison of the magnitude of the effect sizes of genome-wide significant SnPs 
across skeletal-sites
The standardized per allele effect sizes (β) of all the top BMD-associated SNPs were compared 
across three (SK-, UL-, and LL) BMD regions to determine if they preferentially influenced 
one or more skeletal sites (Table 3, Online Resource Figure S8 – S11). Effect sizes of the fol-
lowing variants: rs2130604 (CENPW/RSPO3, 6q22.32), rs3012465 (EYA4, 6q23.2), rs2450083 
(COLEC10/TNFRS11B, 8q24.12), rs10835187 (LIN7C/LGR4, 11p14.1) and rs884205 (TNFRSF11A, 
18q21.33) appeared to be largest for SK-BMD when compared to UL- and LL-BMD (Online 
Resource Figure S8). Furthermore, differences in the magnitude of the effect were evident 
when comparing independent genetic variants that occurred in close proximity within a 
locus, as shown at the CENPW/RSPO3 (6q22.32) and WNT16/FAM3C/CPED1 (7q31.31) loci. 
Specifically, the independent signal (rs2130604, CENPW/RSPO3, 6q22.32) associated with 
SK-BMD [β = 0.11 (CI95: 0.08, 0.15) P = 3.3×10-11], was not strongly related to LL-BMD [β = 0.02 
(CI95: –0.02, 0.05), P = 0.28], or UL-BMD [β = 0.04, (CI95: 0.01, 0.07), P = 0.02] (Table 3, Figure 
2A-III). In contrast, a neighbouring SNP (rs1262476) primarily associated with UL-BMD ap-
peared to influence BMD across all skeletal sites (Table 3, Figure 2B-III). Differential patterns 
of association between SNPs at neighbouring positions were also observed at the WNT16 
locus (Table 3, Figure 3A-C). Effect sizes were largest for UL-BMD at rs2908004 (WNT16, 
7q31.31, Table 3, Figure 3A-II) when compared to SK- and LL-BMD. Interestingly, as com-
pared to LL-BMD, we observed consistently larger effect sizes for rs13223036 and rs798943 
(CPED1, previously known as C7orf58) for SK- and UL-BMD, (Table 3, Figure 3B-II and 3C-II).
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Figure 3: regional association plots of the top SnPs associated with total-body less head-, lower limb-, up-
per limb- and skull-BMD at the 7q31.31 locus, in addition to a comparison of the effect size of the top site-
specific SnP on BMD at the three different skeletal sites. For I: Circles show GWA meta-analysis P-values 
and positions of SNPs found within the 7q31.31 locus. Top SNPs are denoted by diamonds. Different colors 
indicate varying degrees of pair-wise linkage disequilibrium (HapMap 2 CEPH) between the top SNP and all 
other SNPs. Blue vertical shaded areas indicate the position of rs7776725 (top SNP A-I) and rs2908004 (top 
SNP B-I) and rs798943 (top SNP C-I) for each analysis. The red vertical shaded area represents the position of 
rs13223036 (top SNP D-I). For II: The per allele effect in SD (red dot) and the 95% confidence interval (error 
bar) of the top SNP for lower limb (LL), upper limb (UL) and skull (SK) are plotted with their specific strength 
of evidence against the null hypothesis of no association. Please note: FAM3C and CPED1 are also located at 
the 7q.31.31 locus containing WNT16.
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To formally determine whether the standardized regression coefficients of each of the 
above-mentioned variants truly differed across the skeletal sites, we fitted a multivariate 
normal likelihood model to the raw data in ALSPAC and Generation R (see Methods), and 
then meta-analysed the results using Fisher’s method. Using a conservative threshold (i.e., 
α = 5×10-8), we observed robust evidence indicating that i.e., rs13223036 and rs798943, lo-
cated at CPED1 exerted strong effects on UL and SK-BMD, when compared to LL-BMD [P = 
2.01×10-37 and P = 4.44×10-36 (Table 3)], whereas the variant rs2908004 (WNT16) was strongly 
related to UL-BMD in comparison to BMD at the other sites (P = 2.31×10-14). Several variants 
at other loci were also suggestive of some degree of skeletal site specificity including EYA4 
and LIN7C, although they did not formally meet the criteria for statistical significance (Table 
3, Online Resource Figures S8 – S11).
Association of novel variants with hip and spine BMD.
To elucidate if any of the novel primary and/or secondary signals, identified during the 
course of this study, were nominally associated with BMD in adults, we performed a lookup 
of these variants in the publicly available results of the GEFOS-II meta-analysis of hip and 
spine BMD (Online Resource Table S11)  (4). The novel RIN3 variant (rs754388) was not as-
sociated with femoral neck (PFN = 0.87) and lumbar spine BMD (PLS = 0.42). The G allele 
of the EYA4 variant (rs3012465), associated with increased SK-BMD (β = 0.13, SE = 0.02, P 
= 8.3×10-17), but suprisingly showed nominal association with decreased BMD at both the 
hip (P = 7.1×10-3) and spine (P = 0.04). A followup of this variant in a recent published GWAS 
of 4061 premenopausal women aged 20 to 45 revealed no evidence of association with 
FN-BMD (P = 0.73) (15).
A lookup of the secondary independent SNPs revealed no evidence of a relationship 
between the TBLH- and LL-BMD-associated KLHDC5/PTHLH variant (rs4420311) and 
associations with hip or spine BMD (PFN = 0.33 and PLS = 0.45) in GEFOS-II. Similarly no 
evidence of association was detected for the SK-BMD-associated variant at CENPW/RSPO3 
(rs2130604: PFN = 0.98 and PLS = 0.40). Interestingly, the T allele of the CENPW/RSPO3 variant 
(rs4418209), which was associated with increased SK-BMD (β = 0.07, SE = 0.02, P = 1.1×10-6), 
appeared to be nominally associated with decreased hip BMD (P = 5.0×10-3) but not spine 
BMD (P = 0.34). Further inspection revealed that the T allele of rs4418209 was nominally 
associated with decreased BMD at the TBLH (β = –0.03, SE = 0.02, P = 1.7×10-2), LL (β = –0.04, 
SE = 0.02, P = 6.5×10-3) and UL (β = –0.04, SE = 0.02, P = 8.2×10-3). The T allele of rs17536328 
located within TNFSF11, associated with increased TBLH-BMD, showed nominal evidence 
of association with increased hip (P = 0.04) but not spine BMD (P = 0.87). In contrast, the 
G allele of an independent TNFSF11 variant (rs2148072) associated with increased UL-BMD 
was associated with decreased spine BMD (P = 0.05). In addition, the C allele LIN7C/LGR4 
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variant (rs10160456) associated with increased SK-BMD showed weak evidence of associa-
tion with increased hip (P = 0.06) and spine (P = 0.03) BMD.
Bioinformatic analysis of RIN3
We fine mapped the RIN3 region by imputing common and rare variants using a reference 
panel from the 1000 Genomes Project and identified a missense variant (rs117068593) 
that was in strong linkage disequilibrium (r2 = 0.96) with the top LL-and TBLH-BMD associ-
ated RIN3 variant (rs754388). The C allele of rs117068593 (EAF = 0.82) was associated with 
increased BMD of the lower limbs (β = 0.13, SE = 0.020, P = 5.97×10-11) and total-body less 
head (β = 0.12, SE = 0.020, P = 1.87×10-9). A search of the SIFT database  (16) revealed that 
the missense variant could negatively affect RIN3 functioning. This prediction was further 
supported by a search of the Regulome database  (17), which suggested that the missense 
variant alters the binding of the following transcription factors: EBF1, EGR1, SP1, NFKB1 and 
POLR2A, in lymphoblastic cell lines.
RIN3 expression profiling
Evaluation of cis-expression quantitative trait loci (eQTLs) from primary human osteoblasts 
using array-based gene expression suggested that variants located within 1MB of RIN3 (i.e., 
including variants tagging SLC24A4, LGMN, GOLGA5, CHGA and ITPK1) were nominally 
associated with ITPK1 expression (P = 0.04). This observation failed to meet the level of sig-
nificance after correction for multiple testing. Examination of the temporal pattern of gene 
expression across osteoblastogenesis, using mouse calvarial derived cells, starting with the 
pre-osteoblast stage, through to mature osteoblasts revealed that Rin3, Golga5 and Lgmn, 
and Iptk1 were expressed in this cell type (Online Resource Figure S12). In contrast, Slc24a4 
and Chga were not expressed at all in the pre- or mature osteoblast, as determined by 
RNAseq. A further investigation of the expression profiles of the aforementioned genes in 
human mesenchymal stem cells [(hMSCs), differentiated into adipocytes and osteoblasts] 
and peripheral blood monocytes [(PBMCs) differentiated into osteoclasts] indicated the fol-
lowing: SLC24A4 was not expressed in any of these cell lines when differentiated, GOLGA5 
had an intermediate expression level in both differentiating hMSCs and PBMCs and LGMN 
was immediately upregulated upon differentiation into adipocytes (8 fold), osteoblasts (5 
fold) and osteoclasts [(5 fold), Online Resource Figure S13 and S14]. Moreover, we found 
that the expression of RIN3 was 2-fold downregulated during the proliferative phase of 
differentiating PBMCs into osteoclasts (Online Resource Figure S13). Finally a comparison 
of expression profiles across the RIN3 region of illiac bone biopsies derived from 39 osteo-
porotic and 27 healthy postmenopausal donors revealed one transcript (i.e., 220439_at, 
originating from RIN3), that demonstrated reduced expression in the osteoporotic group 
relative to the control group [P = 2.7×10-3, (Online Resource Table S13)].
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DiSCuSSion
This study assessed whether regional analysis of skeletal sites from TB-DXA could be used 
to estimate the extent to which genetic and environmental factors influence bone mass 
accrual of differentially loaded skeletal sites (skull, lower limbs, and upper limbs). Point 
estimates indicated that common SNPs on a commercially available genotyping array, 
explained a larger proportion of the overall variance of SK-BMD, when compared to BMD 
measured at the appendicular sites (i.e., lower and upper limbs). These differences poten-
tially reflect differential exposure of each skeletal site to varying environmental stimuli that 
influence BMD. Specifically the skull, as opposed to appendicular sites, is less influenced 
by environmental factors, particularly those acting through mechanical loading. To explore 
this result further, we estimated the residual correlation (i.e., the proportion of environmen-
tal and other sources of variation not tagged by SNPs on the Illumina platform) across the 
different skeletal sites and found that whilst the environmental (and other residual) factors 
influencing the appendicular sites were moderately similar to each other, they appeared 
to be appreciably different from the factors influencing SK-BMD. Taken together, lower vg 
estimates, coupled with a high residual correlation between the two appendicular sites, 
may reflect the greater exposure of these sites to loading and muscular stimulation, when 
compared to the skull.
Likewise, estimates of the genetic correlations indicated that the appendicular limbs 
shared a more similar genetic architecture when compared to the skull, possibly reflect-
ing the composition of bone at each skeletal site and the biological processes that govern 
their growth and maintenance. For example, appendicular sites consist of broadly equiva-
lent proportions of cortical and trabecular bone. The skull on the other hand is mainly 
comprised of flat bones, which consist primarily of cortical bone  (18). The developmental 
processes also differ between long and flat bones, with dermal bones such as the skull vault 
arising exclusively through intramembranous bone formation, in contrast to long bones, 
which form through endochondral bone formation involving intermediary formation of 
cartilage (19).
To further explore the basis for the above-mentioned differences in underlying genetic 
architecture, GWA meta-analyses of sub-regional TB-DXA data were performed. These 
analyses helped identifying genetic signals that were associated with one or more skeletal 
region(s). When comparing the evidence of association for all SNPs (identified in this ef-
fort) across each skeletal site, our GWA meta-analyses echoed the findings of our GCTA 
results, supporting the notion that although the underlying genetic architecture influencing 
BMD appears to be largely similar, it does vary according to skeletal site. The majority of 
the top SNPs were nominally associated (P ≤ 0.05) with BMD across all skeletal sites (i.e., 
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SNPs at WNT4, WNT16, FAM3C, GALNT3, FUBP3, KLHDC5/PTHLH, TNSF11, LIN7C/LGR4 and 
PPP6R3/LRP5). In contrast, variants near or within CPED1, COLEC10/TNFRS11B and EYA4 
were strongly associated with UL- and SK-BMD, but not LL-BMD. A further variant was 
identified within TNFRSF11A that appeared to be solely related to SK-BMD. Most notably we 
observed a novel association between rs754388 (located within RIN3) and LL-/UL-BMD, 
but not SK-BMD. To the best of our knowledge this is the first GWAS to report an associa-
tion between RIN3 and BMD. It seems likely that this association reflects a true relationship 
with BMD as the same RIN3 signal (as determined by conditional analysis) has previously 
been associated with an increased risk of Paget’s Disease [i.e., rs10498635-C OR: 1.44, 95%-
CI (1.29-1.60) P = 3.x10-11] (20).
In an attempt to further understand how the genetic variation surrounding RIN3 may influ-
ence BMD, we fine mapped RIN3 and identified a missense variant (rs117068593) that was 
in high LD with our LL-BMD associated SNP. Data mining of SIFT and ENCODE databases 
suggested a functional role of the missense variant that putatively affects binding of several 
transcription factors in lymphoblastic cell lines. We further evaluated expression quantita-
tive trait locus (eQTL) data from primary human osteoblasts using SNP data from HapMap 
(i.e., not including rs117068593) and found no substantial evidence that our LL-BMD associ-
ated SNPs located at 14q32.12 regulated the expression of RIN3 or any of the genes located 
nearby. However, differential patterns gene expression were detected when comparing 
RIN3 expression profiles of osteoporotic and healthy individuals. Further, we also observed 
differential expression during osteoclast differentiation that was not present in osteoblast 
and adipocyte differentiation processes. Collectively, the aforementioned observations 
appear to be in line with previous findings that suggest that RIN3 could influence osteoclast 
activity, especially when considering the prior association of RIN3 with Paget’s Disease, a 
disease driven by osteoclast dysfunction and molecular studies that indicate that RIN3 is 
involved in vesicular trafficking, a process critical for bone resorption (20,21). Further study is 
however needed to elucidate the precise role of role of RIN3 in bone metabolism.
To further understand the preferential associations of some variants with different skeletal 
sites, we compared the standardized effect sizes of all the genome-wide significant BMD-
associated variants, across each skeletal site using a formal multivariate normal likelihood 
model. Variants at the CPED1 locus were strongly associated with BMD at the skull and up-
per limb sites, but not with LL-BMD. Similarly variants at WNT16 were more strongly related 
to UL-BMD, than to BMD at the other sites. Several other SNPs showed evidence for site 
specificity including variants at the EYA4 and LIN7C loci that were very strongly related to 
SK-BMD, although these variants did not surpass our conservative criterion for declaring 
significant heterogeneity, corroboration is needed from independent studies.
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Conceivably, differences in the pattern of results across SNPs may have arisen from an 
artefact of the measurement (i.e., where sub-regional-specific associations reflect how 
accurately BMD is measured at each skeletal site). However, if the latter were the case, one 
would expect to observe a consistent pattern of results across all loci (i.e., the strength of as-
sociation should be greatest at those sites measured more accurately). From our results, this 
is clearly not the case as evidence of association is sometimes greatest for the skull, whilst 
for other SNPs evidence is greatest for lower and/or upper limbs. In terms of biological 
explanations, larger effect sizes of genetic variants that influence SK-BMD possibly reflect 
their preferential involvement in cortical as opposed to trabecular bone metabolism and/
or the involvement of intramembranous ossification vs. endochondral ossification (13). Cer-
tain genetic factors also appeared to influence UL-BMD more strongly than LL-BMD, or vice 
versa. Since the composition and developmental origin of these two sites is broadly similar, 
presumably, other explanations are responsible. It is reasonable to think that genetic fac-
tors, which we identified, could be acting to alter responses to stimuli that are themselves 
site-specific. For example, adipose tissue has previously been reported to influence cortical 
bone of the tibia in preference to the radius (22).
Quantitative SK-BMD measurements have traditionally been ignored by genetic and epi-
demiological studies as they are thought to be prone to errors such as dental augmentation. 
Despite these concerns, a study conducted in premenopausal woman found a high corre-
lation between the upper half of the skull (i.e., cranial vault) and total skull-BMD (r2 = 0.991, 
n = 91, Age range 19-30 years), with a mean difference of -0.004 g/cm2, suggesting that 
these two measurements of bone mass are similar  (23). We found that paediatric SK-BMD 
measures are well suited to GWAS, as indicated by the very low P-values obtained at some 
of the known BMD associated loci (10-17 to 10-28) despite our relatively small sample size. 
This observation may reflect the fact that SK-BMD is considerably less subject to environ-
mental influences, such as those acting through mechanical loading. In addition, genetic 
variants associated with SK-BMD identified in this study may primarily reflect molecular 
pathways involved in bone mass accrual and growth, in contrast to variants identified from 
previous adult scans which may be more strongly related to mechanisms involved in bone 
maintenance and/or loss.
Almost all the loci we have identified in this study (i.e., with the exception of SNPs in RIN3 
and EYA4) have been associated with BMD at either the hip or the lumbar spine previously. 
Variants mapping to RIN3 have been implicated in Paget’s disease but this is the first time the 
locus is associated with BMD, and interestingly, the alleles associated with increased BMD 
are associated with increased risk for the condition. This shows that performing GWAS of 
BMD at sites other than at the femoral neck (FN-BMD) or lumbar spine (LS-BMD) can be 
used to identify loci that exert pleiotropic effects on bone. Potential advantages of examin-
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ing these additional sites from a locus discovery perspective are that (i) genetic variants 
may exert stronger effects at these sites than at FN-BMD/LS-BMD, and/or (ii) the genetic 
effects may be more apparent at these sites because the effect of environmental noise is 
minimized. For example, the P-values for skull BMD at several loci (e.g., variants around 
CPED1, EYA4 and LIN7C) are many orders of magnitude stronger than the corresponding 
P-values for TBLH-BMD (see Online Resource Table S8). Likewise variants in LIN7C were 
first discovered using a GWAS meta-analysis of lumbar spine that was over five times the 
size of the present study, and even then only just exceeded the threshold for genome-wide 
significance  (4), whereas in our study a variant at this locus has P < 1 x 10-16 with SK-BMD. 
Hence, GWAS of BMD at sites such as the skull could be used to efficiently detect clinically 
relevant loci that might be more difficult to discover in GWAS of the femoral neck and/or 
lumbar spine.
To further illustrate the value of SK-BMD, we draw attention to rs3012465, a variant proximal 
to the eyes absent (EYA4) gene and associated with increased SK-BMD. We show that the 
signal is analogous to that previously associated with increased volumetric cortical BMD of 
the tibia (i.e., C allele of rs271170: β = 0.11, P = 2.7×10-12), based on a GWAS in ALSPAC and 
other young adult cohorts  (13), suggesting that both findings reflect the relationship of the 
EYA4 locus with cortical bone. However, a look-up in a separate cortical bone site (i.e., the 
femoral neck of the hip), from a GWAS in older adults, revealed that the BMD-increasing 
allele at the EYA4 locus was in fact associated with lower BMD for both rs3012465 and 
rs271170  (4). Taken together, these findings may reflect an age dependent effect of EYA4 
whereby EYA4 contributes to bone accrual in early life, yet maybe influences bone loss in 
older adults. To test this hypothesis, we followed up these EYA4 variants in a recent GWAS 
meta-analysis of FN-BMD in 4061 pre-menopausal women aged 20 – 45 (as described in 
Koller and colleagues (15)) and failed to find any evidence of association with FN-BMD (P = 
0.73). These results suggest that the discrepancy in results between GEFOS and the present 
study is unlikely to be solely due to age, but rather is likely to represent a real difference 
between skeletal sites.
In summary, our strategy of analysing regional paediatric DXA measures of TB-BMD repre-
sents a novel approach to dissecting the genetic architecture influencing bone mass accrual 
and growth at different skeletal sites. Specifically, variants at 13 loci reached genome-wide 
significance with BMD and several displayed different degrees of association according to 
skeletal site. Furthermore, we report a novel association between a variant within RIN3 and 
LL-BMD and note its previous association with risk of Paget’s disease. We additionally pro-
vide suggestive evidence of allelic heterogeneity at the CENPW/RSPO3, KLHDC5/PTHLH 
and LIN7C/LGR4 loci. In conclusion our results provide evidence that different skeletal sites 
as measured by TB-DXA are to a certain extent under distinct environmental and genetic 
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influences. Allowing for these differences may help to uncover new genetic influences on 
BMD, particularly those examined in children as involved in bone growth and accrual.
MAteriAlS AnD MetHoDS
Subjects
ALSPAC
ALSPAC is a longitudinal population-based birth cohort that recruited pregnant women 
residing in the former county of Avon, UK, with an expected delivery date between 1st 
April 1991 and 31st December 1992. This cohort has been described in detail on the website 
(http://www.alspac.bris.ac.uk) and elsewhere (24). DXA, height and weight measurements 
were performed on children who attended the 9 year old focus group clinic [mean age of 
participant 9 (± 0.32 years)]. Ethical approval was obtained from the ALSPAC Law and Ethics 
committee and relevant local ethics committees, and all parents provided written informed 
consent.
Generation R Study
The Generation R Study is a prospective cohort study enrolling 9,778 pregnant women liv-
ing in Rotterdam with a delivery date from April 2002 until January 2006. Details of study 
design and data collection have been described elsewhere  (25). DXA, height and weight 
measurements were performed on children who visited the research centre whilst being 
accompanied by their mothers at a mean age of 6 (± 0.5 years). All research aims and spe-
cific measurements taken during the course of the Generation R Study have been approved 
by the Medical Ethical Committee of the Erasmus Medical Center, Rotterdam. All parents 
provided written informed consent.
Phenotypes
ALSPAC
TB-DXA scans were performed on all participants, using a Lunar Prodigy scanner (Lunar 
Radiation Corp, Madison, WI) with paediatric scanning software (GE Healthcare Bio-
Sciences Corp., Piscataway, NJ). DXA measures of BMD were derived for the following 
regions of interest: TBLH-, UL-, LL- and S. All DXA scans were subsequently reviewed by a 
trained researcher, and re-analysed as necessary, to ensure that borders between adjacent 
ROI’s were placed correctly by the automated software. The coefficient of variation for 
TBLH-BMD measures was 0.8%, based on the analysis of 122 children who had two scans 
performed on the same day. Height was measured to the nearest 0.1 cm using a Harpenden 
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stadiometer (Holtain Ltd., Crymych, UK) and weight was measured to the nearest 50 g using 
Tanita weighing scales (Tanita UK Ltd, Uxbridge).
Generation R Study
TB-BMD was measured in all participants using a GE-Lunar iDXA scanner. Well-trained 
research assistants obtained the DXA scans using the same device and software (enCORE) 
following standard manufacturer protocols. The same regions of interest as described for 
ALSPAC were derived from TB-DXA scan. To ensure that the lines between adjacent ROI’s 
were placed correctly by the automated software, scans were evaluated twice, directly 
after the scanning and at a later time point by a second well-trained research assistant. The 
coefficient of variation for total TBLH-BMD measures was 0.23%, based on duplicate scans 
of children that were performed on the same day.
Genotyping and imputation
ALSPAC
A total of 9,912 subjects were genotyped using the Illumina HumanHap550 quad genome-
wide SNP genotyping platform (Illumina Inc., San Diego, CA, USA) by 23andMe subcon-
tracting the Wellcome Trust Sanger Institute, Cambridge, UK and the Laboratory Corpora-
tion of America (LabCorp Holdings., Burlington, NC, USA). PLINK software (v1.07) was used 
to carry out quality control measures  (26). Individuals were excluded from further analysis 
on the basis of having incorrect gender assignments, minimal or excessive heterozygosity 
(< 0.320 and > 0.345 for the Sanger data and < 0.310 and > 0.330 for the LabCorp data), 
disproportionate levels of individual missingness (> 3%), evidence of cryptic relatedness (> 
10% IBD) and being of non-European ancestry (as detected by a multidimensional scaling 
analysis seeded with HapMap 2 individuals). EIGENSTRAT analysis revealed no additional 
obvious population stratification and genome-wide analyses with other phenotypes indi-
cate a low lambda) (27). SNPs with a minor allele frequency of < 1% and call rate of < 95% were 
removed. Furthermore, only SNPs that passed an exact test of Hardy–Weinberg equilibrium 
(P > 5×10-7) were considered for analysis. After quality control, 8,365 unrelated individu-
als who were genotyped at 500,527 SNPs were available for analysis. Known autosomal 
variants were imputed with Markov Chain Haplotyping software (MACH 1.0.16) (28,29), using 
CEPH individuals from phase II of the HapMap project (hg18) as a reference set (release 
22) (30). The BMD associated RIN3 locus was further imputed using the complete reference 
panel from the third phase of the 1000 Genomes Project (i.e., March 2012) (31).
Generation R Study
Genotyping was performed using the Illumina HumanHap 610 QUAD microarray using 
standard manufacturer protocols. Stringent quality control of the genotype and imputa-
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tion process was performed in this study as previously described (7). Samples with gender 
discrepancy, excess of heterozygosity, low genotype quality and sample replicates were 
excluded from the analysis. A reference panel for imputation, consisting of CEPH, YRI and 
CHB/JPT haplotypes was constructed using data from phase 2 of the HapMap project (hg18, 
release 22) (30). A two-step imputation process was performed using MACH for haplotype 
phasing and Minimac for imputation (28,29). A similar 1000 Genomes imputation strategy (as 
described above for ALSPAC) was used to fine map the RIN3 locus.
Statistical Methods
Choice of covariates
BMD as measured by DXA is strongly influenced by weight, in part because weight is re-
lated to skeletal size. BMD as assessed by DXA, does not correct for the thickness (depth) of 
bone, therefore true (volumetric) bone mineral density is often underestimated in smaller 
individuals and overestimated in larger subjects. Weight is also thought to affect BMD 
by other pathways such as increased skeletal loading, and possibly by other metabolic 
influences. We reasoned that SK-BMD is likely to be relatively unaffected by these other 
pathways, and so whereas TBLH-, UL- and LL-BMD measures were adjusted for weight, 
SK-BMD was adjusted for height.
Genome-wide complex trait analysis
Univariate restricted maximum likelihood (REML) genome-wide complex trait analyses 
(GCTA) (32) were performed on ≥ 4,866 ALSPAC subjects to estimate the proportion of ad-
ditive genetic variance in BMD at each site, explained by directly genotyped variants that 
had a minor allele frequency ≥ 1%. Bivariate REML GCTA analysis  (33) was further used to 
estimate the pair-wise genetic and residual correlations between BMD at each skeletal site. 
A cryptic relatedness cut-off of 0.025 was applied in order to ensure that distantly related 
individuals (i.e., n ~ 444) were removed prior to the analysis, thereby reducing the potential 
for bias (Online Resource Figure S15). GCTA analysis was not performed in the Generation 
R Study given its multi-ethnic composition. Pearson Product Moment Correlation was used 
to estimate the linear relationship between standardised residuals of BMD after adjusting 
for age, gender, and weight or height using the STATA statistical package (34).
Genome-wide association meta-analysis of BMD in ALSPAC and Generation R
To identify genetic loci influencing variation in TBLH-, LL-, UL- and SK-BMD, we performed 
GWAS meta-analyses combining 5,330 children (5,299 for SK-BMD) from the ALSPAC co-
hort and 4,086 children from the Generation R Study, who had DXA BMD measurements 
and imputed GWAS data. Cohort specific GWAS analyses were conducted in ALSPAC and 
Generation R using standardised residuals derived from BMD measures after adjustment 
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for age, gender and weight for all skeletal sites except the skull, where weight was substi-
tuted for height. The first 20 ancestry informative principal components were additionally 
incorporated into the Generation R model to control for population stratification, due to 
the multi-ethnic nature of this cohort as described previously (7). Genome-wide association 
analyses were performed using MACH2QTL (29) as implemented in GRIMP (35), using linear 
regression models based on an expected allelic dosage for SNPs, adjusting for the above 
mentioned covariates where necessary. We combined association data for ~2.5 million 
imputed autosomal SNPs into an inverse variance fixed-effects meta-analysis, using METAL 
and controlled for genomic inflation in each cohort (36). P-values less than 5×10-8 were con-
sidered genome-wide significant. Heterogeneity was evaluated using Cochran’s Q statistic 
and was quantified by the I2 metric. Regional association plots from our genome-wide asso-
ciation scans were generated using Locuszoom (v1.1) (37), using linkage-disequilibrium (LD) 
information estimated from the HapMap 2 (hg18) CEPH reference dataset (38). All pair-wise 
LD estimates were obtained using SNAP software in conjunction with the HapMap2Phase 
II (hg18) CEPH reference dataset (39). All remaining plots were generated in R  (40) using the 
ggplot2 software package (41).
Sensitivity Analysis
In order to test the robustness of our results to the choice of covariates at each site, we 
performed a sensitivity analysis adjusting each region-specific BMD measure for: age, 
gender, height and weight (i.e., Model 1a) and performing GCTA and GWAS meta-analysis 
using the residuals. In order to confirm that our results were not being driven by underly-
ing population substructure, we performed further GWAS meta-analyses using the same 
residuals derived for Model 1a, except that the analyses were restricted to individuals of 
European ancestry (i.e., Model 1b).
Conditional meta-analysis
To identify novel secondary BMD association signals (i.e., independent from those pub-
lished), at loci which reached genome-wide significance for each BMD meta-analysis, we 
carried out conditional meta-analyses by conditioning on all previously published BMD-
associated variants that mapped to between 1 - 2 Mb of the top locus specific SNP [depend-
ing on the extend to LD, (Online Resource Table S12)]. In the case of rs7851693 (FUBP3), not 
present in the Generation R dataset, conditional analysis was performed using a proxy SNP 
(i.e., rs7030440), which was in high LD (r2 > 0.96) with the missing BMD associated variant. 
For RIN3, there were no BMD associated loci previously published, thus for that locus we 
conditioned on the top SNP. After conditional analysis, locus specific significance correc-
tion thresholds (for multiple testing of SNPs which are in linkage disequilibrium with each 
other) were calculated using the Single Nucleotide Polymorphism Spectral Decomposition 
(SNPSpD) software package  (42). Locus specific regions used for SNPSpD were defined as 
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the region proximal (1 – 2 Mb) to each locus specific signal. The presence of independent 
secondary association signals was confirmed in situations where the residual signal (after 
conditional meta-analysis) reached the locus specific threshold corrected for multiple test-
ing.
Comparison of the magnitude of the effect sizes of genome-wide significant SNPs across 
skeletal-sites
As we were interested in whether the genetic variants exerted greater influence on BMD 
at a particular site, it would be misleading to directly compare standardized regression 
coefficients from the meta-analysis by e.g., simple Z test, since the summary statistics were 
derived from correlated measures on the same individuals and are therefore not indepen-
dent. In addition, because we are only testing variants that have already met the criterion for 
genome-wide significance (and were therefore selected on the basis of having an extreme 
regression coefficient at a particular site), it is not appropriate to compare the regression co-
efficients from different sites using an uncorrected type I error level of α = 0.05. To address 
both these considerations, we fitted a multivariate normal model to the standardized BMD 
scores at each site by maximum likelihood using the software package Mx  (43). We fitted 
a model where the standardized regression coefficients for each site (SK-BMD, LL-BMD, 
UL-BMD) were constrained to be equal, and then another model in which the regression 
coefficient most different from the other two was allowed to vary). Twice the difference in 
log-likelihood between these models is distributed as a chi-square statistic with one degree 
of freedom. We analysed each cohort separately using this method and then combined the 
results using Fisher’s product of P-values evaluating statistical significance against a conser-
vative threshold of α = 5×10-8 (i.e., as if we had performed the comparison genome-wide, 
not just post-hoc on the significant sites).
Functional analysis of RIN3
In an attempt to identify a potential functional or regulatory mechanism underlying the 
association between RIN3 and BMD, a range of bio-informatic and functional analyses 
were performed. These included: fine mapping the RIN3 locus, data mining Regulome (17) 
and SIFT  (16) databases and performing eQTL analysis on primary human osteoblasts. The 
expression profiles of RIN3 and neighboring genes: SLC2484, LGMN, GOLGA5, CHGA and 
ITPK1 were also investigated in bone biopsies of healthy and osteoporotic women, in 
addition to murine and human cell lines that were differentiated into osteoblasts and/or 
osteoclasts. Methods specific to each analysis are described below.
Human primary osteoblasts
Expression profiling of untreated primary human osteoblasts, obtained from 113 (51 female 
and 62 male) unrelated Swedish donors, was performed using the Illumina HumRef-8 
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BeadChips in accordance with the manufacturer’s instructions. Up to 3 biological replicates 
were analysed per sample. Genotyping for genotype-expression association was per-
formed using the Illumina HapMap 550k Duo chip. Individuals with low genotyping rate 
and SNPs showing significant deviation from Hardy-Weinberg equilibrium (P < 0.05) were 
excluded. Similarly, low frequency (MAF < 0.05) SNPs and SNPs with high rates of missing 
data were excluded. Genotypes from samples that passed quality control (n = 103) were 
imputed for all SNPs (n = 478,805) oriented to the positive strand from phased autosomal 
chromosomes of HapMap Phase 2 CEPH panel (release 22, build 36) using MACH 1.0. A 
RSQR cut-off of < 0.3 was used to remove poorly imputed markers. Association of imputed 
genotypes using estimated genotype probabilities with nearby expression traits (defined as 
±1Mb window flanking RIN3) was performed using a linear regression model implemented 
in the MACH2QTL software with sex and age as covariates. Detailed methods pertaining to 
the data generation and analysis are described elsewhere (44,45).
Human illiac bone biopsies
Gene expression profiles were generated from iliac bone biopsies donated by healthy 
control (n =27), osteopenic (n = 18) and osteoporotic (n = 39) postmenopausal Norwegian 
women. The affection status of each individual was determined by BMD measurements of 
the total hip or lumbar spine (L1–L4 verterbrae). Individuals with a T-score less than -2.5 and 
with at least one low trauma fracture were deemed osteoporotic, whilst individuals with a 
T-score > -1 were deemed healthy. Expression profiling was performed using an Affymetrix 
HG U133 2.0 plus array. The Affymetrix Cel files were imported into Partek Genomics Suite 
(Partek Inc., St Louis, MO, USA), and normalized using the RMA (Robust Multichip Average) 
algorithm. Gene expression patterns were further adjusted, as reported by Jemtland and 
colleages  (46), for batch effects and differing synthesis times. The gene expression profiles 
of all transcripts located ±250 kb of the top LL-BMD associated RIN3 SNP (i.e., rs754388) 
were compared between the osteoperotic and control group. Note: the intermediate 
osteopenic group was excluded from this analysis.
Murine pre-osteoblasts
All procedures and use of mice for the neonatal osteoblast expression studies were ap-
proved by the Jackson Laboratory Animal Care and Use Committee (ACUC), in accordance 
with NIH guidelines for the care and use of laboratory animals. Pre-osteoblast-like cells 
were isolated from neonatal calvaria from C57BL/6J mice expressing cyan florescent 
protein (CFP) under the control of the Col3.6 promoter (pOBCol3.6CFP), using standard 
techniques (47). Cells were cultured for 4 days in growth media [DMEM containing 10% fetal 
bovine serum (FBS) and 1X penicillin/streptomycin], and thereafter removed from culture 
and subjected to fluorescence-activated cell sorting (FACS) based on the presence/ab-
sence of CFP expression. Cells expressing CFP, and therefore considered pre-osteoblasts, 
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were plated at a density of 1×104 cells per cm2, differentiated into osteoblasts using standard 
methods (αMEM containing 50 µg/ml Ascorbic Acid, 4 mM β-glycerol phosphate, 10% FBS 
and 1X penicillin/streptomycin). RNA was collected at 9 time points post differentiation. 
mRNA profiles for triplicate samples for each time point were generated by Next Gen-
eration High throughput RNA sequencing (RNAseq), using an Illumina HiSeq 2000. The 
alignments for abundance estimation of transcripts was conducted using Bowtie version 
0.12.9 (48) using the NCBIm37 transcriptome as the reference genome. Expression level per 
gene was calculated using RSEM version 1.2.0 using the following parameters: --fragment-
length-mean 280 and --fragment-length-sd 50 (49) and expression level for each sample was 
normalized relative to the per sample upper quartile (50). This data has been submitted to 
the gene expression omnibus (Accession Number: GSE54461).
Human mesenchymal stem cells and peripheral blood mononuclear cells
Human bone marrow derived mesenchymal stem cells [(hMSC), Lonza Group Ltd., Basel, 
Switzerland] were seeded in 12-well plates (5×103 cells per cm2) and differentiated into 
osteoblasts (using α-Mem pH7.5, 10% heat inactivated foetal calf serum (FCS), 100 nM 
Dexamethasone and 10 mM β-glycerophosphate) or adipocytes (using α-MEM pH 7.5, 10% 
heat inactivated FCS, 100 nM dexamethasone, 500 μM IBMX and 60 μM Indomethacin). 
Total RNA was isolated (triplicates) using Trizol (Life Technologies, Carlsbad, CA, USA) twice 
a week during differentiation until the 25 day of culture. Human peripheral blood mononu-
clear cells (PBMCs) were retrieved from buffy coats using Ficoll and seeded in 12-well plates 
(1.3×105 cells per cm2). Monocytes were allowed to attach for 4 hours and non-adherent 
cells were removed by careful washing. In the next three days, cells were grown in α-Mem 
pH7.5, containing 15% heat-inactivated serum and 25 ng/ml macrophage colony stimulat-
ing factor [(M-CSF), R&D Systems Inc., Minneapolis, MN, USA] to stimulate proliferation of 
the monocytes. After 3 days, media was replaced with α-Mem pH7.5 containing 15% heat 
inactivated serum, 25 ng/ml M-CSF and 30 ng/ml RANKL (Peprotech Inc., Rocky Hill, NJ, 
USA) to initiate osteoclastogenesis. Total-RNA was isolated twice a week using Trizol until 
the 21st day of culture. Amplification of total-RNA, Illumina microarray hybridization, data 
extraction and normalization were performed as previously described (51).
Detailed acknowledgements and online resources can be found in the published article 
online: http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1004423
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ABStrACt
Lean and bone mass are heritable traits with high phenotypic correlation, likely reflecting 
the underlying mechanical and biochemical interactions between these tissues. Bone 
mineral density (BMD) is known to be under strong genetic control. Nonetheless, genetic 
variants contributing to lean mass variation remain largely unknown, yet a shared genetic 
component influencing both traits is expected. We aimed to estimate the shared SNP-her-
itability (genetic correlation) of both traits in children and to identify genetic determinants 
displaying pleiotropic effects on lean mass and bone mass accrual, by using a bivariate 
GWAS approach. We estimated the heritability of both traits in children to be between 
30-45% with a genetic correlation of ~ 0.30. Bivariate GWAS meta-analysis in ~10,000 
children identified seven established BMD loci as having an effect on both traits: WNT4 
(P=4.7x10-9), GALNT3 (P=3.6x10-8), MEPE (P=3.3x10-8), CPED1/WNT16 (P=3.1x10-20), TNFSF11 
(P=1.3x10-8), RIN3 (P=3.3x10-8) and PPP6R3/LRP5 (P=2.2x10-9). Another signal (P=1.4x10-10) 
with stronger effect on lean mass than on BMD mapped to the TOM1L2/SREBF1 locus. Using 
publicly available databases for functional annotation, we identified active enhancers and 
other regulatory elements in relevant cells underlying this signal: We describe here the use 
of bivariate GWAS meta-analysis that powerfully replicate known BMD loci and unveil loci 
with pleiotropic effects on lean mass and BMD. SREBP-1, the product of SREBF1, an adi-
pocyte differentiation factor, drives muscle protein synthesis by regulating MYOD1, MYOG 
and MEF2C factor and henceforth muscle cell differentiation. In addition, overexpression 
of this protein in osteoblastic cells increases the number of mineralized foci thus regulating 
mineralization.
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introDuCtion
The interaction of skeletal muscle and bone has long been perceived as a mechanical 
one, where bone provides an attachment site for muscles and where muscles apply load 
to bone. Such muscle-derived forces drive an adaptive response in bone effecting its 
morphology, structure and strength as described by mechanostat theory  (1). Thus, a high 
phenotypic correlation between these traits is expected, as muscle mass constitutes a key 
contributor to bone mineral density (BMD) variation (2-4). Whenever mechanical challenges 
exceed an acceptable level, bone tissue is added at the location where it is mechanically 
necessary (5). Furthermore, in recent years, we have begun to appreciate that the tight cou-
pling of these two tissues is much more complex, exceeding the mechanical interaction, 
and begins already during embryonic development, when bones and muscle cells share a 
common mesenchymal precursor (6). Throughout life, there is a constant paracrine crosstalk 
across bone and muscle tissues, as they are both able to respond to the influence of com-
mon hormones and to produce and secrete factors that signal on nearby tissues and on 
each other (7). Under this perspective of coupled development, growth, and physiological 
relationships, it is highly likely that common genetic determinants exert pleiotropic effects 
on each component of the musculoskeletal system.
The most studied bone phenotype at a genetic level is bone mineral density (BMD), as it is 
commonly used in clinical practice to diagnose osteoporosis and assess fracture risk. Heri-
tability studies have demonstrated that between 50-85% of BMD variation can be explained 
by genetic factors (8). Heritability estimates for muscle traits, as lean mass, grip strength, arm 
flexion and leg strength range between 30-65% (9,10). Genetic association Studies (GWAS), 
which allow the simultaneous examination of several genetic variants (Single Nucleotide 
Polymorphisms (SNPs)) to identify their association with a trait of interest, has been suc-
cessful in unveiling the genetic architecture of BMD with close to 60 different loci robustly 
associated with the trait at different body sites (11-14). On the contrary, no robust associations 
have been reported today by GWAS of lean mass. Thus, the potential molecular genetic 
mechanisms regulating lean mass remain largely unknown. Nonetheless, twin studies have 
calculated the additive genetic correlation of bone and muscle traits to be above 30% (15,16).
Traditionally, GWAS test one trait at the time, although new methods have emerged which 
enable multivariate analysis to be performed. Multivariate methodologies have advantages 
such as increased power in the presence of genetic correlation, reduction of the multiple 
testing burden and biological insight in the case of pleiotropy (17). Bivariate GWAS analysis 
of appendicular lean mass with femoral neck bone geometry  (18) have suggested that the 
GLYAT gene underlies variation of bone size and body lean mass, although this result is yet 
to be replicated by other studies or proven in a functional setting.
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Here we applied a bivariate GWAS approach for Total-body lean mass (TB-LM) and BMD 
(TB-BMD) in pediatric cohorts, to identify genes exerting pleiotropic effects on both traits 
and to elucidate possible biological pathways, which underlie the crosstalk between these 
two tissues during skeletal development.
MetHoDS
Study populations
Total body bone mineral density and lean mass were measured in four pediatric popula-
tion-based studies: the Generation R Study, the Avon Longitudinal Study of Parents and 
their Children (ALSPAC), the Bone Mineral Density in Childhood Study (BMDCS) and the 
Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) cohort. All par-
ticipants underwent DXA scans; measurements were conducted by well-trained research 
assistants and daily quality control assurance was performed. Prior to the scan procedure, 
participants were asked to take off their shoes, heavy clothes, and metal accessories. As rec-
ommended by the International Society for Clinical Densitometry (19), total body less head 
BMD was the measurement used in the analysis in all four studies, henceforth TB-BMD. 
Also, all individuals included in this study had genome-wide array data imputed to the 
HapMap Phase II reference panel (build 36 release 22). All research aims and the specific 
measurements used in this study have been approved by the Medical Ethical Committee of 
each of the involved institutions and written informed consent was provided by all parents 
or custodians.
Statistical Methods
Total-body BMD less head and Total-Body Lean Mass measurements were derived from 
DEXA scans and adjusted by age, gender, height, fat percent and study specific covariates 
(genetic principal components and measurement center when applicable). Standardized 
residuals were then generated and used as input for all analyzes described here. Pheno-
typic correlation between these variables was assessed by Pearson correlation tests in each 
study independently.
SNP-Heritability and genetic correlation
To characterize the extent to which common genetic variants determine pediatric BMD 
and lean mass, and the shared genetic etiology of these traits, we applied a recently 
proposed approach for estimating SNP-heritability and genetic correlation based on 
genome-wide sharing between distantly related individuals, as implemented in the GCTA 
software  (20,21). These assessments were performed in independent genotyped markers 
data from the ALSPAC and Generation R studies. In the latter, given its multiethnic nature, 
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relatedness coefficients used in the genetic relationship matrix (GRM) were estimated from 
REAP (Relatedness Estimation in Admixed Populations) (22). This modified matrix was then 
used as input for the GCTA analysis (Supplementary Note). No pairs exceeded the standard 
cutoff coefficient of 0.025 for genetic relatedness, confirming that no two individuals in the 
analysis were closer than third-degree cousins in either of the two studies. In total 431 and 
1,043 individuals were excluded from ALSPAC and Generation R for this calculation.
Univariate and Bivariate GWAS
Analysis of the two quantitative traits was performed in each study individually based on 
best guess data using the “qt-command” available in PLINK  (23) to obtain the means and 
standard deviations of both lean mass and BMD stratified by genotype. Meta-analysis of 
2,276,811 SNPs present in at least two of the studies was performed following an inverse 
variance methodology. In the meta-analysis approach, we used a newly proposed method 
for bivariate meta-analysis, which is based on calculating the within-studies covariances of 
the outcome specific estimates  (24). The algorithm uses a general approach and has been 
proposed for both, discrete and continuous outcomes, but in the case of continuous out-
comes, such as the one encountered here, a direct extension of the method proposed by 
Wei and Higgins (25) is applied. We used the additive model of inheritance (per-allele mean 
difference of the quantitative phenotype) for both outcomes and the method of moments 
for estimation with the mvmeta command in Stata  (26). Source code and details are given 
in (http://www.compgen.org/tools/multiple-outcomes). The overall bivariate associa-
tion test was obtained by a standard Wald-type statistic (chi-square on 2 d.f.) that tests the 
null hypothesis that the particular SNP is not associated with either one of the outcomes. 
Genome-wide significance (GWS) was defined as a P value less than 5x10-8. Results were 
summarized in Manhattan plots generated in Easystrata (27) and QQplots from a modifica-
tion of EPACTS (28) scripts.
Bioinformatic annotations and eQtl analysis
We identified variants in data from the 1000 Genomes Project that Phase 1 that are in strong 
linkage disequilibrium (LD) [CEU r2 > 0.8] with the lead SNPs in the new susceptibility loci, 
using HaploReg 3 (http://www.broadinstitute.org/mammals/haploreg/haploreg_v3.php), 
for functional annotation. These SNPs were first searched in the GWAS catalog (https://
www.genome.gov/26525384) to ascertain possible association with other traits. Identified 
nonsynonymous variants were interrogated for likely downstream functional consequences 
using SIFT (http://sift.jcvi.org/) and POLYPHEN2 (http://genetics.bwh.harvard.edu/pph2/) 
databases. Additionally, we interrogated two public databases for micro-RNAs, namely 
miRbase (http://www.mirbase.org/)  (29) and miRDB (http://mirdb.org/miRDB/)  (30). Vari-
ants were also assessed for overlap with regions of predicted regulatory function generated 
by the Encyclopedia of DNA Elements (ENCODE) Project and the ROADMAP epigenomic 
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project including: regions of enhancer activity, DNase I hypersensitivity, local histone 
modifications or proteins bound to these regulatory sites in cell lines of potential interest as 
HSMM (Skeletal Muscle Myoblast), HSMMtube (Skeletal Muscle myotubes differentiated 
from the HSMM), SKMC (skeletal muscle cells) and when present in the different assays 
Osteobl (Ostoblasts). In addition, evidence of chromatin interactions was further explorer 
by Chromatin Interaction Analysis by Paired-End Tag Sequencing (ChIA-PET) data from the 
ENCODE project in both MCF-7 and K562 oncologic line cells. The UCSC Genome Browser 
(https://genome.ucsc.edu/) was used for visualizing ENCODE data tracks indicative of 
regulatory function. Topologically associated domains (TADs) were also retrieved from a 
recent web-based tool for this end (http://promoter.bx.psu.edu/hi-c/download.html) for 
K562.
The eQTL analysis was completed using recently published eQTL data sets: a meta-
analysis of the transcriptional profiles from the peripheral blood cells of 5,311 Europeans 
(http://genenetwork.nl/bloodeqtlbrowser)  (31) and the GTEx database based on 1,641 
samples across 43 tissues from 175 individuals (http://www.gtexportal.org/home/) (32).
reSultS
Characteristics of the 10,414 children, from four different cohorts, included in this study are 
shown in table 1. The phenotypic correlation between BMD and lean mass (after adjust-
ment for sex, age, height, fat percent, and genomic principal components) was significant 
in all four cohorts and of similar magnitude: Generation R (ρ=0.437), ALSPAC (ρ=0.449), 
BMD-CS (ρ=0.486) and COPSAC (ρ=0.420).
table 1. Anthropometric characteristics of study participants.
Generation r AlSPAC BMD-CS CoPSAC
n=4,071 n=5,251 n=821 n=273
Age, years 6.21 0.32 9.94 0.32 8.74 1.91 6.89 0.72
Women, % 2,035 49.98% 2,673 50.90% 431 61.80% 144 53.14%
Ceu ancestry, % 2,171 53.32% 5,251 100.00% 634 77.22% 271 100.00%
Height, m 1.19 0.63 1.4 0.64 1.32 0.12 1.24 0.61
Weight, kg 23.08 4.08 34.7 7.41 30.78 8.76 24.6 4.25
total body lH BMD, g/cm2 0.555 0.05 0.777 0.053 0.67 0.10 0.583 0.05
total body lH BMC, g 528.5 104.21 891.92 181.85 726.12 205.92 2,932 591.04
total body lean Mass, g 16,393 2,284 24,553 3,184 22,360 5,830 17,460 2,600
total body Fat Mass, g 5,862 2,328 8,561 5,108 7,590 3,580 7,010 2,490
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SnP-Heritability and genetic correlation
SNP-Heritability and Genetic correlation for adjusted TB-BMD and TB-LM were calculated 
for the Generation R (N=3,027) and ALSPAC (N=4,820) studies and are displayed in table 
2. SNP-Heritability estimates were between 30 and 45% for both traits. All calculated esti-
mates except the genetic correlation in Generation R were statistically significant (P<0.05).
table 2. trait SnP-heritability and genetic correlation tB-BMD/tB-lM in pediatric populations. Only unre-
lated individuals (e.g., no two individuals in the analysis were closer than third degree cousins in either of the 
two studies) were included in the analysis.
Study n tB-BMD Heritability tB-lM Heritability Genetic correlation
tB-BMD/tB-lM
h2 SE P h2 SE P ρ SE P
Generation R 3,028 0.311 0.12 0.004 0.4 0.12 0.0003 0.299 0.21 0.126
ALSPAC 4,820 0.437 0.07 6x10-10 0.325 0.07 3x10-6 0.323 0.12 0.016
univariate and Bivariate GWAS
Results from the univariate GWAS meta-analysis identified variants associated at GWS level 
with BMD in four different loci: WNT16/CPED1 locus, leading SNP rs917727-T (beta=0.129SD, 
P=1.28x10-16); LRP5/PPP6R3 locus, leading SNP rs12272917-C (beta=-0.097SD, P=1.42x10-9); 
WNT4 locus, leading SNP rs3765350-G (beta=-0.094SD, P=9.75x10-9); and the GALNT3 
locus, leading SNP rs6726821-G (beta=-0.077SD, P=2.95x10-8). A Manhattan plot showing 
the results of this GWAS is displayed in Figure 1. The univariate GWAS meta-analysis of lean 
mass yield no GWS associations. QQ-Plots for these two analyses showed no evidence 
for early inflation as consequence of bias (i.e., possible stratification issues or genotyping 
errors) (Supplementary Figure 1).
Figure 1. Manhattan plot of association statistics (-log10(P values)) for tB-BMD. Dashed red and yellow 
lines mark the GWS threshold (P<5x10-8) and suggestive threshold (P<1x10-6), respectively.
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Based on the adjusted TB-BMD and TB-LM phenotypes, the genomic inflation factor λ was 
<1.08 (Supplementary Figure 1). Bivariate meta-analysis displayed eight different GWS 
peaks (Figure 2): 1p36.12, 2q24.3, 4q22.1, 7q31.31, 11q13.2, 13q14.11, 14q.2.12, 17p11.2, most of 
these associations driven by the TB-BMD analysis, except for signals in 2q24.3, 11q13.2 and 
17p11.2 where there is evidence of association (P<0.05) with both traits (table 3). In 1p36.12, 
the signal GWS SNPs extends for 264 Kb, with variants in WNT4 and in close vicinity from 
the 5’region of ZBTB40 (leading SNP rs6684375, P=2.8x10-9). The low LD between the SNPs 
located at the opposite ends of this region are indicative of at least two independent as-
sociation signals mapping to this locus (Supplementary Figure 2a). GWS variants harbored 
in 2q24.3 (Supplementary Figure 2b) are in high LD and located in the vicinity of 3’region of 
CSRNP3 and GALNT3 (leading SNP rs6726821, P=2.8x10-8). The signal in 4q22.1 (Supplemen-
tary Figure 2c) is located in the vicinity of the 3’regions of MEPE (leading SNP rs11733405, 
P=3.3x10-8). The signal in 7q31.31 spans for 307 Kb in a region harboring CPED1, WNT16, and 
FAM3C (Supplementary Figure 2d), the LD pattern of this region is compatible with the 
presence of different signals underlying the captured association (leading SNP rs917727, 
P=3.1x10-20). SNPs in 11q13.2 (Supplementary Figure 2e) are in high LD and spans throughout 
the PPP6R3 gene, moreover, they are in moderate correlation with markers mapping to 
the 3’region of LRP5 (leading SNP rs12271290, P=4.4x10-9). Variants underlying the signal in 
13q14.11 (Supplementary Figure 2f) are in high LD and located in TNFSF11 or its vicinity (lead-
ing SNP rs9525638, P=1.4x10-8). The signal on 14q.2.12 (Supplementary Figure 2g) arises from 
variants mapping to RIN3 (leading SNP rs754388, P=3.3x10-8). The signal on 17p11.2 (leading 
SNP rs7501812, P=1.4x10-10) is the only of the GWS signals where associations are stronger 
with TB-LM than with TB-BMD, although all GWS SNPs show nominally significant opposite 
effect in both traits. The region underlying this signal (Figure 3) extends along an LD-block 
harboring several genes including RAI1, LRC48, MIR33B, C17orf39, DRG2, MYO15A, SREBF1, 
TOM1L2, ATPAF2, the latter four all shown to be expressed in skeletal muscle.
Figure 2. Manhattan Plot of the fixed effects bivariate meta-analysis of the association analysis of tB-
BMD and tB-lM. Dashed red and yellow lines mark the GWS threshold (P<5x10-8) and suggestive threshold 
(P<1x10-6), respectively.
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Bioinformatic annotations and eQtl analysis
Using Haploreg we identified proxies (r2>0.8, 1000 Genomes CEU population) of our GWS 
SNPs in the 17p11.2 region to include them in an integrative approach to identify the pos-
sible association mechanism underlying this signal; this was made based on a literature 
review and several sources of bioinformatics’ annotation. A total of 163 proxy SNPs were 
found from which 78 were present in our analysis (Supplementary table 1). Only one SNP 
in the associated region was previously reported in the GWAS catalog, rs11868035. The 
G-allele of this SNP was reported to have a protective effect for Parkinson’s disease in a 
meta-analysis of ~30,000 individuals (P=5.6x10-8) (33). The same SNP approaches significance 
in our bivariate meta-analysis (Pbivariate=8x10-7) with the G-allele being nominally positively 
associated with lean mass (beta=0.05SD; P=3x10-4). Yet, in our analysis, another SNP in high 
LD with rs11868035 (rs11654081, r2>0.8) surpassed the GWS threshold (table 3). In the 
proximity of these variants and also in high LD (r2>0.8) with rs11654081, we identified two 
missense variants within the RAI gene (Supplementary table 1). One of them (rs11649804, 
Pbivariate=8.8x10-7) Pro165Thr, is predicted to be tolerated by SIFT and as probably damaging 
by Polyphen2. The other missense variant (rs3803763) Gly90Ala was not present in our 
analysis.
Figure 3. regional association plot for the bivariate meta-analysis of tB-BMD and tB-lM displaying the 
17p11.2 locus. Genetic coordinates are as per Hapmap phase II-CEU.
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We further retrieved information on micro-RNA databases for the associated region and 
found it harbors two micro-RNAs, mir6777 and mir33b. This last microRNA is co-transcribed 
with SREBF1. Additionally, as most of the association signal in 17p11.2 is arising from non-
coding variants, we reviewed the possible regulatory annotation of these SNPs by using the 
information from ENCODE and ROADMAP projects through the UCSC-browser. The visual 
summary of this information can be found in Supplementary Figure 3. Shadowed areas 
correspond to CTCF-associated areas of chromatin interaction by looping, as assessed by 
ChIA-PET in the MCF-7 and K562 cell-lines. As these ChiA-PET experiments are not avail-
able for musculoskeletal cells, we have chosen interactions, in MCF-7 and K562, for which 
the CTCF binding sites are also predicted to exist in the musculoskeletal cells. Three se-
lected regions are shown, the first one brings together an intronic region of TOM1L2 and the 
3’region of SREBF1. The second one, two regions within TOM1L2 and the third one, intronic 
regions from TOM1L2 and ATPAF2. TADs were in line with these results evidencing complex 
chromatin structures (Supplementary Figure 4). Moreover, as the region described by the 
association signal is broad there are marks of histone modifications that are signatures of 
transcribed regions, transcription factor binding, active transcription sites, enhancers or 
repressed regions, and CPG island both methylated and unmethylated.
The SNP with the strongest bivariate association with TB-BMD and TB-LM in this locus, 
rs7501812, is also a cis-eQTL that was found to regulate the expression of SREBF1, C17orf39, 
TOM1L2 and ATAPF2 (FDR < 0.05) on whole blood. Nonetheless, SREBF1 expression, 
represented by two probes in the dataset, showed the highest correlation with rs7501812. 
The G-allele, which was associated with higher TB-BMD (beta=0.043SD; P=2x10-3) and 
lower TB-LM (beta=-0.056SD; P=5.5x10-5) in our study, decreased the expression of the two 
SREBF1 probes in whole blood. By interrogating the dataset per gene, rather than per SNP, 
we found that in general alleles from the GWS-bivariate SNPs associated with higher TB-
BMD and lower TB-LM in the region are associated with decreased expression of SREBF1, 
TOM1L2, and C17orf39 but increased expression of ATPAF2 in whole blood (Supplemen-
tary table 1). GTEx collection also supported the significant association of rs7501812 with 
the expression of SREBF1 in whole blood. Additionally, the rs4925114 A-allele, nominally 
associated with higher TB-BMD (beta=0.036SD; P=0.01) and lower TB-LM (beta=-0.051SD; 
P=3.6x10-4), significantly downregulated (FDR<0.01) the expression of SREBF1 in skeletal 
muscle. Several other SNPs in the 17p11.2 locus were also reported as being associated with 
SREBF1 expression in other tissues (data not shown).
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table 3. Genome-wide significant SnPs for the bivariate meta-analysis of total body bone mineral density 
(tB-BMD) and total body lean mass (tB-lM).  Estimates were derived from 10,414 children participants of 4 
different pediatric studies worldwide.
SnP CHr Position A1 A2 eAF Beta
tB-BMD
P
tB-BMD
Beta
tBlM
P
tBlM
P-bivariate lD
rs3765350 1 22319903 G A 0.23 -0.0939 9.75E-09 -0.0083 0.64 5.92E-09 0.005
rs2235529 1 22323074 T C 0.15 -0.1064 1.60E-08 -0.0134 0.51 1.72E-08 0.011
rs3820282 1 22340802 T C 0.15 -0.1077 1.13E-08 -0.0162 0.40 1.50E-08 0.002
rs12741884 1 22467282 A G 0.22 -0.0912 3.73E-08 -0.0124 0.46 3.79E-08 0
rs7524102 1 22571034 G A 0.19 0.0795 8.18E-06 -0.0290 0.11 1.35E-08 1
rs12568930 1 22574818 C T 0.19 0.0790 9.65E-06 -0.0268 0.15 3.12E-08 1
rs10493013 1 22575622 C T 0.19 0.0840 2.63E-06 -0.0270 0.14 5.61E-09 1
rs6684375 1 22579021 T C 0.19 0.0842 2.47E-06 -0.0273 0.14 4.69E-09 top
rs6426749 1 22584060 C G 0.19 0.0823 4.24E-06 -0.0291 0.11 6.26E-09 1
rs6426749 1 22584060 C G 0.19 0.0823 4.24E-06 -0.0291 0.11 6.26E-09 1
rs12185748 2 166285202 T C 0.45 -0.0762 3.98E-08 -0.0102 0.49 4.90E-08 0.966
rs7586085 2 166285735 G A 0.45 -0.0764 3.68E-08 -0.0098 0.51 4.08E-08 0.966
rs6726821 2 166286360 G T 0.45 -0.0769 2.95E-08 -0.0104 0.48 3.56E-08 top
rs6710388 2 166291387 T C 0.45 -0.0769 2.95E-08 -0.0118 0.42 4.22E-08 0.966
rs6710518 2 166291490 T C 0.45 -0.0767 3.18E-08 -0.0112 0.44 4.27E-08 0.966
rs7672749 4 89017308 A G 0.09 0.0822 4.35E-04 -0.0591 0.01 3.29E-08 1
rs11733405 4 89017674 G T 0.09 0.0822 4.35E-04 -0.0591 0.01 3.29E-08 1
rs2110281 7 120513045 A G 0.35 -0.0859 3.24E-09 -0.0032 0.81 4.57E-10 0.003
rs2968345 7 120516108 G A 0.35 -0.0838 6.90E-09 -0.0015 0.91 8.80E-10 0.003
rs6466767 7 120518813 G C 0.34 -0.0827 1.22E-08 -0.0049 0.73 3.61E-09 0.003
rs1917113 7 120522298 A G 0.34 -0.0840 7.88E-09 -0.0046 0.74 1.82E-09 0.003
rs12673968 7 120524294 A G 0.34 -0.0825 1.35E-08 -0.0047 0.74 3.93E-09 0.003
rs6466769 7 120529339 G A 0.34 -0.0831 1.14E-08 -0.0037 0.78 2.38E-09 0.003
rs6954757 7 120530418 A G 0.34 -0.0831 1.12E-08 -0.0039 0.77 2.41E-09 0.003
rs13223036 7 120534544 G T 0.35 -0.0825 1.29E-08 0.0007 0.98 1.14E-09 0.003
rs798943 7 120546135 A G 0.38 -0.0789 3.36E-08 0.0148 0.30 9.86E-11 0.006
rs7801723 7 120561396 T C 0.37 -0.0793 3.21E-08 0.0166 0.25 5.15E-11 0.006
rs12706318 7 120562177 G A 0.37 -0.0798 2.46E-08 0.0119 0.41 1.53E-10 0.003
rs13232048 7 120563517 T G 0.37 -0.0797 2.57E-08 0.0119 0.41 1.63E-10 0.003
rs6947453 7 120564419 T G 0.37 -0.0720 4.71E-07 0.0141 0.33 3.87E-09 0.003
rs6952113 7 120564855 A G 0.37 -0.0799 2.37E-08 0.0115 0.42 1.64E-10 0.003
rs872007 7 120567185 T C 0.37 -0.0801 2.14E-08 0.0111 0.44 1.61E-10 0.003
rs10275439 7 120570661 A G 0.37 -0.0777 5.18E-08 0.0143 0.31 2.06E-10 0.003
rs10261671 7 120570787 T C 0.37 -0.0774 5.68E-08 0.0147 0.30 2.27E-10 0.003
rs13245690 7 120572300 G A 0.37 -0.0800 2.37E-08 0.0164 0.25 3.51E-11 0.003
rs6950680 7 120577523 G A 0.37 -0.0801 2.28E-08 0.0157 0.27 4.31E-11 0.003
rs7798060 7 120609622 T C 0.40 -0.0715 4.34E-07 0.0219 0.12 4.16E-10 0.001
rs1554634 7 120613474 C T 0.40 -0.0686 1.14E-06 0.0208 0.14 2.30E-09 0.001
rs10085590 7 120619259 G A 0.41 -0.0665 2.32E-06 0.0220 0.12 4.21E-09 0.001
rs7797976 7 120630752 T C 0.40 -0.0709 5.21E-07 0.0215 0.13 6.21E-10 0.001
rs6947494 7 120630944 T C 0.41 -0.0670 1.98E-06 0.0209 0.14 4.76E-09 0
rs1917118 7 120631560 T C 0.40 -0.0680 1.45E-06 0.0213 0.13 2.82E-09 0.004
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table 3 (continued)
SnP CHr Position A1 A2 eAF Beta
tB-BMD
P
tB-BMD
Beta-
tBlM
P-tBlM P-bivariate lD
rs6954210 7 120635621 A G 0.40 -0.0675 1.72E-06 0.0217 0.12 3.02E-09 0.001
rs6970762 7 120639270 T A 0.40 -0.0692 9.64E-07 0.0242 0.09 6.30E-10 0
rs1357756 7 120639429 T C 0.41 -0.0662 2.54E-06 0.0223 0.11 4.23E-09 0.001
rs1534015 7 120640301 A G 0.41 -0.0663 2.49E-06 0.0224 0.11 4.08E-09 0.001
rs7786203 7 120640843 A G 0.40 -0.0688 1.11E-06 0.0208 0.14 2.16E-09 0.001
rs1404268 7 120644983 A G 0.41 -0.0648 4.16E-06 0.0209 0.14 1.08E-08 0.001
rs1524503 7 120655239 C A 0.39 -0.0713 4.71E-07 0.0210 0.14 5.92E-10 0.001
rs3779381 7 120754026 G A 0.26 0.1188 4.77E-14 -0.0054 0.72 1.25E-16 0.874
rs2908004 7 120757005 A G 0.49 0.1127 2.83E-16 0.0012 0.98 1.19E-18 0.478
rs2536189 7 120760857 G C 0.49 0.1109 8.03E-16 0.0012 0.99 4.55E-18 0.461
rs3801387 7 120762001 G A 0.28 0.1281 1.29E-16 -0.0021 0.87 2.36E-19 1
rs2707466 7 120766325 T C 0.48 0.1046 3.16E-14 0.0008 1.00 4.06E-16 0.505
rs2536182 7 120778073 G C 0.48 0.1103 1.49E-15 0.0086 0.57 7.38E-17 0.462
rs2536180 7 120781909 C T 0.49 0.1109 9.52E-16 0.0060 0.70 2.44E-17 0.471
rs3801382 7 120785513 G T 0.28 0.1282 1.29E-16 -0.0029 0.83 1.72E-19 1
rs2254595 7 120794485 C T 0.49 0.1096 1.80E-15 0.0049 0.76 3.88E-17 0.471
rs917727 7 120805815 T C 0.29 0.1289 5.29E-17 -0.0042 0.77 3.07E-20 top
rs917726 7 120806093 T A 0.28 0.1291 5.83E-17 -0.0045 0.75 3.26E-20 1
rs718766 7 120812738 C T 0.28 0.1271 2.20E-16 -0.0041 0.77 2.23E-19 1
rs4727924 7 120819115 T C 0.48 0.1125 4.33E-16 -0.0045 0.70 3.06E-19 0.471
rs7776725 7 120820357 C T 0.27 0.1299 5.46E-17 -0.0031 0.81 5.45E-20 1
rs11228258 11 68010904 A C 0.26 -0.0877 2.39E-08 -0.0661 2.53E-05 2.30E-08 0.955
rs7116994 11 68011203 T C 0.26 -0.0893 1.33E-08 -0.0669 2.04E-05 1.29E-08 0.908
rs12294029 11 68013635 C A 0.26 -0.0893 1.33E-08 -0.0669 2.04E-05 1.29E-08 0.908
rs7126340 11 68013869 T C 0.26 -0.0874 2.53E-08 -0.0654 3.03E-05 2.62E-08 0.955
rs12272917 11 68019946 C T 0.24 -0.0971 1.42E-09 -0.0639 7.07E-05 3.27E-09 1
rs11228262 11 68031483 T G 0.25 -0.0948 2.65E-09 -0.0657 3.95E-05 4.55E-09 1
rs10896334 11 68038070 T C 0.26 -0.0908 8.31E-09 -0.0687 1.25E-05 6.71E-09 0.955
rs10896337 11 68040812 C T 0.26 -0.0895 1.30E-08 -0.0678 1.60E-05 1.08E-08 0.955
rs11228269 11 68046372 G A 0.26 -0.0907 8.40E-09 -0.0706 7.00E-06 5.09E-09 0.955
rs7925275 11 68047009 C T 0.25 -0.0939 4.19E-09 -0.0662 3.52E-05 6.17E-09 1
rs6591340 11 68054212 G A 0.25 -0.0940 4.00E-09 -0.0657 3.94E-05 6.25E-09 1
rs7106259 11 68055088 G T 0.26 -0.0909 7.95E-09 -0.0709 6.46E-06 4.67E-09 0.955
rs10896339 11 68059422 C G 0.27 -0.0872 2.02E-08 -0.0713 4.65E-06 8.77E-09 0.818
rs12281742 11 68060205 C T 0.28 -0.0852 3.81E-08 -0.0737 2.01E-06 8.92E-09 0.955
rs4316515 11 68065416 T A 0.25 -0.0939 4.11E-09 -0.0658 3.87E-05 6.34E-09 1
rs7944870 11 68065684 G C 0.26 -0.0926 4.34E-09 -0.0727 3.94E-06 2.21E-09 0.955
rs948315 11 68065716 C T 0.26 -0.0875 2.60E-08 -0.0666 2.24E-05 2.31E-08 0.955
rs948316 11 68066246 T G 0.25 -0.0939 4.11E-09 -0.0658 3.87E-05 6.34E-09 1
rs10896341 11 68069756 A G 0.26 -0.0928 4.08E-09 -0.0721 4.74E-06 2.31E-09 0.955
rs7104345 11 68073348 A G 0.25 -0.0939 4.11E-09 -0.0658 3.87E-05 6.34E-09 1
rs12284933 11 68076065 A G 0.24 -0.0969 1.85E-09 -0.0699 1.49E-05 2.19E-09 top
rs11228284 11 68079343 T A 0.25 -0.0939 4.11E-09 -0.0658 3.87E-05 6.34E-09 0.954
rs12271290 11 68082812 T C 0.26 -0.0914 6.67E-09 -0.0705 7.47E-06 4.40E-09 0.955
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table 3 (continued)
SnP CHr Position A1 A2 eAF Beta
tB-BMD
P
tB-BMD
Beta-
tBlM
P-tBlM P-bivariate lD
rs7102898 11 68085446 A G 0.25 -0.0946 3.25E-09 -0.0660 3.58E-05 5.04E-09 1
rs2155730 11 68086050 C T 0.26 -0.0876 2.32E-08 -0.0713 4.98E-06 9.51E-09 0.955
rs7109294 11 68088669 C T 0.25 -0.0946 3.25E-09 -0.0660 3.58E-05 5.04E-09 1
rs2282563 11 68089776 T C 0.25 -0.0949 2.81E-09 -0.0662 3.38E-05 4.37E-09 1
rs6591341 11 68092054 T C 0.28 -0.0862 2.73E-08 -0.0741 1.74E-06 6.51E-09 0.955
rs3740631 11 68098298 G T 0.25 -0.0949 2.81E-09 -0.0662 3.38E-05 4.37E-09 1
rs11228287 11 68106330 G A 0.25 -0.0951 2.72E-09 -0.0664 3.22E-05 4.15E-09 1
rs10896347 11 68109703 A G 0.25 -0.0949 2.81E-09 -0.0662 3.38E-05 4.37E-09 1
rs10896348 11 68113944 C T 0.28 -0.0866 2.36E-08 -0.0739 1.84E-06 5.99E-09 0.955
rs7118897 11 68117256 A G 0.25 -0.0921 6.78E-09 -0.0656 3.74E-05 1.01E-08 1
rs6591344 11 68117449 A G 0.25 -0.0944 3.57E-09 -0.0660 3.59E-05 5.49E-09 1
rs7123564 11 68118740 T C 0.25 -0.0963 1.69E-09 -0.0686 1.78E-05 2.23E-09 1
rs7127948 11 68119638 A G 0.25 -0.0940 4.08E-09 -0.0657 3.98E-05 6.46E-09 1
rs3758643 11 68123769 T C 0.25 -0.0929 6.23E-09 -0.0646 5.36E-05 1.05E-08 1
rs12283755 11 68128234 G A 0.25 -0.0942 3.90E-09 -0.0655 4.19E-05 6.37E-09 1
rs7113287 11 68128762 T A 0.28 -0.0866 2.36E-08 -0.0739 1.84E-06 5.99E-09 0.955
rs7104877 11 68134178 C A 0.26 -0.0904 8.27E-09 -0.0717 4.54E-06 4.14E-09 0.955
rs2236708 11 68134621 A G 0.25 -0.0932 5.39E-09 -0.0650 4.90E-05 8.92E-09 1
rs11228292 11 68136348 A G 0.25 -0.0933 5.21E-09 -0.0652 4.67E-05 8.47E-09 1
rs4988291 11 68138183 A G 0.25 -0.0933 5.21E-09 -0.0652 4.67E-05 8.47E-09 1
rs11228293 11 68141222 C T 0.25 -0.0932 5.39E-09 -0.0650 4.90E-05 8.92E-09 1
rs7102273 11 68142155 C T 0.26 -0.0895 1.26E-08 -0.0685 1.32E-05 9.69E-09 0.955
rs749934 13 42006245 A G 0.46 0.0693 6.25E-07 -0.0110 0.43 1.56E-08 0.87
rs17458078 13 42009354 C A 0.46 0.0684 8.48E-07 -0.0116 0.41 2.19E-08 0.875
rs9533143 13 42009405 C G 0.46 0.0687 7.40E-07 -0.0112 0.42 2.05E-08 0.875
rs9525638 13 42026577 C T 0.42 0.0756 6.42E-08 -0.0006 0.97 1.35E-08 top
rs1325798 13 42037049 T C 0.42 0.0734 1.46E-07 -0.0016 0.89 2.98E-08 0.901
rs9533154 13 42038102 T C 0.42 0.0744 1.01E-07 -0.0013 0.92 1.98E-08 1
rs17536328 13 42041029 T C 0.42 0.0735 1.42E-07 -0.0023 0.85 2.47E-08 1
rs7325635 13 42043319 A G 0.42 0.0741 1.18E-07 -0.0021 0.87 2.07E-08 1
rs9525643 13 42057516 C T 0.42 0.0744 1.06E-07 -0.0021 0.87 1.83E-08 1
rs754388 14 92185163 G C 0.18 -0.0862 3.26E-06 0.0210 0.24 3.36E-08 top
rs4925109 17 17602527 A G 0.35 0.0202 0.163 -0.0641 1.06E-05 3.09E-08 0.445
rs11654081 17 17648854 T C 0.41 0.0318 0.025 -0.0531 1.84E-04 3.90E-08 0.765
rs4925114 17 17651995 A G 0.41 0.0362 0.011 -0.0508 3.64E-04 2.39E-08 0.765
rs4925115 17 17662182 A G 0.39 0.0388 0.007 -0.0550 1.18E-04 2.37E-09 0.806
rs11656665 17 17665514 G A 0.43 0.0361 0.009 -0.0523 1.77E-04 9.50E-09 0.881
rs9899634 17 17668668 T A 0.41 0.0415 0.003 -0.0528 1.93E-04 1.69E-09 0.92
rs8066560 17 17668768 A G 0.38 0.0422 0.003 -0.0559 8.84E-05 3.82E-10 0.881
rs9902941 17 17674485 C T 0.40 0.0398 0.005 -0.0566 6.26E-05 6.22E-10 0.92
rs1889018 17 17675465 G A 0.42 0.0387 0.005 -0.0506 2.78E-04 8.20E-09 0.92
rs4925119 17 17683629 A G 0.39 0.0419 0.003 -0.0561 7.98E-05 3.92E-10 0.92
rs9891957 17 17685164 G A 0.40 0.0431 0.002 -0.0524 1.82E-04 8.79E-10 0.92
rs3183702 17 17688014 A G 0.39 0.0433 0.002 -0.0559 8.05E-05 2.05E-10 0.96
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DiSCuSSion
We have confirmed the important role of genetic factors in both TB-BMD and TB-LM at 
an early age. Heritability estimates, calculated in more than 9,000 children, are in the 
range of 30-45% percent for both traits. Moreover, we found evidence for the presence 
of share genetic influences across the traits, estimating a genetic correlation of about 30%. 
The bivariate GWAS meta-analysis we conducted identified eight loci associated with both 
TB-BMD and TB-LM. All loci but 17p11.2 -harboring genes as RAI1, LRRC48, MIR33B, SREBF1, 
TOM1L2, ATPAF2- have been previously reported as associated with BMD in large genetic 
studies. The 17p11.2 locus is marked by a long stretch of linkage disequilibrium and several 
lines of evidence point to an enrichment of DNA looping interactions in this region, making 
it difficult to unveil the gene responsible for the association signal.
SNP-heritability in two of the participant cohorts reached similar results for both TB-BMD 
and TB-LM, consistent with genetic factors influencing each of them. We found that about 
one-third of the additive genetic effect is shared between TB-BMD and TB-LM. These esti-
mates are lower than those derived from a previous twin study that estimated the heritability 
for TB-BMD to be between 80-90%, for TB-LM between 70-88% and a genetic correlation 
between these traits of 46% (34). Similar to other complex traits, SNP-heritability estimates 
table 3 (continued)
SnP CHr Position A1 A2 eAF Beta
tB-BMD
P
tB-BMD
Beta-
tBlM
P-tBlM P-bivariate lD
rs2236513 17 17688091 A C 0.39 0.0433 0.002 -0.0559 8.05E-05 2.05E-10 0.96
rs9915248 17 17688239 C T 0.40 0.0417 0.003 -0.0561 6.81E-05 3.07E-10 0.96
rs3744115 17 17690547 G A 0.40 0.0421 0.003 -0.0558 7.05E-05 2.86E-10 0.96
rs1052299 17 17691144 A G 0.40 0.0440 0.002 -0.0549 9.09E-05 1.96E-10 0.96
rs1108648 17 17691283 G A 0.41 0.0424 0.002 -0.0560 6.11E-05 2.21E-10 0.96
rs7501812 17 17691632 G A 0.41 0.0431 0.002 -0.0563 5.53E-05 1.44E-10 top
rs12951376 17 17693534 T C 0.31 0.0369 0.014 -0.0617 3.41E-05 1.17E-09 0.672
rs4925120 17 17695358 C T 0.40 0.0458 0.001 -0.0525 2.22E-04 3.61E-10 0.96
rs16960744 17 17695984 A G 0.40 0.0453 0.001 -0.0528 2.03E-04 3.77E-10 0.96
rs8079321 17 17701514 T C 0.40 0.0446 0.002 -0.0541 1.32E-04 2.64E-10 0.92
rs4924823 17 17705227 A G 0.39 0.0404 0.004 -0.0567 6.51E-05 5.87E-10 0.92
rs12941039 17 17706380 C T 0.43 0.0396 0.004 -0.0515 2.22E-04 4.29E-09 0.92
rs1889014 17 17707890 T C 0.53 -0.0409 0.003 0.0499 3.33E-04 3.46E-09 0.781
rs9907246 17 17711690 T C 0.42 0.0392 0.005 -0.0528 1.58E-04 3.33E-09 0.92
rs9907287 17 17714843 C T 0.39 0.0403 0.005 -0.0569 6.15E-05 5.71E-10 0.92
rs8080061 17 17717114 C T 0.40 0.0416 0.003 -0.0530 1.90E-04 1.82E-09 0.92
rs4925125 17 17735169 T C 0.41 0.0386 0.006 -0.0481 6.26E-04 4.09E-08 0.813
rs6502625 17 17789011 G C 0.53 -0.0385 0.005 0.0461 8.95E-04 4.46E-08 0.74
rs2955382 17 17888435 T C 0.54 -0.0363 0.008 0.0528 1.48E-04 6.73E-09 0.75
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for TB-BMD and TB-LM were lower than heritability estimates from twin studies (35,36). One 
explanation could be that the SNP-heritability is attributed to the common SNPs while that 
estimated with the related individuals is attributed to the entire genome. Also, we have 
used only genotyped independent variants thus, if the selected markers are not sufficiently 
correlated with the true genetic variants explaining the trait-variance heritability would 
certainly be underestimated (37).
We used a bivariate approach for meta-analysis of GWAS. This methodology proved to 
be more powerful than the univariate analysis, particularly for those variants, exerting an 
opposite effect on both traits under study. The univariate approach for TB-BMD identified 
only four GWS signals, all of them reported before in BMD site-specific GWAS (12,13,38). Up 
to date, four loci have been identified to be associated with TB-LM in adults, but none of 
them overlap with the loci identified in this research (submitted manuscript). Further imple-
mentation of the bivariate methodology resulted in eight loci identified. Results showed 
that except for signals in 2q24.3, 11q13.2 and 17p11.2, all other GWS signals were pulled to 
significance by their association with TB-BMD, rather than by an association (P<0.05) with 
both traits.
A previous study for TB-BMD including only Generation R and ALSPAC GWAS identified 
as many as seven different loci associated with TB-BMD (13). The difference in the number 
of discovered loci (7 vs. 4) could have derived from the model used to adjust TB-BMD. In 
Kemp et al.  (13) we adjusted the outcome for age, sex, weight, height and principal com-
ponents while in this new effort we included age, sex, height, fat percent and principal 
components on analysis. As recently demonstrated by Aschard et al.  (39), adjusting for 
heritable covariates, as weight, height, and fat percent can affect the association results. 
In the present study then, we replaced weight by fat percent. Fat percent is a heritable 
variable but its correlation with TB-BMD and TB-LM in Generation R is 0.3 and 0.1 which 
would represent a rather small bias in the effect size of variants correlated with this trait and 
TB-BMD/TB-LM, and thus this would not likely resulting in a false discovery. Moreover, for 
protein products of genes as LRP5  (40), TNSF11(41), WNT16  (42) and WNT4  (43) identified in our 
study and previous GWAS meta-analyses (11-13,38,44-46) –regardless of the adjustment variables 
used in the association model- their role in bone metabolism is long-established.
We focused our effort on the region of 17p11.2 as it is new in the GWAS of musculoskeletal 
traits and was the only region in which the association signal was stronger in TB-LM than 
in TB-BMD. This region was described recently as a QTL in heterogeneous stock rat (47). In 
the same publication, they attribute the possible association to Rai1 as previous studies 
have shown knockout mice for this gene are growth retarded and display malformations 
in both the craniofacial and the axial skeleton (48). This gene in humans is responsible for 
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the Smith-Magenis syndrome, which as in mice is presented with craniofacial and skeletal 
abnormalities (49). Nonetheless, the two exonic variants in LD with the bivariate GWS SNPs 
have not been reported as responsible for the disease. We retrieved different lines of 
evidence to disentangle the gene(s) underlying the association signal although results were 
not conclusive as, besides a long stretch of LD in the region there is evidence of complex 
chromatin interactions that could result in regulation by the associated variants of more 
than one gene. These chromatin interactions assessed by ChIA-PET experiments were 
retrieved for two oncogenic cell lines. Nonetheless, the CTCFs described are also present 
in the muscular cells and osteoblast, and TADs have been shown to be largely invariant 
across cell types, and physiological conditions  (50). Therefore, we believe similar interac-
tions might take place in osteoblasts and muscular cells, suggesting that associated SNPs 
can be influencing distant genes within the TAD. For example, The SNP leading the signal 
(rs7501812) has a strong correlation with the expression of various genes in the region in 
whole blood (Supplementary table 1), in line with the predicted complex looping in this 
locus. However, its correlation with SREBF1 is the strongest. In addition, another bivariate-
GWS SNP acts as cis-eQTL of this gene in skeletal muscle. Hence, it is reasonable to believe 
that SREBF1 is the gene underlying the signal.
SREBF1, an adipocyte differentiation factor, produces SREBP-1, a ubiquitously expressed 
transcription factor, strongly expressed in lipogenic tissues  (51). In skeletal muscle SREBP-1 
proteins regulate the expression of hundreds of genes, but particularly its role in down-
regulating MYOD1, MYOG and MEF2C suggests it acts as a key regulator of myogenesis. 
In-keeping with this view, overexpression of SREBP-1 inhibits myoblast–to-myotube differ-
entiation (52), reduces cell size and leads to loss of muscle-specific proteins in differentiated 
myotubes (51). Contrary to its inhibitory role in myogenesis, SREBP-1, in its active form, has 
been shown to be important for the mineralization of osteoblastic cultures in vitro and 
bone formation in vivo as its overexpression increases the number of mineralized foci (53).
Thus, there is compelling evidence that SREBF1 has opposite effects on the differentiation 
of myocytes and osteoblasts. This opposite effect is shown in the SNPs associated with TB-
BMD/TB-LM in our bivariate approach, and therefore, it is conceivable to think that SREBF1 
is underlying the association signal. Nonetheless, the eQTL analysis seems to contradict 
the expected effect direction. The G-allele from rs7501812, shown to downregulate the 
expression of SREBF1 in whole blood, is actually associated with higher TB-BMD and lower 
TB-LM, which is opposite to that predicted by its function bone and muscle metabolism. 
This different behavior could be due to tissue-specific effects. Additionally, SREBP-1 need to 
be activated by proteolytic cleavage in the endoplasmic reticulum, nuclear transport and 
intra-nuclear activation/degradation within the nucleus, actions that cannot be captured 
by expression analysis.
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In summary, in this first large-scale bivariate GWAS meta-analysis of TB-BMD and TB-LM in 
pediatric cohorts, eight GWAS loci (in/near WNT4, GALNT3, MEPE, CPED1/WNT16, TNFSF11, 
RIN3, TOM1L2/SREBF1, and PPP6R3/LRP5) have been identified. Although for most of these 
loci the association with TB-BMD is the dominant association responsible for their signifi-
cance. Only the 17p11.2 locus containing among other genes TOM1L2 and SREBF1, showed 
a stronger association with TB-LM than with TB-BMD. The genomic region described by 
the association signal in this locus spans ~290Kb in a long stretch of LD and chromatin 
interactions. Nonetheless, SREBF1 arises as a strong candidate to underlie the association 
as this transcription factor is known to play an opposite role in the differentiation of osteo-
blasts and myoblasts. To disentangle the mechanism by which associated variants in this 
study influence SREBF1 action in musculoskeletal metabolism further functional studies are 
required. This study demonstrates a considerable increase in power can be achieved when 
using a bivariate methodology as compared to testing each component of a multivariate 
phenotype individually, particularly in those cases where the effect of the associated vari-
ant goes in opposite directions in the involved phenotypes. Moreover, we show that this 
methodology may help discover previously unknown mechanisms of pleiotropic effects of 
genetic variants.
Additional detailed methods, results and acknowledgements are to be provided in the 
online Supplement of the journal containing this publication.
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Supplementary Figure 1. QQPlots for the genome-wide meta-analyses. Quantile-Quantile plots showing 
P-Values for association, deviating from the null hypothesis of no association (identity line), per minor allele 
frequency category.
Supplementary Figure 2. regional plots. Regional association plot for each of the genome-wide signifi cant 
loci. (A. 1p36.12, B. 2q24.3, C. 4q22.1, D. 7q31.31, e. 11q13.2, F. 13q14.11, G.14q.2.12). SNPs are plotted by posi-
tion in a 1Mb window against association with the bivariate LM/BMD (–log10 P). Plot highlighting the most 
signifi cant SNP in the meta-analysis . Blue peaks indicate recombination rates. The SNPs surrounding the most 
signifi cant SNP are color coded to refl ect their LD with this SNP (from pairwise r2 values from the HapMap 
CEU). Genes, exons and the direction of transcription from the UCSC genome browser are noted.
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Supplementary Figure 3. 17p11.2 locus displaying binding peaks and interaction tracks by CtCF ChiA-Pet 
data together with histone marks based on chromatin state characterization. Predicted strong interac-
tions shared in MCF-7 or K562 cell lines are shadowed in blue while a weaker interaction in both cell lines 
is shadowed in pink. These interactions overlap with predicted CTCF binding sites in osteoblast, myoblast 
and myotubes, hypothetically localizing SNPs in TOM1L2 close to transcribed regions in SREBF1 and ATPAF2. 
Histone markers in muscular cells display high representation of associated SNPs in active enhancer predict-
ed regions. Chromatin states are defined as follows, Bright Red: Active Promote, Orange: Strong enhancer, 
Yellow: Weak/poised enhancer, Blue: Insulator, Dark Green: Transcriptional elongation, Light Green: Weak 
transcribed
Supplementary Figure 4. A topological associated domain (TAD) includes associated variants and RAI1, 
SREBF1, TOM1L2, LRRC8 and ATPAF2. In line with the chromatin interactions, TADs in K562 cell line suggest a 
complex regulation structure in the 17p11.2 locus.
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Evolutionary perspective of bone 
fragility
BMD Loci Contribute to Ethnic And 
Developmental Differences in Skeletal 
Fragility Across Populations: Assessment of 
Evolutionary Selection Pressures
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ABStrACt
Bone mineral density (BMD) is a highly heritable trait used both for the diagnosis of os-
teoporosis in adults and to assess bone health in children. Ethnic differences in BMD have 
been documented, with markedly higher levels in individuals of African descent, which 
partially explain disparity in osteoporosis risk across populations. To date, 63 independent 
genetic variants have been associated with BMD in adults of Northern-European ancestry. 
Here, we demonstrate that at least 61 of these variants are predictive of BMD early in life by 
studying their compound effect within two multiethnic pediatric cohorts. Furthermore, we 
show that within these cohorts and across populations worldwide the frequency of those 
alleles associated with increased BMD is systematically elevated in individuals of Sub-
Saharan African ancestry. The amount of differentiation in the BMD genetic scores among 
Sub-Saharan and non-Sub-Saharan populations together with neutrality tests, suggest that 
these allelic differences are compatible with the hypothesis of selective pressures acting 
on the genetic determinants of BMD. These findings constitute an explorative contribution 
to the role of selection on ethnic BMD differences and likely a new example of polygenic 
adaptation acting on a human trait.
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introDuCtion
Enormous progress in mapping complex traits has been achieved in the last decade with 
thousands of loci identified by the implementation of genome-wide association studies 
(GWAS)(1). While individually, variants at these loci each make modest contributions, col-
lectively, the effect of large sets of variants increase significantly the amount of explained 
trait variance. These discoveries have also enabled studying how selective pressures influ-
ence the genetic architecture of complex traits across populations. For some phenotypes 
such as skin pigmentation (2), type 2 diabetes (3), height (4), biliary liver cirrhosis and ulcerative 
colitis (5), there is increasing evidence that the genetic basis of trait differences across human 
populations has been shaped by evolutionary selective pressures (6).
Just as in most other medical areas, the field of genetics of osteoporosis has also been 
revolutionized by the advent of the GWAS approach, with up to 63 independent genetic 
variants identified as robustly associated with BMD in adults of Northern-European ances-
try (7). BMD measured by Dual-energy X-ray Absorptiometry (DXA) is a highly heritable trait 
used to diagnose osteoporosis and assess the risk of fracture (8). BMD levels are determined 
by the processes of bone accrual (throughout childhood until young adulthood) and bone 
loss (from peak bone mass acquisition to senescence). Ethnic differences in BMD are well 
documented and partially explain differences in osteoporosis and fracture risk across 
populations. Individuals of Sub-Saharan African ancestry tend to have higher BMD levels 
and lower fracture risk as compared to other populations (9,10).
It is likely that the skeletal system as a whole (and its derived bone strength) has been 
subjected to selective pressures throughout human evolution  (11). This includes changes 
brought about through human history ranging from early nomadism to the domestication 
of animals, crops and even more recently, a tendency to ever increasing levels of seden-
tariness  (12). In order to understand how selective pressures have shaped bone strength 
variation across human populations we 1) studied the collective effect of BMD associated 
variants within two independent multiethnic pediatric cohorts; 2) examined the allele 
frequency distribution of these variants across diverse ethnic populations using two differ-
ent catalogues of genetic variation; and 3) assessed the presence of selective pressures by 
testing for deviation from genetic drift.
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reSultS
total Body BMD differences across ethnic ancestries
To characterize pediatric ethnic differences in BMD, we selected a sample of 3,994 
children (mean age of 6 years) of multi-ethnic background taking part in the Generation 
R Study  (13), who had GWAS data and DXA measurements. First, we determined genetic 
population substructure from genotyped data, children were assigned to one of the three 
main genetic ancestry groups (Figure 1): Sub-Saharan African (n=336), European (n=3,499) 
and East Asian (n=159) descent. Table 1 summarizes the characteristics of the Generation R 
participants under study. Children of European and East Asian ancestry had respectively, 
4% (0.552 g/cm2, P<2x10-16) and 2.8% (0.559 g/cm2, P=7x10-6) lower BMD than children 
who clustered in the Sub-Saharan African group (0.575 g/cm2), after controlling for age, 
sex, height, fat and lean mass. These differences remained statistically significant after cor-
rection for lifestyle factors affecting mothers and children. Furthermore, we observed that, 
in European children, the proportion of genetic Sub-Saharan African ancestry in their ge-
nomes (range 0.00-0.49) was positively associated with BMD levels, representing a BMD 
increase of 0.0003 g/cm2 per increase in genomic Sub-Saharan African component (beta= 
0.72, P=1.87x10-5). Thus, the BMD difference between an individual with 0% Sub-Saharan 
Figure 1. Genetic substructure of the Generation r Study. A: Two-dimensional plots from multidimensional 
scaling analyses of the Generation R Study based on the first two genomic principal components. B.: Cluster-
ing rule based on ancestral proportions. Children were assigned to one of the three main genetic ancestry 
groups, based on their highest fraction of estimated ancestry (i.e., >0.50) proportion: European (blue), Sub-
Saharan African (red) and East Asian (green). Individuals with no ancestry proportion >0.50 were excluded.
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African ancestry and one with 49.99% Sub-Saharan African ancestry in their genomes will 
be equivalent to 0.016 g/cm2, suggesting that genetic factors play a role in the observed 
ethnic BMD differences.
We confirmed the existence of these ethnic differences in BMD in an independent 
multi-ethnic set of 1,670 U.S. children from the Bone Mineral Density in Childhood Study 
(BMDCS), using the same ethnic definition and analytical approach. Characteristics of the 
BMDCS participants under study are presented in Table 1. Consistent with our findings, after 
adjustments children of European (n=1,277) and East Asian (n=78) ancestry had 4.7% (0.778 
g/cm2, P=0.0002) and 2.5% (0.794 g/cm2, P<2x10-16) lower BMD levels than children of 
Sub-Saharan African ancestry (n= 315) with mean BMD 0.816 g/cm2, respectively.
Bone Mineral Density Genetic Score (BMD-GS) association with pediatric BMD
We constructed a genetic score –composed of BMD-increasing alleles- for each child us-
ing single nucleotide polymorphisms (SNPs) known to be associated with BMD in adults 
of Northern-European ancestry  (7) (Online Resource Table S1). In the Generation R Study, 
the calculated BMD-GS explained 4.5% of the BMD variance in all the sampled children 
(P<2x10-16). Additional correction by ten genomic principal components, addressing 
potential residual population stratification, indicated that up to 2.6% of BMD variation is 
explained by the BMD-GS (P<2x10-16). In children from the BMDCS, the BMD-GS explained 
5.7% and 2.2% of the BMD variance, before and after correction by ten principal compo-
nents (Online Resource Table S2). The BMD-GS was positively associated with BMD in 
children of predominantly European and African descent of both studies, albeit the latter 
reached nominal significance only in the BMDCS cohort. In children of predominantly 
East Asian ancestry (with the lowest sample size) the effect of the score on BMD did not 
reach statistical significance in either study. Joint analysis of the Generation R and BMDCS 
resulted in significant associations of BMD with the BMD-GS in children of European (beta= 
4.43, P<2x10-16) and Sub-Saharan African (beta=2.41, P=0.016) background, but not in those 
of East Asian (beta=1.18, P=0.472) descent.
We then examined BMD levels across quintiles of the calculated BMD-GS in the two pe-
diatric cohorts. There was a positive correlation between the score and the adjusted BMD 
in both studies. In the Generation R Study, as compared to children in the middle quintile 
(55.8% of the population with the mean BMD; n=2,232), children in the highest quintile 
(2.2% of the population; n=88) had 0.72 SDs higher BMD (P<1x10-6), while those in the 
lowest quintile (1.3% of the population; n=53) had 0.53 SDs (P=4x10-6) lower BMD. Similar 
results were obtained in the BMDCS study where children in the highest quintile (1.1% of the 
population; n=19) had 0.42 SDs higher BMD (P=0.06) and those in the lowest quintile (2.9% 
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of the population; n=49) 0.55 SDs lower BMD (P=0.001) as compared to the children in the 
middle quintile (51.3% of the population, n=860).
As depicted in Figure 2, the overrepresentation of children of Sub-Saharan African descent 
across the higher quintiles of the BMD-GS was highly significant in both studies (Generation 
R: P=2.7x10-71 and BMDCS, P=2.3x10-70). In the Generation R Study 60.7% of children of Sub-
Saharan African ancestry are found in the two highest GS quintiles, as compared to children 
of European (20.8%) and East Asian (15.1%) ancestry. For the BMDCS, 47.9% of children of 
Sub-Saharan African ancestry are found in the two highest GS quintiles, as compared to 
children of European (9.2 %) and East Asian (6.4%) ancestry. In both pediatric cohorts the 
mean BMD-GS values were highest in the Sub-Saharan African group (Generation R: 0.537, 
BMDCS: 0.542), while remaining similar in the European (Generation R: 0.495, BMDCS: 
0.493) and East Asian (Generation R: 0.487, BMDCS: 0.491) groups.
Computing BMD-increasing allele scores using additional sets of markers associated with 
BMD at lower levels of significance showed that the greatest difference in mean GS values 
between subjects of African and European background was observed with the original 
BMD-GS including 61 markers (Online Resource Figure S1). The addition of more (less 
significantly-associated) SNPs to the score decreased the mean allele score difference 
observed between the two ethnic groups and did not improve significantly the BMD ex-
plained variance.
Figure 2. Distribution of the BMD-increasing allele score by genetic ancestry in the Generation r Study 
and BMD in Childhood Study. The increasing-BMD GS has been divided in 5 category bins. Colors in the 
stacked bars represent ethnic background: European (blue), East Asian (green) and Sub-Saharan African (red). 
Black dots represent the mean BMD adjusted for age, gender, height, fat and lean mass. Magenta dots repre-
sent the mean BMD per bin, adjusted for all former variables plus the first 10 principal components.
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Worldwide geographical distribution of the BMD-increasing alleles
We then sought to understand the observed ethnic mean differences in BMD-GS by de-
composing it and considering each of the BMD-increasing alleles independently. In the 
Generation R Study, where the sample size allows more accurate statistical inferences, we 
found that in children of Sub-Saharan African ancestry 23 of these alleles had ≥10% higher 
frequency as compared to only 12 in Europeans (P=0.04). When examining HapMap data (14), 
similar allele frequency differences were observed between the CEU and YRI populations, 
independent of the CEU SNP minor allele frequency (MAF) (Online Resource Table S1).
In order to broaden the scope of our findings, we analyzed the spatial distribution of 
the BMD-GS SNPs worldwide, using the populations from the Centre D’Etude du Poly-
morphism Humaine-Human Genome Diversity Project (CEPH-HGDP) panel  (15) (Online 
Resource Table S3). As shown on Figure 3, examining the BMD-GS across all individuals 
Figure 3. Worldwide geospatial distribution of BMD-increasing alleles. A. The density map of the com-
bined frequency of the BMD GS was generated by inverse to distance interpolation using the observed values 
across the 53 HGDP populations. B. Total number of BMD-increasing alleles per individual in the 53 popula-
tions of the HGDP. Populations are ordered by geographic groups: Sub-Saharan Africa (red), North-Africa 
(orange), Europe (blue), Middle East (grey), Central Asia (pink), East Asia (green), Oceania (purple), and Native 
Americans (yellow).
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from the different populations, we confirmed that Sub-Saharan African populations had 
the highest number of BMD-increasing alleles, together with other two Latin-American 
populations located in the tropics. Likewise, the populations out of Africa in general had 
lower BMD-GS scores.
Signatures of natural selection in the BMD-GS SnPs and associated regions
We followed sixth different lines of evidence to discard that genetic drift was explaining the 
observed spatial distribution of the mean BMD-GS (Figure 3). First, we observed that the 
BMD-increasing alleles were enriched for ancestral alleles (73% actually constitute ancestral 
alleles; P=1.8x10-4). Second, taking advantage of the geographical coverage of the HGDP, 
we quantified the differentiation between continents, where for each HGDP individual 
we generated 100,000 permuted scores by randomizing the coded effect allele in each of 
the BMD-GS variants. The BMD-GS differentiation between Sub-Saharan African and non-
Sub-Saharan African populations was higher for the original BMD-GS (P=0.025) than for 
the different sets of sampled scores. Third, in line with the previous test, we evaluated the 
population specific departure of the BMD-GS score from its expected genomic value and 
determined that the proportion of variance attributable to the categorization into Sub-Saha-
ran African and non-Sub-Saharan African populations, was significantly higher (P=0.011) for 
the original BMD-GS than that observed in 100,000 GS sets of 61 SNPs randomly sampled 
from the genome (after matching for factors related to GWAS discovery bias). These results 
provide additional statistical support to the contention that the observed differentiation 
of Sub-Saharan African populations, as shown by the multidimensional scaling (MDS) and 
ADMIXTURE analyses using only the markers of the BMD-GS (Online Resource Figure S2), 
is not due to genetic drift. Fourth, we estimated the QX statistic(6), which analyzes extreme 
patterns of genetic differentiation among populations, which was not significant (Qx = 
46.67, P= 0.68). Fifth, to assess if selective pressures acting on the score explained these 
results, we scrutinized the YRI, CHB and CEU populations and found no signals of strong 
selective sweeps acting on the loci harboring the BMD-GS SNPs (Online Resource Table 
S4). Nonetheless, we did find evidence for departure by chance from neutrality in CEU and 
CHB (Hierarchical Bayesian binomial modeling, and Online Resource Table S5); resulting 
in a possible excess of intermediate-frequency alleles in the BMD-GS. Sixth, we applied 
tests for differences in mean MAF and determined that as compared to SNP sets randomly 
ascertained from the GWAS catalogue, the SNPs of the BMD-GS have significantly higher 
(P=8.3x10-3) mean MAF in European (MAF=0.30 in CEU), but not in East Asian (MAF=0.26; 
P=0.13 in JPT+CHB) or African (MAF=0.21; P=0.83 in YRI) populations. Altogether, five out of 
sixth different lines of evidence argue against genetic drift explaining the observed ethnic 
differences in mean BMD-GS values.
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DiSCuSSion
In this study we established that ethnic differences in BMD are already present early in 
life and are partially explained by variation in BMD-associated loci. Furthermore, we 
demonstrate in two independent pediatric multiethnic cohorts that those alleles positively 
associated with BMD are systematically elevated in populations of Sub-Saharan African an-
cestry. The same pattern was also observed in a broader framework of catalogues of human 
genetic variation. Five out of six tests indicate deviation from neutrality and are suggestive 
of polygenic adaptation acting on the loci harboring the variants of the score. Our results 
confirm that the Sub-Saharan African versus non-Sub-Saharan African distribution of the 
BMD increasing alleles worldwide cannot be simply explained by demographic factors or 
genetic drift.
We assessed the existence of ethnic differences in BMD levels first within the Genera-
tion R Study. In contrast to ethnic comparisons conducted across different geographical 
areas (16-18), these research subjects were relatively standardized as they were all residents of 
the city of Rotterdam, The Netherlands; measured using the same DXA device; and within 
a similar age range. This study design reduces the impact of inter-machine variance, as well 
as local environmental and lifestyle exposures influencing BMD variation such as major 
differences in access to medical care, sunlight exposure, diet or physical activity. Children 
of Sub-Saharan African ancestry showed higher BMD in this set even after correction for 
lifestyle factors affecting both mothers and children. Nevertheless, since each child might 
have a varying degree of each of the three ancestral populations in their genome (Figure 
1), actual ethnic BMD differences might be even higher than reported here when more 
stringent ethnic definitions are used. These differences found in the Generation R study 
and replicated in the BMDCS, together with the positive association of Sub-Saharan Afri-
can genomic ancestry proportion and BMD, suggests that genetic factors play a role in the 
observed phenotypic differences in BMD.
The fact that the BMD-GS was significantly associated with BMD in children from both 
the Generation R and BMDCS (Figure 2), implicate developmental effects of the studied 
variants acting on the bone accrual process. The systematic higher frequency of the BMD 
increasing-alleles in children of Sub-Saharan ancestry mirrored their higher BMD, advocat-
ing that ethnic differences in BMD are to a given extent genetic in origin and not likely due 
to population stratification (enduring correction for genomic principal components).
Our results indicate that the BMD-GS is more predictive in subjects of European descent 
(where variants were discovered) than in other ethnic groups. Nevertheless, differences 
in the effect of the score across ethnic populations in our pediatric studies could simply 
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reflect greater uncertainty in estimating effect sizes of the BMD-SNPs for these populations 
given their small sample size. Despite not finding an association in children of East Asian 
background, previous studies in East Asian populations have replicated associations with 
BMD for several variants of the genetic score  (19-21). In fact, high trans ethnic replicability 
has been described between these populations for other complex traits  (22). Additionally, 
ethnic differences in the degree of association of the BMD-GS can also reflect population 
differences in the relationship between tagging and true underlying genetic variants  (22). 
This is especially evident in African populations where blocks of LD are the shortest and 
associations with phenotypes can result in dilution of effects (23). Therefore, the true direc-
tional population differentiation at causal SNPs could be even larger than the directional 
population differentiation observed in tagging SNPs, likely comprising a large fraction of 
the variants in the GS we employed. Further, other variants more frequent in African or 
Asian populations may contain additional set of alleles contributing to BMD variation in 
those groups; this contention is also supported by the significant association of the fraction 
of Sub-Saharan African ancestry in Europeans, which remained significant independently 
of the BMD-GS.
In the GEnetic Factors of Osteoporosis (GEFOS) BMD meta-analysis a weighted version of 
the BMD-GS explained 5.8% of the femoral neck BMD variance in a cohort of unrelated 
postmenopausal Danish women  (7). The BMD-GS explained relatively lower variance in 
our two pediatric multiethnic cohorts (Generation R: 2.6%, BMDCS: 2.2%), likely as conse-
quence of the different weighting scheme, age range (24), skeletal site specificity (25) or ethnic 
context. The use of a weighted scores could increase predictive ability but also introduce 
possible bias due to the above mentioned differences in study setting as well as residual 
population stratification intrinsic in GWAS studies (4).
By interrogating publicly available databases we could establish that the results observed in 
the two pediatric cohorts were paralleled in a worldwide scenario (Figure 3). Frequency dif-
ferences in the Generation R Study reflected the differences observed in the HapMap YRI 
and CEU populations (14). The magnitude of these differences was such, that by employing 
only the BMD-GS SNPs we could unequivocally separate Sub-Saharan African individuals 
from all others in the populations from the HGDP-CEPH panel (Online Resource Figure S2). 
This geographic pattern is in line with the geographical disparities in fracture risk worldwide 
and parallel a potential association with latitude (26-29). However, we did not find any clear 
BMD-GS south to north gradient among the HGDP-CEPH populations. Yet, an association 
with latitude may be attenuated as the populations part of the HGDP-CEPH panel are 
unevenly distributed (30).
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Likewise, careful consideration is needed when drawing conclusions about findings in 
African populations, as Africa is a continent characterized by profound genetic diversity 
and home to a vast array of heterogeneous lifestyles (31). Given the limited representation 
of African populations in the HGDP-CEPH and HapMap datasets, the association between 
the BMD-GS and Sub-Saharan African ancestry is not to be directly extrapolated across 
the whole African continent. Nevertheless, our findings suggest that a fraction of the 
population differences in BMD levels are genetic in origin, without disregarding the large 
environmental influences contributing to trait variation and ethnic differences.
The overrepresentation of ancestral alleles in the BMD-GS, indicates that phenotypic 
states related to increased BMD, such as bone robustness (11), represent the ancestral state 
in humans and show an amount of phenotypic differentiation that cannot be uniquely 
explained by demographic factors. A similar result was observed by Wu and Zhang (32) when 
analyzing genes that had been associated with the skeletal system in humans. The authors 
concluded that such excess of derived variants in populations from European and East 
Asian ancestry was suggestive of selective pressures out of the African continent, although 
this could also be consequence of a relaxed constraint. We observed that the BMD-GS dif-
ferentiation between Sub-Saharan African and non-Sub-Saharan African populations was 
significantly larger than expected under neutrality for both the randomization test of allele 
effects and when compared with the rest of the genome. In fact, departure of the BMD-GS 
from neutrality was supported by five of six different types of tests, including: 1) Detection 
of enrichment of ancestral alleles in the set of BMD increasing alleles in the BMD-GS; 2) 
Randomization of the BMD increasing allele and quantification of the differentiation be-
tween continents; 3) Population departure of the expected genomic value of BMD-GS; 4) 
Detection of departure of neutrality in sequence based tests; and 5) Presence of an excess 
of intermediate allele frequencies. We acknowledge that the statistical evidence derived 
from these five tests was marginal. However, such magnitude of statistical significance is in 
agreement with those reported for other complex phenotypes(5,33). Only on the 6) Qx index 
test (6) we did not find any evidence for departure from neutrality.
This discrepancy could be due to the wide range of hypotheses about differentiation 
considered by the Qx, which models all different population levels. In contrast, the other 
tests (i.e., ANOVA) were motivated by the empirical observation that the BMD-GS is in-
creased in Sub-Saharan populations and applied specifically to detect differences between 
two groups (Sub-Saharan vs. non-Sub-Saharan African populations). Our results, (Online 
Resource Table S4) as expected under polygenic adaptation, showed no enrichment 
for strong selective sweeps in the BMD-associated loci but rather displaying small allele 
frequency shifts between populations(34). One plausible explanation is that methods for de-
tecting strong selective sweeps are under powered in regions containing a relative excess 
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of intermediate-frequency alleles compared to the rest of the genome. We observed that 
in the European populations the BMD-GS SNPs have a systematic excess of intermediate-
frequency alleles as compared to that observed in other SNPs reported in the GWAS 
catalogue(35). This footprint of intermediate-frequency alleles in the BMD-GS SNPs can be 
produced by the presence of selective pressures increasing the genetic variability, such as 
balancing or directional selection on standing variation(36) or by SNP ascertainment bias on 
the GWAS discoveries(37). Nevertheless, since our sampling SNPs sets were drawn from the 
GWAS catalogue, and controlled for multiple putative confounder factors, ascertainment 
bias is an unlikely explanation.
The skeletal system as a whole and its derived bone strength are likely to have been subject 
to natural selection during human evolution(11). Multiple factors may have been responsible 
for selective pressures such as: long distance running and trekking (indispensable for hunt-
ing and scavenging), the establishment of a more sedentary lifestyle (with the advent of 
agriculture), which would have favored skeletal gracility (11,12); adaptation to less sunlight at 
more distant latitudes from the equator (i.e., skin color and vitamin D metabolism) or differ-
ences in milk/calcium intake (i.e., lactase persistence), among several others. Therefore, it 
is conceivable that evolution would favor an optimal balance between bone thickness and 
bone strength within the context of the structural and metabolic functions that the skeleton 
must serve. However, the ultimate reason for the presence of this genetic signature out of 
Africa, remains to be elucidated. Understanding of the evolutionary and genetic mecha-
nisms shaping BMD variation and peak bone mass acquisition across populations will 
facilitate pinpointing critical factors underlying ethnic differences in the risk of osteoporosis 
later in life.
In summary, we provide evidence that disparities in global patterns of BMD-increasing 
allele frequencies contribute to disparities in BMD levels across different ethnicities, ef-
fects which are already present at early ages, postulating a critical role of these variants 
in the developmental process of peak bone mass accrual. We also show that these allelic 
differences are compatible with the hypothesis of selective pressures acting on the genetic 
determinants of BMD. These findings constitute an explorative contribution to the role of 
selection on ethnic BMD differences and likely a new example of polygenic adaptation 
acting on a human trait.
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MAteriAlS AnD MetHoDS
Study Populations
The Generation R Study
The Generation R Study is a population-based prospective cohort study from foetal life 
onwards in Rotterdam, the Netherlands (13). Data from a total of 3,994 children with blood 
collected at birth, subsequently genotyped, and valid DXA scans at 6 years of age, was 
included in these analyses. Participants underwent DXA measurements with a GE-Lunar 
iDXA device (GE Healthcare Lunar, Madison, WI) following standard manufacturer pro-
tocols. DNA samples were genotyped either on the Illumina HumanHap 610 or Illumina 
HumanHap 660 chip. Duplicated samples or with excess of heterozygocity and gender 
mismatches were excluded from the dataset. SNPs with a MAF < 1%, call rate<98% or out of 
Hardy-Weinberg equilibrium (P<10-6) were removed from further analyses. Imputations to 
the combined HapMap Phase II Build 36 Release 22 panel(14) , composed of dense geno-
types from four populations: Utah residents of European Ancestry (CEU), Yoruba people 
from Ibadan, Nigeria(YRI), Han Chinese individuals from Beijing China and a Japanese 
population from the Tokyo area, Japan (CHB+JPT), were performed following a two-step 
procedure as implemented in the MACH/minimac suit.
Bone Mineral Density in Childhood Study (BMDCS)
The Bone Mineral Density in Childhood Study (BMDCS) is a longitudinal multicenter study 
in the U.S.A. designed with the goal of obtaining standard pediatric reference data for bone 
mineral density assessed using DXA(17,38). In total, 2,521 boys and girls aged 5 to 20 years old 
were recruited between 2002 and 2007 and DXA measurements were obtained annually 
at five clinical centers in the United States for up to 7 measurements. Another 507 Cauca-
sian children aged 5 to 18 year old were subsequently enrolled for a one-time visit in two 
of the five centers. Enrollment criteria were established to identify research subjects with 
normal development, including healthy bones. DXA scans were obtained using Hologic, 
Inc. (Bedford, MA) bone densitometers. The baseline measurements for 1,670 individuals 
were used for this analysis. All samples were genotyped on the HumanOmniExpressExome-
8v1 chip. Samples with gender discrepancy, low genotype quality, sample replicates and 
siblings were excluded from the analysis. SNPs with MAF < 0.5% and call rate of < 95% were 
removed. Imputation was performed following a two-step procedure; haplotype phasing 
was carried out using ShapeIT while imputation to the combined HapMap Phase II Build 36 
Release 22 panel was performed with Imputev2.
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Centre D’Etude du Polymorphism Humaine-Human Genome Diversity Project panel 
(HGDP-CEPH)
The HGDP-CEPH is a collection of DNA samples from lymphoblastoid cell lines representing 
1,064 individuals sampled from 53 populations throughout the world (15). We downloaded 
Illumina 650Y data for 1,043 samples from the HGDP-CEPH (http://www.hagsc.org/hgdp/
files.html, last accessed February 2, 2014). After excluding duplicates, ethnical outliers, first 
or second degree relatives (39) and individuals with more than 2% missing SNPs, we selected 
a panel comprising 940 individuals (Online Resource Table S3). SNPs were removed if the 
MAF was less than 1%, call rate<98% or if they were out of Hardy-Weinberg equilibrium 
(P<10-6). All samples were imputed to the combined HapMap Phase II Build 36 Release 22 
panel. Imputations were performed following a two-step procedure as proposed by the 
MACH/minimac suit.
individual BMD estimation
Total body bone mineral density was measured in the two population-based studies (Gen-
eration R Study and the BMDCS) using DXA scans. In both studies measurements were 
conducted by well-trained research assistants and daily quality control assurance was per-
formed. Prior to the scan procedure, participants were asked to take off their shoes, heavy 
clothes and metal accessories. As recommended by the International Society for Clinical 
Densitometry (40), total body less head BMD was the measurement used in the analysis, as 
both studies are embedded in pediatric populations.
BMD associated Single nucleotide Polymorphisms
For this study, we used 61 out of the 63 autosomal SNPs reported as genome wide associated 
with either Femoral Neck or Lumbar Spine BMD (P≤5x10-8) in the large scale GWAS meta-
analyses of BMD from the GEFOS(7) successfully imputed in the different study populations. 
Description of these SNPs can be found in the Online Resource Table S1. Comparison of 
BMD-increasing allele frequency was completed based on the Generation R children of 
Sub Saharan African and European ancestry and on the YRI and CEU HapMap project(41) 
populations, in dbSNP (42).
estimation of genomic principal components and genetic ancestry determination
Ancestry determination was performed in each of the studies, Generation R and BMDCS, 
separately but following the same protocol. Autosomal genotyped SNPs of all samples were 
pruned, so that no pair of SNPs within a window of 200 markers were in LD (r2=0.05). Based 
on these ~35,000 SNPs we described the genetic ancestry of the whole dataset by means of 
classical MDS in PLINK, generating 10 genomic principal components. We then performed 
estimation of the genetic ancestry components of each individual on basis of the maximum 
likelihood using ADMIXTURE software (43). This program models the probability of observed 
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genotypes using ancestry proportions and ancestral population allele frequencies. The clus-
tering method was set to group individuals in 3 ancestral populations (K = 3), corresponding 
to the expected main Sub-Saharan African, European and East Asian ancestry components. 
Children were assigned to one of the three ancestry groups, labeled after the HapMap Phase II 
populations, based on their highest fraction of estimated ancestry (i.e., >0.50) proportions. In 
case none of the 3 ancestral populations reached this proportion, the participant was excluded 
from further analyses. Ancestry determination was also calculated for the HGDP individuals 
based exclusively in the 61 BMD-associated variants and assuming K = 3 ancestral proportions. 
Furthermore, we computed genomic principal components using the MDS routine and clus-
tered the individuals with the R package Mclust (http://cran.r-project.org/web/packages/
mclust/index.html, last accessed April 10, 2014) This algorithm assigns individuals to clusters 
by fitting multivariate normal distributions using the coordinates of the proposed dimensions 
and put forward the best clustering based on the Bayesian Information Criterion (BIC).
BMD Genetic Score calculation
Scores were obtained for each individual as an un-weighted sum across the 61 BMD-asso-
ciated SNPs of the number of putative increaser alleles (0, 1 or 2) using the profile scoring 
routine in PLINK. BMD-GS calculations were performed for each population independently 
based on best guess genotypes obtained using GCTA software(44) after imputation and qual-
ity control of the imputed dataset. Extensions of the score to include SNPs associated at 
the meta-analysis level with BMD at different significance thresholds were also generated. 
We used the PLINK clumping function, following a strategy described elsewhere(4). Briefly, 
we combined publicly available results of the stage 1 lumbar spine and femoral neck BMD 
meta-analyses (7), data publicly available (http://www.gefos.org/?q=content/data-release, 
last accessed March 20, 2015). We assigned to each SNP the lowest p-value reached 
genome-wide in any of the two association analyses by skeletal site. Then we clumped the 
dataset with an r2 ≥ 0.1 using as reference the most BMD-associated SNPs and pruned re-
maining SNPs within 0.5 Mb of each other. Using different thresholds of significance (5x10-8, 
5x10-7, 5x10-6, 5x10-5, 5x10-4, 5x10-3, 0.05 and 0.1) we generated eight different scores. Each 
cumulative threshold set contains the SNPs included in sets defined by previous thresholds 
(e.g., the set with threshold 5x10-6 includes all the SNPs with a p-value smaller than 5x10-6, 
comprising those at p-value thresholds of 5x10-8, 5x10-7, etc). For each score we calculated 
both the BMD explained variance and the mean difference of BMD increasing alleles be-
tween children of Sub-Saharan and those of European ancestry. Some differences between 
our score and the one including only GWS SNPs apply. The GEFOS meta-analysis involved 
a two-stage meta-analysis. In the first stage of the meta-analysis (discovery), only GWAS 
studies were included. For the second stage (replication), follow-up was pursued for only 
96 SNPs. Since the genome-wide summary statistics are confined to the discovery setting, 
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only 40 SNPs are classified as associated at GWS level, with the rest achieving genome-
wide significance in the meta-analysis of both stages.
estimation of the genetic ancestry association with pediatric BMD
The effect of genetic ancestry on BMD was first evaluated by least-squares means using 
the R package lsmeans (http://cran.r-project.org/web/packages/lsmeans/index.html, last 
accessed April 10, 2014). BMD was adjusted for age, gender, height, fat and lean mass index 
(which mimic the equation of BMI by dividing the referred mass by the squared height) for 
all participants independently in both pediatric studies before comparison. Moreover, in 
a subsample of the Generation R Study (n= 1,750), a model that additionally included birth 
weight, hours of physical activity of the children at age 5, age and height of the mother 
right before pregnancy, smoking during pregnancy and breastfeeding was assessed. Fur-
thermore, we evaluated the effect of Sub Saharan African and East Asian genetic ancestry 
proportions on adjusted BMD. For each individual genetically identified as European in the 
Generation R Study, the percentage of genetic ancestry estimated by ADMIXTURE  (43) for 
either Sub-Saharan African or East Asian genetic ancestry was included as variable in the 
basic model.
estimation of the BMD- GS association with pediatric BMD
BMD adjusted variability explained by the GS was evaluated based on the linear regression 
coefficient of determination for both multi-ethnic populations, namely the Generation R 
and the BMDCS, for the whole populations and by ethnic group. Analyses were further 
adjusted for 10 genomic principal components, when specified. Specific sets of principal 
components were generated in each of the two pediatric studies for the analyses within 
each of the ethnic clusters. Then results were pooled together. To quantify the magnitude 
of BMD increase across the genetic score in each study, we divided the obtained BMD-GS 
in quintiles. In each score-bin we calculated the mean adjusted BMD. Comparisons among 
quintiles were made with reference to the middle quintile using t-tests, and p-values were 
corrected for multiple testing. Deviation from the observed ethnic distribution across 
quintiles was evaluated using the Chi squared distribution, comparing the observed ethnic 
distribution with the one we would expect if the BMD-GS would be randomly distributed.
Worldwide geographic distribution of the BMD-increasing alleles
The BMD-GS was calculated for each individual across the 53 HGDP populations and box 
plots per population were generated. To visualize the spatial distribution of the GS alleles, 
we created a density map with the median BMD-GS value observed at each population 
using MapViewer 7.1.1767. Point interpolation of the locations where no data was available 
was performed by means of inverse to distance.
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Signatures of natural selection in the 61 BMD SnPs and associated regions
In order to test whether the observed BMD-GS score differentiation pattern among popula-
tions was explained by genetic drift, we performed six different analyses:
1) Detection of enrichment of ancestral alleles in the set of BMD increasing alleles
Estimates of ancestral state were determined from the dbSNP database using BioMart (45). 
Assessment of ancestral alleles enrichment in the BMD-GS was performed comparing the 
actual distribution of ancestral status to a Bernoulli distribution expected under random 
events. We based this calculation on 55 SNPs only, whose alleles were not palindromic 
(A/T or G/C) in order to avoid strand bias.
2) Randomization of the BMD increasing allele and quantification of the differentiation 
between continents by means of a two-way nested ANOVA design.
Each individual of the HGDP panel was hierarchically classified according to its sampling 
population, and the populations classified either to the Sub-Saharan African or non-
Sub-Saharan African category. The amount of BMD-GS variation between the two ethnic 
categories was computed by means of a two-way nested ANOVA comprising three levels 
including 1) categories: Sub-Saharan and non-Sub-Saharan categories; 2) populations with-
in categories; and 3) individuals within populations. In order to test whether the observed 
percentage of explained variation between these two categories was due to genetic drift, 
100,000 permuted scores were generated, in which the sign of the effect for each of the 
61 SNPs was randomly assigned to one of the two alleles. For each permuted dataset, we 
have constructed a new individual GS and determined the GS difference between African 
and non-African groups. A one-tail p-value was estimated as the number of times that the 
explained variance (SSamong/SStotal) of the sampled set was greater than the one obtained for 
the original BMD-GS (variance: 0.225).
3) Population departure of the expected genomic value of BMD-GS scores estimated by 
means of a two-way nested ANOVA design
We applied an empirical genomic-based approach in order to obtain the expected null 
genomic distribution of the BMD-GS differentiation among the Sub-Saharan and non-Sub-
Saharan populations under the assumption of genetic drift. Under this contention we ran-
domly sampled 100,000 datasets of 61 SNPs across the genome showing similar genomic 
characteristics as the BMD-GS SNPs. Following the SNP matching framework described by 
Berg and Coop(6), each BMD-GS SNP was matched by the imputed status at HGDP-CEPH 
dataset, the B-value(46) and the allelic frequency of each of the BMD-increasing alleles in 
a proxy population (Orcadians) to the one where the SNPs were initially associated to the 
BMD phenotype (Europeans). A genomic SNP was considered as putative proxy for a given 
BMD-SNP if it was at least >100Kb far away from the physical position of the BMD-SNP, the 
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B statistic difference was smaller than 0.05 (calculated by http://www.phrap.org/other-
software.html, last accessed February 27, 2015) and had a similar allelic frequency (<0.05) 
of the ancestral allele in the Orcadian population. At each iteration, 61 SNPs were sampled 
at random from the pool of proxy SNPs and a new genetic scores was computed for each 
individual. A two-way nested ANOVA framework (described above) was used to compare 
the differentiation between Sub-Saharan and non-Sub-Saharan categories. One tail p-value 
was computed comparing the number of times that the explained variance (SSamong/SStotal) 
of the sampled set was bigger than the explained variance of the original BMD-GS.
4) QX statistic calculation
The QX statistic proposed by Berg and Coop(6), represents a measure of the among popula-
tion variance in estimated genetic values that is not explained by drift and shared history. 
We assessed the covariance matrix matching by SNP ascertainment characteristics includ-
ing imputed status, B-value and Orcadian allele frequency, as described above. In order to 
construct the null covariance F matrix, we sampled a maximum of 200 proxy SNPs for each 
BMD-GS SNP at a physical distance of at least 100Kb to ensure pairwise independence 
(total number of SNPs = 11,655). We computed the covariance F matrix and QX statistic as 
described (6), using formulas 17 and 10, respectively).
5) Detection of departure of neutrality in sequence based neutrality tests
We used the 1000 Genomes project selection browser(47) to detect signatures of positive 
selection in the 61 genomic regions harboring BMD-GS SNPs in the CEU, CHB and YRI 
populations. For each population, nine different summary statistics incorporated in the 
browser were used to evaluate the 61 regions simultaneously partitioning across windows 
of an average size of 30kb: CLR, XPCLR of PopA vs PopB and XPCLR of PopA vs PopC, Fay 
and Wu’s H, Fu and Li’s D, Fu and Li’s F, R2, Tajima’s D and Wall’s B. Hierarchical Bayesian 
binomial model using a logit transformation, as implemented in Winbugs(48), was used to 
estimate the distribution of the frequency of statistically significant neutrality tests at 5% and 
asses if the 95% Credible Interval (CI) included the expected 5% by chance.
6) Mean MAF test
We compared the mean MAF in each population to that under the expectation of random 
genetic drift. In order to avoid the effect of GWAS ascertainment bias in our results, we first 
sampled 100,000 sets of 61 SNPs across the genome, assuring that the selected markers: 
i) have been associated in Europeans by GWAS to at least one of the phenotypes/traits 
described in the GWAS catalog(35), https://www.genome.gov/26525384, last accessed 
March 20, 2015) and ii) are also present in the HapMap population of interest. In the case 
of CEU individuals, the number of BMD-GS SNPs present in the HapMap Phase II dataset 
was 61 and the number of GWAS SNPs from where to sample was 8,349. In the case of YRI 
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individuals, the number of GS-BMD SNPs was 58 and the number of GWAS SNPs from 
where to sample was 7,500; for JPT+CHB individuals, there were 58 GS-BMD SNPs and 
7,552 GWAS SNPs from where to sample. A one-tailed p-value was computed counting the 
number of times that the sampled mean was higher than the observed one.
Detailed acknowledgements and online resources can be found in the published article 
online: http://mbe.oxfordjournals.org/content/early/2015/07/29/molbev.msv170.long
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General Discussion
Bone homeostasis during childhood has a complex and dynamic etiology influenced by en-
vironmental and genetic factors. In this thesis, these factors were characterized by studying 
bone traits using dual-energy X-ray absorptiometry (DXA) in participants of the Generation 
R study, a multi-ethnic birth cohort based in Rotterdam the Netherlands. The bone health 
outcomes of participants included in the different investigations presented in this thesis were 
assessed using the same DXA device at a similar average age of 6 years, which constitutes a 
unique and favorable setting for both epidemiological and genetic investigations. In addition 
to studying the sexual and ethnic dimorphism of bone, the effects of maternal nutrition, early 
growth, and muscle mass in pediatric bone mass were also researched. This thesis placed 
particular focus on the influence of genetic factors underlying the heterogeneity of bone 
mineralization. As Generation R is one of the largest pediatric studies worldwide with both 
bone phenotype and genome-wide genotyping information, our contribution to the field of 
genetics of bone attainment has been substantial. One of the elements that have facilitated 
the advancement in the investigation of the genetic architecture of complex traits, such as 
bone accrual, is the successful application of the hypothesis-free genome-wide association 
studies (GWAS) approach. Notably, the Generation R Study has made part of the vast major-
ity of GWAS leading to the discovery of variants associated with bone traits in children.
Throughout this thesis, I have presented compelling evidence that genetic factors account 
for a substantial proportion of the variance in pediatric bone mineral density (BMD). Lower 
bound heritability estimates, determined by single nucleotide polymorphisms (SNPs) pres-
ent in commercial genotyping arrays, range between 35-50% (Chapter 4.3). Therefore, it is 
expected that the bone acquisition variance, explained by the additive effect of the com-
plete set of polymorphisms in the genome, is even higher. The description of the genetic 
discoveries in the pediatric setting described in this section is partly based on a recently 
published review (1).
`1. SCientiFiC iMPACt oF tHiS tHeSiS
The creation of the GWAS dataset of the Generation R Study has been of great scientific 
impact, as reflected by approximately 50 studies published to date in different research 
areas  (2-50). Moreover, this dissertation provides tools for the analysis of this dataset and 
brings new ideas to benefit from the multiethnic background of participants.
In the particular case of musculoskeletal traits, we have so far identified 14 different loci 
to be associated with pediatric BMD and 8 with the combined phenotype of BMD and 
lean mass in children, were only one was driven by the lean mass association (Figure 1). 
The studies presented here are providing valuable insights as to how molecular pathways 
influence bone growth and accrual. Genetic variants discovered so far unveil well-known 
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bone metabolism pathways, such as the Wnt signaling pathway, but also pinpoint novel 
genes and pathways not previously implicated in bone traits.
2. GWAS Set-uP oF tHe Multi-etHniC GenerAtion r StuDy
In the last decade, GWAS have provided insights into the biological complexity of different 
diseases  (51). Chapter 2.1 describes the different challenges I coped with in setting up the 
GWAS dataset of the multiethnic Generation R Study. Back in 2011, (when the first efforts 
described in this thesis were started) the information regarding the steps for quality control, 
Figure 1. Musculoskeletal loci identified by GWAS in children and/or young populations described in this 
thesis. Loci are annotated with the most representative gene(s), as prioritized by the different GWAS publica-
tions. BMD= Bone Mineral Density, LM= Lean Mass.
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study design and analytical procedures in admixed populations was scarce, considering 
that most GWAS have been performed in individuals with Northern-European ancestry. Ex-
clusion of ethnic outliers from analyses in the Generation R Study, as was then the custom-
ary practice, was not an efficient strategy. This would have implied a high loss of statistical 
power for the study as well as a waste of resources given the large number of individuals of 
non-European origin (~50%) in the population. Likewise, the inclusion of admixed or non-
European populations in the GWAS arena is steadily growing, bringing the opportunity to 
boost power by means of increasing sample size and, additionally, allowing the assessment 
of trans-ethnic replicability of GWAS findings. In this thesis, I have demonstrated that statis-
tical methodologies (i.e., principal component analysis and linear mixed models) can suc-
cessfully correct for high population substructure potential bias. This was evidenced using 
highly stratified traits like red hair pigmentation (Chapter 2.1, (52)) and Bechet’s disease risk 
(Chapter 2.3,  (9)) as proof of principle. This was then further corroborated by the success-
ful application of the methodology across several musculoskeletal traits (Chapter 4,  (3,7,8)). 
Nevertheless, differences in minor allele frequency (MAF) and linkage disequilibrium (LD) 
across populations from different ancestries can still result, for specific variants, in a dilution 
of the effect during the association analysis (53). One such example is given in Chapter 2.1, 
where an association between rs13223036 and skull (SK-BMD) detected at genome-wide 
significance level (GWS, P<5x10-8) in individuals of non-European ancestry, did not reach 
the GWS threshold in a similar number of individuals from the European ancestry subset. 
Yet, this variant was also associated at GWS level with SK-BMD in the combined dataset. 
Therefore, the GWAS design for admixed or multi-ethnic populations involves a tradeoff 
between the size of the study panel and the possible dilution of the effect of the variant 
(assuming potential stratification control is in place). There are alternatives at the meta-
analytical level to combine data from studies of different ethnic background (54), but these 
are still not a solution for populations as the Generation R study withholding a large fraction 
of highly admixed individuals.
To note, the majority of the studies presented in this thesis are based on genotyped, or 
HapMap imputed data and consequently use common variants (MAF<0.05) in the analy-
ses. It is plausible that the effect of MAF and/or LD differences across populations on the 
association results (e.g., false-negative associations) might be accentuated at a spectrum 
of lower allele frequencies. This would occur mainly because as shown by the 1000G 
project (55), rare variants are more specific to a given ethnic group, owing to demographic 
or evolutionary forces. Consequently, less frequent and rare variants are in general less cor-
related to each other than common variants(56).
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3. loW-FreQuenCy AnD rAre vAriAntS iMPutAtion iMProveMent
Aside from the analytical challenges posed by low frequency and rare variants (MAF<0.05), 
it is of high relevance to association studies to maximize the imputation quality of these kind 
of variants, in order to provide a more comprehensive picture of genetic factors influencing 
a specific trait. Whereas the development of next-generation arrays and new and larger 
sequence-based reference panels (e.g., the Genome of the Netherlands GoNL(57), the 1000 
Genomes panel(58), UK10K  (59) or more recently the Haplotype Reference Panel (HRC)(60)) 
facilitate imputation of low frequent single nucleotide polymorphisms (SNPs) by ensuring 
sufficient coverage, the efficiency of the imputation methodology remains determinant 
to increase the number of variants for genotype-phenotype analysis, due to the stringent 
quality checks used in GWAS. In Chapter 2.2, I describe a two-step strategy to improve the 
imputation performance by adding an intermediate step, the imputation to a local refer-
ence panel, previous to the imputation to a denser reference set from broader geographic 
origin. This strategy not only increased the number of high-quality markers (r2>0.3) by 18% 
for variants in the lower frequency spectrum (MAF 0-5%) but also increased the general 
imputation quality (28% average increase) and genotype accuracy (overall accuracy up to 
97.9%)  (61). It has to be noted, however, that this strategy was tested only in individuals of 
European ancestry and using a particular reference panel (e.g., the European subset from 
the 1,000 Genomes reference panel Version 3, November 2010). The increasing quality 
and size of the reference panels available (i.e., HRC: 64,976 haplotypes (60) as opposed to 
the 362 haplotypes from European ancestry from the 1000 Genomes (55) used in the study) 
may optimize significantly imputation performance and, therefore, decrease the boost 
provided by the proposed strategy. The applicability of this strategy to admixed popula-
tions, as the Generation R Study, is limited as no “local panel” would be properly defined. 
Recently, we have employed a specialized software for imputation of admixed populations 
(e.g., MaCH-Admix  (62)), which uses effective reference panels to impute genomic regions 
based on their local ancestry. The use of this strategy resulted in a mean imputation quality 
of 95% based on 990,000 SNPs, for a combined set of Generation R and the Netherlands 
Twin Register (NTR) subsets (N~6,000) (45). This result suggests that the use of local ancestry 
aware imputation has the potential to improve imputation performance, and thus increase 
GWAS coverage and power.
4. SourCeS oF HeteroGeneity in GWAS oF PeDiAtriC 
MuSCuloSKeletAl trAitS
Up to 60 different loci have currently been described as associated, at GWS level, with 
adult BMD(63-68), most of them discovered by the large international collaboration em-
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braced by the GEnetic Factors for Osteoporosis (GEFOS) consortium in elderly adults. 
Despite this success, only ~5.8% of the estimated heritability of adult BMD is accounted for 
by 56 of these loci in a GWAS that encompassed up to 84,000 adults (64), suggesting that 
many more genetic variants remain to be discovered. It is expected that a larger sample 
size GWAS of adult and elderly individuals would unveil more variants. Nonetheless, an 
alternative strategy is to perform BMD GWAS in cohorts of children and/or young adults. 
BMD measured early in the life-course, may be less influenced by the cumulative effect of 
non-genetic (i.e., environmental or lifestyle) factors (1). Therefore, this alternative can prove 
to be more powerful as the effect of specific loci regulating bone acquisition and peak 
bone mass attainment, can be much less prominent in elderly populations (Chapters 4.1 & 
4.3). Although, presented in the context of BMD, this strategy of identifying genetic variants 
in younger populations rather than older groups, might well be applied to other traits with 
large environmental effects as lean mass (Chapter 4.4).
Another possible source of heterogeneity inherent to the analysis of BMD (providing 
both challenges and opportunities) is that the genetic determinants of BMD can exert 
site-specific effects throughout the human body, as a reflection of the intrinsic complexity 
of the skeletal system. Previous GWAS have already shown the existence of skeletal site 
heterogeneity, in which specific loci are more strongly associated with BMD at the femoral 
neck (FN) than BMD at the lumbar spine (LS) or vice versa (64,66,67). The exact reason underly-
ing this difference is still to be fully elucidated. Studies of pediatric BMD represent an ideal 
setting in which to investigate skeletal-site differences, as these routinely include total body 
(TB-) DXA scans, whereas most adult studies use DXA to measure BMD only at sites where 
fracture usually occurs (e.g., the hip, spine, and forearm). Nevertheless, since total body 
DXA is employed for the assessment of body composition, TB-BMD can also be used in an 
integrative approach in children and adults (Chapter 4.2). As performed in Chapter 4.4, the 
TB-measurement can be further decomposed in order to study BMD at sites not normally 
investigated, such as the skull (SK), lower limbs (LL) and upper limbs (UL).
The availability of healthy children with DXA measurements is less than in adult popula-
tions, constituting a limitation for the large sample sizes needed by GWAS. In Chapter 4.5, 
a multivariate approach was implemented incorporating BMD-correlated measurements 
also obtained by DXA. While this is a way to maximize power by benefiting from using the 
correlation between measurements obtained in the same scans, it also examines pleio-
tropic relations, which feature another important source of heterogeneity reflecting the 
complex genetic architecture of developmental musculoskeletal traits.
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4.1 Age-dependent effects as a possible source of BMD genetic heterogeneity
The first GWAS of TB-BMD involving the Generation R Study reported an association of this 
trait with variants in the 7q31.31 locus (3). As described in Chapter 4.1, this analysis comprised 
~2,600 six-year-old children from this study, as discovery population, and an additional five 
cohorts that represented distinct age groups, ranging from 10 – 75 years (n = 11,052). Results 
from the discovery set showed a significant association of variants in this locus with TB-
BMD and SK-BMD, that was successfully replicated across the other five studies. Variants in 
this locus, harboring the WNT16, CPED1, and FAM3C genes, had been associated with adult 
FN- and LS-BMD, in a previous GEFOS GWAS meta-analysis (64). Since then, this association 
has been replicated by us (Chapters 4.1 and 4.2) and others in several studies across diverse 
bone traits  (69-73). The sample sizes needed to detect this association signal at GWS-level 
in our analysis in children (discovery set N=2,660), and another study of pre-menopausal 
women (discovery set N= 4,061) (69) are considerably smaller than the one in the initial meta-
analysis (N=32,000), mostly composed of elderly subjects (64). In Chapter 4.1, in the SK-BMD 
GWAS, but not in the TB-BMD analysis, I describe the age heterogeneity of rs7801723, an 
SNP mapping to CPED1, with a larger effect in young populations, that seems to mimic the 
natural trajectory of BMD, decreasing with age after peak bone mass attainment. Nonethe-
less, there was not statistical evidence for the effect of variants in this locus to be different 
between children and adolescents (4-15 years; N= 11,800), and the elderly population (>60 
years; N=20,300) in the TB-BMD GWAS meta-analysis following a life-course approach 
(Chapter 4.3). However, ten variants from this locus were nominally significantly (P<0.05) 
different between the two groups. Interestingly, those variants mapping in the vicinity of 
the 3’-end of CPED1 had effects 1.8 times larger in the elderly as compared to the children 
and adolescents, while those elsewhere in CPED1 had effect sizes almost two times larger in 
children as compared to the elderly individuals.
In Chapter 4.1, via conditional analysis, the existence of allelic heterogeneity (at least two 
different signals) in this locus was demonstrated, sheding some light on the understanding 
of the seemingly contradictory results described above. In addition to variants in this com-
plex locus, in Chapter 4.3, age-dependent effects for variants mapping within or near ESR1, 
RIN3, RANKL and other loci were found, most of them showing the strongest associations 
in children. Variants in the ESR1 locus had pretty weak associations with BMD in children. 
This is likely explained by the majority (>80%) of children in this group being pre-pubertal 
with low sex hormone level and not expected to play a role on BMD levels. Whereas in 
adults estrogen and sex hormones are key regulators of bone. The origin of the age effect 
heterogeneity underlying the other two loci remains to be elucidated.
As shown by the findings described in this thesis, age is an important source of hetero-
geneity in the effect estimate of genetic variants assessed by meta-analysis. This can also 
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be reflected on less power for the discovery of genetic associations and restrict the prob-
ability of success for replication of true findings (Chapter 4.3). Age-dependent effects have 
been assessed in GWAS by the introduction of “age X SNP” interaction in the association 
models  (74). The main drawback of this strategy is the need of cohorts with a sufficiently 
broad age range to contribute valuable information to a large meta-analysis. Accordingly, 
relationships as the ones displayed in Chapter 4.1 or Chapter 4.3 will most likely not be 
captured by that approach. In Chapter 4.3,  the effect of the majority of the loci associated 
with BMD displaying a high degree of age heterogeneity was smaller in older adults than 
in the pediatric population. This suggests that the study of BMD and other complex traits 
with a large influence of lifestyle factors in young populations will increase power for the 
discovery of associated genetic factors as also shown for blood pressure  (49) and BMI  (75). 
A better understanding of age-dependent effects would also provide insight into the role 
of gene-environment interactions in the determination of complex traits as accumulative 
effects of most of the environmental factors evaluated so far (i.e., smoking (76,77) or physical 
activity (78,79)) relate to aging.
4.2 Site-specific effects as a possible source of BMD genetic heterogeneity
As mentioned above, the first time the 7q31.31 locus was reported as associated with BMD 
was in a meta-analysis including more than 32,000 individuals, comprising adult and elderly 
populations part of the second GEFOS meta-analysis (64). However, no variants in these loci 
were identified in the first GEFOS effort encompassing 19,195 subjects in 2009 (63). So, the 
larger sample size required to detect the signal in the elderly is in contrast to the smaller 
sample size required to identify the same GWAS signal in younger populations. Although 
these results point to age-specific effects, I show in Chapter 4.3 a GWS association mapping 
to this region with TB-BMD in about 20,000 individuals >60 years old. Moreover, Zheng 
and colleagues also depicted the association at forearm (FA-) BMD in 5,672 individuals 
around their fifth decade of life (73). Therefore, skeletal site-specificity might be underlying 
the larger power of our study. Indeed, the second GEFOS and our meta-analyses were 
performed assessing distinct skeletal sites (e.g., LS-, FN-BMD vs. TB-BMD).
In Chapter 4.4, I explored the heterogeneity underlying skeletal site-specificity in the 
BMD-association analyses. It was found that, in children, BMD heritability estimates differ 
across skeletal sites. Actually, common variants explained a larger proportion of the overall 
BMD-variance at the skull as compared to BMD measured at the appendicular sites (UL- 
upper limb and LL- lower limb). Moreover, there was a higher genetic correlation between 
BMD measured at the appendicular sites (UL-BMD and LL-BMD) than between any of 
these measurements and SK-BMD. This observation could reflect the differential exposure 
of each skeletal site to varying environmental stimuli that influence BMD. Specifically, the 
skull may be less influenced by factors acting through mechanical loading, as compared to 
Chapter 6
324
appendicular sites. Similarly, these differences could be a consequence of the biological 
processes that govern growth and maintenance of the bone at these sites (e.g., intramem-
branous ossification at the skull and endochondral ossification at the long bones) or reflect-
ing the composition of bone at each skeletal site (e.g., trabecular vs. cortical fraction). For 
instance, variants upstream of the EYA4 gene, which are not associated with BMD at other 
skeletal sites, are strongly associated with SK-BMD (7).
Even if the biological mechanism driving this association is still unknown, variants in the 
same locus have been associated with cortical volumetric BMD, assessed by peripheral 
quantitative computed tomography (pQCT) at the tibia in children and young adults  (80), 
supporting the role of this locus on bone metabolism. In addition to EYA4, variants showing 
site-dependent effects located within or near TNFRSF11A, TNFRSF11B, RSPO3, and LGR4 were 
found. Most interestingly, the locus CPED1/WNT16 displayed once more complex patterns 
of association in this study. Variants located closer to CPED1 were associated with SK- and 
UL-BMD, but not with LL-BMD; whereas variants at close proximity or within WNT16 were 
most strongly related to UL-BMD when compared to the LL- and SK-BMD. This is in line 
with the allelic heterogeneity described above.
Importantly, I demonstrated in Chapter 4.2 that TB-BMD is a suitable phenotype for the 
identification of genetic factors influencing BMD. Through the study of this phenotype, 
53 different loci were detected, many of them previously reported in the literature and 
showing site (e.g., LS-, FN-, FA-BMD) or compartmental specificity (e.g., trabecular bone, 
cortical bone). I also described novel loci, whose role on bone  metabolism remains to be 
elucidated, although with a large fraction enriched by genes involved in the WNT-pathway. 
Taken together, all the independent variants identified in this chapter explained approxi-
mately 8% of the TB-BMD variance, suggesting that larger GWAS would still provide the 
opportunity for finding many more variants associated with this TB-BMD trait.
4.3 Genetic pleiotropic effects of BMD and lean mass
There is an evident mechanical interaction between bone and muscle mass, and also at a 
molecular level, biochemical cross-talk. Consequently, it is likely that genetic factors have 
pleiotropic effects, influencing both muscle and bone phenotypes. Lean mass (LM) or fat-
free mass is highly correlated with muscle mass and derived from the same DXA scan as TB-
BMD, allowing the study of variants exerting simultaneous effects on both bone and muscle 
development. Modeling simultaneously two correlated phenotypes increases the effective 
sample size for analysis, providing a crucial improvement in statistical power of GWAS. This 
strategy was followed in Chapter 4.5, where I describe a bivariate analysis of TB-BMD and 
TB-LM yielding eight GWS signals of association mapping within or near WNT4, GALNT3, 
MEPE, CPED1/WNT16, PPP6R3/LRP5, and TOM1L2/SREBF1. The association with TB-BMD 
drove for a large fraction the GWS signals of these implicated variants except for those 
325
General Discussion
mapping to the last two loci. Whereas, there is evidence of association in the bivariate 
analysis for PPP6R3/LRP5 for TB-LM (P<10-6), the association of this locus is stronger with TB-
BMD (P<10-9). There is robust evidence supporting the role of LRP5 in mechanotransduc-
tion (reviewed elsewhere (81)), what might explain the bivariate association observed in our 
analysis. Conversely, the association arising within the TOM1L2/SREBF1 locus was driven by 
both TB-BMD (beta=0.043SD; P=2x10-3) and TB-LM (beta=-0.056SD; P=5.5x10-5), although 
stronger in the latter. Noteworthy, by comparing results from this study I confirmed that the 
bivariate analysis outperforms the univariate analysis, particularly when the direction of the 
effect is opposite in sign (82).
Examining further the TOM1L2/SREBF1 locus, substantial evidence pointing to SREBF1 being 
the gene underlying this association was collected. Active SREBP-1, the product of SREBF1, 
is known as a negative regulator of myogenesis  (83) and protein synthesis in differentiated 
myotubes  (84). Similarly, a high concentration of the active form of this protein induces 
mineralization of osteoblastic cultures in-vitro and bone formation in-vivo  (84). Therefore, 
the cross-phenotype association suggests biological pleiotropy, meaning the same gene 
causing different effects across different tissues. Nevertheless, in-vitro or in-vivo models 
evaluating both muscle and bone simultaneously are needed to determine if the effect 
of the associated allele is direct or indirect in both myogenesis and osteoblast mineraliza-
tion. Overall, SREBP1 affects both bone and muscle tissues yet in opposite directions; this 
contention is in  agreement with the opposite effect of the leading SNP observed in both 
univariate and bivariate association analyses.
It is important to highlight that the genetic architecture underlying muscle mass remains 
predominantly unknown and consequently, there is considerable room for genetic 
discoveries. Unfortunately, considering that large GWAS meta-analyses have yielded a 
limited number of associated loci with muscle traits (i.e. lean mass, muscle strength), in-
novative analytical methodologies (like bivariate/multivariate analysis) would be proven 
fruitful. Genes associated with LM as FTO  (85), and SREBF1 (Chapter 4.5) are also known to 
be key factors in adipogenesis. This implies that a multivariate analysis including the third 
major component of body composition, body fat, would increase our understanding of 
both muscle and bone metabolism and in general, of human physiology. Alternatively, 
additional analytical models managing to reduce the phenotypic variance of muscle mass 
by including important cofounders as physical activity, for example, should be explored. 
Early this year Korostishevsky and colleagues implemented a combined metabolomics and 
genomics approach to study lean mass, setting an example of integrative alternatives for the 
discovery of genetic polymorphisms associated with LM (86).
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4.4 trans-ethnic genetic studies of BMD
I explained above the challenges in the GWAS set-up of multiethnic studies. In Chapter 5, in 
turn, an original approach to study the well-documented racial differences in BMD (87-92) by 
combining genomic and evolutionary methods was proposed, profiting this way from the 
ethnic heterogeneity intrinsic to the Generation R Study. It was found that indeed, children 
of Sub-Saharan ancestry had significantly higher levels of TB-BMD when compared with 
children of European or East-Asian ancestry. This result was mirrored at the genetic level af-
ter it was confirmed that the compound effect of variants associated with BMD in adults(64) is 
associated with infant BMD. The frequency of those alleles associated with increased BMD 
was systematically elevated in individuals of Sub-Saharan African ancestry, observation that 
was paralleled across a worldwide population distribution (i.e. Human Genome Diversity 
Panel  (93)). Certainly, it is also possible that variants, not captured by the current GWAS in 
European populations, may contain an additional set of alleles contributing to BMD varia-
tion in African or Asian populations. The overrepresentation of ancestral alleles in the set of 
alleles increasing BMD indicates that phenotypic states related to increased BMD represent 
the ancestral state in humans. Studies of hominin fossil records have reached similar con-
clusions for phenotypes as bone stiffness (94) or high trabecular density (95). Most importantly, 
they have provided strong evidence that the gracility of modern humans is the result of 
decreased biomechanical loading due to a tendency to ever increasing levels of sedentari-
ness (96). As the amount of BMD differentiation between sub-Saharan and not sub-Saharan 
populations, cannot be uniquely explained by demographic factors, the presented results 
are compatible with the hypothesis of selective pressures acting on the genetic determi-
nants of BMD, thus, providing a new example of polygenic adaptation to a human trait (8).
Trans-ethnic efforts have traditionally used admixture mapping to foster the discovery 
power in admixed populations  (97). Admixture mapping might be applied to populations 
that have recently undergone gene flow from two ancestrally isolated populations, when 
these ancestral populations differ both in allele frequencies and disease prevalence, as 
usually applied to case-control designs(98). In Chapter 2.1, I acknowledge that the complex 
structure of the Generation R Study, where admixture of individuals cannot be easily 
discerned just by assessing the combination of two ancestral populations, constrains the 
use of this technique. Nevertheless, in Chapter 5, following a similar approach based only 
on participants with European Ancestry, it was shown that the proportion of genetic Sub-
Saharan African ancestry in their genomes was associated with higher BMD levels.
As the catalogue of genetic variation in the non-European subpopulations increases, and 
the sample size of BMD-GWAS for these populations enlarges, we would get a more com-
plete picture of the genetic factors underlying ethnic BMD variation and partially explaining 
disparities in fracture risk worldwide.
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5.  ePiDeMioloGiCAl AnAlySeS oF tHe HeteroGeneity oF Bone 
AttAinMent
5.1 Sexual dimorphism of bone density and strength
Along with the skeletal changes associated with age, there is a pronounced sexual di-
morphism in the skeletal system. In Chapter 3.3, I investigated this kind of heterogeneity 
between sexes from an epidemiological perspective. However, SNP-sex interaction at a 
large scale was not evaluated in any of the studies presented in this dissertation. Sexual di-
morphism in genetic loci has been evaluated for BMD previously in powerful settings (64,99) 
and only variants mapping to the X chromosome, not scrutinized in our association studies, 
showed statistical evidence of sex-dependent effects (64).
Bone development processes alter the amount of bone tissue within bones as well as its 
spatial distribution. Both of these parameters contribute independently to explain bone 
strength. Sexual dimorphism in bone strength is evident in the elderly population, confer-
ring higher osteoporotic fracture risk to women. The risk of fragility fractures is 2.5 times 
higher in women compared to men (100). In Chapter 3.3, I investigated pediatric hip geom-
etry, by implementing the Hip Structural Analysis (HSA) software for analysis of the hip DXA 
scans of the participants of the Generation R Study. It was found that there are significant 
differences in the bone structure, even at pre-pubertal age, between boys and girls. Girls 
have thinner cortices and wider femurs, a configuration that confers their bones greater 
stress  (101). This study suggests that both men and women construct their bone differently 
since an early age, and girls have an innate structural disadvantage with respect to boys. 
Yet, such sex differences are attenuated after adjustment by lean mass. This indicates that 
the sexual dimorphism of bone is partly explained by differences in muscle mass. In line 
with these findings, a recent study on children of the same age showed that longitudinal 
changes in lean mass predict tibial bone geometry and mineralization, as assessed by 
pQCT(102). In sum, these results highlight the importance of the establishment of exercise 
programs during the pre- and peri-pubertal years. These programs would be particularly 
beneficial for girls, as they have on average lower physical activity than boys of their same 
age  (103) and “weaker” bone configurations. Indeed, different investigations have demon-
strated that intervention strategies, targeting physical activity at early ages result in gains 
in peak bone mass that persist throughout life(104,105). Noteworthy, palaeontological studies 
have allowed researchers to implicate patterns of physical activity, rather than nutrition, 
as the most important factor influencing the decrease in bone strength in modern human 
populations(96), as also discussed in this section.
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5.2 Parental, fetal and infant determinants of bone accrual
In Chapter 3.2, the relationship between early growth patterns and childhood bone mass 
was evaluated. It was found that both fetal growth and infant growth independently contrib-
ute to explain bone mass variability at school-age. Furthermore, growth during the first year 
appeared to have the largest impact on bone mineral accrual at age six years. This relation 
between longitudinal growth and bone accretion might be, at least partially, mediated by 
an overlapping genetic architecture of these traits, or the hormonal levels that govern skel-
etal growth, which also (to a large extent) are genetically determined. To demonstrate this, 
assessing the genetic correlation between growth and bone parameters (like height and 
BMD) is needed. Nevertheless, the calculation of the genetic correlation between height 
and BMD might prove difficult as DXA measurements of pediatric BMD must be adjusted 
by size to avoid biases due to area changes during skeletal development and growth.
Chapter 3.1 focused on evaluating the effect of maternal first-trimester diet, a modifiable 
factor, on bone parameters at school age, we found a positive effect of diverse dietary 
nutrients like calcium and protein intake, homocysteine and vitamin B-12 blood concentra-
tions and maternal phosphorus on the bone of the offspring at 6 years(106). While maternal 
levels of calcium and phosphorous, the main bone forming minerals, and protein intake, 
a component of the organic bone matrix, are thought to exert a direct effect on the early 
fetal skeletal growth, other molecular mechanisms may play a significant role. For example, 
maternal dietary intake is known to modulate the fetal epigenome(107). Nutrients can reverse 
or change epigenetic marks such as DNA methylation and histone modifications, thereby 
modifying gene expression(108). For instance, vitamin B-12 can act as a methyl donor and 
accordingly affect the DNA-methylation patterns(107). Likewise, protein intake is associated 
with reduced methylation of the glucocorticoid receptor in mice experiments(109). Based 
on all these findings, it is clear that epigenetic mechanisms (further discussed below) will 
constitute a next step to understand the regulatory mechanisms underlying peak bone 
mass acquisition.
Altogether, these results (e.g., a positive relationship between early growth and bone mass 
at school age) show how early life processes can “track” bone development at later ages. In 
addition, they confirm the beneficial effect of a balanced maternal diet during pregnancy, 
including minerals, vitamins and proteins, in the offspring bone health with effects lasting 
at least to their school-age. The post-natal nutrition during the first years might be just as 
important as maternal diet. Notwithstanding, it was found the growth during the first year 
to be an important determinant of bone health at six years. There is also evidence that the 
trajectory of skeletal growth may be modified by factors as nutrient availability. While in the 
analysis presented in Chapter 3.1, we adjusted for breastfeeding, no evaluation of the ma-
ternal nutritional status or an assessment of other nutrients consumed by the infant during 
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this post-natal period that might affect bone homeostasis were included. In an additional 
study assessing nutrition at 13 months in participants of the Generation R Study (N=2,850), 
we found that adherence to a diet pattern rich in whole grains and dairy was positively 
associated with BMD at six years(110). Hence, fetal and early post-natal nutritional exposures 
may permanently influence bone development.
6.  FunCtionAl FolloW-uP oF loCi WitH PutAtive CliniCAl 
relevAnCe
Studies in Chapter 4 highlighted the influence of WNT16 in bone mass acquisition. Most 
clinically relevant, WNT16 has been associated with risk of any type (64) and forearm (73) frac-
ture. This scientific evidence has led to a number of functional studies characterizing the 
important role of WNT16 in skeletal regulation. Wnt16 knockout (KO) mice had reduced 
total body BMD, and gene expression profiles in human bone biopsies supported a role 
of both CPED1 and WNT16 on the BMD phenotypes (Chapter 4.1). The initial hypothesis 
of WNT16 influencing cortical bone, as the associated traits were mainly cortical (e.g., TB-
BMD, skull BMD, femoral neck BMD, forearm BMD), was confirmed by KO-mice develop-
ing spontaneous fractures as a result of low cortical thickness and high cortical porosity(111). 
No trabecular phenotype was observed in these mice. Likewise, mechanistic studies 
revealed that WNT16 is predominantly expressed in osteoblasts, in the cortical bone mi-
croenvironment, and inhibits osteoclastogenesis (111). However, as a matter of fact, the most 
recent study of this molecule found that overexpression of Wnt16 results in higher TB-BMD 
in mice, particularly at expenses of higher trabecular bone mass(112). Therefore, this work of 
Mòverare and colleagues demonstrated that the loss of endogenous Wnt16 results spe-
cifically in cortical bone loss, whereas its pharmacological overexpression increases mainly 
trabecular bone mass  (112). As WNT16 signaling in bone does not require normal estrogen 
action, it may be useful for the treatment of postmenopausal trabecular bone loss, which is 
accelerated in menopausal women (112).
The clinical translation of this GWAS finding will be particularly meaningful as most of the 
pharmacological treatments for osteoporosis function as anti-resorptives that halt further 
bone loss. Only one osteoanabolic drug (i.e., Teriparatide) is presently FDA approved; 
however, it is far from ideal as it is very expensive and requires daily administration via 
injection to ensure adequate bone formation (113).
While mapping the same locus as WNT16, CPED1 has received less attention from the 
bone research community. Nonetheless and in line with the allelic heterogeneity in this 
locus, where at least two independent signals are influencing bone accrual, Cped1 is highly 
Chapter 6
330
expressed in osteoblasts isolated from neonatal C57BL/6J mice and robustly correlated 
with the expression of genes that compose the extracellular matrix in the work led by Dr. 
Ackert-Bicknell. Also, she and her group are performing functional follow-up in knockout 
mice models at the University of Rochester, NY (114).
7. Future PerSPeCtiveS
7.1 refinement of the phenotype
The main disadvantage of DXA is its two-dimensional methodology of a 3D structure, which 
results in areal density estimates of a true volumetric BMD. By using this 2D technique, 
it is impossible to differentiate trabecular from cortical bone, and even more challenging 
to assess geometric and micro-architectural properties that modulate bone strength (i.e., 
periosteal expansion, cortical density and thickness, and trabecular number and thickness). 
In contrast, pQCT offers density values independent of bone size as well as measurements 
at cross-sections of predominantly cortical or trabecular bone, enabling different constitu-
ents of bone mass to be analyzed separately (e.g., cortical and trabecular volumetric den-
sity (vBMD)). Nowadays, pQCT is increasingly being used to study determinants of bone 
strength, even at the genetic level (80,115). Most importantly, pQCT enables the study of the 
bone-muscle unit, as from the muscle cross-section, area and density are also measured. 
Nevertheless, given the high radiation dosages intrinsic to CT, assessments are limited to 
peripheral body regions (e.g., tibia or forearm).
The new round of assessments of the Generation R Study starting in 2015, in which par-
ticipants are in average nine years old, has implemented pQCT measurements. Likewise, 
the inclusion of jumping mechanography can go beyond the evaluation of the musculosk-
eletal structure to evaluate its actual function (i.e. muscle strength and power).
The combination of pQCT -and mechanography- derived information, will allow the 
investigation of the functional muscle–bone relationships, as performed before  (116), in a 
powerful pediatric setting. Overall, measurements derived from these assessments would 
help to elucidate further the role of muscle in the sexual dimorphism of bone. In the same 
way, the study of pleiotropy (Chapter 4.5) could benefit from the refined phenotypes 
obtained by these techniques.
7.2 longitudinal assessment of bone accrual
The results presented in this thesis are in agreement with the notion that both, genetic 
and environmental factors are interconnected and determine bone metabolism. The 
contribution of these factors as causal explanations in the variability of bone accrual is best 
studied from a longitudinal perspective, with the additional benefit of testing their impact 
on bone accrual rate. The Generation R Study has DXA-measurements of bone mass at six 
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months in a subset of 252 individuals (117), what has somehow limited our power to conduct 
a follow-up study at six years of age. Besides the measurements at six years (school age 
period), follow-up measurements are currently taking place (focus at 9) and programmed 
again when participants will have a mean age of 13 years. The acquisition of this prospective 
data, can provide a better framework to test the effect of lean mass in bone mass acquisi-
tion, or the evaluation not only of mother nutrition but infant nutrition in the rate of bone 
accrual. Moreover, studies analyzing the effect of BMD-associated SNPs in the rate of bone 
accrual from 9-13 years, identified loci not necessarily detected in the cross-sectional pedi-
atric studies presented here (118). Similar approaches have been applied to understand the 
interaction of these BMD-SNPs with sex and or maturation status (119,120). While the signals 
detected by these studies are not novel and are captured by our life-course approach, the 
longitudinal study of their effect in the Generation R Study may contribute a missing piece 
to the bone accrual puzzle.
7.3 enhancement of bone-related GWAS
The GWAS of bone traits of children and young adults have already proven its value. Never-
theless, our current knowledge concerning the impact of genetic factors in the determina-
tion of pediatric bone health may still be limited due to the lack of availability of other large 
pediatric cohorts with GWAS data. Also, the dynamic nature of BMD (i.e., changes with 
age), particularly during the growth years, and the influence of several other modifiable fac-
tors like physical activity and nutrition might decrease the statistical power of GWAS for this 
trait. Nonetheless, it remains critical that we stay on the path of uncovering the complete 
genetic architecture of pediatric BMD. One obvious route forward is to extend the number 
of studies involved in the research of genetic factors affecting bone accrual. As the price for 
GWAS genotyping is steadily declining, this array technology can soon be within reach for 
cohorts that at this moment have only collected bone measurements and DNA.
In addition, the availability of larger reference panels including samples from diverse popu-
lations and deeper sampling within populations like the Haplotype Reference Consortium 
(HRC)(60) would permit more accurate imputation of GWAS cohorts. The benefits will be 
greatest at low-frequency variants (MAF<0.05) since there is a higher chance for these vari-
ants to be poorly represented in smaller reference panels, and for studies in more ethnically 
diverse settings. The Generation R GWAS data has already been imputed to this panel. Ac-
cording to the developers, using this resource will lead to accurate genotype imputation at 
MAF as low as 0.1%, and a large increase in the number of SNPs tested within association 
studies  (60). Performing GWAS across very large samples of children and young adults im-
puted to reference panels of extended variant coverage would make possible to identify the 
great majority of genetic variants that are responsible for the variation in bone acquisition, 
as recently suggested for other complex traits such as body height or body mass index (75).
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Alternatively, studies are applying other technologies such as whole-exome sequencing 
(WES) or whole-genome sequencing (WGS) to explore further the genetic architecture of 
complex traits. WES reads represent only ~2% of the genome, reducing storage and analysis 
cost. Nonetheless, many variants of interest map to non-coding regions and are not in LD 
with coding exons, hence not being captured by WES. The importance of these non-coding 
variants has been recently recognized, thanks to the ENCODE project (121), as they play an 
essential role in the regulation of gene expression and thus, in the observable phenotypic 
differences. Therefore, in contrast to the success observed for the mapping of monogenetic 
conditions, WES is not expected to yield much for the identifi cation of genetic variants 
underlying complex traits, like BMD and other musculoskeletal phenotypes. WGS, on 
the other hand, allows the examination of non-coding and coding regions even though 
the generation of larger data signifi cantly increases the computational burden for analy-
sis. In osteoporosis research, a handful of BMD-associated variants with MAF<0.5% has 
been identifi ed through the analysis of a combination of WGS data and imputed-GWAS 
data (65,66,68). At this moment, the real benefi t of sequencing approaches will only be seen 
through its application in large consortia efforts.
7.4 novel omics technologies
While this dissertation has focused on genomics as charactherized by GWAS data, epi-
genetics and transcriptomics provide extra layers of information of the multiple levels of 
cell regulation that ultimately generate the observable phenotypic variability (Figure 2). 
These data sources are dynamic in nature and thus, feature high variability, not only at the 
individual level but also within an individual, for instance, at the tissue level. This dynamic 
attribute poses new challenges, from collecting sample sizes large enough to overcome the 
inherent error introduced per-se by the variability of the data, to the tissue-specifi city of its 
Figure 2. Scheme of the omics space. Integration of the different omics to defi ne human phenotype.
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signatures. On the top of these issues, the identification of the tissue most relevant to the 
disease/trait under investigation is not a straightforward task. Hence, there is undoubtedly 
a need for enlarging initiatives as GTEx(122), capturing gene expression in different human 
tissues or even further generate of a cell-specific omics atlas.
DNA methylation is key during human fetal development. Therefore, this data is essential 
in the study of early environmental and genetic causes of normal and abnormal growth, 
development and health from fetal life until young adulthood (123), the aim of the Genera-
tion R Study. In the immediate future, it will be possible to take advantage of the deep phe-
notyping of mothers and children acquired in this study for the investigation of differential 
methylation patterns as a link between environmental factors and trait variability. The 
Generation R Study methylation data is available for a subsample of around 900 children, 
collected from umbilical cord white blood cells. This small sample size provides limited 
statistical power for an hypothesis-free approach; nonetheless, it has already been used 
in association with specific genes(124). Opportunely, the Pregnancy And Child Epigenetic 
(PACE) consortium is pulling a big effort to bring together all birth cohorts with methylation 
data, providing sufficient statistical power to perform genome-wide methylation surveys.
Similarly, there are ongoing efforts to characterize the association of the microbiome with 
phenotypic variability in which, with no doubt growth and bone health are to be inves-
tigated  (125). For instance, recent studies have demonstrated that gut microbiota regulates 
bone health via effects on the immune system in mice, which in turn regulates osteoclas-
togenesis (126). Microbiome data from more than thousand participants of Generation R is 
currently being generated. As exploited by the GWAS approach described thoroughly in 
this thesis, the multiethnic nature of the Generation R Study will result in diverse challenges 
as well as opportunities for the analysis of microbiome data. With regard to the latter, some 
of the most interesting research questions will relate to obtaining a better understanding of 
health disparities across ethnic groups. Like for every new technology, in the microbiome 
field, new analytical frameworks and replication strategies are required. Therefore, some 
time will pass before it is feasible to apply such approximation on population-based studies 
in thousands of individuals.
Alternatively, the ENCODE project (121) has generated results of several experiments across 
the genome, epigenome and transcriptome for the evaluation of DNA methylation (e.g., 
Methyl RRB-seq), Open chromatin (e.g., DNase-seq), RNA binding proteins (e.g., RIP-
seq), RNA profiling (e.g., RNA-seq), Transcription factor binding sites and histones (i.e., 
ChIP-seq), that are publicly available. The integration of this data into meta-dimensional 
analyses, even if still to be fully developed will unravel complex biological processes (127).
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8. ConCluDinG reMArK
In this thesis, I have approached the etiology of bone health outcomes from different 
perspectives. The presented results show that modifiable factors, prone to interventions, 
as maternal diet and post-natal nutritional exposures influence bone development. The 
presented findings stress the importance of exercise programs from pre-pubertal ages to 
build up strong bones, particularly in girls. We have been pioneers in the use of GWAS to 
identify genetic factors influencing bone mineraIization in children. Many of the genetic 
variants associated with BMD in adults, have effects on bone since an early age and the 
strategy of investigating young populations in several cases could provide gains in statisti-
cal power for gene discovery. Additionally, I have shown the complex manners in which 
genetic factors influence bone, varying by skeletal-site or age of evaluation or even exerting 
pleiotropic effect. This thesis has brought new ideas to the horizon of bone research as a 
result of the study of pediatric populations, the implementation of new statistical methods 
and the embracement of an evolutionary perspective to the traditional genetic studies. This 
research provides a first glance to the genetics of bone accrual and highlights the impor-
tance of a healthy lifestyle for early life for bone health, which could effectively reduce the 
risk of osteoporosis later in life.
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Bone accrual during childhood and adolescence largely determines the peak (maximal) 
bone mass achieved approximately in the third decade of human life. This process is es-
sential to assess the risk of fracture throughout life. Therefore, understanding the factors 
influencing bone accrual is crucial to design strategies aiming to prevent the early onset of 
osteoporosis and low bone mass later in life. To date, a considerable amount of literature 
has been published on lifestyle choices that influence peak bone mass. Physical activity 
and infant calcium intake are the strongest factors for which there is evidence of a posi-
tive effect on bone growth and mineralization. In addition, genetic studies in families have 
demonstrated that more than 50% of the variability of bone mineral density (BMD) is at-
tributable to genetic variants and that this heritability tends to decrease with age, probably 
as a result of the accumulation of environmental perturbations over many years.
As described in Chapter 1, throughout this thesis we aimed to disentangle the multifacto-
rial process of bone accretion in children by assessing the influence of factors like genetic 
background, fetal exposures and infant body size and composition on bone status in chil-
dren at school age. The studies of this thesis are embedded in the Generation R Study, a 
multiethnic population-based prospective cohort study from fetal life onwards, based in 
Rotterdam, The Netherlands.
In Chapter 2, the methodological framework to perform genome-wide association studies 
(GWAS) in admixed populations is detailed. In Chapter 2.1, an exhaustive description of 
the Generation R genetic data generation and possible analysis procedures to cope with 
its multiethnic nature. The generation of this data for 5,732 participants of Generation R 
has contributed already to at least 50 publications in fields as diverse as kidney research, 
childhood growth or infant behavioral problems. In Chapter 2.2, we propose a imputation 
method which adds an intermediate step, the imputation to a local reference panel, prior 
to the imputation to a denser reference set from broader geographic origin (e.g., two-step 
imputation). This method improved in 28% the quality of the imputation, representing 
an increase of 18% in the number of genetic markers to be surveyed by GWAS studies, 
compared to the traditional one-step imputation method. In Chapter 2.3, we use the 
Generation R genetic data from an admixed background as a suitable set of controls for the 
study of genetic factors influencing the risk of the low prevalent Behçet’s disease in which 
cases were from different genetic ancestries. By using linear mixed models and principal 
component adjustment strategies, we were able to replicate the association of variants in 
the HLA locus, already reported in homogeneous populations of Asian origin, as well as 
identify a novel association mapping to an intronic region in IL2A.
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Chapter 3 is dedicated to epidemiological studies of pediatric BMD. In Chapter 3.1, we 
show that factors influencing bone status at school age date back to fetal life. Maternal 
phosphorous intake and homocysteine concentrations strongly influence the amount of 
bone mass at six years, whilst vitamin B-12 concentration and protein intake predicted 
BMD levels. In Chapter 3.2, we prove that both fetal growth and infant growth contribute 
independently to bone mass at six years of age, with the first year of age being the most 
critical period in the contribution. In Chapter 3.3, we make emphasis on bone geometry, 
another parameter that together with bone mass determines bone strength. Our results 
indicate that on average the femur of boys has better resistance to axial and bending forces 
in comparison to girls. However, these sex differences were partially explained by differ-
ences in the amount of muscle mass between boys and girls. Considering the evidence 
of this and other studies, we promote the establishment of exercise programs during the 
pre- and peri-pubertal years, particularly for girls whose bones have a relatively “weaker” 
configuration.
In Chapter 4, we focus on genetic studies of pediatric BMD. In Chapter 4.1, we identified 
a strong association signal for pediatric BMD in the 7q31.31 locus. WNT16 and CPED1 are 
the genes underlying this association and different variants mapping in these two genes 
influence both total body less head (TBLH-) BMD and skull BMD. By means of conditional 
analysis, we found that at least two different signals arise from this genomic region and that 
their effect on skull BMD could vary with aging. Most importantly, Wnt16 knockout (KO) 
mice had reduced total body BMD and gene expression profiles in human bone biopsies 
support a role of CPED1 and WNT16 on the BMD phenotypes observed at the human 
population level. Altogether we provided different lines of evidence for the role of these 
molecules in the process of bone mineralization. In Chapter 4.2, we demonstrate that TB-
BMD is a relevant trait for genetic studies of bone quality not only in children but also in the 
general population and thus suitable for the study of osteoporosis. We identified variants 
known to influence different bone compartments at different skeletal sites. Moreover, we 
identified 18 novel genetic loci influencing BMD variation: 1p13.3 (CSF1), 2p11.2 (TCF7L1), 
2p22.1 (SLC8A1), 2q33.1 (FZD7), 5q22.2 (APC), 5q23.2 (CNK1G3), 7p14.3 (AQP1), 10q26.13 
(BTBD16), 11p13 (LDLRAD3), 11p15.5 (RIC8A), 12q21.33 (ATP2B1), 12q21.33 (BTG1), 15q14 (TM-
CO5A), 15q22.33 (SMAD3), 16q22.3 (ZFHX3), 17q24.1 (CEP112), 20q12 (MAFB) and 21q22.12 
(RUNX1). Several of these regions code for factors embedded in Wnt signaling, yet the 
possible role of others remain to be elucidated. In Chapter 4.3, we analyse the same TB-
BMD data but stratifying by age-bins of 15 years. This manner of analysing the data reached 
three additional association signals. One mapping to the 14q32.12 (RIN3) evident only in 
children, another one in 11p15.1 (PTPN5) evident in the 30-45 years group, and the third one 
in 7q22.1 (ZNF789/ZSCAN5) evident only in the old adults (e.g., >60 years). Moreover, we 
found variants in different loci whose effect magnitude depends on age, most of them with 
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larger effects in children. The strongest evidence of this varying effect with age came from 
variants located in 14q32.12 (RIN3) and 6q25.1 (ESR1/CCDC70). In Chapter 4.4, based on pe-
diatric populations we pinpoint genetic factors whose relative contribution to explain BMD 
variability was uneven across skeletal sites. The genetic correlation between appendicular 
sites was higher than the one reported for each of these sites and the skull. We described 
thirteen different loci associated with BMD in one or more skeletal sites (i.e. SNPs at WNT4, 
GALNT3, CPED1/WNT16/FAM3C, RSPO3, FUBP3, PTHLH, TNFSF11, TNFRSF11B, TNFRSF11A, 
LRP5, LGR4, RIN3 and EYA4). In Chapter 4.5, we found evidence for genetic variants within 
or nearby SREBF1 exert effects on bone and muscle tissues simultaneously and in opposite 
directions. Using publicly available databases we compiled evidence that these SNPs could 
regulate the expression of SREBF1, whose product SREBP-1 indeed downregulates muscle 
cell differentiation, while also increasing the number of mineralized foci in osteoblasts.
In Chapter 5, we confirmed that at school age children from African ancestry have higher 
BMD levels than their counterparts from European or Asian ancestry. We found that the 
combined effect of variants reported in literature as associated with BMD in adults was 
significantly associated with pediatric BMD, suggesting that many of these variants exert 
effects in bone since early age. Children from African background were found to carry a 
higher number of BMD-increasing variants than children of non-African background, sug-
gesting that the known BMD ethnic differences are at least partially from genetic origin. 
This result was parallel by comparing genetic data from different populations worldwide. 
Moreover, after applying multiple cutting-edge evolutionary analyses, we found evidence 
pointing to natural selection as the engine driving these genetic patterns.
Finally, in Chapter 6, the results are interconnected and discussed more generally. Also, 
methodological issues regarding the studies contained in this thesis are elaborated. Impli-
cations of our findings and future directions for research are also presented in this chapter.
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Botvorming en groei bij kinderen bepaald grotendeels de maximale hoeveelheid botmassa 
die wordt verkregen, meestal in het derde decennium, tijdens het menselijke leven. Dit 
proces is essentieel voor het risico op botfracturen tijdens het leven. Het is daarom cruciaal 
om te begrijpen welke factoren een rol spelen bij deze botvorming, en hieruit strategieën 
te bedenken om de eerste symptomen van osteoporose en lage bot dichtheid als volwas-
sene te voorkomen. Een aanzienlijke hoeveelheid literatuur is gepubliceerd over de keu-
zes in leefstijl die de maximale botmassa beïnvloeden. Gezond bewegen en voldoende 
calcium inname als kind zijn de sterkste bekende factoren die botgroei en mineralisatie 
positief beïnvloeden. Daarnaast hebben genetische studies in families laten zien dat meer 
dan 50% van de variatie in bot-mineraal dichtheid (BMD) toegewezen kan worden aan 
genetische variaties, en dat deze erfelijkheid toeneemt met leeftijd, waarschijnlijk vanwege 
een opsomming van verstorende omgevingsfactoren tijdens het leven. Zoals beschreven in 
Hoofdstuk 1, streven wij in dit proefschrift naar het ontleden van het multifactoriële proces 
van botvorming bij kinderen door de invloed van factoren als genetische achtergrond, 
blootstellingen van buitenaf aan de foetus, en de grootte en samenstelling van het lichaam 
als kind op de status van het bot bij schoolgaande kinderen. De studies uit dit proefschrift 
maken onderdeel uit van de Generation R Studie, een multi-etnische prospectieve popu-
latie cohort studie vanaf foetaal leven, opgezet in Rotterdam, Nederland.
In Hoofdstuk 2 wordt de methodologische benadering van genoom-wijde associatie 
studies (GWAS) in gemengde populaties in detail beschreven. In Hoofdstuk 2.1 volgt een 
uitgebreide beschrijving van het generen van de genetische data voor Generation R en 
worden verschillende analysemethoden voorgesteld om met de multi-ethnische samen-
stelling van deze dataset om te gaan. Deze genetische data van 5,732 deelnemers aan 
Generation R heeft inmiddels al bijgedragen aan ten minste 50 wetenschappelijke publi-
caties in onderzoeksgebieden als nieronderzoek, groei bij kinderen of gedragsproblemen 
bij jonge kinderen. In Hoofdstuk 2.2 stellen wij een imputatie methode voor die gebruik 
maakt van een tussenstap, imputatie naar een lokaal referentiepanel, voor de imputatie 
naar een geografisch uitgebreidere referentie dataset (zogenaamde “two-step imputation”). 
Deze methode verbeterde de imputatie in 28% van de gevallen, met daardoor 18% meer 
genetische markers tijdens de GWAS studie, in vergelijking met de traditionele “one-step 
imputation” methode. In Hoofdstuk 2.3 gebruiken wij de genetische data uit de gemengde 
populatie van Generation R als controle dataset voor het bestuderen van de genetische 
factoren die het risico op de ziekte van Behçet beinvloeden, waarbij de aangedane mensen 
van verschillende genetische achtergronden kwamen. Door middel van “linear mixed 
models” en correctie van principale componenten waren wij in staat om de associatie van 
varianten in de HLA locus, welke al eerder gerapporteerd waren in homogene Aziatische 
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populaties, te bevestigen, maar ook een nieuwe associatie in het intronische gebied van 
IL2A te identificeren.
Hoofdstuk 3 is toegewijd aan epidemiologische studies bij pediatrische BMD. In Hoofd-
stuk 3.1 laten we zien dat de factoren die botstatus bij schoolgaande kinderen beïnvloeden 
terug te herleiden zijn tot de periode als foetus. De inname van fosfor van de moeder 
en homocysteïne concentraties beïnvloeden sterk de hoeveelheid botmassa op 6-jarige 
leeftijd, terwijl vitamine B-12 concentraties en eiwit inname BMD niveaus voorspellen. In 
Hoofdstuk 3.2 laten we zien dat zowel foetale groei en de groei als klein kind onafhankelijk 
bijdragen aan de botmassa op 6-jarige leeftijd, waarbij het eerste levensjaar de meest 
kritieke bijdrage levert. In Hoofdstuk 3.3 leggen we de nadruk op de bot-geometrie, een 
andere parameter die samen met botmassa de sterkte van het bot bepaald. Onze resultaten 
laten zien dat het dijbeen (de “femur”) van jongens gemiddeld een hogere weerstand heeft 
tegen axiale en buigkrachten dan dat van meisjes. Een deel van deze verschillen werd ech-
ter verklaard door het verschil in spiermassa tussen jongens en meisjes. Met dit resultaat, 
en andere studies in acht nemend, moedigen wij het oprichten van sportprogramma’s voor 
en tijdens de puberteit aan, vooral voor meisjes waarbij het bot een relatief “zwakkere” 
configuratie heeft.
In Hoofdstuk 4 gaan we in op genetische studies bij pediatrische BMD. In Hoofdstuk 4.1 
hebben we een sterke associatie gevonden voor pediatrische BMD in de 7q31.31 locus. 
WNT16 en CPED1 zijn de genen die deze associatie teweegbrengen, en verschillende vari-
anten in deze twee genen beïnvloeden zowel BMD van het hele lichaam (zonder hoofd; 
TBLH-BMD) als van de schedel (Skull-BMD). Door middel van conditionele analyses 
hebben we ten minste twee verschillende signalen gevonden in dit genomische gebied, 
waarbij hun effect op BMD van de schedel met leeftijd kan variëren. Belangrijker, een 
Wnt16 knockout muis had een verlaagde (“total body”-BMD) TB-BMD, en gen expressie 
profielen in humane bot biopsies ondersteunen een rol voor CPED1 en WNT16 bij de 
BMD fenotypen op een populatie niveau. Alles bij elkaar genomen hebben we meerdere 
aanwijzingen gevonden voor de rol van deze moleculen in het botmineralisatie proces. 
In Hoofdstuk 4.2 demonstreren we dat TB-BMD niet alleen relevant is voor genetische 
studies bij botkwaliteit bij kinderen, maar ook toepasbaar voor het bestuderen van os-
teoporose in de hele populatie. We hebben varianten gevonden waarvan bekend is dat 
zij invloed hebben op verschillende boteigenschappen in verschillende gebieden op het 
skelet. Daarnaast hebben wij 18 nieuwe genetische gebieden gevonden die invloed heb-
ben op de variatie van BMD: 1p13.3 (CSF1), 2p11.2 (TCF7L1), 2p22.1 (SLC8A1), 2q33.1 (FZD7), 
5q22.2 (APC), 5q23.2 (CNK1G3), 7p14.3 (AQP1), 10q26.13 (BTBD16), 11p13 (LDLRAD3), 11p15.5 
(RIC8A), 12q21.33 (ATP2B1), 12q21.33 (BTG1), 15q14 (TMCO5A), 15q22.33 (SMAD3), 16q22.3 
(ZFHX3), 17q24.1 (CEP112), 20q12 (MAFB) en 21q22.12 (RUNX1). Verschillende van deze 
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gebieden coderen voor onderdelen van de Wnt signaling pathway, terwijl de mogelijke 
rol van anderen nog nagegaan moet worden. In Hoofdstuk 4.3 hebben we dezelfde TB-
BMD data geanalyseerd in leeftijd categorieen van 15 jaar. Deze manier van analyseren 
leverde nog eens drie additionele signalen op. Een daarvan op 14q32.12 (RIN3) was alleen 
gevonden bij kinderen, een andere in 11p15.1 (PTPN5) alleen in de categorie van 30-45 
jaar, en de laatste in 7q22.1 (ZNF789/ZSCAN5) alleen de in de oudste categorie (60 jaar 
of ouder). Daarnaast hebben we varianten in verschillende regios gevonden waarvan het 
effect afhankelijk is van de leeftijd, meestal met sterkere effecten in kinderen. Het sterkste 
voorbeeld van dit varierende effect kwam van de varianten in 14q32.12 (RIN3) en 6q25.1 
(ESR1/CCDC70). In Hoofdstuk 4.4 bekijken we genetische factoren waarvan het effect op 
BMD verschilde tussen skeletale gebieden in onze pediatrische populaties. De genetische 
correlatie was hoger tussen skeletale gebieden in verschillende ledematen dan tussen deze 
ledematen en de schedel. We beschrijven dertien verschillende regios die geassocieerd 
zijn met BMD in een of meerdere skeletale gebieden (bijvoorbeeld SNPs in WNT4, GALNT3, 
CPED1/WNT16/FAM3C, RSPO3, FUBP3, PTHLH, TNFSF11, TNFRSF11B, TNFRSF11A, LRP5, LGR4, 
RIN3 en EYA4). In Hoofdstuk 4.5 laten we zien dat genetische variaties in of bij SREBF1 op 
hetzelfde moment een tegengesteld effect kunnen hebben op bot en spierweefsel. Met 
behulp van publieke databases hebben we bewijs verzameld dat deze SNPs de expressie 
van SREBF1 kunnen reguleren, waarbij het product SREBP-1 inderdaad spiercel differentiatie 
onderdrukt, terwijl het het aantal gemineraliseerde foci in osteoblasten verhoogd.
In Hoofdstuk 5 bevestigen we dat schoolgaande kinderen van Afrikaanse afkomst hogere 
BMD levels hebben dan kinderen van Europese of Aziatische afkomst. We vonden dat het 
gecombineerde effect van de varianten die in de literatuur geassocieerd zijn met BMD in 
volwassenen significant geassocieerd was met pediatric BMD, wat suggereerd dat veel van 
deze varianten hun effect al uitoefenen op jonge leeftijd. Kinderen van Afrikaanse afkomst 
hadden een groter aantal BMD-verhogende varianten dan kinderen van andere afkomsten, 
suggererend dat de bekende ethnische verschillen in BMD ten minste deels van genetische 
oorsprong zijn. Dit resultaat was hetzelfde na het bestuderen van populaties over de hele 
wereld. Daarnaast, na het uitvoeren van verschillende cutting-edge evolutionaire analyses, 
vonden we bewijs dat natuurlijke selectie aanwijst als de veroorzaker van deze genetische 
patronen.
Uiteindelijk worden de resultaten in Hoofdstuk 6 en in meer algemene zin besproken. 
Ook worden de methodologische aspecten met betrekking tot de studies in dit proefschrift 
toegelicht, en worden de implicaties van onze bevindingen en suggesties voor verder on-
derzoek in dit hoofdstuk gepresenteerd.
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and encourage us to have that loyalty feeling with each other, making it really special to be 
part of this group. Of course, I have no words to express my gratitude towards Fernando, 
I would, in any case, give it a try. Fer, you have been for me much more than a supervisor, 
and perhaps the least important things I have learned from all these years working under 
your shelter, are the ones concerning bone biology or clinical interpretation of my findings. 
You are a great human being and I admire your professionalism and continuous concern 
to really dig out the best of every person, your will to help and share your knowledge… 
that makes you really a leader rather than a boss, and is very touching. Thanks for so much, 
especially for making so palpable every day your faith on me, on my work!!. I know my 
political skills are not entirely developed yet, I have not been a fast learner as for basic 
research… but I hope at the end I won’t disappoint you. As you have been part of my family, 
I would like to thank yours for great days and for letting me in.
I am really grateful to the members of the reading committee for their time and feedback. 
Professor Manfred Kayser, Professor Cornelia van Duijn, and Professor Babette Zemel. 
I have been able to get familiar with your work, through small collaborations and your 
publications. Also, I have had the opportunity to get close to people from your respective 
groups, so I really know how busy you are with your own projects, thanks. I would also 
like to take the opportunity to thank the members of the external committee Professor Jon 
Tobias, Professor Claes Ohlsson, and Professor Patrick Groenen, I hope we will have a great 
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At the beginning of my PhD I had the blessing to work and learn from one of the sharpest 
minds I have ever encountered, who shared with me his knowledge and has consistently 
been present all these years Dr. Karol Estrada. Capo, you have been a great older brother 
(jjajajajja), thanks for all the advices, the codes, for giving me so much inspiration at work, 
I should even thank you for marrying Liz from who I also learned a lot. You, together with 
BeBe are a great family and have warmed my days even from the distance.
Besides Karol, in our group of the laboratory of human genetics, I had the pleasure to work 
with great scientists and persons, even if with some of you I got closer, and then perhaps 
will extend a bit longer in my comments, I want to thank you for the excellent feedback not 
only for my projects but in general for my life, so to Lisette, Marjolein Peters, Marjolein de 
Kruif, Hanneke, Fatima, Robert, Carola, Joyce, Annemieke, Pooja, Jia Lian, Joost, Annelies, 
Anke, Cindy, Djawad, Ester, Tom, Linda, Jeroen, Olja, Enisa, Fjorda, BiBi, KT, Tamara, Marta, 
Nata, Ling, Eskil, and all other students who have joined our lab. Cindy and Linda, I know 
sometimes I am really not in the best of moods when working… but thanks for being patient, 
Cindy we will continue jumping I hope for a long time. Ling beauty, I always felt we were 
such a great team, you are very intelligent and so professional, now you are next!. Marta, 
usted mujer es una verraca en todo el sentido de la palabra, gracias por el apoyo, por dar 
siempre la cara, seguro la vida le esta recompensando ese carácter tan templado. Natis, 
amiguita, eres un ser humano excepcional, yo no sé como agradecerte haber compartido 
tanta luz conmigo, tenerme siempre en tus oraciones y estar tan pendiente, te quiero. Olja, 
Enisa, Fjorda, BiBi, KT… what can I say I have an inclination to the east, and I have loved 
being surrounded by it (through you), you are all such hard workers. Jeroen and KT, I know 
you were a little bit surprised that I asked you to be my paranymphs…. But I was not, per-
haps I failed to show you more often, but I am a great FAN of you!!!, I think you are brilliant, 
I mean workwise, precise, creative, persistent… but also, I admire you as persons… I believe 
you are kind and honest, really transparent and that amuse me. Thanks for accepting and 
investing time on planning all this with me. I also want to recognize the people who are not 
that visible in our publications but whose work has been vital to our group, Mila, Pascal, 
Michael, Marijn, Joost, Anis, Eline, Annelies, Liz (again), Thanks.
As the work presented in this book started even before I started the PhD, embedded in 
the Generation R Study, my gratitude to all participants, doctors, technicians, nurses and 
sponsors, PIs, without you literally this work would not have been possible. Vincent, it has 
been excellent working within the Generation R which you lead pretty successfully, thanks 
for your feedback in all articles which you always had the time to read. Clau, I know I say 
this quite too often but I would not have known what to do without you… thanks for always 
being so keen to help me, although, I can imagine you had other hundred students asking 
you for variables, mismatches, etc. Denise, beauty you worked so hard and thanks to your 
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professionalism we got high-quality data. I also had the chance to get to know you outside 
the work-context and you are just as great!, working with you was a pleasure and you write 
so perfect, I would have liked you to coauthored the discussion of my thesis jajajjajaj.
Other people from the university regularly challenged my knowledge with really smart 
discussions or questions. So to: Abbas, Paul, Symen, Janine, Claire, Maryam, Romy, Luba, 
Marjolein, Hieab, Alex, Oscar, Irene, Ralf, Elisa, Najaf, Cornelia, Lennart, Prof. Tiemeier, 
Prof. Hofman. Thanks for preparing me for the day of the defense (I do not think even the 
committee will get to the level of some of your inquiries, or at least I hope). Also, I had 
the opportunity to participate in the endocrinology meetings, where I learned more about 
bone biology and relevant clinical pathways. This was a great complement to my educa-
tion in ErasmusMC, so to the organizers and regular participants of these meetings, Jeroen, 
Bram, Marta, Hans, Marjolein and all the others, thanks.
If you ever look through this thesis you will notice, there is a name enriched in my list of 
publications: John Kemp. John, you have been the best comrade-in-arms during all these 
years, thanks for all the support, the analyses at the last minute, all the brainstorming, the 
long Skype calls even with our time difference, the never ending conversations in the differ-
ent congresses. You are pretty talented and hard worker; I hope we will continue working 
together. I would also like to thank the whole ALSPAC team, Jon and Dave, thanks for all 
feedback; I know I write quite a lot of emails… is just that I value your concepts highly. 
Other people have also contributed their knowledge, time and energy to produce this 
dissertation, so to all coauthor in the publications not only in which my thesis is based on, 
but all the ones I have participated on, my sincerest gratitude. Oscar Lao, thanks for being 
always eager to run an extra mile… at the end we did like a marathon together, and regard-
less of the amount of lactic acid, I enjoyed it a lot. The GEoCoDE program enabled me to 
go to the Children Hospital of Philadelphia (CHOP) for a short stage, thanks for the support. 
Ale, it was awesome meeting you and sharing all my time in Philly working with you. Struan 
and Babette thank you for your time, for allowing me share ideas in your groups and learn 
in CHOP. Eskil, it was great having you here and working together… I have not heard from 
you for so long, hope everything is going fine with you.
I want to acknowledge all the GEFOS/GENOMOS community that has always shown 
respect for my work and are eager to help, to explore, to follow-up. I would like especially 
to thank Tom Beck, David Karasik, Evangelia, Vangelis and Cheryl, with who I have worked 
in close collaboration and always are keen to extend me a hand when I am drowning in 
my data, analysis or so ever. Other consortia also have brought me a position and I have 
learned a lot from their TCs or analyst meetings, so to all the participants of CHARGE, EGG 
and GIANT thanks.
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All this Rotterdam adventure, would not have happened if Professor Emmanuel Lessafre, 
who I met during my Master thesis, would not have invited me to come to Rotterdam for 
my PhD and established the contact with Fernando. Emmanuel, I would always be in debt 
with you. Also, in the department of statistics, I had the luck of working with Prof. Paul Eilers, 
who I would like to thank. Few months before coming to Rotterdam I developed my MSc 
thesis. In LUMC, I worked with a great team Jeanine, Stefan, Hae-Won, Wendim, and Bru 
thanks for all the patience and hard work.
I was under a lot of pressure on my job, involved in a lot of projects, feeling homesick 
sometimes, with my heart half broken in other instances and the lunch or coffee breaks 
were my buoyancy aid, so to my girls (even if a couple of guy names will indeed be on the 
list, but with who I felt so free as with girls!). Dasha, Cris, Camila, Mariana, Meli, Ivancho, 
Aran, Veci, Princess, Tammy, Pau, Lady, Fabi, Sandrita, Giovanni, Monica, Adri and Pachito 
thanks for making my life lighter by carrying some of the weight of my concerns, for crying 
and laughing with me, and listen to all that crossed my mind to the limit of … Lady, amiga 
gracias por enloquecerte conmigo cada vez… por esconderme el tornillo que me falta pa 
que nunca lo encuentre. Also, coming to the Netherlands gave me the opportunity of meet-
ing great people who provide me good vibes everytime and have formed a circle around 
me full of care, thank to you all: Diego, Jessica, Alex, Mark, Juli, Bruna, Moe, Jonathan, Ana, 
Kristof, Favi, Fatima, Edu (supongo me echaras una porra de vez en cuando dese el cielo) 
and Marius (you know how much I appreciate the giant amounts of vitamine :D of these 
years…)
Even before I came here I had established longlife relationships with many people who has 
never, even in the distance, left me alone and who I try to express day by day my gratitude 
for their presence in my life, regardless of the place where I live. I know it is not fair that I 
just place your name in a list, please forgive me, just consider the extension of this book 
give me a call, and I will be precise in my acknowledgement… My primary- ,secondary- , 
high-school and still friends: Flaca, Lake, Lili, Sanchino, Cami, Angie, Mayis, Vero, Andre 
Cardenas, Cata Zapata, Caro Vergara, Meli, Pete, Pau Arevalo and Maria Paula. Mis parceros 
de la U, Cami, enana, Cata, enano, Germi, Andrecho, Alejo, Roni, Osqui, Malala, Mildi, 
Orlandito, Carino, Duque,Leo, Edgar, Keka, Magno, Churro, Mona, Adri Caro, Manu, Nico 
and Carlos Jaramillo (who convinced me in his first lecture that chemical engineering was 
not the path I wanted to follow). Los amigos de la segunda linea de la mano: Conde, Juanjo, 
Girata, Fasti, Chiquitico, Benavidez, Vic, Hugui, Carlos Andres, Clau, Mousa, Jan, Gabor, 
Alex, Cesitar, Juan C. Enciso, JuanDi, Alex, Ernestico. All the people who Belgium gave me 
the opportunity to meet and who have demonstrated me that the world is pretty small or 
I am damn lucky: Dona, Consu (who taught me that every cocomero is a good excuse to 
celebrate), Bea, Ambi, Pia, Ari, Sylvain, Kim, Tania, Martin, Renata, Eva, Jimmy, Kurt, Hellen, 
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Amparo, Migue, Ema, Urko, Sarita, Lidia, Lio, Laurent, Fortu (calvo, gracias por tanto, fue 
bello vivir in slow motion the first years of this journey). Surtout, je remercie à Gaby et Mark 
pour offrir moi a vraie famille donc loin de la Colombie.
After six hours and with the certainty I have forgotten half of the people I would have liked 
to acknowledge, I want to offer all this work to my family. A mis primos, tíos y abuelo que 
siempre están tan pendientes de mi y me llenan de amor en cada encuentro. A Ra, Janeth y 
mis niñas que son los protagonistas de cada salvapantalla en el compu, el cel, la tablet, para 
que la vida sea mas llevadera. A mi abuelita, que sé que aún hoy está sentada en primera 
fila con su dulce sonrisa y sus ojos fijos en los mios. To Filippo, who has not only sign the 
cover of this book but, is also the main author of my sporadic smiles, of the turbulence in 
my eyes, and who without hesitation enclose me in his arms and there, let me be. To his 
parents Chiarella and Franco, who have received me naturally in their nucleus and always 
support me.
Y a mis padres, los que siempre han creído, los que esperan, los que callan, los que cuidan, 
porque el mayor sacrificio para poder escribir este texto hoy, han sido todos estos años de 
distancia, de ausencia. Yo sé que ustedes se sienten muy orgullosos de mis logros y si este 
libro les hace latir fuerte el corazon… entonces valió la pena.
